Defining novel therapeutic targets in chronic myeloid leukaemia stem cells : targeting self-renewal through hedgehog pathway inhibition by Irvine, David Arthur
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
 
Irvine, David Arthur (2013) Defining novel therapeutic targets in 
chronic myeloid leukaemia stem cells: targeting self-renewal through 
hedgehog pathway inhibition. PhD thesis. 
 
 
 
 
http://theses.gla.ac.uk/4584/  
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any format 
or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given 
 
 
1 
 
Defining Novel Therapeutic Targets in Chronic Myeloid  
Leukaemia Stem Cells; Targeting Self-Renewal 
 Through Hedgehog Pathway Inhibition 
 
 
 
David Arthur Irvine 
 
A thesis submitted for the degree of Doctor of Philosophy to the 
University of Glasgow March 2013 
 
 
College of Medical, Veterinary and Life Sciences  
Institute of Cancer Sciences 
 
 
 
 
 
 
 
 
 
 
 
 
© David Irvine 2013 
2 
 
Dedication 
 
 
 
This work is dedicated to the memory of my younger brother, Michael Irvine - 
alumnus of this university, life-long companion, confidant, raconteur and fellow 
adventurer; I wish there had been more time. 
 
 
Michael Irvine BSc (Hons) MBChB MRCS MRCGP 
29th April 1977 – 10th July 2011 
3 
 
Summary 
 
Chronic myeloid leukaemia (CML) is a clonal disorder that arises following a 
reciprocal genetic translocation event between chromosomes 9 and 22 
t(9;22)(q34;q11) in a haemopoietic stem cell. This produces a constitutively active, 
oncogenic tyrosine kinase, BCR-ABL which leads to deregulated mitotic signalling, 
inhibition of apoptosis and altered normal cellular adhesion and stromal 
interaction.  As a result there is expansion of leukaemic stem cell numbers and 
accumulation of leukaemic myeloid progenitors.  Untreated there will be acquisition 
of further genetic abnormalities leading to disease progression, blast crisis and 
death.  
The development of tyrosine kinase inhibitors (TKI) (e.g. imatinib, dasatinib, 
nilotinib, bosutinib and ponatinib) that block BCR-ABL kinase activity has radically 
improved the management of CML leading to unprecedented levels of cytogenetic 
and molecular responses in chronic phase (CP) patients.  However a substantial 
minority of patients fail to reach optimal treatment targets, TKI resistance can 
develop over time and even optimally responding patients after prolonged 
treatment with TKI continue to harbour primitive leukaemic cells that have the 
capacity to cause disease relapse or progression.  
One reason for disease persistence is that primitive CML cells are resistant 
to pharmacologically achievable concentrations of TKI and are not actually 
dependent on BCR-ABL kinase signaling for survival.  Therefore eradication of the 
CML clone will require alternative therapeutic strategies involving novel 
pharmacological targets against these primitive CML cells.  In this work, two 
complementary approaches to define novel survival mechanisms and characterise 
new potential therapeutic targets in CML are described.   
Gene expression microarray technology was used to measure gene 
expression differences between the most highly purified and rigorously defined 
stem and progenitor populations from chronic and advanced phase CML patients 
at diagnosis compared with normal volunteers.  Flow activated cell sorting (FACS) 
was used to purify haemopoietic stem cells [HSC] CD34+38-Lin-CD45RA-CD90+ 
and progenitor populations (multipotent progenitors [MPP] CD34+38-Lin-CD45RA-
CD90-; common myeloid progenitors [CMP] CD34+38+Lin- CD123+ CD45RA-; 
granulocytic/monocytic progenitors [GMP] CD34+38+Lin- CD123+ CD45RA+ and 
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megakaryocytic/erythroid progenitors [MEP] CD34+38+Lin- CD123- CD45RA-) from 
primary CML samples and samples derived from normal volunteers.  FISH 
analysis confirmed that >90% cells from all sub populations harboured the BCR-
ABL transgene and that this was most highly expressed in the HSC population.  
Global analysis of the microarray data indicated that the normal gene expression 
profile was deregulated in CML.  While mature progenitor populations (GMP and 
MEP) from CML or normal haemopoiesis were very similar at a transcriptional level 
there were significant differences in expression between normal HSC and CML 
HSC.  These differences include broad up regulation of many aspects of cellular 
machinery required for proliferation, DNA replication and repair and segregation 
and mitosis.  There was also down regulation of various cell adhesion molecules.   
Strikingly, there was comparative down regulation of many genes associated with 
stem cell function, self-renewal and maintenance of the HSC population in CML 
HSC compared to normal HSC.  Thus CML HSCs appear to have a more mature 
transcriptional phenotype, with similarities to the normal MPP and CMP 
populations.  In addition to this, CML stem and progenitor cells were noted to have 
reduced expression of HLA molecules and other antigen presentation mediators.  
Thus from these studies, CML HSC appear to be mature, readily able to enter cell 
cycle but deficient in expression of various mediators of self-renewal and antigen 
presentation. 
Targeting the mechanisms that regulate self-renewal might offer a 
mechanism of targeting CML HSC.  One pathway that has an important role in 
influencing stem cell self-renewal is the Hedgehog (Hh) signalling pathway.  In 
embryogenesis this pathway is critically involved in patterning but remains active in 
adult tissue contributing to tissue homeostasis, regeneration and healing.  In adults 
it is known to contribute to oncogenesis and is critical for the propagation of CML 
in murine models but appears to be dispensable in normal haemopoiesis.  If self-
renewal could be inhibited in CML, it follows that there would be reduced primitive 
CML HSC available for disease propagation.  Therefore parallel studies were 
performed to investigate whether Hh signalling was active in CP CML HSC and 
progenitor cells and whether inhibition of Hh signalling alone or in combination with 
conventional TKI treatment might eradicate CML HSC. 
 Targeted expression analysis confirmed that critical mediators and targets 
of Hh signalling were enriched in both normal and CML primitive haemopoietic 
populations.  There was differential expression of several Hh signalling mediators 
5 
 
and targets in primary CML populations.  Most notably there was reduced 
expression of the key negative regulators of Hh signalling (GLI3 and SUFU) in CP 
and advanced phase CML.  There was also up regulation of several targets of Hh 
signalling (GLI1, PTCH1, CCNB1/2, FOXM1 and STIL) in CML compared with 
normal populations. 
Inhibition of Hh signalling with the clinical grade smoothened (SMO) 
inhibitor, LDE225 led to modest and variable reduction in expression of the Hh 
target GLI1 in CD34+ CML HSC.  Short term in vitro culture of CP CML CD34+ cells 
with LDE225 ± nilotinib did not affect viable cell counts, exert an additive anti-
proliferative effect, inhibit cell cycle progression nor augment TKI mediated 
apoptosis.  Additionally CFSE cell tracking experiments up to 12 days confirmed 
the lack of effect of LDE225 on cell division kinetics and maturity as measured by 
surface expression of CD34.  However if SMO inhibition predominantly exerted 
influence through modulation of self-renewal activity in CP CML HSC then targeted 
inhibition of SMO would not alter measures of apoptosis, proliferation or cell cycle 
progression in these short term in vitro experiments and assays designed to 
interrogate the number and function of self-renewing progenitors would be required 
to discern the effect of LDE225 on CML HSC function. 
Pre-treatment with LDE225 did not affect primary colony formation in colony 
forming cell (CFC) assays reflecting the fact that primary colony formation is 
largely driven by committed progenitor proliferation and not HSC self-renewal.     
However, serial replating assays demonstrated that LDE225 reduced secondary 
and tertiary colony formation (an in vitro surrogate of self renewal activity).  
Furthermore, while pre-treatment with nilotinib increased apparent re-plating 
capacity of CD34+ CP CML cells, combination treatment with LDE225 and nilotinib 
led to the greatest reduction in CD34+ CP CML cells with replating capacity.  
Similarly, pre-treatment of CD34+ CP CML cells with LDE225 alone or in 
combination with nilotinib led to reduction of residual primitive haemopoietic cells 
as measured by long term colony initiating cell (LTC-IC) assay, while pre-treatment 
normal CD34+ cells with LDE225 alone or in combination with nilotinib did not 
affect LTC-IC read-out.  
 It is well recognised that stem cell fate decisions are formulated in the 
context of complex microenvironmental signalling.  To assess the effect of long 
term exposure to LDE225 ± nilotinib on CP CML CD34+ cells in the presence of 
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microenvironmental factors, CD34+ CP CML cells were directly inoculated into pre-
prepared mixed M210B4 and SL/SL stromal co-cultures and cultured in the 
presence of LDE225 alone or in combination with nilotinib over 5 weeks prior to 
assessment of residual colony forming cells.  Prolonged exposure to LDE225 
resulted in a significant reduction in residual colony forming cells.   
In conclusion these studies indicate that Hh signalling is active in CP CML 
HSC and that the abrogation of Hh signalling through SMO inhibition alone or in 
combination with conventional TKI treatment is a potentially useful therapeutic 
strategy to target resistant CML HSC.  These findings provided the impetus for 
collaborative murine modelling studies and together these have provided the 
preclinical background for clinical trials of Hh signalling in combination with TKI in 
CML. 
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1 Introduction 
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1.1 Overview of Haemopoiesis 
The haemopoietic system is incredibly dynamic; its central feature is 
constant, massive cell turnover. In the average adult human it is estimated that 
around one million blood cells are produced and destroyed every second simply to 
maintain homeostasis (Ogawa, 1993).  The mechanisms that serve to fulfil and 
sustain this enormous requirement throughout the life of an organism, whilst 
avoiding catastrophic error, have been the object of intense investigation and 
debate over the past 50 years.  These endeavours have yielded important insights, 
not only into the process of haemopoiesis itself, but also into the development of 
other tissues, into aspects of regeneration and healing and lastly into the 
pathological processes leading to aberrant haemopoiesis and oncogenesis. 
1.1.1 Hierarchical haemopoiesis and the concept of stem cells 
It has been apparent since the middle of the last century that reconstitution 
of an irrevocably damaged haemopoietic system in mice or other mammals, 
including humans, was possible through the transplantation of bone marrow (BM) 
cells (Lorenz et al., 1951; Thomas and Epstein, 1965; Thomas et al., 1957). 
However, whether the required cells descended from a single parental 
haemopoietic cell or whether there were different parental cells for each lineage 
was not initially clear.  Series of elegant experiments taking full advantage of 
advances in scientific understanding and technology in many fields have 
painstakingly dissected the haemopoietic system of mouse and man and have 
culminated in our current hierarchical model of haemopoiesis (Bhatia et al., 1997; 
Dick et al., 1997; Hogan et al., 2002; Kiel et al., 2005; Majeti et al., 2007; Morrison 
and Weissman, 1994; Notta et al., 2011; Spangrude et al., 1988).   
It is generally accepted that a small population of haemopoietic stem cells 
(HSC) gives rise to a committed proliferative progenitor cell population and 
ultimately, through successive cell divisions, to progenitors with increasingly 
restricted potential leading to production of the terminally differentiated effector 
cells that comprise the blood system.  This model owes its core premise to the 
work of Aleksandr Maximow who postulated the existence of a common precursor 
haemopoietic cell in 1909, but definitive experimental verification and subsequent 
elaboration is attributed to Till, McCulloch and many others over the last 50 years 
(Maximow, 1909; Till and McCulloch, 1961). 
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In order for this model to explain how the haemopoietic system is sustained 
throughout life, HSCs must possess two key properties; firstly, the capacity to give 
rise to all the constituents of the haemopoietic system (multipotency); and 
secondly, the capacity to re-duplicate without differentiation, thereby maintaining 
the stem cell pool (self-renewal).  Experimental confirmation of the existence of 
cells possessing these unique characteristics was first provided by Till and 
McCulloch who observed colonies of haemopoietic cells in the spleens of lethally 
irradiated mice following transplantation.  These colonies (colony forming unit–
spleen, [CFU-S]) contained multipotent cells, some with the capacity to produce 
further colonies in the spleens of secondary transplant recipients (Becker et al., 
1963; Till and McCulloch, 1961; Wu et al., 1967).   
Since the identification of these cells, there have been extensive efforts to 
develop assays to investigate the behaviour, proliferative capacity, differentiation 
potential and self-renewal properties of HSCs and their progeny.  Technical 
advances, primarily in monoclonal antibody production, fluorescence activated cell 
sorting (FACS) and refinements in the manufacture and purification of essential 
haemopoietic growth factors (GFs), not to mention the development of 
progressively more robust in vitro and in vivo stem and progenitor cell assays have 
led to a rapid increase in our understanding of the behaviour of HSC and their 
progeny.    
1.1.2 Defining the haemopoietic hierarchy 
The cell population defined by Till and McCulloch was quickly realised to be 
a heterogeneous population including HSC, but largely comprised of more mature, 
committed haemopoietic cells that lacked multipotency and self-renewal capacity.  
In order to better understand stem cell behaviour and unravel the mechanisms 
controlling stem cell behaviour it is critical to begin with a pure stem cell 
population.   The challenge since then has been to attempt the purification of 
increasingly functionally homogeneous populations of HSC and progenitor cells 
from haemopoietic tissue through the parallel application of cell sorting strategies 
and functional assays.  
1.1.2.1 Defining the haemopoietic hierarchy in the mouse 
Despite the obvious differences between mice and humans in terms of size, 
life span and proliferative requirement in the haemopoietic system, our 
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progressively refined model of murine haemopoiesis has greatly informed our 
understanding of human haemopoiesis.  Prospective selection for populations 
enriched for stem cell activity can be performed using various strategies including 
fluorescent dye exclusion due to higher expression of ATP binding cassette (ABC) 
multidrug transporters (Zhou et al., 2001), by specific enzymatic activity e.g. 
aldehyde dehydrogenase (ALDH) (Storms et al., 1999), or since HSC are largely 
not cycling, through their relative quiescence through retention of DNA, 
mitochondrial or protein binding dyes (Goodell et al., 1996).  Following the advent 
of reliable flow cytometry and sorting procedures coupled with the availability of 
high quality monoclonal antibodies it has become common to use FACS to sort 
populations based on surface phenotype and then to characterise their stem cell 
activity in a functional assay e.g. their capacity to cause long term complete 
haemopoietic reconstitution in a lethally irradiated mouse (Bhatia et al., 1997; 
Cashman et al., 1997; Dick et al., 1997; Hogan et al., 2002; Kiel et al., 2005; Majeti 
et al., 2007; Morrison et al., 1997a; Morrison and Weissman, 1994; Murray et al., 
1995; Notta et al., 2011; Spangrude et al., 1988).  Using these technologies and 
various surface markers, tiny cell populations with different purities and 
repopulation characteristics have been identified in murine BM.   Spangrude and 
colleagues were the first to demonstrate that they could isolate a population 
containing all the cells with the capacity for long term engraftment - long term HSC 
(LT-HSC) - in the murine haemopoietic system by isolating cells positive for stem 
cell antigen-1 (Sca-1) but negative for mature lineage markers and with low 
expression of thymocyte antigen-1 (Thy-1).   This population was again 
heterogeneous with these cells making up only a tiny minority of the whole 
(Spangrude et al., 1988).  Subsequent refinement, adding various additional 
markers, e.g. the expression of the mast/stem cell GF receptor (c-Kit/CD117) or 
lack of expression of the markers of commitment (e.g. FMS-like kinase-2 [Flk-
2/CD135]) and the lack of surface protein CD34 yielded purer LT-HSC enrichment. 
These techniques also demonstrated the presence of multipotent populations with 
more limited repopulation capacity: - short term HSC (ST-HSC) with only transient 
repopulation capacity (< 16 weeks) and a multipotent progenitor population (MPP) 
(Morrison et al., 1997a; Morrison and Weissman, 1994).     Recently use of further 
surface phenotypic markers, in particular recognition that the signalling lymphocyte 
activation molecules (SLAM) antigens are differentially expressed in primitive 
murine haemopoietic cells has allowed further enrichment (Kiel et al., 2005; Yilmaz 
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et al., 2006).  Table 1-1 below summarises the surface phenotype of various HSC 
populations.  
Phenotype Approx. ratio of cells with 
LT-HSC activity 
Reference 
Lin
-
, Sca-1
+
, Thy-1
lo
 1 in 10 (Spangrude et al., 1988) 
Lin
-
, Sca-1
+
, c-Kit
+
 (LSK) <1 in 10 (Okada et al., 1992) 
Lin
-
, Sca-1
+
, Thy-1
lo
 c-Kit
+
  (KTSL) 1 in 5 (Wagers et al., 2002) 
CD34
−
, Sca-1
+
, Lin
−
,  c-Kit
+ 
(+ hoescht 33342 staining) 
1 in 5 
(1 in 1.1) 
(Osawa et al., 1996b) 
(Matsuzaki et al., 2004) 
CD150
+
, CD48
-
, Sca-1
+
, Lin
-
, c-Kit
+
 1 in 2 (Kiel et al., 2005) 
Table 1-1:  Murine HSC phenotypes 
Table indicating predominant phenotypic populations of murine HSC studied and the 
approximate enrichment of cells with long term engraftment capacity in each phenotype. 
It is a testament to the power of these techniques, as well as further 
validation of the hierarchical nature of haemopoiesis, that murine HSC populations 
can now be prospectively enriched to near purity (Benveniste et al., 2003; Kiel et 
al., 2005; Matsuzaki et al., 2004; Osawa et al., 1996a).  
1.1.2.2 Defining human HSCs and their progeny 
Successful therapeutic human BM transplantation has been performed 
since 1958; however the identities of the cell or cells responsible for durable 
engraftment was not initially clear (Thomas et al., 1957).  Attempts to isolate 
human HSCs have progressed utilising broadly similar strategies to those detailed 
above; that is by prospective phenotypic isolation of populations enriched for HSC 
activity followed by their functional characterisation in in vitro or in vivo quantitative 
assays.  It would be fair to say, however, that our understanding of early human 
haemopoiesis remains significantly behind that of the murine counterpart.  One of 
the reasons for this relates to the complexities of developing quantitative assays of 
human stem cell activity.  This requires either stromal supported, prolonged in vitro 
assays or xenotransplantation repopulation assays using immuno-compromised 
mice. 
1.1.2.3 Human HSC assays 
The most rigorous in vitro surrogate assay for stem cell activity is the long 
term culture-initiating cell (LTC-IC) assay and this identifies and quantifies a 
population of cells that harbour a variable capacity to initiate and sustain 
haemopoiesis with BM or stromal support for prolonged periods (60 days or 
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longer) (Eaves et al., 1991; Hao et al., 1996; Sutherland et al., 1994; Sutherland et 
al., 1991; Sutherland et al., 1993a; Sutherland et al., 1993b; Sutherland et al., 
1995; Sutherland et al., 1990).  While these assays are widely used and are useful 
in vitro assays, they are limited by lack of capacity to demonstrate multipotency (as 
the culture conditions will not support lymphoid development). They are also 
unable to demonstrate reconstitution of the full haemopoietic system or directly 
measure self-renewal activity.  In order to truly demonstrate HSC activity, it is 
necessary to demonstrate full reconstitution of the haemopoietic system in vivo.  
While clinical stem cell transplantation demonstrates the capacity for long term 
engraftment in humans using BM and selected peripheral blood (PB) sub-
populations, quantitative assays require surrogate transplant models (Weissman, 
2000).   
Several groups have utilised various immunocompromised murine models 
(severe combined immune deficiency [SCID] mice, non-obese diabetic [NOD] -
SCID mice and more recently NOD-SCID gamma chain deletion [NSG]) mice as 
xenotransplantation recipients to assay haemopoietic reconstitution activity in vivo 
(Bhatia et al., 1997; Cashman et al., 1997; Dick et al., 1997; Hogan et al., 2002; 
Lapidot et al., 1992; Shultz et al., 2005). These studies functionally identified a 
candidate HSC population known as the SCID repopulating cell (SRC) in human 
BM, mobilised PB and cord blood (CB) that could be measured in limiting dilution, 
demonstrated reconstitution of all features of the haemopoietic system and was 
potentially transplantable into secondary and tertiary recipients indicating the 
capacity for self-renewal.  A limitation of these xenotransplantation assays is that 
the read-out depends on recipient factors which are unrelated to the characteristics 
of the cells under study, including method of administration and the degree of 
immunocompetency in the recipient mice.  This is clearly illustrated by the 
improved efficiency of repopulation witnessed in the more profoundly 
immunocompromised NSG mice compared to other models (Shultz et al., 2005). 
1.1.2.4 Phenotypic characterisation of human HSC 
Phenotypic characterisation of putative HSC populations in human tissue 
began with attempts to generate antibodies allowing the identification of early 
haemopoietic cells and led to the discovery of CD34, a surface glycoprotein highly 
expressed in primitive haemopoietic tissue but absent in mature differentiated 
cells.  Its function has not been established although it is thought to be involved in 
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adhesion and possibly signalling. Its main utility is as a surrogate marker for 
primitive haemopoietic cells.  Approximately 1-4% of BM haemopoietic cells 
express CD34+ and this population is multipotent, highly enriched for colony 
forming cells in in vitro assays in addition to harbouring virtually all the cells with 
the capacity to effect long term haemopoietic reconstitution in murine xenograft 
models, primates and humans (Krause et al., 1996; Lu et al., 1993b; Sutherland et 
al., 1989; Sutherland et al., 1990; Udomsakdi et al., 1992c).  Recognition of CD34 
as a single phenotypic marker that allowed identification and enrichment of this 
HSC-containing population was a crucial event in human HSC research and has 
been of immense value both in a research and a clinical context.  Despite its 
clinical utility it has been clear for many years from functional studies that this 
population is heterogeneous, containing both multipotent and lineage restricted 
cells and cells with long term and short term repopulating capacity in 
xenotransplant recipients (Hogan et al., 2002; Sutherland et al., 1989).   Further 
characterisation of this population has been performed using other surface 
markers notably CD38 and CD90.  Between 90 and 99% of CD34+ haemopoietic 
cells also express CD38 (cyclic ADP ribose hydrolase - a glycoprotein with roles in 
cell adhesion, signal transduction and regulation of intracellular calcium), however, 
CD34+CD38+ cells do not form the more primitive fraction and it is the CD34+CD38- 
fraction which is enriched for LTC-IC and particularly SRC activity (Bhatia et al., 
1997; Hao et al., 1996; Huang and Terstappen, 1994).  Additional studies 
demonstrated that while CD34+38+ cells produced rapid transient engraftment that 
was not transplantable into secondary hosts, the CD34+38- fraction produced 
stable long term engraftment that was more comprehensive (including lymphoid 
lineage cells, specifically T cells) and could be transplanted into secondary 
recipients (Bhatia et al., 1997; Conneally et al., 1997).  Expression of CD90 (Thy1) 
has been used by various groups to identify a primitive haemopoietic population 
(Baum et al., 1992; Craig et al., 1993; McCune et al., 1988; Murray et al., 1995).  It 
is a glycosylphosphatidylinositol (GPI)-linked cell surface protein with a single 
variable immunoglobin domain.  In humans it is expressed on stem cells from 
various organ systems including the liver, neurological system and BM (Craig et 
al., 1993).  Its expression correlates with an immature phenotype with CD90+ cells 
representing a fraction of the CD34+38- population (Craig et al., 1993; Majeti et al., 
2007).  Its expression declines in the presence of markers of maturity and lineage 
commitment.  Populations exhibiting CD90 in addition to CD34 are highly enriched 
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for LTC-IC and SRC and have demonstrated greater efficiency in repopulating not 
only murine haemopoiesis but human haemopoiesis as well (Bhatia et al., 1997; 
Craig et al., 1993; Majeti et al., 2007; Michallet et al., 2000; Murray et al., 1995). 
It is generally held that LTC-IC represent a more mature functional 
population than the SRC.  Likewise while CD34+ cells are well characterised they 
are a heterogeneous population comprising cells with and without stem cell 
activity.  The CD34+38- population is more primitive but still heterogeneous with 
approximately 1 in 650 CD34+38- cells exhibiting SRC activity (Bhatia et al., 1997). 
Majeti and colleagues further sub-divided this population using expression of 
CD90 and CD45RA (Majeti et al., 2007). They defined a population of candidate 
HSC (CD34+38-90+lin-45RA-) that exhibited multipotency and long term 
repopulation capacity in about 1 in 10 cells but also contained virtually all the cells 
with capacity to engraft secondary recipients and a second population (CD34+38-
90-lin-45RA-) – akin to the MPP population in mice.  While exhibiting multipotency 
and long term repopulation capacity, these cells were less able to engraft 
secondary recipients (Majeti et al., 2007). The HSC population was shown to give 
rise to the putative MPP population demonstrating it to be more primitive than the 
latter (Majeti et al., 2007).  More recently, in an attempt to further refine this 
population of HSC isolated, Notta et al found that expression of the cell adhesion 
and signalling molecule CD49f was associated with enriched long term HSC 
activity and when combined with rhodamine exclusion in addition to the phenotype 
above, could refine the HSC population isolated to about 1 in 5, although this was 
variable between samples (Notta et al., 2011).   Table 1-2 summarises these 
populations, their frequency and gives an indication of their approximate HSC 
enrichment. 
Phenotype Proportion of BM 
HSC 
Approx. ratio of 
cells with LT-HSC 
activity 
Reference 
Whole BM 100% 1 in 1x10
6
 (Wang et al., 1997) 
CD34
+
 1-4% 1 in 9.3x10
5
 (Bhatia et al., 1997) 
CD34
+
, CD38
-
 0.01-0.4% 1 in 650 (Bhatia et al., 1997) 
CD34
+
, CD38
-
, CD90
+
, CD45RA
-
  0.003-0.013% 1 in 10 (Majeti et al., 2007) 
CD34
+
, CD38
-
, CD90
+
, CD45RA
-
, 
CD49f
+ 
, rhodamine exclusion 
N/A 1 in 5 (Notta et al., 2011) 
Table 1-2:  Human HSC phenotypes 
Table indicating phenotypic populations of human HSC studied and the approximate 
enrichment of cells with long term engraftment capacity in each phenotype. 
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Further refinements of this model of haemopoiesis are available from 
meticulous clonal tracking of HSC in transplantation experiments where different 
clones were noted to have differing contributions to re-establishing haemopoiesis. 
While some were dominant at early stages, others, while present, remained 
dormant or had a substantially delayed contribution.  Thus phenotypically similar 
HSC have different self-renewal behaviours in transplantation (Dick et al., 2001; 
Mazurier et al., 2004; McKenzie et al., 2006).  
1.1.3 Progenitor differentiation in mouse and man 
The massive amplification required to deliver a sufficient number of 
haemopoietic cells to maintain homeostasis occurs through a series of highly 
proliferative but increasingly lineage restricted progenitor intermediates.  
Notwithstanding differences in cell phenotype, similar hierarchies of progenitor 
cells have been described in humans and in mice. It is now generally accepted that 
MPP give rise to the oligo-potent progenitors the common lymphocyte progenitor 
(CLP) and the common myeloid progenitor (CMP), each with the limited capacity to 
form committed daughter lymphoid or myeloid progenitors respectively (Akashi et 
al., 2000; Galy et al., 1995; Kondo et al., 1997; Manz et al., 2002).  Following 
differentiation into CMP, either megakaryocyte/erythroid progenitors (MEP) or 
granulocytic/monocytic progenitors (GMP) are formed, each with the capacity to 
give rise to erythrocytes or megakaryocytes and granulocytes or monocytes 
respectively (Manz et al., 2002; Pronk et al., 2007).  Maturation, survival and 
proliferation are supported by combinations of exogenous GFs and regulated by 
expression of specific transcriptional programmes at critical junctures during 
development.  This strict differentiation pathway has been challenged in recent 
years by mounting evidence that, as HSC mature, they may develop a lymphoid or 
myeloid bias earlier than had previously thought (Challen et al., 2010) and that 
early myeloid and lymphoid development may not be completely disparate.  For 
example, in murine systems the existence of multipotent lymphoid-primed MPP 
(LMPP; LSKCD34+FLT3+) population with lymphoid and GMP potential but 
reduced capacity to give rise to MEP have been described.   Recent evidence 
suggests that a similar population may exist in humans (Adolfsson et al., 2005; 
Kawamoto et al., 2010; Goardon et al., 2011).  In other studies myeloid cells were 
derived from lymphoid specified cells and vice versa (Doulatov et al., 2010; 
Dykstra et al., 2007).   
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The advent of in vitro clonogenic assays and purified haemopoietic GFs 
allowed characterisation of the broad stages between the primitive multipotent 
populations and the mature effector cells that constitute the murine blood system 
(Ogawa, 1993).  These assays demonstrate the ultimate developmental fate of a 
progenitor cell held in single cell suspension in semi-solid medium under the 
influence of selected cytokine GFs.  In the context of myeloid differentiation, the 
colonies formed are comprised of a mixture of cell types dependent on the 
developmental potential of the originator cell and are either mixed (granulocytic, 
erythroid, megakaryocyte, monocytic; [CFU-GEMM], granulocytic, monocytic; 
[CFU-GM]) or single cell type colonies (granulocytic [CFU-G], monocytic [CFU-M] 
or erythroid burst [BFU-E] or erythroid  [CFU-E]) which broadly reflect the stages of 
myeloid differentiation described above.  
Thus, haemopoiesis can be regarded as a highly hierarchical process 
where multipotency and self-renewal are the properties of a small number of tightly 
regulated cells that gives rise to increasingly committed progenitors.  The 
enormous cell turnover is serviced by the massive amplification that occurs 
through this system.  The fate of the cells close to the top of the hierarchy is critical 
as even small imbalances would be expected to reverberate through the entire 
hierarchy (Figure 1-1).   
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Figure 1-1:  Simplified model of human haemopoiesis 
 Simplified model of human haemopoiesis modified from Doulatov et al and Majeti et al. 
(Doulatov et al., 2012; Majeti et al., 2007) 
1.2 Stem Cell Fate 
Potential fates of an HSC at any given moment are maintenance of 
quiescence, entering cell cycle, apoptosis or senescence (see Figure 1-2).  When 
an HSC divides, the outcome can either be commitment to differentiation or self-
renewal.   As discussed earlier in this chapter, self-renewal is a fundamental 
property of HSC.  In order to sustain a steady supply of haemopoietic cells 
throughout the life of an organism, the HSC pool must be maintained and in order 
to achieve this, HSC loss through apoptosis, senescence or commitment to 
differentiation must be balanced by replenishment of the HSC population.  This is 
achieved through self-renewal.   
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Figure 1-2:  Possible stem cell fates.  
HSCs are largely quiescent; entry into cell cycle requires a choice between self-renewal 
and differentiation.  Alternative fates include senescence or apoptosis. 
1.2.1 Haemopoietic stem cell kinetics 
It is clear that HSCs comprise a rare population in contrast to the massive 
turnover required to maintain haemopoiesis.  Curiously, despite the massive 
variation in size and longevity, evidence suggests that total HSC numbers are 
relatively conserved between mammals (Abkowitz et al., 2002).  In humans, it is 
estimated that there are between 11,200 and 125,000 HSC (Gordon et al., 2002).  
While in early developmental haemopoiesis, HSC are thought to be predominantly 
in active cell cycle, in steady state adult haemopoiesis the majority of HSC settle 
into a state of quiescence; that is in reversible G0 cell cycle arrest and enter cell 
cycle comparatively infrequently (Bowie et al., 2006; Cheshier et al., 1999). 
Furthermore, different HSC may have distinct cycling profiles.  It has been 
suggested that at least two differing populations exist with a rare particularly 
dormant population of HSC cycling very infrequently compared to a more active 
fraction (Cheshier et al., 1999).  One study demonstrated that 90% of murine Lin-, 
Sca-1+, Thy-1lo, c-Kit+ HSC had incorporated BrDU within 30 days (d) of exposure 
and 99% by 6 months, indicating that virtually all HSC had divided at least once in 
this time frame with about 25% in cycle at any given time (Cheshier et al., 1999).  
Another study suggested an average division rate of 1:2.5 weeks (Abkowitz et al., 
2000).  Wilson et al found evidence of dual populations of HSC (LSK SLAM CD34-) 
with a dormant population dividing on average every 145d and a more active 
population dividing every 38d (Wilson et al., 2008).   Studies in humans indicate 
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HSC division occurs much less frequently – approximately once every 40 weeks 
(Catlin et al., 2011; Shepherd et al., 2004). 
Preservation of the quiescent state and the maintenance of HSC activity are 
intrinsically linked; robust repopulation and self-renewal activity segregates to the 
quiescent fraction (Cheshier et al., 1999; Passegue et al., 2005).  Under normal 
conditions quiescence is required to maintain a pool of viable stem cells 
throughout the life of an organism.   When this is disrupted through manipulation of 
internal or external signalling, the HSC population can be exhausted (Cheng et al., 
2000b).   Thus HSC quiescence and proliferation are carefully controlled through a 
myriad of cell intrinsic and extrinsic (microenvironmental) mechanisms which feed 
into the cell cycle machinery. 
Key control of the cell cycle resides with cyclin proteins active at specific 
phases of the cycle and the opposing effects of cyclin dependent kinases (CDK) 
and cyclin dependent kinase inhibitors (CDKI).  The maintenance of HSC in G0 is 
through high levels of hypophosphorylated retinoblastoma (Rb) transcriptional 
repressor which prevents expression of E2F transcription factors and inhibits 
progression out of G0 (Wikenheiser-Brokamp, 2006).  Triple deletion of Rb, p130 
and p107 causes HSC expansion, loss of function and exhaustion (Viatour et al., 
2008).  Emergence from G0 to G1 relies predominantly on the D cyclins (CCND) 
and CDK4/6 interaction and this is positively regulated by the v-akt murine 
thymoma viral oncogene homolog 1 (AKT)/phosphatidylinositide 3-kinase (PI3K) 
pathway. Therefore PI3K/AKT signalling must be suppressed in HSC to maintain 
quiescence (Warr et al., 2011).  This occurs through phosphatase and tensin 
homolog (PTEN) signalling which restrains PI3K activity and allows forkhead box 
O (FOXO) family transcription factors to transit to the nucleus where they have a 
predominantly cell cycle inhibitory function through activating the expression of 
CDKI p21cip and p27kip and reducing intracellular reactive oxygen species (ROS) 
levels (Massague, 2004; Miyamoto et al., 2007; Tothova et al., 2007).  The main 
families of CDKI are cip/kip and Ink4.  Elements of both families are expressed in 
HSC; CDKI p21cip, p27kip and p57 kip2 inhibit G1 and S phase entry.  Deletion of 
p21cip1 and p57 kip2 in HSCs causes HSC expansion but loss of long term 
repopulation potency (Cheng et al., 2000a; Matsumoto et al., 2011).  Lastly of the 
Ink4 family of CDKI proteins which repress G0-G1 transition, p18
ink4c is strongly 
expressed in HSC and its abrogation appears to increase stem cell numbers and 
activity suggesting that it has a critical role in repressing HSC division (Bowie et 
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al., 2007; Passegue et al., 2005). These key intracellular mechanisms are not 
isolated but respond to extracellular signalling and microenvironmental conditions 
allowing the activity of HSC to adjust to prevailing external conditions.   
   There are various advantages to this organisational structure. Relative 
quiescence preserves the HSC pool over time. It also protects the HSCs from 
damage through genotoxic insults e.g. through exposure to radiation or chemicals 
and minimises the accumulation of mutations during DNA replication in the self-
renewing population.  While largely quiescent, the HSC pool could potentially be 
recruited rapidly if required for regeneration of the blood system under stress e.g. 
following chemotherapy or blood loss (Cheshier et al., 2007; Morrison et al., 
1997b).  The committed progeny are then swept into differentiation programmes 
becoming proliferating progenitors with massive amplification potential and 
ultimately giving rise to the terminal effector cells.   
1.2.2 Haemopoietic stem cell survival 
Clearly, in order to participate in haemopoiesis an HSC must survive. 
Apoptosis is critically important in embryogenesis and initial body patterning and in 
adult HSC it offers one possible mechanism to delete aged, abnormal or damaged 
clones prior to significant contribution to the haemopoietic cell pool.  The DNA 
damage repair apparatus plays an important role in HSC survival signalling.  HSC 
have robust DNA damage and cell cycle checkpoint controls and genomic damage 
has been shown to limit stem cell activity and induce activation of apoptosis and 
senescence pathways  (Alenzi et al., 2009; Oguro and Iwama, 2007).  Likewise, 
intracellular ROS levels influence HSC and high levels of ROS are associated with 
increased likelihood of oxidative damage to the cell and its genome.  High levels of 
ROS activate DNA damage pathways, e.g. through p53 (Vazquez et al., 2008).  
High levels of ROS e.g. in ataxia telangiectasia mutated knock-out (ATM-/-) mice 
have been associated with reduced stem cell activity and the activation of 
apoptosis and senescence pathways (Ito et al., 2004; Kazuhito et al., 2008; Oguro 
and Iwama, 2007).  
Cell intrinsic anti-apoptotic factors also have a role in HSC as evidenced by 
the effect of over-expression of B-cell CLL/lymphoma 2 (BCL2) in murine HSC 
which led to protection from apoptotic stimulae, expanded the HSC population and 
increased its self-renewal potential (Domen et al., 2000).   Likewise, expression of 
the anti-apoptotic protein  myeloid cell leukemia sequence 1, BCL2-related (MCL1) 
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is a critical requirement for human HSC survival and signalling through fms-related 
tyrosine kinase 3 (FLT3) is an important survival signal in primitive human HSC as 
it causes up regulation of MCL1 expression (Kikushige et al., 2008; Opferman et 
al., 2005).  
HSC require other survival signals from the environment to avert apoptotic 
cell death. They require a minimal cytokine exposure to survive. In one study, 
over-expression of BCL2 alone was not capable of preventing apoptosis in murine 
HSC populations in serum free culture; however the addition of KIT ligand 
prevented apoptosis but initiated differentiation (Domen and Weissman, 2000).  
This is the case for many “classical” cytokines e.g. thrombopoietin (TPO), 
interleukin (IL) 3, IL6 or granulocyte/monocyte colony stimulating factor (GMCSF), 
underlining the complexities in understanding and replicating the milieu that 
supports stem cell maintenance in vivo (Domen and Weissman, 2000; Oguro and 
Iwama, 2007). 
An alternative HSC fate is the occurrence of senescence.  In contrast to the 
reversible quiescent state, senescence represents an irreversible state of cell 
cycle arrest in metabolically active cells (Collado et al., 2007).  HSC can divide a 
finite number of times as evidenced by their limited re-transplantation capacity (5 in 
murine models) and replicative senescence may occur due to telomere attrition as 
a consequence of successive divisions and age-related chromatin alterations 
(Harrison and Astle, 1982 ; Zimmermann and Martens, 2008).  Senescence also 
occurs as a consequence of unrectified DNA damage.  Senescence is mediated 
through pRB, p53, p14ARF and p16INK4a and is negatively regulated by the action of 
polycomb protein complexes (Hidalgo et al., 2012; Sauvageau and Sauvageau, 
2010).  Recent evidence suggests that cellular response to ROS, which increase 
with HSC age is another important mediator of senescence in HSC (Brown et al., 
2013; Ito et al., 2006).  
1.2.3 Self-renewal  
Self-renewal is a fundamental property of HSC.  Self-renewal, very simply, 
is the ability of a multipotent stem cell to undergo division such that the progeny 
include at least one cell with a similar level of multipotency to the original stem cell.  
This can be accomplished by symmetrical or asymmetrical division. Symmetric 
division results in two identical daughter cells either committed to differentiation 
(not self-renewal) or each retaining the stem cell properties of the mother cell; in 
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either case the total number of stem cells in the population is increased or 
decreased accordingly.  Asymmetrical division results in the production of one 
daughter stem cell and one cell committed to differentiation thus asymmetric 
division has no net effect on the size of the stem cell pool. 
The possible mechanisms behind asymmetric division are interesting.  
Asymmetric stem cell division has been most extensively studied in stem cell 
populations in lower organisms e.g. Drosophila (Knoblich, 2008; Lin and Schagat, 
1997).  These studies have provided the basic model through which asymmetric 
division is thought to occur.  In Drosophila larvae, the neuroblast cells divide 
symmetrically along the epithelial surfaces that they are proximate to, and in these 
divisions the mitotic spindle is oriented along the apical / basal axis (Knoblich, 
2008).   When the mitotic axis rotates 90o and mitosis occurs perpendicular to the 
original plane, asymmetrical division occurs producing a differentiating neuronal 
progenitor cell (ganglion mother cell) and a copy of the original neuroblast 
(Knoblich, 2008; Lin and Schagat, 1997).  This asymmetry is caused by cell 
polarity proteins which accumulate on the side destined to become the remaining 
neuroblast and this causes accumulation of cell fate determinants (e.g. numb) at 
the side destined to differentiate (Knoblich, 2008).  These are examples of cell 
intrinsic autonomous asymmetric division.  An alternate model is suggested by the 
maturation of Drosophila germ cells.  Here germ-line stem cells exist in close 
proximity to supportive hub cells.  When the germ-line stem cell divides, it does so 
perpendicular to the face that is in contact with the hub cells.  The outermost 
daughter cell differentiates whereas the innermost cell still in contact with hub cell 
signalling retains self-renewal properties (Fuller and Spradling, 2007).  Thus 
asymmetric division occurs through the influence of external microenvironmental 
signalling.   Interestingly, disruption of the apparatus that regulates these 
processes leads to aberrant unrestrained self-renewal and accumulation of stem 
cells in a process with similarities to carcinogenesis (Knoblich, 2008).  
While evidence of stem cell expansion (hence symmetric division) can be 
obtained from examining the development of the early haemopoietic system and 
inferred through the capacity of small numbers of transplanted cells to reconstitute 
the haemopoietic system in the transplant recipient, specific evidence that 
asymmetric division occurs in HSC has been difficult to garner (Iscove and Nawa, 
1997; Osawa et al., 1996b).  Direct demonstration of asymmetric division has been 
difficult to achieve and whether asymmetric division occurs at all in HSC has been 
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a subject of debate.  Given that the haemopoietic system must both maintain 
homeostasis and respond to haemopoietic stress, it is attractive to speculate that 
stem cell expansion through symmetric division primarily has a role in the initial 
expansion of HSC in the development of the haemopoietic system and in response 
to haemopoietic stress e.g. post transplantation, whereas asymmetric division is 
primarily involved in homeostasis of the HSC pool under steady state conditions. 
However this need not necessarily be the case, homeostasis could also be 
achieved by balanced symmetric divisions or indeed through initial symmetric 
divisions with the progeny subsequently following different fates as a consequence 
of differing external factors. 
Several in vitro studies of human and murine HSC division at the single cell 
level have demonstrated that the resultant progeny can have different 
developmental fates, providing indirect evidence of asymmetric division 
(Brummendorf et al., 1998; Ema et al., 2000; Giebel et al., 2006; Leary et al., 1985; 
Punzel et al., 2002; Suda et al., 1984; Takano et al., 2004).   Direct evidence of 
this phenomenon was provided by recent work by Wu et al who reported the 
division behaviour of murine primitive haemopoietic cells in real time using a Notch 
driven GFP reporter system (Wu et al., 2007). They found evidence of both 
symmetric and asymmetric division in these cells, demonstrated that asymmetric 
division corresponded with segregation of the cell determinant Numb and the 
balance of self-renewal or asymmetric divisions compared with differentiation 
divisions could be influenced by external signalling depending on the type of 
supportive stroma used (Wu et al., 2007).  Likewise Beckman et al demonstrated 
that several other proteins e.g. CD53, CD63 and CD71 segregated in a subgroup 
(20%) of dividing human HSC (Beckmann et al., 2007) suggesting a potential role 
for these molecules in asymmetrical division. Additionally Ting et al recently 
demonstrated that expression of the cell polarity gene, adaptor-related protein 
complex 2, alpha subunit 2 (AP2A2), in murine HSC enhances stem cell function 
without markedly affecting the size of the HSC population (in contrast to several 
other candidates that enhanced self-renewal and caused expansion of the HSC 
pool) and therefore postulated that it is an effector of asymmetric self-renewal in 
HSC (Ting et al., 2012).  Furthermore they demonstrated its asymmetric 
localisation in HSC during division suggesting a possible mechanistic role in this 
type of self-renewal (Ting et al., 2012).   
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 Thus, there is evidence that asymmetric division can occur in mammalian 
HSC and that the underlying mechanisms may be similar to those described in 
Drosophila, i.e. influenced by cell fate determinants distributing unequally within an 
HSC prior to division.  Whether this in turn is driven by external factors e.g. stromal 
adhesion, is an interesting but as yet incompletely addressed question in HSC.  
Figure 1-3 summarises the mechanics of stem cell self renewal division.  
 
Figure 1-3:  The potential fates of a dividing stem cell.   
(A) represents symmetric division, where the dividing HSC (grey) gives rise to 2 daughter 
cells with the same level of multipotency and capacity to self-renew, resulting in 
expansion of the HSC pool.  (B) and (C) represent asymmetric divisions, where the dividing 
HSC gives rise to 1 daughter cell with the same level of multipotency and capacity to self-
renew and one daughter cell committed to differentiation (black).  In (B) asymmetric 
division has arisen due to asymmetric localisation of cell determinants within the parent 
HSC and in (C) asymmetric division has arisen as a consequence of proximity and 
interaction with a third “niche” cell.   
1.2.4 Control of stem cell fate 
The balance between self-renewal and differentiation must be highly 
regulated to maintain a stable HSC pool and allow expansion for regenerative 
purposes.   This is achieved by a combination of external signals originating from 
the microenvironmental supporting cells and stroma e.g. direct cell-cell contact and 
developmental signalling pathways such as wingless (Wnt), Notch and Hedgehog 
(Hh), prevailing chemical conditions such as oxygen tension, in addition to internal 
cues related to epigenetic modifications and chromatin priming.   
1.2.4.1 Cell intrinsic control of self-renewal  
Accumulating information regarding the processes contributing to self-
renewal within stem cells in general and HSC in particular has led to improvements 
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in our understanding of these mechanisms.  As would be expected, many are 
critical in embryonic development of haemopoiesis and have been highlighted in 
genetic manipulation studies or in studies designed to analyse the effect of 
leukaemic translocations.  While not comprehensive, the next section presents a 
few important examples. 
1.2.4.1.1 HOX genes 
The family of homeobox (HOX) genes are a highly conserved and closely 
related set of genes encoding transcription factors with a fundamental role in 
embryonic development and patterning (Spitz and Duboule, 2008).  They exist in 
four clusters (A,B, C, and D), each comprising several different individual members 
with additional members dispersed throughout the genome and have diverse, 
overlapping roles in the development and maintenance of homeostasis in different 
tissues including haemopoietic tissue (Abramovich and Humphries, 2005).    
Several members of this family are highly enriched in primitive HSC and are down 
regulated with maturity (Pineault et al., 2002; Sauvageau et al., 1994).  Functions 
have been defined in various murine and human knockout (KO) and over-
expression models (Argiropoulos and Humphries, 2007).  While several HOX 
members appear to have a role in haemopoietic development and differentiation, 
others have a role in the maintenance of HSC (Argiropoulos and Humphries, 
2007). HOXB4 has been shown to be critical in the maintenance and expansion of 
HSC (Antonchuk et al., 2001; Antonchuk et al., 2002; Sauvageau et al., 2004; 
Sauvageau et al., 1994).  Over expression of HOXB4 results in significant 
expansion of functional murine and human HSC without HSC exhaustion 
(Antonchuk et al., 2001; Antonchuk et al., 2002; Sauvageau et al., 1995).   It has 
been proposed that HOXB4 drives HSC towards symmetrical self-renewal division.  
Deletion of HOXB4 does not have as definitive a phenotype. Development of the 
haemopoietic system occurs in HOXB4 KO mice and the resultant HSC exhibit 
only mild impairment of function (Bijl et al., 2006; Brun et al., 2004).  Similarly, 
HOXA9 is also highly expressed at the HSC level (Sauvageau et al., 1994).  
Deletion of HOXA9 leads to a significant reduction in HSC function while over-
expression enhances function but additionally leads to leukaemogenesis (Bijl et 
al., 2006; Lawrence et al., 2005; Thorsteinsdottir et al., 2002).   
Expression of HOX genes is regulated by the trithorax group of proteins 
including mixed-lineage leukaemia (MLL) and the caudal type homeobox (CDX) 
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homeobox genes (Lengerke et al., 2007; Schuettengruber et al., 2007).  
Expression of MLL is critical for ordered haemopoiesis and deficiency leads to 
profound haemopoietic developmental abnormalities during embryogenesis and an 
inability to maintain the HSC population in adults (Ernst et al., 2004; Jude et al., 
2007; McMahon et al., 2007).  In contrast, while the CDX system is critical in 
development of the haemopoietic system and CDX4 is expressed preferentially in 
primitive haemopoietic precursors, conditional deletion of CDX4 in adult 
haemopoiesis does not lead to marked haemopoietic deficiency, suggesting either 
a lesser role or greater degree of redundancy in CDX function in adult 
haemopoiesis (Bansal et al., 2006; Koo et al., 2010).  
Downstream co-factors of HOX proteins include Meis homeobox 1 (MEIS1) 
and pre-B-cell leukaemia homeobox 1 (PBX1) which interact directly with the HOX 
proteins to modify their activity (Abramovich and Humphries, 2005; Shanmugam et 
al., 1999).  Expression of these entities maintains or increases self-renewal in 
murine haemopoietic cells (Ficara et al., 2008; Unnisa et al., 2012; Wang et al., 
2006). Furthermore, deletion studies of these co-factors resulted in profound 
abnormalities in the developing haemopoietic system and the self-renewal 
capacity of early primitive haemopoietic cells (Abramovich and Humphries, 2005), 
suggesting a non-redundant role in modulating the output of the complex HOX 
transcriptional system. 
1.2.4.1.2 Polycomb genes and epigenetic regulation 
Epigenetic control of gene transcription, i.e. the modification of the tertiary 
structure of DNA through biochemical modification of the chromatin structure, e.g. 
acetylation, ubiquitination and methylation of histone proteins, allows silencing or 
activation of transcription of large numbers of genes simultaneously (Cedar and 
Bergman, 2011).  This epigenetic control has been recognised to be critically 
important in developmental processes and in the control of stem cell fate (Cedar 
and Bergman, 2011).  Polycomb protein complexes are important epigenetic 
regulators and are large multi-protein complexes that function as transcriptional 
repressors and serve to establish patterns of gene repression (Denell and 
Frederick, 1983).  In Drosophila, one of their roles is regulating embryonic 
patterning through activation and repression of hox transcription factors along the 
length of the embryo, thus specifying body shape (Lewis, 1978).  In mammals 
there are two main polycomb complexes, PRC1 and PRC2 each with differing 
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functions (Lund and van Lohuizen, 2004; Majewski et al., 2010; Sauvageau and 
Sauvageau, 2010).  The PRC1 complex is heterogeneous and comprises 
combinations including the following - chromobox homolog proteins (CBX) 2/4/8, 
BMI1 polycomb ring finger oncogene (BMI1), polycomb group ring finger 2 
(PGRF2/MEL18), polyhomeotic homolog (PHC) 1/2/3 and ring finger proteins 
(RING) 1A/1B; depending on the cellular context (Morey and Helin, 2010).  The 
PRC2 complex comprises enhancer of zeste homolog (EZH) 1/2, embryonic 
ectoderm development protein (EED), suppressor of zeste 12 homolog (SUZ12) 
and phd finger protein (PHF) 1 (Morey and Helin, 2010).  The silencing effect of the 
PRC2 complex is due to EZH2 mediated tri-methylation of histones (H3K27) 
(Morey and Helin, 2010).  This also allows recruitment of PRC1 which can have 
additional transcriptional repression activities.  PRC complexes are known to play 
an important role in the maintenance of embryonic stem (ES) cells (Lee et al., 
2006), but evidence is also accumulating for an important role in the maintenance 
of self-renewal in various somatic stem cells, including HSC, where they are 
largely involved in suppression of genetic programmes that would result in 
proliferation, apoptosis or senescence and differentiation. (Iwama et al., 2004; 
Lessard and Sauvageau, 2003; Morey and Helin, 2010; Park et al., 2003; 
Radulovic et al., 2013; Rizo et al., 2009).  In the context of HSC, PRC1 
components have a repressive effect on the expression of the Ink4a locus, 
mitigating expression of the CDKIs p16Ink4a and p19Arf (Park et al., 2003).   It has 
been postulated that this activity allows HSC to enter cell cycle when required, as 
unrestrained expression of these CDKI resulted in cell cycle arrest, senescence or 
apoptosis (Park et al., 2003).   BMI1 is enriched in HSC compared with progenitor 
cells (Lessard et al., 1998).  It is clear that expression of the PRC1 component 
BMI1 is required for maintenance of HSC function (Park et al., 2003).  HSC from 
BMI1 deficient mice have severely impaired self-renewal activity, as do human 
CD34+ cells following repression of BMI1 (Rizo et al., 2009).  Additionally, over 
expression of BMI1 is associated with increased symmetrical division and self-
renewal potential (Iwama et al., 2004; Lessard and Sauvageau, 2003; Rizo et al., 
2009).  Another component of PRC1, PGRF2, appears to be expressed at higher 
levels in progenitors and is associated with differentiation in this context (Kajiume 
et al., 2004).  Additionally PGRF2 deletion has been shown to accentuate self-
renewal capacity in HSC through promotion of HOXB4 expression (Kajiume et al., 
2004).  Components of the PRC2 complex also have demonstrable roles in 
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haemopoiesis.   Over-expression of the PRC2 component, EZH2 confers 
enhanced long term repopulating capacity in HSC, preventing their exhaustion in 
serial transplantation (Kamminga et al., 2006).  On the other hand, deletion studies 
did not confirm a non-redundant role in this process as EZH2-/- mice have normal 
HSC activity (O'Carroll et al., 2001). It has recently been proposed that EZH1 may 
compensate for EZH2 loss in EZH2 deficient adult HSC (Mochizuki-Kashio et al., 
2011).   A model for polycomb function in HSC has thus been proposed suggesting 
that PRC1 and PRC2 may have differing and opposing roles in haemopoiesis and 
activate discrete transcriptional programmes (Majewski et al., 2010).  
1.2.5 External regulation of stem cell fate 
In the preceding section we discussed selected cell intrinsic processes that 
serve to control self-renewal activity.  However if HSC self-renewal is responsive to 
haemopoietic stress then these processes must be influenced by external factors.  
It has long been clear that this is the case.  Self-renewal is intrinsically linked to the 
environment and to extracellular signalling, particularly to signalling along 
embryonic developmental pathways.  In this section I provide an overview of key 
elements of these processes and the environment in which they occur. 
1.2.5.1 The stem cell niche 
The BM is a specialised environment with a profound influence on 
haemopoietic development.  It is a protected, profoundly vascular and intensely 
cellular space.  Cortical bone forms the hard mechanical shell of the BM, the 
interior comprises a meshwork of bony trabeculae, cellular spaces, fat and stromal 
tissue.  The inner surfaces of the bone cavity and the bony trabeculae within are 
lined with endosteal cells and tissue including osteoblasts.  The substance of the 
BM is highly vascular, being penetrated by a web of blood vessels and vascular 
sinusoids providing nutrients, draining venous blood and allowing passage of 
myelinated and unmyelinated nerves.   
It has been clear for many years that the BM structure is integral to the 
haemopoietic process.  The environment is not homogenous, and the distribution 
of the structures within the BM create specialised microenvironments, where there 
is local enrichment for specific cell types that have critical roles in the support of 
haemopoiesis (Calvi et al., 2003; Kiel et al., 2007; Zhang et al., 2003).    
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Trentin and colleagues first demonstrated that the differentiation fate of 
haemopoietic progenitors could be influenced by different tissue environments 
(Trentin, 1971).  The concept of specialised areas within the BM in which HSC 
reside was first formalised by Schofield in 1978 as a potential explanation for the 
variability found in the CFU–S population (Schofield, 1978).  He proposed that 
CFU-S cells only exhibited HSC behaviour when resident in a stem cell niche; a 
specific microenvironment that provided the necessary interactions that would 
prevent the HSC from differentiating but allow division when dislodged from this 
environment.  The concept of a stem cell niche was subsequently supported by 
investigations in other model systems, e.g. the Drosophila ovary and testes where 
specialised local environments or cell interactions were required to allow stem cell 
maintenance (Xie and Spradling, 2000).  The modern interpretation of a stem cell 
niche is of a geographical and functional nexus that integrates signalling that 
influences HSC behaviour.  Some of the most important factors are shown in Table 
1-3. 
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Entity  Effect on HSC population References 
Oxygen tension Hypoxia maintains HSC  quiescence 
(Jing et al., 2012) 
(Suda et al., 2011) 
Ca
2+
 Loss of Ca
2+
 receptor reduces BM HSC content (Adams et al., 2006) 
N-cadherin  
Expressed on both HSCs and osteoblasts, 
postulated to be required for direct adhesion and 
signalling 
(Zhang et al., 2003) 
(Calvi et al., 2003) 
PTH 
Endocrine source, increases notch signalling 
through jagged, expands HSC population 
(Calvi et al., 2003) 
BMP / BMPR1A 
KD of BMPR1A in osteoblasts led to increased 
numbers of osteoblasts and HSC, BMP ligands 
have dose-dependent effects on HSC. 
(Zhang et al., 2003) 
(Bhatia et al., 1999) 
 
TGF 
Maintains HSC quiescence, produced by BM 
Schwann cells 
(Yamazaki et al., 2011) 
Ang1 / Tie2 
 Maintains quiescence, upregulates N-cadherin 
on HSC 
(Arai et al., 2004) 
CXCR4 / 
CXCL12  
Critical in adhesion / migration, produced by 
variety of BM cells e.g. osteoblasts, CXCR12 
abundant reticular (CAR) cells, Nestin
+
 
mesenchymal stem cells (MSC) .  Abrogation 
leads to disordered migration and reduced HSC 
numbers 
(Sugiyama et al., 2006) 
(Semerad et al., 2005) 
TPO 
Paracrine and endocrine delivery, deficiency 
leads to contraction of HSC population  
(Yoshihara et al., 2007) 
(Qian et al., 2007) 
Osteopontin 
Produced by osteoblasts and HSC, maintains HSC 
quiescence 
(Nilsson et al., 2005) 
Hh variable effects 
(Bhardwaj et al., 2001) 
(Trowbridge et al., 2006) 
(Gao et al., 2009) 
(Hofmann et al., 2009) 
Jagged  1 
(JAG1) 
 / Notch 
variable effects 
(Calvi et al., 2003) 
(Duncan et al., 2005) 
(Mancini et al., 2005) 
(Stier et al., 2002) 
Wnt variable effects 
(Nemeth and Bodine, 2007) 
(Oh, 2010) 
Table 1-3:  List of selected niche factors and their influence on stem cell fate.   
 
The nature of the stem cell niche and its constituent parts has been subject 
to intense investigation over the past 30 years.  Broadly speaking, two anatomical 
sites have been proposed; the endosteal area in close proximity to osteoblasts – 
termed the ‘osteoblastic niche’ and the perivascular areas – termed the 
‘perivascular niche’ (Calvi et al., 2003; Kiel et al., 2007; Zhang et al., 2003).  The 
endosteal areas are found along the surface of trabecular and cancellous bone 
and are rich in osteoblasts and osteoclasts, Ca2+ and may be relatively hypoxic.  
The perivascular areas are found surrounding the vasculature and sinusoids that 
penetrate the BM and are in close proximity to vascular endothelial cells, MSC and 
perivascular cells.     
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Evidence for an endosteal niche extends from studies demonstrating 
enrichment of primitive quiescent haemopoietic cells in endosteal areas (Nilsson et 
al., 2001).  Calvi et al and Zhang et al both proposed the osteoblasts as the key 
cell supporting haemopoiesis (Calvi et al., 2003; Zhang et al., 2003).  Both groups 
induced excess osteoblast production in murine models and were able to 
demonstrate that this excess was accompanied by an excess of functional HSC in 
the BM through direct interaction with  N-cadherin  (Zhang et al., 2003) and indirect 
interaction through JAG1 (Calvi et al., 2003), a Notch specific ligand. This led them 
to postulate an endosteal niche where HSC were maintained in a state of relative 
quiescence, in physical contact with osteoblasts via N-cadherin expression (Zhang 
et al., 2003).  Certainly the osteoblast has several features that make it an 
attractive candidate niche cell.   It has been demonstrated that HSC localise to the 
endosteal areas in close proximity with osteoblasts.  Osteoblasts express many of 
the signalling molecules that have subsequently been determined to be important 
in influencing HSC fate, e.g. JAG1 (Calvi et al., 2003), N-cadherin; (Zhang et al., 
2003), ANG1 (Arai et al., 2004), TPO (Yoshihara et al., 2007) and CXCL12 
(Semerad et al., 2005) and are capable of supporting haemopoiesis in in vitro 
culture (Taichman and Emerson, 1994).  
On the other hand, the studies suggesting endosteal localisation have been 
criticised as 5’-bromo-2-deoxyuridine (BrDU) or carboxyfluorescein succinimidyl 
ester (CFSE) labelling (used to identify quiescent cells) may be insufficiently 
sensitive or specific (Kiel et al., 2007).  Although osteoblasts produce factors that 
are critical in defining stem cell fate, they are not the exclusive source of these 
agents and the role of close adhesion between HSC and osteoblasts has recently 
been questioned (Kiel and Morrison, 2008).  Furthermore, reduction in osteoblast 
number or function has not necessarily resulted in parallel reduction in HSC 
quantity (Visnjic et al., 2004; Wilson and Trumpp, 2006).  However, osteoblasts 
themselves are part of a hierarchically organised structure of maturing cells 
involved in bone metabolism with osteoblastic progenitors giving rise to 
osteoblasts and ultimately osteocytes embedded within trabecular bone. The 
capacity to support haemopoiesis may be limited to specific subgroups within this 
lineage (Raaijmakers et al., 2010).  This concept is supported by recent work by 
Raajmakers et al who demonstrated that deletion of dicer-1, a critical component 
of miRNA and RNA processing, in osteoblastic precursors but not mature 
osteoblasts, resulted in disruption of normal haemopoiesis that was associated 
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with the microenvironment and not the haemopoietic cell lineages (Raaijmakers et 
al., 2010). 
Evidence for a perivascular niche extends from studies demonstrating that 
the majority of the most primitive murine HSC (SLAM) are to be located 
surrounding the vascular sinusoids of the BM (Kiel et al., 2007).  These 
perivascular areas contain multiple different cells that contribute to HSC fate. The 
proposal of a perivascular niche for HSC is perhaps not surprising as endothelial 
cells and the haemopoietic system are closely related and develop in parallel in 
embryogenesis (Cumano and Godin, 2007; Huber et al., 2004; Medvinsky and 
Dzierzak, 1996).  One question that has yet to be resolved, however, is whether 
the seeming enrichment of primitive HSC in the perivascular areas is due to stem 
cell trafficking through the vasculature rather than representing a stable population 
(Kiel et al., 2005; Wright et al., 2001). 
Recent evidence has suggested that the majority of HSC are closely 
associated with mesenchymal cells such as Nestin+ MSC or CXCR12 abundant 
reticular (CAR) cells (Mendez-Ferrer et al., 2010; Omatsu et al., 2010; Sugiyama 
et al., 2006).  Both cell types contribute to the osteoprogenitor lineage and express 
HSC maintenance-related molecules.  These cells are found in both perivascular 
and endosteal regions and represent a potential rationalisation of the above 
distinct niche model.  Furthermore autonomic nerve, particularly sympathetic 
nerve, signalling input has a role in HSC maintenance (Katayama et al., 2006).  
Nestin+ MSCs interact with sympathetic nerves and translate signals to HSC 
allowing HSC egress and trafficking (Mendez-Ferrer et al., 2008; Mendez-Ferrer et 
al., 2010).  
1.2.6 External signalling through developmental pathways 
Another level of external regulation that has drawn increasing interest are 
the embryonic regulators of stem cell fate that are critical to the developing 
embryo, through establishment of initial patterning and organogenesis.  These 
ligand dependent signalling pathways e.g. Notch, Wnt and Hh are fundamentally 
required for normal embryogenesis and are critical to the developing haemopoietic 
system.  Evidence has accumulated since their discovery that they may also play a 
significant role in the adult organism, particularly during stress or regeneration, as 
signalling through these pathways can stimulate expansion of the stem cell 
population.  It is also increasingly appreciated that they have a role in 
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oncogenesis.  Here the Hh signalling pathway and its role in the haemopoietic 
system is reviewed in detail followed by a brief discussion of Wnt and Notch 
signalling. 
1.2.6.1 The Hh pathway and normal haemopoiesis – an example of 
stem cell fate regulation through developmental signalling 
The Hh signalling pathway was initially discovered by Nusslein–Wolhard and 
Weischaus in 1980 through a genetic screen for factors influencing Drosophila 
embryonic patterning (Nusslein-Volhard and Wieschaus, 1980).  Characterisation 
of the hh gene revealed that it encodes a secreted protein expressed in a repeated 
pattern across the Drosophila embryo.  Absence of this hh protein prevented 
normal segmentation and gave the Drosophila embryo a characteristic “prickly” 
appearance reminiscent of a curled hedgehog.  As studies progressed, it became 
clear that Hh signalling is a conserved process between species and is critically 
important in vertebrate embryogenesis where it is required for development of 
internal organ, midline and neurological structures, limb patterning and 
development of the haemopoietic system.  It has been well established that 
absence of functional Hh signalling causes dysmorphisms such as 
holoprosencephaly (cyclopia), limb abnormalities and improper biological system 
and organ development (Chiang et al., 1996; Roessler et al., 1996). 
Hedgehog signalling exerts its biological effect through controlling the 
behaviour of stem cells within the target tissue.  Hedgehog concentration gradients 
are generated and, in concert with or in opposition to other similar signalling 
pathways, exert a topological and time-dependent influence on the apoptosis, 
proliferation and differentiation programmes of local stem and progenitor cells.  
Thus populations of tissue-specific stem and progenitor cells can be driven to 
expand or contract and be guided towards a particular specialised function (Blank 
et al., 2008; Cridland et al., 2009; Dyer et al., 2001; Roessler et al., 1996). 
Following its critical role in embryogenesis, Hh signalling remains active in a 
more limited extent throughout the life of the organism, where it is plays a key role 
in the maintenance and expansion of somatic stem cell populations through 
modulation of self-renewal activity. It is important in response to injury, tissue 
stress, healing and regeneration (Beachy et al., 2004; Ingham and Placzek, 2006; 
Ruiz i Altaba et al., 2007; Trowbridge et al., 2006).  
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1.2.6.2 The mechanism of Hh signalling  
Hedgehog is a ligand-dependent signalling pathway. Secretory cells 
produce three possible isoforms of the Hh ligand; Sonic (SHH), Desert (DHH) or 
Indian (IHH). These are initially 45kDa precursor proteins which are cleaved and 
subjected to cholesterol and palmitoyl modification to produce an active N-terminal 
fragment of 19kDa (Beachy et al., 1997; Lee et al., 1994).  These proteins are 
similar in structure and may be partially redundant in function; however, they also 
have tissue-specific roles in the developing organism and in the adult stem cell 
microenvironment (Pathi et al., 2001).  Sonic HH influences development of many 
tissues in the embryo, IHH is produced in haemopoietic tissue and bone and has a 
role in early haematological development and DHH, is expressed in the testes and 
nervous system where deficiency leads to male sterility and peripheral nerve 
defects (Bitgood et al., 1996; Chiang et al., 1996; Dyer et al., 2001).   
Hedgehog signalling requires strict spatial limitation and tight modulation.  
Numerous proteins are involved in receiving and transmitting the Hh signal to the 
nucleus; positive feedback loops accentuate and maintain the signal and negative 
feedback loops switch off the pathway following signal activation. The central 
components of the pathway comprise a pair of 12-span transmembrane receptor 
proteins – patched (PTCH) 1 and 2; a 7-span transmembrane protein – smoothened 
(SMO) and the family of glioma (GLI) zinc finger transcription factors; GLI1, GLI2, 
and GLI3 (see Figure 1-4).  Unusually, the Hh receptor PTCH is a negative 
regulator of pathway activity whereas the immediately downstream element SMO 
is the major positive regulator.  In the resting state, PTCH represses SMO activity, 
but following Hh binding this repression is removed (Robbins and Hebrok, 2007).  
The mechanism of signal transduction between PTCH and SMO in vertebrates is 
not known but the two receptors do not appear to interact directly. Patched 
proteins bear a striking homology to a trans-membrane lipid transporter protein 
(Neimann Pick C1 protein [NPC1]) and SMO appears to belong to the G-protein 
coupled receptor family (Ayers and Therond, 2010; Ioannou, 2000).  Current 
evidence suggests that PTCH influences SMO activity through oxysterol 
trafficking. Oxysterols activate Hh signalling through SMO, whereas secretion of 
pro-vitamin D3 is inhibitory (Bijlsma et al., 2006; Corcoran and Scott, 2006).  
Following receptor ligand interaction, PTCH is internalised and SMO accumulates 
on the plasma membrane and interacts with the GLI family of transcription factors 
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(Denef et al., 2000).  While GLI3 is predominantly a transcriptional repressor, GLI2 
exists in both a full length active form and a truncated repressor form (Hui and 
Angers, 2011; Sasaki et al., 1999). Activated SMO alters the balance between 
these forms (Hui and Angers, 2011; Ruiz i Altaba et al., 2007).  In many vertebrate 
cell types this signalling occurs within the primary cilium (Corbit, 2005; Rohatgi et 
al., 2007). SMO and GLI proteins accumulate there through interaction with the 
intra-flagellar transport (IFT) proteins facilitating activation and onward 
transduction of the Hh signal (Corbit, 2005; Hui and Angers, 2011; Kim et al., 
2009). However this is dispensable in haemopoietic cells as they appear not to 
possess primary cilia although, interestingly, they do express IFT proteins (Finetti 
et al., 2009).   
When Hh signalling is “off” GLI2 and GLI3 are retained in the cytoplasm by 
a protein complex including the inhibitory molecule suppressor of fused (SUFU) 
and are phosphorylated by non-specific kinase activity mediated by glycogen 
synthase kinase 3 (GSK3), casein kinase (CSI) and protein kinase A (PKA) 
(Humke et al., 2010; Kise et al., 2009; Pan et al., 2009; Tempe et al., 2006).  
Following phosphorylation, GLI2 and GLI3 undergo C-terminal ubiquitination and 
partial proteasome-mediated proteolysis to the truncated inhibitory form prior to 
nuclear translocation, resulting in repression of the pathway (Tempe et al., 2006).   
In the presence of Hh ligand, GLI2 and GLI3 phosphorylation is prevented and full 
length active forms of the transcription factors translocate to the nucleus (Pan et 
al., 2009; Sasaki et al., 1999). This activates the transcription of downstream 
targets that include both positive (GLI1) and negative (PTCH1/2) regulatory 
elements which drive the Hh transcription programme and down regulate ongoing 
signalling, respectively (Hui and Angers, 2011).  Figure 1-4 summarises the 
mechanism of Hh signalling. 
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Figure 1-4:  The mechanism of Hh signalling 
In the resting state (a), PTCH 1/2 is expressed on the plasma membrane and acts to 
repress SMO activity by preventing its expression and localisation to the primary cilium. 
GLI2/3 transcription factors are within a complex including SUFU - an inhibitor of Hh 
signalling.  This conformation promotes nonspecific phosphorylation of the C terminus by 
GSK3, CSI and PKA resulting in E3 ubiquitin ligase activity and subsequent partial 
proteasomal proteolysis to the C terminal truncated repressor form.  Following 
translocation to the nucleus the repressive forms of GLI2 (GLI2-R) and particularly GLI3 
(GLI-3R) potently inhibit the Hh transcriptional programme.  Interaction of Hh ligand with 
PTCH promotes PTCH internalisation and degradation, and releases the repression of 
SMO causing its accumulation within the primary cilium.  Active SMO in the primary 
cilium stabilises the full length forms of GLI2 (GLI2-A) and GLI3 (GLI3-A) and accentuates 
the effect of other positive regulators of Hh signalling, including serine threonine kinase 
36 (STK36) and kinesin family member 7 (KIF7) which may be involved in translocation of 
GLI into the primary cilium.  Following translocation to the nucleus GLI2-A potently 
activates transcription of downstream Hh targets including GLI1 and PTCH1, and 
influences chromatin conformation, apoptosis, cell cycle activity and differentiation.  
Figure reproduced from Irvine and Copland (Irvine and Copland, 2012).
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More broadly, Hh signalling manifests change through regulation of target 
gene expression.  Several targets of Hh signalling have been identified in various 
tissues and can be broadly categorised into those regulating cell cycle and 
proliferation, survival, self-renewal and cell fate determination, adhesion and 
epithelial-to-mesenchymal transition (EMT) – see Table 1-4. 
Functional role Gene Reference 
Proliferation N-MYC 
CCND1 & 2 
CCNB1 
FOXM1 
p53  
IGFBP6 
CDC25B 
(Kenney et al., 2003) 
(Yoon et al., 2002), (Trowbridge et al., 2006) 
(Barnes et al., 2001) 
(Teh et al., 2002) 
(Yoon et al., 2009) 
(Yoon et al., 2002) 
(Katoh and Katoh, 2009) 
Stem cell 
associated 
BMI1 
JAG2 
BMP4 
SOX2  
NANOG 
Osteopontin 
Nkx2.2 
(Liu et al., 2006) 
(Katoh and Katoh, 2009) 
(Bhardwaj et al., 2001) 
(Takanaga et al., 2009) 
(Po et al., 2010) 
(Yoon et al., 2002) 
(Vokes et al., 2007) 
Adhesion CXCR4 (Yoon et al., 2009) 
Survival  BCL2 (Regl et al., 2004) 
EMT FOXC2 
TWIST2 
SIP1 
ZEB1/2 
(Katoh and Katoh, 2009) 
(Isohata et al., 2009) 
(Isohata et al., 2009) 
(Katoh and Katoh, 2009) 
Table 1-4:  Selected additional targets of Hh signalling and GLI activation from disparate 
gene expression studies 
 
It should be noted that the majority of these studies were performed in 
neurological tissue and response to Hh signalling is likely to vary in a tissue 
dependent manner. However these data do provide insight into the potential 
mechanisms through which Hh signalling might regulate stem cell fate in 
haemopoietic tissue.   
Lastly, there is recent provocative work that identifies mechanisms of non-
canonical signalling in Hh-responsive cells.   PTCH may interact directly with cell 
proliferation and apoptosis machinery independently of SMO and, in the absence 
of Hh signalling, can act to restrain proliferation and promote apoptosis through 
CCNB1 and caspase activity, respectively (Robbins et al., 2012).  In a second 
model of non-canonical Hh signalling, SMO may act via Rho GTPases, 
independently of GLI transcription factors, to regulate the cytoskeleton and 
intracellular Ca2+ concentration in some tissues (Robbins et al., 2012).  
51 
 
 
1.2.6.3 Hedgehog signalling and haemopoiesis  
Hedgehog signalling has multiple complex roles in both adult and 
embryonic haemopoiesis depending on the stage of development and whether the 
haemopoietic system is under regenerative pressure.  Indian HH expressed by 
endodermal cells specifies haemopoietic differentiation at the earliest stages of 
primitive haemopoiesis and has roles in haemopoietic and vascular development 
(Cridland et al., 2009; Dyer et al., 2001).  However 50% of Ihh null mice survive, 
suggesting that Ihh functions are partially redundant (St-Jacques et al., 1999).  
Definitive haemopoiesis is the second wave of haemopoietic activity, characterised 
by the development of HSC.  This process is initiated in the aorta-gonad-
mesonephros region but relocates to the foetal liver and subsequently the BM 
(Cumano and Godin, 2007).   Studies in zebrafish and mice indicate that Hh 
signalling has a role in establishing definitive haemopoiesis (Cridland et al., 2009; 
Gering and Patient, 2005; Peeters et al., 2009).  Furthermore, Hh ligand has been 
shown to expand definitive haemopoietic progenitors in mice and humans 
(Bhardwaj et al., 2001; Cridland et al., 2009; Kobune, 2004).  
Early studies of adult haemopoiesis suggested that Hh signalling caused 
expansion and increased functional activity of the HSC compartment (Bhardwaj et 
al., 2001; Trowbridge et al., 2006).  More recently, there has been controversy over 
the role, if any, that Hh signalling plays in adult haemopoiesis due to the differing 
results of murine studies dissecting the role of Hh mediators in adult 
haemopoiesis.   
Dierks et al and Trowbridge et al both demonstrated that Ptch1 
heterozygosity (hence Hh activation) was associated with increased stem cell 
number, faster haematologic recovery post challenge with 5-fluorouracil and 
increased transplantability in murine models (Dierks et al., 2008; Trowbridge et al., 
2006).  Additionally, Trowbridge and co-workers found that LT-HSCs were 
ultimately exhausted through constant Hh activation (Trowbridge et al., 2006). In 
contrast to this; Dierks et al found no diminution of LT-HSC function (Dierks et al., 
2008). Siggins et al examined adult mice subject to conditional deletion of Ptch1 in 
various tissues including primitive haemopoietic cells, demonstrating that 
conditional deletion of Ptch1 increased circulating primitive haemopoietic cells but 
did not result in enhanced engraftment in transplantation experiments or 
exhaustion of long term re-populating capacity (Siggins et al., 2009).  Furthermore, 
their experiments suggested that Ptch1 deletion only altered proliferation and 
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mobilisation of HSC when occurring within the supporting BM stroma as, when 
specific deletion limited to HSC was performed, these differences disappeared.  
This suggests that the effects are through signalling extrinsic to the HSC and not a 
direct affect of Hh on the HSC themselves (Siggins et al., 2009).   
These discrepancies may be partly explained by the alternative 
experimental approaches employed.  Dierks et al used foetal liver HSC from 
Ptch1+/- embryos, whereas Trowbridge et al studied adult Ptch1+/- HSC (Dierks et 
al., 2008; Trowbridge et al., 2006).   In these studies, Ptch1 deletion was present 
during embryogenesis.  In the germ-line mutant, Ptch1 heterozygosity would be a 
feature of all cells and tissues rather than being confined to the haemopoietic 
system. In contrast, Siggins et al employed conditional and targeted approaches 
utilising the Mx-Cre system.  They induced deletion of Ptch1 in haemopoietic 
tissue of mature mice and also used the stem cell leukaemia (SCL) enhancer to 
target Ptch1 deletion to adult murine HSC (Siggins et al., 2009).  
Because absence of Smo is lethal, analysis of Smo null mutants is not 
possible.  Four groups have investigated the effect of Smo deletion, either through 
recovery of Smo null HSC from foetal liver or through two different conditional 
deletion methodologies (Dierks et al., 2008; Gao et al., 2009; Hofmann et al., 
2009; Zhao et al., 2009).    Dierks et al found no significant difference in the 
behaviour of foetal HSC recovered from Smo null mice compared to normal mice 
(Dierks et al., 2008).  Gao et al and Hoffman et al both used the Mx1-Cre system 
to create a murine model where Smo deletion could be induced.  Neither found 
any significant difference in the short or long term measures of haemopoiesis 
following deletion of Smo and therefore abrogation of Hh signalling (Gao et al., 
2009; Hofmann et al., 2009).  In contrast, Zhao et al demonstrated profound 
reduction in stem cell activity as indicated by secondary transplant capacity 
following Vav-driven Cre-Lox mediated conditional Smo deletion (Zhao et al., 
2009).  
While on the surface these conflicts appear irreconcilable, the alternative 
experimental strategies go some way to explaining these differences. The Mx1-Cre 
system allows deletion in adulthood and predominantly affects haemopoietic and 
liver cells whereas the Vav-Cre-Lox system is active throughout embryogenesis 
and is less selective, affecting both haemopoietic and endothelial tissue, raising 
the possibility that Hh signalling was disrupted in a wider range of tissues and at 
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an earlier time point (Dierks et al., 2008; Gao et al., 2009; Hofmann et al., 2009; 
Zhao et al., 2009).   
Genetic studies have also been performed on the main downstream 
mediators of Hh signalling.  Merchant et al characterised the effect of Gli1 deletion 
on haemopoiesis in a Gli1 null murine model (Merchant et al., 2010).   No 
abnormalities in gross haemopoiesis were found, however there was a reduction in 
proliferation within the stem and myeloid progenitor compartments as well as 
reduction in myeloid differentiation and delayed recovery following 5-fluorouracil 
exposure. 
Hedgehog acts in concert with other morphogenic signals to influence 
development of T and B lymphocytes.   Thymic stroma and T cells both express 
Hh pathway mediators (Andaloussi et al., 2006; Outram et al., 2009).  Early studies 
suggested that Hh signalling negatively regulated T cell development (Outram et 
al., 2000), however subsequent work indicates that Hh signalling has a positive 
regulatory role in early T cell development (Andaloussi et al., 2006; Outram et al., 
2009; Shah et al., 2004; Siggins et al., 2009; Uhmann et al., 2007; Uhmann et al., 
2011). Both IHH and SHH affect T cell proliferation and maturation (Outram et al., 
2009; Shah et al., 2004).  Conditional deletion of Smo at different levels of T cell 
development, performed by Andaloussi et al, suggested that abrogation of Smo 
expression mainly affects primitive thymocytes, leading to thymic atrophy and 
profound defects in early T cell survival, proliferation and maturation (El 
Andaloussi et al., 2006). Uhmann et al studied a Ptch1 conditional deletion murine 
model and demonstrated that KO of Ptch1 led to profound loss of mature T and B 
cells (Uhmann et al., 2007; Uhmann et al., 2011).  Siggins et al demonstrated that 
Ptch1 deletion led to significant apoptosis in pre-B cells, blocked T cell 
specification in BM T cells and caused apoptosis of CD4+CD8+ T cells due to 
deletion of Ptch1 in the supporting microenvironment (Siggins et al., 2009; 
Uhmann et al., 2011). 
Overall it appears that Hh signalling has effects on the haemopoietic system 
dependent on developmental stage and cell lineage. These effects are due to a 
complex interplay between the cells and their microenvironment at certain 
developmental stages rather than being purely haemopoietic cell intrinsic 
mechanisms. Thus, while Hh signalling may still have a role in normal adult 
haemopoiesis, from the data above, it is likely to be dispensable, at least in steady 
state conditions. 
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1.2.6.4 Other key developmental pathways 
Other key ligand dependent embryonic development pathways with ongoing 
roles in adult haemopoiesis include Notch and Wnt signalling.   Like Hh signalling 
their existence and developmental importance were also established in lower 
species particularly Drosophila (Mohr, 1919; Rijsewijk et al., 1987). 
1.2.6.4.1 Notch signalling 
The importance of this pathway was established in Drosophila.  Notch 
signalling has been shown to act through lateral inhibition.  Notch signalling in one 
cell influences the fate of an adjacent similar cell e.g. maintaining stem cell-like 
activity in primitive progenitor cells or, as we have already seen, through 
asymmetrical localisation of cell fate determinants prior to mitosis (Bray, 2006).  
Notch proteins are highly conserved cell surface receptors.   In humans there are 4 
Notch receptors (NOTCH 1-4) and 5 ligands Delta-like (DLL1,3,4) and Jagged 
(JAG1,2) which interact with varying specificity (Pajcini et al., 2011).   Ligand 
binding to the extracellular portion of the receptor leads to cleavage of the 
intracellular portion of the transmembrane receptor through the action of ADAM10 
and secretase enzymes (Bray, 2006).  The intracellular portion of the Notch 
receptor (NICD) can then transit to the nucleus where it forms an activation 
complex with core binding factor 1 (CBF1) which complexes with various other 
factors, including mastermind-like (MAML), stimulating transcription of its 
downstream targets (Baron, 2003).  Notch signalling is critical in embryonic 
haemopoiesis.  Deletion of the gene for the ligand Jag1 and receptor Notch1 
indicate that these components of the Notch pathway are crucial, whereas others, 
e.g. Jag2 and Notch 2-4, appear not to be imperative in this context (Kumano et 
al., 2003; Pajcini et al., 2011; Robert-Moreno et al., 2008). In adult haemopoiesis 
the role of Notch signalling remains controversial.   Notch1 is expressed in normal 
HSC but also in mature progenitor populations and in mature effector cells of 
lymphoid and myeloid lineages.  There is a requirement for Notch signalling in 
maturing T cells, but Notch may also influence B cell development (Duncan et al., 
2005; Milner and Bigas, 1999).    Some studies have indicated that Notch 
signalling can expand human and murine HSC populations; however others have 
challenged this notion.  Soluble JAG1 appeared to expand CD34+38- cells and 
immobilised DLL1 ligand (in combination with traditional supportive cytokines) 
caused significant expansion of transplantable HSC from human cord blood in in 
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vitro culture systems (Delaney et al., 2010; Karanu et al., 2000).  In contrast, 
murine models with conditional deletions of various components of Notch 
signalling e.g. Notch1 and Jag1 failed to demonstrate significant effects on the 
HSC population (Mancini et al., 2005; Radtke et al., 1999).   
1.2.6.4.2 Wnt Signalling 
WNTs are secreted glycoproteins that initiate signalling through their 
receptors, a family of 7-span transmembrane proteins termed frizzled (FZD) that 
exhibit some homology to the Hh membrane activator SMO (Malhotra and 
Kincade, 2009).  Wnt signalling was first defined in Drosophila where it serves as a 
segment polarity gene required for correct embryonic patterning (Malhotra and 
Kincade, 2009; Rijsewijk et al., 1987).  In mammals, Wnt signalling is complex, 
comprising multiple ligands, receptors and accessory molecules acting along 
several different and potentially opposing intracellular signalling cascades 
(Macdonald et al., 2007; Staal and Luis, 2010).  Furthermore, Wnt signalling is 
dose, time and cell context specific rendering the study of Wnt signalling in 
haemopoiesis particularly challenging (Luis et al., 2012).  Nevertheless 
considerable effort has been applied to try to unravel its effect in the development 
and maintenance of the haemopoietic system (Luis et al., 2012). 
Canonical Wnt signals are transduced when a WNT molecule interacts with 
an appropriate FZD receptor (Malhotra and Kincade, 2009). This interaction 
prevents degradation of cytoplasmic -catenin and allows its transit to the nucleus 
where it interacts with members of the TCF/LEF transcription factor family 
(Malhotra and Kincade, 2009).  In combination with other nuclear accessory 
factors, this allows the transcription of target genes.  When Wnt signalling is not 
present cytoplasmic catenin interacts with a negative regulatory complex 
comprised of GSK3, AXIN and adenomatous polyposis coli (APC) (Malhotra and 
Kincade, 2009).  This complex targets cytoplasmic -catenin for rapid destruction 
preventing nuclear translocation (Luis et al., 2012).  Components of Wnt signalling 
are expressed in primitive and various lineages of differentiated haemopoietic 
tissue, suggesting a role in haemopoietic development (Malhotra and Kincade, 
2009; Reya and Clevers, 2005; Staal et al., 2008).   Indeed Wnt signalling is 
essential for T cell development and proliferation in the thymus (Malhotra and 
Kincade, 2009; Staal et al., 2008).  The effect of Wnt signalling in HSC remains 
controversial as in vitro culture experiments and gain- or loss-of-function studies of 
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key elements of the canonical Wnt pathway have yielded differing effects on HSC 
number and function.  Willert et al and Reya et al indicated that murine normal or 
Bcl2 transgenic HSC populations either exposed in vitro to purified WNT3A and 
SCF, or transfected with a constitutively active form of -catenin underwent 
significant expansion while retaining self-renewal capacity (Reya et al., 2003; 
Willert et al., 2003).  Likewise, HSC from Wnt3a-/- murine foetal liver reconstituted 
the haemopoietic system in primary transplant but had severely impaired 
secondary transplant capacity, suggesting impaired self-renewal potential (Luis et 
al., 2009).  In contrast, other murine models expressing high levels of -catenin 
ultimately resulted in HSC exhaustion and block of erythroid differentiation through 
reduction in expression of HoxB4, Cdkn1a, Bmi1 and PU.1 mediated Gata1 down 
regulation (Kirstetter et al., 2006).   Additionally, conditional deletion of both -
catenin and its close homologue -catenin in adult HSC using the Mx-Cre system  
had no apparent effect on stem cell number or function in one study but another 
using the Vav-Cre conditional deletion system to delete -catenin in embryonic 
haemopoiesis found significant impairment of self-renewal in HSC (Zhao et al., 
2007).  In some respects these results mirror the inconsistencies found in the 
similar experiments interrogating Hh signalling (Gao et al., 2009; Hofmann et al., 
2009; Merchant et al., 2010).  
1.2.6.5 Integration of self-renewal signalling  
As the above discussion illustrates, internal and external mechanisms that 
serve to control HSC function are complex and comprise a plethora of inputs that 
act in a stage, cell and environment specific manner.  Although discussed 
individually, in vivo such control is mediated by a complex network of 
complementary signalling and cross talk across various pathways that are 
integrated at the HSC level resulting in cell fate outcome.  There is evidence that 
these pathways interact at multiple levels influencing the level of signalling from 
these and other pathways culminating in a finely modulated activation/repression 
of broad downstream transcriptional programmes influencing HSC fate.  For 
example, GSK3 activity influences Notch, Wnt and Hh signalling (Espinosa et al., 
2003; Kise et al., 2009; Staal et al., 2008; Tempe et al., 2006).  Wnt activity 
influences Hh activity and vice versa (Mullor et al., 2001). Wnt signalling can 
influence the stability of GLI1 mRNA allowing accumulation of GLI1 whereas 
downstream targets of Hh include Wnt ligands (Maeda et al., 2006).  Downstream 
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targets of Notch include components of the Hh and Wnt pathways (Li et al., 
2012b).   Hedgehog signalling can influence BMP signalling and both Wnt and 
BMP act cooperatively to affect CDX/HOX activity in embryonic haemopoiesis 
(Bhardwaj et al., 2001; Lengerke et al., 2008).  Figure 1-5 presents a map based 
on selected key regulatory molecules in these pathways and their potential 
interactions.   
Additionally, the level of signalling from each pathway plays an important 
role, indeed it has been proposed that HSC response to these ligands may vary 
depending on the concentration to which they are exposed in a manner analogous 
to the effect of gradient of diffusible morphogens in the developing embryo (Luis et 
al., 2012; Ruiz i Altaba et al., 2007).  Thus factors influencing level of ligand 
secretion and distance from the secreting cell are likely to be important.  The 
picture that emerges is one of converging signals with differing effects dependent 
on the composition and strength of each input and this reinforces the importance of 
the specific cellular relationships within the niche. 
 
Figure 1-5:  Interactions between selected cell fate determinants 
Interaction map generated from Ingenuity Pathway Analysis® highlighting the complex 
network of interactions that exist between selected stem cell fate determinants.  
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1.2.7 Self-renewal and malignancy 
Given the central role of self-renewal control in maintenance of 
haemopoiesis it is not surprising that aberrant expression of components of these 
pathways is associated with haematological malignancy. 
1.2.7.1 Aberrancy in the intracellular control of self-renewal  
Aberrant expression of the HOX gene family and associated factors has 
long been associated with leukaemogenesis (Abramovich et al., 2005; 
Argiropoulos and Humphries, 2007; Imamura et al., 2002).  These genes are 
frequently involved in leukaemic translocations seen in patients with myeloid and 
lymphoid leukaemias and are frequently associated with a poor prognosis 
(Abramovich et al., 2005; Argiropoulos and Humphries, 2007; Drabkin et al., 2002; 
Golub et al., 1999; Imamura et al., 2002).  Furthermore a causative role has been 
suggested by murine over-expression models indicating that excess expression of 
various several HOX genes (e.g. HoxA9, HoxA10 or HoxB3) results in a leukaemic 
phenotype (Argiropoulos and Humphries, 2007; Thorsteinsdottir et al., 2002).  
Perhaps the classical example of a leukaemogenic HOX translocation is the 
translocation of the N-terminal portion of nucleoporin 98kDa (NUP98) to the C-
terminus of several HOX partners; the resultant fusion protein confers excess 
HOX-related gene expression and activity with resultant leukaemic transformation 
(Gough et al., 2011).   Expression of Nup98-HoxA9 or HoxD13 is sufficient to 
cause leukaemia in murine models and is capable of conferring extensive self-
renewal capacity to myeloid progenitors (Gough et al., 2011; Pineault et al., 2005).   
Aberrancy in factors controlling or influencing HOX gene expression is also 
involved in leukaemia.  The CDX family of transcription factors influence HOX 
gene expression in normal haemopoiesis, CDX4 is preferentially expressed in 
primitive HSC compared with more mature progenitors (Bansal et al., 2006).   
Additionally, CDX4 is expressed in almost 25% of human acute myeloid leukaemia 
(AML) and CDX2, while not normally expressed in haemopoiesis, was aberrantly 
expressed in 90% of human AML samples in one study (Scholl et al., 2007).  In 
murine models, transfection of Cdx2 or Cdx4 resulted in deregulated expression of 
various HOX family members, increased serial replating capacity in vitro and 
induced leukaemia in murine models (Bansal et al., 2006; Scholl et al., 2007).   
Deregulated MLL expression is a common feature of both AML and acute 
lymphoid leukaemia (ALL) (Bernt and Armstrong, 2011).  It is a promiscuous 
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partner in leukaemogenesis. Typically the N-terminal region of MLL associates 
with the C-terminal region of one of over 70 different translocation partners, 
forming a novel oncogenic transgene which affects the transcription of a wide array 
of downstream gene targets (Marschalek, 2011). Unsurprisingly, given the role of 
MLL in HOX regulation, deregulation of MLL expression often results in 
deregulation of HOX gene (e.g. HOXA9) and co-factor (e.g. MEIS1) expression 
(Fine et al., 2004).  Whether HOX expression is necessary in MLL driven 
leukaemia may depend on the specific translocation partner. In one murine study 
investigating the role of MLL-ENL; HoxA9 was required, and indeed forced 
expression of HoxA9 and Meis1 could substitute for the presence of MLL-ENL 
(Zeisig et al., 2004).   However in another model investigating the role of another 
translocation, MLL-AF9, HoxA9 expression was not required (Kumar et al., 2004).  
Furthermore analysis of MLL leukaemias indicate that while some MLL 
translocations drive HOX expression and confer enhanced self-renewal, others 
appear not to affect, at least in vitro, measures of self-renewal (Marschalek, 2011).  
It has been observed in murine and human studies that leukaemias induced by 
MLL translocations have a longer latency in mice and that these translocations 
may be present for a long time prior to manifestation of leukaemia in humans 
therefore suggesting that cooperating leukaemic mutations are required (Bernt and 
Armstrong, 2011). 
Similarly polycomb proteins have a significant role in malignancy.  Aberrant 
expression is seen in a variety of contexts including haemopoietic neoplasia 
(Martin-Perez et al., 2010; Radulovic et al., 2013; Sauvageau and Sauvageau, 
2010).  Over-expression of BMI1 is seen in myeloid disease (e.g. myelodyplastic 
syndrome [MDS], AML and chronic myeloid leukaemia [CML]), and in CML 
correlates with disease progression (Mohty et al., 2007; Radulovic et al., 2013).   
Additionally, other members of the PRC1 e.g. RING1A/1B are deregulated in 
MDS/AML (Radulovic et al., 2013).  The core PRC2 complex members are also 
aberrantly expressed in several haematological malignancies. For example, EZH2, 
SUZ12 and EED deletion are found in various haemopoietic neoplasms and EZH2 
over-expression is seen in both Hodgkin (HL) and non-Hodgkin lymphoma (NHL) 
(Martin-Perez et al., 2010; Raaphorst et al., 2000; van Kemenade et al., 2001).  
Thus aberrant activities of both PRC1 and PRC2 components have potential roles 
in malignancy (Rajasekhar and Begemann, 2007; Sparmann and van Lohuizen, 
2006).  While the aberrant expression of polycomb genes is not thought to be 
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sufficient to cause malignancy as a sole agent, they are seen as critical co-factors 
in transformation, repressing expression of key genetic programmes that facilitate 
tumourigenesis and a common polycomb repressive signature has been proposed 
where aberrant polycomb activity prevents the activation of the normal 
differentiation pathways or confers/augments stem cell properties (Martin-Perez et 
al., 2010).  It has also been proposed that a critical level of polycomb activity is 
required in HSC, with too little leading to a tendency to differentiate or senesce and 
too much leading to unrestrained expansion or the conferral of stem cell-like 
properties and the development of malignancy (Sauvageau and Sauvageau, 
2010). 
1.2.8 Developmental signalling in malignancy 
Just as there are emerging roles for the key developmental signalling 
pathways Notch, Wnt and Hh in self-renewal, it is becoming increasingly clear that 
signalling through these pathways is intrinsically involved in the pathogenesis of 
multiple human cancers including various haemopoietic malignancies.  
1.2.8.1 Hedgehog signalling -a paradigm for developmental 
signalling in malignancy 
Abnormal Hh signalling is associated with diverse human malignancies 
(Teglund and Toftgard, 2010).    Its oncogenic properties were first identified 
through the realisation that the genetic abnormality causing Gorlin’s syndrome 
(associated with an excess risk of rhabdomyosarcoma, medulloblastoma and 
basal cell carcinoma [BCC]) is an inherited inactivating PTCH mutation (Gorlin, 
2004).  Sporadic cases of the same malignancies are frequently associated with 
either inactivating mutations of PTCH or activating mutations of SMO, indicating 
that PTCH and SMO act as tumour suppressor and oncogene, respectively 
(Teglund and Toftgard, 2010).  Further work confirmed that GLI transcription 
factors were responsible for driving tumour formation (Grachtchouk et al., 2000).   
Recent evidence suggests that Hh signalling may have distinct mechanisms 
of action in different tumour environments (Ruiz i Altaba, 2008).   Indeed, Hh 
related mechanisms of oncogenesis can be divided into those that are due to 
constitutive activation of the pathway and those that retain a requirement for ligand 
dependent signalling. For example, in human sporadic BCC and medulloblastoma, 
the most common lesions in Hh signalling are gain-of-function SMO mutations or 
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loss-of-function PTCH mutations (Reifenberger et al., 2005; Wolter et al., 1997).  
Other mutations have been recognised, for example inactivating mutations in the 
negative regulator SUFU in medulloblastoma (Taylor et al., 2002).      
Mutations of Hh signalling components are comparatively rare in other 
malignancies, however there is evidence that Hh signalling remains important as 
tumour cells respond to Hh ligand secreted from the surrounding 
microenvironment.  This mechanism has been demonstrated in various tumour 
types e.g. lymphoma, glioma, small cell lung cancer and colon cancer (Dierks et 
al., 2007; Ehtesham et al., 2007; Varnat et al., 2009; Watkins et al., 2003).    
Furthermore, while Hh signalling is important in pancreatic cancer tumourigenesis, 
this is not through direct signalling to tumour cells but rather, at least in part, due to 
Hh ligand production by tumour cells interacting with the local stroma leading to a 
more permissive microenvironment (Tian et al., 2009; Yauch et al., 2008). 
  Thus Hh signalling appears to be associated with development and 
maintenance of malignancy through (i) ligand independent signalling due to cell 
intrinsic mutations or (ii) autocrine / paracrine signalling between tumour cells and 
stroma or vice versa (Ruiz i Altaba, 2008).  Figure 1-6 illustrates these possibilities. 
Following activation, either by acquisition of an enhancing mutation or 
through ligand binding, there is induction of expression of downstream mediators 
in the receiving cell.   Hedgehog, as we have discussed, influences a wide range 
of downstream transcriptional targets with multiple potentially oncogenic roles e.g. 
cell cycle, proliferation, apoptosis, transformation and self-renewal (Katoh and 
Katoh, 2009).  Dierks et al found that Hh signalling from supportive stroma in the 
E-Myc model of lymphoma acted as a survival signal through Bcl2 (Dierks et al., 
2007).  Additionally, direct evidence from glioblastoma and breast cancer suggests 
that functional BMI1 is required for Hh-mediated oncogenesis, suggesting that its 
role, and therefore the role of polycomb repression is important in this context (Liu 
et al., 2006; Michael et al., 2008).  The effect that Hh signalling has on 
microenvironmental stromal cells is not known at present; however various soluble 
factors including WNTs, TGF and insulin-like GFs are produced in response to 
Hh signalling. Therefore, it seems possible that such signalling would induce 
production of these factors in the receiving stromal cells (Harris et al., 2011). 
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Figure 1-6:  Possible mechanisms of Hh signalling in malignancy.   
A:  Activating mutations of positive regulators such as SMO or inactivating mutations of 
pathway inhibitors such as PTCH, HHIP or SUFU cause constitutive Hh signalling in the 
affected cell as seen in medulloblastoma or BCC (Teglund and Toftgard, 2010).  B:  
Autocrine/paracrine signalling between cancer cells. C:  Interaction with the 
microenvironment; in Ci malignant cells are supported by Hh ligands produced by the 
stromal microenvironment e.g. lymphoma and myeloma as reported by Dierks et al 
(Dierks et al., 2007), in Cii the signalling is reversed; malignant cells secrete Hh ligands 
causing supporting cells to provide a more permissive environment through provision of 
additional growth or survival signals as has been described in pancreatic cancer (Tian et 
al., 2009; Yauch et al., 2008). 
1.2.8.2 Notch and Wnt signalling in oncogenesis 
Notch signalling has been associated with diverse solid malignancies and 
plays a key role in the pathogenesis of haematologic malignancies such as T-ALL, 
chronic lymphocytic leukaemia and various lymphomas.  The relevance of Notch 
signalling in the pathogenesis of T-ALL is particularly well characterised and is due 
to mutation or chromosomal translocation resulting in constitutive activation of 
NOTCH1 (South et al., 2012).   In other contexts Notch has been suggested to 
have tumour suppressor capacity, e.g. in the skin where Notch appears to retard 
Hh and Wnt signalling, Notch deficient mice have increased Gli2 expression and a 
tendency to develop BCC (Shao et al., 2012), underlining the complexity and 
tissue-specific nature of developmental pathway signalling.  
63 
 
 
Similarly, Wnt signalling is up regulated in various malignancies and in 
some instances appears to be necessary for propagation of the tumour (Clevers, 
2006; Lustig and Behrens, 2003; Polakis, 2012).  Wnt pathway mutations are 
frequently seen in human malignancy.  The most obvious example of this is familial 
adenopolyposis coli, an inherited condition leading to the generation of multiple 
intestinal polyps and ultimately colon cancer which occurs due to mutation of the 
key Wnt regulator APC (Morin et al., 1997).  APC is also mutated in sporadic 
colorectal cancer.  Sporadic mutations of AXIN, another key inhibitor of Wnt 
signalling, are seen in sporadic hepatocellular cancer and colorectal cancer 
(Clevers, 2006).  Non mutation-related up regulation of Wnt signalling is also 
frequently found in cancer.  This frequently occurs as a consequence of epigenetic 
silencing of Wnt inhibitory regulators and can be mediated by the action of PRC2 
polycomb complexes (Polakis, 2012).  Recent evidence also suggests a role in 
several haemopoietic malignancies including AML and CML (Eaves and 
Humphries, 2010; Luis et al., 2012; Wang et al., 2010; Zhao et al., 2007).  The role 
of Wnt in CML will be discussed later.  Wnt signalling is often active in murine 
models of AML and primary AML samples.  In murine models, deletion of -catenin 
significantly reduced development and transplantation of AML driven by MLL-AF9 
or HoxA9 (Eaves and Humphries, 2010; Luis et al., 2012; Wang et al., 2010).    
1.2.9 The concept of cancer stem cells 
Malignant cells within a tumour are heterogeneous as a result of following 
pre-existing differentiation programmes, genetic differences that arise as a result 
of clonal evolution and as a result of environmental influence (Anderson et al., 
2011; Ding et al., 2012; Greaves and Maley, 2012).  However, a concept that has 
gained traction over recent years is that malignancies, like the normal tissues from 
which they arise, may have a hierarchical structure comprised of comparatively 
differentiated cells, transit amplifying cells or progenitors and more primitive cells 
with stem cell properties.   In this model, the capacity for tumour initiation and 
propagation is limited to the small number of very primitive cells within the larger 
tumour bulk.  These cancer stem cells (CSCs) exhibit similar characteristics to 
normal stem cells including the ability to undergo symmetric and asymmetric self-
renewal divisions, thereby maintaining or expanding their number in addition to 
giving rise to more differentiated progeny (Clarke et al., 2006; Jordan et al., 2006; 
Reya et al., 2001).  If malignancies are organised in this manner, then the 
propagation of the tumour relies on a comparatively small population of cells with 
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specific and critical oncogenic activity within the tumour bulk.  Therefore, traditional 
measures of response which are largely aimed at measuring residual tumour mass 
following treatment will not accurately define the effect of a treatment on the 
malignant stem cell population and will therefore not necessarily reflect likelihood 
of progression or future relapse, two key clinical measures of treatment efficacy.  
This notion was supported by early work observing the behaviour of teratomas 
(Pierce et al., 1959).  However, the advent of cell sorting techniques, monoclonal 
antibodies and stem cell assaying techniques in vitro and in vivo, parallel to a 
desire to better understand the molecular and cellular basis for the limitations of 
treatment in many malignancies has allowed the phenotypic and functional 
characterisation of these populations and led to a resurgence of interest in this 
area. 
1.2.9.1 Identification of CSC populations 
The existence of a CSC population in AML was first described by Bonnet 
and Dick in 1997. It was demonstrated that the capacity to propagate the disease 
resided in the most primitive CD34+CD38- cell populations in the AML samples that 
were analysed.  Since then, similar approaches have been used to isolate putative 
CSC populations from other haematological malignancies e.g. CML, myeloma, 
lymphoma and solid tumours such glioblastoma, breast and prostate cancer 
(Bonnet and Dick, 1997; Brennan et al., 2010; Holyoake et al., 1999; Jones et al., 
2009; O'Brien et al., 2010; Peacock et al., 2007).  Evidence that these populations 
were rare extended from the number of cells required to recapitulate the disease in 
secondary transplant xenograft models.  Our understanding of the biology of CSC 
activity has expanded over recent years and with it the CSC model has become 
increasingly complex.  Additionally, the model has been questioned in terms of its 
broad applicability – is it a general model of oncogenesis or does it apply only to a 
few specific examples? (Magee et al., 2012).  Furthermore the rarity of CSCs in 
some malignancies has been questioned following the implementation of more 
immunocompromised xenograft models. In one study, melanoma CSC were found 
to be far less rare than previously thought when the immunological barriers to 
transplantation were reduced by the utilisation of the profoundly 
immunocompromised murine NSG model as a recipient (Quintana et al., 2008). 
Likewise leukaemic CSCs (LSC) appear more frequent in syngeneic models, 
although the frequencies reported are variable (Kelly et al., 2007; Somervaille and 
Cleary, 2006). 
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1.2.9.2 Origin of CSCs 
While some cancers can arise from the normal stem cell compartment, 
through acquisition of mutations or deregulation of the self-renewal machinery, 
others appear to result from the reacquisition of stem cell characteristics in 
progenitor cells.    Using AML as a model for discussion, in the original 
demonstration of LSCs in AML, the LSC activity was primarily found in the primitive 
CD34+38- compartments, suggesting an HSC origin (Bonnet and Dick, 1997; 
Lapidot et al., 1994; Ishikawa et al.,2007).  These findings were supported by 
evidence that leukaemic translocations were found in both lymphoid and myeloid 
lineages.  However it has subsequently been demonstrated that although LSC 
activity is often enriched in the CD34+38- cell population.  In some AMLs there is 
significant LSC activity in more mature progenitor populations e.g. CD34+38+ 
(Eppert et al., 2011; Taussig et al., 2008).  Goardon et al recently demonstrated 
the presence of distinct subsets of AML cells with LSC activity in the CD38- and 
CD38+ haemopoietic progenitor fractions corresponding to lymphoid primed 
multipotent progenitors (LMPP) and GMP, respectively, with the latter derived from 
the former (Goardon et al., 2011).  These findings suggest that the reacquisition of 
stem cell properties in these cells may be required for AML leukaemogenesis.  
Forced reacquisition of stem cell characteristics has been demonstrated 
experimentally by the generation of LSCs from committed murine progenitors 
following insertion of a leukaemogenic translocation (AML-ETO, MLL-AF9, MLL-
ENL or MOZ-TIF2) (Huntly et al., 2004; Krivtsov et al., 2006; Somervaille and 
Cleary, 2006; Steffen et al., 2011; Cozzio et al., 2003).  A contrasting model is 
found in chronic phase (CP) CML (discussed in detail in subsequent sections) 
where CSCs reside within the HSC population (Holyoake et al., 1999). However in 
myeloid blast crisis (mBC) CML, the prevalent LSC population is derived from the 
progenitor GMP population, suggesting that one of the drivers for progression is 
the reacquisition of HSC characteristics by leukaemic progenitors (Jamieson et al., 
2004).    
It is possible that both mechanisms could exist in parallel, with an initial LSC 
population within the stem cell compartment giving rise to malignant progenitor 
progeny of which some ultimately develop CSC characteristics.  This might explain 
why some malignancies with long latencies e.g. CML, progress to advanced 
disease with a more aggressive phenotype. 
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1.2.9.3 Mechanisms of resistance to therapy 
Stem cells have several characteristics that provide comparative protection 
to therapeutic intervention.  As discussed in normal HSC, quiescence protects 
from DNA damage sustained through mitosis and will protect against standard 
chemotherapeutic approaches. Evidence has generally pointed to the fact that 
LSCs exist in a state of relative quiescence compared to their progeny (Alison et 
al., 2012; Guan et al., 2003; Guzman et al., 2001; Holyoake et al., 1999; Terpstra 
et al., 1996).  More recently, this has been challenged by Somervaille et al who 
found a cycling CSC population in AML (Somervaille et al., 2009).   Additionally, 
HSC/LSC express high levels of ABC multi-drug transporters, preventing 
accumulation of intracellular toxins (Alison et al., 2012; Dean et al., 2005; 
Gottesman et al., 2002; Scharenberg et al., 2002). Furthermore, LSCs are 
relatively resistant to anti-apoptotic stimulae, exhibit other cell survival behaviours 
such as autophagy and may be subject to genomic instability and subsequent 
mutation, particularly under selection pressure (Helgason et al., 2011; Sallmyr et 
al., 2008).  Failure to effectively target these cells results in a residual LSC 
population and the likelihood of future relapse.  
1.2.9.4 Control and function of CSCs 
Factors with a role in the generation and maintenance of CSC include the 
developmental signalling pathways Wnt, Notch and Hh.   Evidence is emerging 
that their oncogenic activity may be due to their effect on CSC populations.  Wnt 
signalling is critical for LSC activity in AML and CML (Jamieson et al., 2004; Wang 
et al., 2010).   As has been discussed, signalling along these pathways impacts on 
the activity of key intracellular regulators of stem cell fate.   Hh signalling in CSC is 
an area of rapidly expanding interest. Hedgehog signalling has a demonstrable 
role in the maintenance of CSC characteristics in several malignancies e.g. 
glioma, medulloblastoma, gastrointestinal cancer and breast cancer, in addition to 
several haemopoietic malignancies including myeloma and CML which is 
discussed in detail later (Clement et al., 2007; Dierks et al., 2008; Liu et al., 2006; 
Peacock et al., 2007; Varnat et al., 2009; Zhao et al., 2009).  In accordance with 
the suggestion that Hh signalling  influences CSC through key downstream 
mediators of cell fate,  the effect of Hh signalling in breast cancer is dependent on 
the action of BMI1 (Liu et al., 2006).   
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The obvious clinical extension of this theory is that, for the majority of these 
CSC driven cancers, cure will likely require the eradication of the CSC population.  
One approach is through targeting these developmental pathways to abrogate 
their effects on survival, proliferation and influence on self-renewal in CSCs.  
Targeting self-renewal is a particularly attractive notion as, if CSC self-renewal 
behaviour could be specifically reduced or completely abrogated, in the absence of 
significant effect on the un-diseased HSC population, the CSC clone would be 
gradually extinguished.  The demonstration that CSCs are dependent on 
developmental signalling for acquiring / maintaining CSC behaviour suggests that 
inhibitors of these pathways may be excellent CSC targeting therapies.   
1.2.9.5 Targeting the Hh pathway - a paradigm for therapeutic self-
renewal inhibition 
While the Hh signalling pathway is only one of several different pathways 
with overlapping roles in the complex processes that govern self-renewal 
behaviour, it is the lead pharmaceutical target. This is due to the fact that SMO - 
the main positive regulator of Hh signalling - is readily targetable, in contrast to 
Notch or Wnt, similar pathways lacking an identifiable and directly targetable 
positive regulator.  Additionally the identification of the naturally occurring SMO 
inhibitor, cyclopamine, has provided a molecular “prototype” on which the structure 
of synthetic inhibitors could be based (Chen et al., 2002; Incardona et al., 1998).  
 Cyclopamine was identified some 50 years ago following investigation into 
a spate of birth defects, including cyclopia, in lambs born in sheep farms across 
Idaho.  It transpired that pregnant ewes were grazing on the corn lily “Veratrum 
Californicum” which is a rich source of steroidal alkaloids that include cyclopamine.  
Cyclopamine was subsequently found to be a potent inhibitor of SMO with anti-
tumour activity in in vitro and in vivo systems. (Chen et al., 2002)  It exerts its effect 
through directly binding to the hepta-helical bundle of SMO, preventing the 
conformational change that would normally occur when PTCH repression was 
released (following Hh ligand binding) and causing the redistribution of SMO away 
from the plasma membrane (Incardona et al., 2002).   Although cyclopamine is an 
effective inhibitor of Hh signalling, it is unstable, relatively non-specific and has 
significant toxicities and therefore has not been effectively employed clinically 
(Heretsch et al., 2010). However, these results provided impetus to synthesise and 
test derivatives of cyclopamine and screen large scale synthetic molecule libraries 
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for agents with anti-SMO activity. Several years on, there are now a number of 
clinical grade SMO inhibitors undergoing pre-clinical evaluation or early stage 
clinical trials in various malignancies. 
An orally active agent, GDC-0449, showed significant (>50% response) 
clinical efficacy against Hh-driven malignancies such as advanced or metastatic 
BCC in a phase 1 clinical trial (Von Hoff et al., 2009).   A subsequent study 
reported that other solid malignancies did not respond, although the participants 
had advanced, multiply-treated malignancies with relatively short follow-up limiting 
the likelihood of a positive result (LoRusso et al., 2011).  In both cases, SMO 
inhibition was well tolerated with little toxicity (predominantly low grade fatigue, 
hyponatremia and dysgeusia); no maximum tolerated dose was reached.  Notably, 
there was a lack of haematological toxicity in treated patients confirming the 
observations that Hh signalling is not required for normal adult haemopoiesis 
(LoRusso et al., 2011; Von Hoff et al., 2009).   
1.2.9.6 Targeting Hh in haematological malignancy 
There is great interest in utilising anti-Hh therapies in haematological 
malignancies.  This extends from accumulating evidence suggesting that Hh 
signalling may be critical in the genesis, maintenance, progression and relapse of 
various haematological conditions through both direct and indirect mechanisms as 
described above.  Attention has particularly focused on CML where Hh signalling 
has been implicated in CSC persistence despite conventional therapy. 
1.3 Chronic Myeloid Leukaemia 
Chronic myeloid leukaemia is a clonal myeloproliferative disorder 
characterised by massive myeloid expansion, accumulation of differentiating 
granulocytic precursors and terminally differentiated effector cells leading to the 
key clinical features at presentation of marked PB granulocytosis, basophilia, 
splenomegaly and often thrombocytosis and anaemia (Lichtman et al., 2006).   
Chronic myeloid leukaemia is a relatively rare disease, accounting for about 
15% of all leukaemias.  It has a world-wide incidence of about 1-2 per 
100,000/year (Lichtman et al., 2006).  While CML does occur in children and 
young adults, its incidence increases with age, peaking in the seventh decade 
(Lichtman et al., 2006).  There is no concordance between twins or significant 
evidence of a familial susceptibility (Lichtman et al., 2006).   The only 
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environmental aetiological agent that has been recognised is exposure to ionising 
radiation.  This relates to the increased incidence of CML observed in survivors of 
the atomic bomb explosions that terminated World War 2 or the medicinal use of 
spinal radiation in sufferers of ankylosing spondylitis (Lichtman et al., 2006). 
Untreated, the clinical course of CML is one of inevitable progression from a 
stable CP lasting about 5 years from diagnosis, where there is gradual 
accumulation of leukaemic myeloid progenitors, to accelerated phase (AP), 
characterised by accumulation and clonal evolution of increasingly primitive 
myeloid precursors in the blood or BM before terminating in BC with rapid 
accumulation of immature myeloid or lymphoid precursors resembling acute 
leukaemia (Lichtman et al., 2006).  Transformation to BC directly from CP is also 
recognised.   
Our current understanding of the pathogenesis of CML is informed by the 
important contributions of various investigators.  Nowell and Hungerford first 
recognised the presence of the pathognomonic cytogenetic alteration, a shortened 
chromosome 22 – termed the Philadelphia chromosome (Ph) in CML cells (Nowell 
and Hungerford, 1960).   Rowley demonstrated that this cytogenetic abnormality 
was due to a balanced translocation between chromosomes 9 and 22.  De Klein et 
al, Bartram et al and Groeffen et al demonstrated that this translocation caused the 
juxtaposition of the Abelson (c-ABL) tyrosine kinase from chromosome 9q with the 
break point cluster region (BCR) on chromosome 22q (Bartram et al., 1983; de 
Klein et al., 1982; Groffen et al., 1984a; Groffen et al., 1984b).  Lugo et al 
demonstrated that this event caused the expression of a constitutively active 
oncogenic tyrosine kinase BCR-ABL, while McLaughlin et al and Daley et al first 
demonstrated that expression of BCR-ABL was sufficient for leukaemic 
transformation in vitro  and in vivo  (Daley and Baltimore, 1988; Daley et al., 
1990a; Lugo et al., 1990; McLaughlin et al., 1987).  
1.3.1 Chronic myeloid leukaemia cell of origin 
Chronic myeloid leukaemia is thought to arise following the malignant 
transformation of a single HSC.  Several lines of evidence lead to the conclusion 
that CML is a clonal stem cell disease.  Firstly, the presence of the Ph 
chromosome in multiple haemopoietic lineages suggests that it must be present in 
a sufficiently primitive cell to give rise to all myeloid lineages in addition to some B 
cells. Furthermore, molecular analysis of the precise translocation points in 
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different cell types from the same patient demonstrated that they were identical 
and consequently likely to be clonally derived from a primitive multipotent 
originator cell (Groffen et al., 1984b; Martin et al., 1980).  Secondly, the presence 
of a single isoform of glucose-6-phosphate dehydrogenase (G6PD) in leukaemic 
cells, but not other non haemopoietic cells derived from women carrying both 
isoforms of G6PD (Fialkow et al., 1967; Fialkow et al., 1977).  Thirdly, study of X-
linked chromosomal inactivation patterns of hypoxanthine 
phosphoribosyltransferase (HPRT) in the leukaemic cells of heterozygous females 
demonstrated clonality (Yoffe et al., 1987).  Whether the cell of origin may be more 
primitive still is an extremely interesting question.  While it is clear that BCR-ABL 
driven haemopoiesis contributes to myelopoiesis, cells of the lymphoid lineage 
have also been demonstrated to descend from the LSC as patients may have a 
mix of BCR-ABL+ and BCR-ABL–  B cells (Nitta et al., 1985; Takahashi et al., 1998).  
Furthermore, while most mature T cells and NK cells are BCR-ABL-, BCR-ABL 
expressing T cell progenitors have been described suggesting that the leukaemic 
clone also contributes to B and T cell lymphoid haemopoiesis, but that the progeny 
may not expand or may undergo apoptosis (Haferlach et al., 1997; Jonas et al., 
1992; Takahashi et al., 1998).  Lastly, haemangioblast-like BCR-ABL+ cells have 
been reported in some studies suggesting the possibility of an even more primitive 
cell of origin (Fang et al., 2005; Gunsilius et al., 2000; Wu et al., 2009).   
1.3.2 Molecular biology of BCR-ABL 
The initiating translocation event in CML causes the juxtaposition of a 
variable length of the 5’ end of the BCR region with exon a2 of the c-ABL gene.   
Most commonly, the mRNA produced from transcription of this area results in the 
production of a 210kDa chimeric protein, p210BCR-ABL(Melo, 1996).  Why this 
results in oncogenic transformation can be related to the normal functions of the 
individual components and the molecular changes that occur as a consequence of 
the translocation.  The c-ABL gene is conserved between humans and lower 
species indicating its pivotal biological role (Van Etten, 1999). The c-ABL gene 
encodes a 140kDa protein. The N-terminal portion has homology with SRC family 
proteins containing 3 SRC homology (SH) domains and a myristoylated residue at 
the N-terminus (Van Etten, 1999).  The first SH domain harbours tyrosine kinase 
activity (Van Etten, 1999).  Other domains include those that allow direct 
interaction with other proteins; regions that undergo autophosphorylation and 
phosphorylation by other protein kinases, nuclear localisation and DNA and actin 
71 
 
 
binding (Van Etten, 1999).  Under normal conditions, c-ABL is present in the 
cytoplasm, where it is associated with the cytoskeleton and is a substrate for 
various cytoplasmic kinases, and the nucleus where it has the capacity to interact 
with nuclear proteins, e.g. RAD51, and directly bind DNA in response to tightly 
regulated intracellular signalling processes (Van Etten, 1999).  Under physiological 
conditions the tyrosine kinase function of c-ABL undergoes auto-inhibition by the 
myristoylated N-terminal region and conformational changes induced by 
interaction via SH2 and SH3 domains (Hantschel et al., 2003; Maru, 2012; Nagar 
et al., 2003). Overall its key roles appear to be integration of cell cycle, apoptosis 
and environmental signalling (Van Etten, 1999).   
The BCR region encodes a ubiquitously expressed cytoplasmic 160kDa 
protein which acts as a serine threonine kinase via a domain at the N-terminus 
(Maru and Witte, 1991). Other domains include a dimerisation domain, central and 
C-terminal domains that allow interaction with RAS, RHO and p21RAC signalling 
factors (Deininger et al., 2000).  Additionally, phosphorylation at Y177 allows 
activation of the RAS signalling pathway via GRB2 (Deininger et al., 2000). 
 The translocation event results in constitutive production of the chimeric 
protein BCR-ABL.  Fusion of BCR prevents normal auto-inhibition of c-ABL activity 
and furthermore potentiates c-ABL tyrosine kinase activity including auto-
phosphorylation through oligomerisation (Maru, 2012; Quintas-Cardama and 
Cortes, 2009).  Additionally, the cellular localisation of BCR-ABL is abnormal; 
BCR-ABL is retained in the cytoplasm allowing exclusive interaction with the 
cytoskeleton, cytoplasmic signalling pathways and preventing its interaction with 
nuclear proteins and DNA (Wetzler et al., 1993).   
Cytoplasmic BCR-ABL deregulates a variety of critical cellular processes 
through interaction with cytoplasmic proteins.  While it is beyond the scope of this 
work to discuss in detail the multiplicity of BCR-ABL interactions,  its net effect is to 
confer a survival and proliferation advantage on cells through deregulated mitotic 
signalling and GF independence (e.g. via activation of RAS/RAF/MAPK , 
PI3K/AKT or JAK/STAT signalling),  inhibition of apoptosis machinery (via BCL2, 
BCLXL and BAD expression) and altered cellular adhesion or stromal interaction 
(through reduced CXCR4 expression and cytoskeletal interactions via F-actin, 
focal adhesion molecules such as paxillin and 1-integrin),  (Deininger et al., 2000; 
Li et al., 2007b; Maru, 2012; Quintas-Cardama and Cortes, 2009).  As a result 
there is expansion of leukaemic stem and progenitor cells. 
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1.3.3 Treatment of CML 
The major treatment goal in CML is to reduce the leukaemic burden, 
normalise haemopoiesis and avert progression to advanced phase disease.  Prior 
to the advent of specific tyrosine kinase inhibitors (TKIs) for BCR-ABL, treatment of 
CML relied on cytoreduction with conventional chemotherapeutics (e.g. busulphan, 
hydroxycarbamide and cytarabine), interferon based regimens and allogeneic 
transplant (Lichtman et al., 2006). Allogeneic transplantation is an effective and 
potentially curative therapy due to the exquisite sensitivity of CML cells to graft 
versus leukaemia interactions,  however lack of donor availability and high levels 
of associated morbidity and mortality (particularly in older patients) limited its use 
(Gratwohl et al., 2006).  For those unable to undergo transplantation, interferon-
containing regimens appeared to target CML cells, induced a complete cytogenetic 
response (CCyR – absence of Ph+ cells in a minimum of 20 metaphases) in a 
minority of patients (13%) and had a survival advantage compared to purely 
cytoreductive regimens (around 70% 10 year survival in optimally responding 
patients) (Bonifazi et al., 2001).  
The development of TKI, such as imatinib, dasatinib, and nilotinib that block 
BCR-ABL kinase activity has radically improved the management of CML, leading 
to unprecedented levels of cytogenetic and molecular responses in CP patients 
(Druker et al., 2006; Kantarjian et al., 2011; Kantarjian et al., 2012). 
1.3.3.1 Defining response to treatment 
Several studies have suggested that patient outcome in CML correlates with 
speed and depth of response to treatment (Druker et al., 2006; Hanfstein et al., 
2012; Hochhaus et al., 2009; Hughes et al., 2010 ; Jabbour et al., 2011; Kantarjian 
et al., 2008; Quintas-Cardama et al., 2011).  As treatments have become more 
effective, more stringent measures of leukaemic burden have been required and 
developed.  Reaching a CCyR is clearly associated with improved prognosis in 
CML clinical trials (Druker et al., 2006; Hochhaus et al., 2009; Jabbour et al., 2011; 
Kantarjian et al., 2008; Quintas-Cardama et al., 2011).  Degree of cytogenetic and 
molecular response is defined by the criteria set out in Table 1-5.  Achieving a 
CCyR at 12 months is an important landmark as it correlates with progression free 
survival (PFS). In the IRIS trial, 97% of those with a CCyR at 12 months remained 
in CP compared to 81% of those with less than a partial cytogenetic response 
(PCyR) (Druker et al., 2006).  Additionally, those that fail to achieve a CCyR at 1 
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year are subsequently less likely to do so (Iacobucci et al., 2006). Overall survival 
(OS) at 6 years correlated with the degree of cytogenetic response at 12 months: 
92% for patients in CCyR, 89% for those in PCyR, and 63% for those failing to 
achieve at least a PCyR at 12 months (Hochhaus et al., 2009). 
Likewise, early reduction in molecular evidence of disease as measured by 
quantitative reverse transcriptase polymerase chain reaction (qRTPCR) 
quantification of residual BCR-ABL transcripts in PB is a favourable prognostic 
factor (Hanfstein et al., 2012; Hughes et al., 2010; Kantarjian et al., 2008; Marin et 
al., 2012; Palandri et al., 2009; Wang et al., 2003).   Early reduction of BCR-ABL 
correlates with eventual achievement of a CCyR (Wang et al., 2003).  Maintenance 
of a molecular response is associated with stability in cytogenetic response and a 
reduced risk of progression (Hughes et al., 2010; Hughes et al., 2003).  Recently it 
has been suggested that long term CCyR, PFS  and OS are predictable on the 
basis of initial response to imatinib with those not achieving a BCR-ABL level of 
less than approximately 10% within 3 months of commencing therapy less likely to 
achieve CCyR and having reduced PFS and OS (Marin et al., 2012).  Thus modern 
indications of satisfactory response to therapy rely on cytogenetic and molecular 
assessment of disease status.   
  
74 
 
 
 Response Criteria 
complete haematologic response (CHR) Normalisation of PB  / resolution of splenomegaly 
minimal cytogenetic response 
 (minimal CyR) 
>65-95% Ph
+
 in BM 
minor cytogenetic response (minor CyR) >35-66% Ph
+
 in BM 
partial cytogenetic response (PCyR) >0-35% Ph
+
 in BM major cytogenetic 
response (MCyR) complete cytogenetic response (CCyR) 0% Ph+ in BM 
major molecular response (MMR
3log
) 3 log reduction in BCR-ABL relative to control 
major molecular response (MMR
4.5log
) 4.5 log reduction in BCR-ABL relative to control 
complete molecular response (CMR) Undetectable BCR-ABL transcripts by qRTPCR  
Table 1-5:  Accepted levels of haematologic, cytogenetic and molecular response to 
treatment in CML.   
 
The European Leukemia Network (ELN) recognised  and formalised these 
factors into a set of treatment milestones which form the basis of modern CML 
monitoring and enable the objective assessment of response to therapy and 
recognition of patients who are responding sub-optimally or failing therapy (Table 
1-6) (Baccarani et al., 2009). 
Time from diagnosis Response level Response achieved 
3 months 
Optimal CHR 
Sub-optimal Less than CHR 
Failure Stable disease or progression 
6 months 
Optimal PCyR or better 
Sub-optimal Less than PCyR 
Failure No CHR / No CyR 
12 months 
Optimal CCyR 
Sub-optimal Less than CCyR 
Failure Less than PCyR 
18 months 
Optimal MMR 
Sub-optimal Less than MMR 
Failure Less than CCyR 
Table 1-6:  ELN criteria detailing minimum required response to TKI therapy according 
to time from initiation.   
Loss of haematologic or cytogenetic response at any time is regarded as treatment failure 
as is the acquisition of a significant BCR-ABL kinase domain mutation.  Loss of MMR and 
development of additional cytogenetic abnormalities in Ph+ cells is regarded as a 
suboptimal response (Baccarani et al., 2009).  Patients are monitored every 3 months. In 
recent years with the advent of robust and standardised qRTPCR, molecular monitoring is 
often substituted for repeated BM cytogenetics in responding / stable patients. 
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1.3.3.2 Imatinib 
Imatinib was the first TKI used in the treatment of CML and changed the 
natural history of the disease.  Its superiority was unequivocally demonstrated in a 
phase III trial of interferon and imatinib (IRIS; International Randomized study of 
Interferon and STI-571) in newly diagnosed patients with CML in CP. Ninety eight 
per cent of patients who received imatinib as an initial therapy achieved a CHR 
and 82% achieved a CCyR (Druker et al., 2006).  At 60 months, estimated OS was 
89% (Druker et al., 2006).  Importantly, only an estimated 6% of all patients 
progressed to AP or BP (Druker et al., 2006).  
This study has been criticised for censoring patients that discontinued 
imatinib (either for failing to respond adequately or due to toxicity) thereby creating 
a potential bias as these patients are likely to have had a poorer outcome.   In 
another study, the probability of OS and likelihood of sustained CCyR while taking 
imatinib was 83% and 63%, respectively (de Lavallade et al., 2008).  Other studies 
have indicated that the likelihood of sustaining a satisfactory response (according 
to ELN criteria above) to imatinib is closer to 50% in the general CML population 
(Lucas et al., 2008). 
Thus a significant number of CP patients are not optimally benefiting from 
TKI therapy with imatinib, additionally imatinib responses in advanced phase 
disease are less impressive; a phase 2 study of imatinib demonstrated CCyR rates 
of 17% and 7% in AP and BC, respectively (Sawyers et al., 2002; Talpaz et al., 
2002).  Estimated 12-month PFS and OS rates for patients in AP were 59% and 
74% (Talpaz et al., 2002). Patients in BC survived for a median of approximately 7 
months (Sawyers et al., 2002).   
1.3.3.3 Second generation TKIs 
Potent second generation TKIs have since been developed and are in 
clinical use.  Bosutinib, nilotinib and dasatinib have been studied in newly 
diagnosed patients and as second line agents following intolerance or treatment 
failure with imatinib.  
Bosutinib is a dual SRC/ABL kinase inhibitor with increased potency against 
BCR-ABL and various SRC family kinases (e.g. gardiner –rasheed feline sarcoma 
viral oncogene homologue [Fgr], v-yes-1 Yamaguchi sarcoma viral related 
oncogene homolog [Lyn], sarcoma oncogene [Src] and spleen tyrosine kinase 
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[Syk]) (Puttini et al., 2006). Notably it has reduced inhibitory activity against c-Kit or 
PDGFR (Puttini et al., 2006).  Bosutinib binds to the active and inactive 
conformations of BCR-ABL.  The efficacy of bosutinib in imatinib resistant or 
intolerant patients has been assessed in phase 1/2 clinical trial (Cortes et al., 
2011a).  The majority of patients in this study did not have CHR at commencement 
and 78% achieved CHR with bosutinib.  After a median 24 months follow up 52% 
had achieved a MCyR and 41% a CCyR.   Of those that achieved a CCyR, 65% 
also achieved a MMR and 49% of imatinib resistant patients achieving MMR 
actually achieved a CMR (Cortes et al., 2011a).  Thus those that did respond to 
bosutinib appeared to achieve deeper remissions.    
Bosutinib has also been investigated in the primary treatment setting.  The 
BELA trial compared bosutinib 500mg od with imatinib 400mg od.  This trial 
demonstrated similar CCyR rates at 12 and 24 months post treatment (12 months:  
bosutinib 70% vs. imatinib 68%; 24 months: bosutinib 79% vs. imatinib 80%) but 
faster molecular responses and a higher cumulative rate of MMR (12 months:  
bosutinib 41% vs. imatinib 27%; 24 months:  bosutinib 61% vs. imatinib 50%) 
(Cortes et al., 2012c; Cortes et al., 2011b).   
Dasatinib is a dual SRC/ABL inhibitor with activity against BCR-ABL and a 
wide range of other intracellular kinases (Rix et al., 2007).  Dasatinib binds to both 
the inactive and active states of ABL and is 325-fold more potent than imatinib in 
vitro (O'Hare et al., 2005).  Efficacy of either 70mg twice daily (bd) or 100mg once 
daily (od) dasatinib in imatinib resistant and intolerant CP CML patients has been 
investigated in phase 2 clinical trials (Hochhaus et al., 2008a; Shah et al., 2008).  
The START C trial evaluated the efficacy of dasatinib in imatinib resistant or 
intolerant CP patients.  MCyR was reached in 52% of the resistant cohort and 80% 
of the intolerant cohort.  These responses were long lasting with over 97% of 
patients achieving MCyR maintaining this response at a median follow up of 15 
months and with PFS and OS at 24 months of 80% and 94%, respectively 
(Hochhaus et al., 2008b).  Treatment with 100mg od dasatinib appeared to be 
similarly effective in CP, but was less toxic (Shah et al., 2008).  Equivalent trials 
have been performed in advanced phase CML indicating that dasatinib is effective 
in AP and BC CML (Kantarjian et al., 2009; Saglio et al., 2010), however, the 
recommended starting dose of dasatinib in advanced phase disease remains 
70mg bd.   
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Given the clear therapeutic effect of dasatinib in the second line setting, 
phase 2 and subsequently phase 3 trials comparing dasatinib with imatinib in 
newly diagnosed CP CML patients were instigated.   The phase 3 DASISION trial 
demonstrated that treatment with dasatinib 100mg od improved CCyR and MMR 
rates at 2 years compared to imatinib 400mg od (CCyR 86% vs. 82%; MMR 64% 
vs. 46% respectively) (Kantarjian et al., 2012).  Additionally, more patients had 
deep molecular responses in the dasatinib arm (log 4.5 reductions in BCR-ABL 
transcripts 17% vs. 8%) (Kantarjian et al., 2012). 
Nilotinib is a TKI with activity against BCR-ABL, KIT, PDGFR and ephrin 
receptor kinase (Manley et al., 2010).  It is an analogue of imatinib and exerts its 
anti-leukaemic activity in a similar fashion, i.e. it binds to and stabilises the inactive 
conformation of ABL.  However, because the topologic fit to ABL is improved, 
nilotinib has approximately 30-fold greater potency in vitro (Weisberg et al., 2005). 
A series of clinical studies investigating the clinical effectiveness of 400mg bd 
nilotinib in imatinib resistant or intolerant CML patients in CP, AP and BC have 
been performed (Giles et al., 2012; Kantarjian et al., 2007; le Coutre et al., 2008).   
A group of 321 CP patients intolerant or resistant to imatinib received nilotinib 
200mg bd. Overall MCyR rates were 63% in the intolerant group and 56% in the 
resistant group.  Again, these responses were durable with 84% remaining in 
MCyR for 18 months (Kantarjian et al., 2007).  Estimated OS was reported as 91% 
at 18 months (Kantarjian et al., 2007).  Equivalent trials have been performed in 
advanced phase CML indicating that nilotinib has effect in AP and BC (Giles et al., 
2012; le Coutre et al., 2008).   
Nilotinib has also been studied in newly diagnosed patients.  The pivotal 
phase 3 clinical trial - ENESTnd compared two doses of nilotinib with imatinib for 
primary treatment of CP CML (Kantarjian et al., 2011).  This trial indicated the 
superiority of either 300mg bd or 400mg bd nilotinib over imatinib in this setting 
with a significantly higher MMR rate at two years (nilotinib 300mg bd 71%, nilotinib 
400mg bd 67% and imatinib 44%) (Kantarjian et al., 2011).  Again, substantially 
more nilotinib treated patients were in deep molecular remissions (log 4.5 
reduction in BCR-ABL transcripts nilotinib 300mg bd 26%, nilotinib 400mg bd 21% 
and imatinib 400mg od 10%) (Kantarjian et al., 2011).   
Thus second generation TKI have demonstrated efficacy in both newly 
diagnosed and imatinib resistant or intolerant patients in all phases of CML.  It is 
clear that these agents have the capacity to induce rapid cytogenetic and 
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molecular responses in newly diagnosed patients.  This rapid reduction in 
leukaemic burden might be expected to reduce the likelihood of progression and 
indeed there is evidence for this in both frontline trials described above. Although 
the numbers of progressing patients was small, each trial reported a progression 
rate of approximately half that of the imatinib arm after 2 years follow up (BELA:  4 
vs. 13 patients; DASISION: 6 vs. 13 patients and ENESTnd 5 vs. 12 patients) 
(Cortes et al., 2011b; Kantarjian et al., 2011).  These agents were also able to 
rescue patients intolerant or poorly responsive to front line imatinib, therefore 
providing alternative therapeutic strategies in these patients.  Bosutinib, nilotinib 
and particularly dasatinib are active in advanced phase CML however responses, 
like those seen with imatinib are less profound and more transient (Giles et al., 
2012; Kantarjian et al., 2009; le Coutre et al., 2008; Saglio et al., 2010).   
1.3.3.4 Resistance and persistence  
Resistance to TKI and persistence of disease despite TKI therapy represent 
major clinical concerns.  An estimated 16% of IRIS patients had primary (intrinsic) 
resistance to imatinib at 12 months (failure to achieve at least a PCyR) and 24% 
had primary resistance after 18 months (failure to achieve a CCyR) (O'Brien et al., 
2003).  Additionally, resistance can develop over time; in one study 16% of 
patients relapsed within years 1–3 because of secondary (acquired) resistance 
(Druker et al., 2006). The incidence of resistance and relapse is higher in patients 
with more advanced CML.  While second generation TKIs can rescue a proportion 
of sub-optimally responding patients, review of the data above suggests that these 
responses are not universal and not necessarily robust (Giles et al., 2012; 
Hochhaus et al., 2008a; Kantarjian et al., 2009; Kantarjian et al., 2007; le Coutre et 
al., 2008; Saglio et al., 2010; Shah et al., 2008).  Even in optimally responding 
patients treated with the most potent TKIs in clinical use about 29-36% of patients 
fail to achieve an MMR at 2 years (Kantarjian et al., 2011).  
1.3.3.4.1 TKI resistance mechanisms  
There have been strenuous efforts to elucidate the biological basis of TKI 
resistance. These mechanisms can be broadly divided into BCR-ABL–dependent 
mechanisms and BCR-ABL–independent mechanisms.  While amplification of the 
BCR-ABL fusion gene has been associated with resistance to imatinib this is not 
common (Hochhaus et al., 2002).  More clinically relevant are the presence of 
relatively TKI resistant clones.  Imatinib binds to the ATP binding site of the 
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inactive conformation of BCR-ABL (Savage and Antman, 2002).  Broadly 
speaking, point mutations afford resistance by blocking this interaction either 
directly  through mutation of residues critical for TKI binding or (in the case of 
imatinib) indirectly by stabilising the protein in the active conformation (P-loop 
mutations) or preventing adoption of the inactive conformation (A-loop mutations) 
(Apperley, 2007). The BCR-ABL gene is affected by genomic instability resulting 
from its own kinase product, mutagenic ROS and by compromised DNA repair 
mechanisms leading to the development of point mutations that are then selected 
under the pressure of TKI therapy (Grant et al., 2010; Koptyra et al., 2006; Shah et 
al., 2002).  A host of mutations are now described, with different in vitro 
sensitivities to TKI – ranging from mild insensitivity to virtually complete resistance 
in the case of theT315I mutation (Apperley, 2007; Shah et al., 2002).  While some 
mutations may pre-exist treatment initiation and not all necessarily impact on 
prognosis, development of a clinically significant mutation will presage relapse in 
responding patients and will require alteration of therapy (Branford et al., 2003; 
Jabbour et al., 2006; Khorashad et al., 2008; Soverini et al., 2011).  Fortunately the 
TKIs in current clinical use have differing potencies against the various BCR-ABL 
kinase domain mutations described thus expansion of a clone bearing a clinically 
significant mutation can often be managed by instigating treatment with an 
alternative TKI (Soverini et al., 2011).  Until recently the major exception to this 
was development of the T315I mutation which is completely resistant to 
pharmacologically achievable concentrations of imatinib, dasatinib, nilotinib and 
bosutinib (Puttini et al., 2006; Soverini et al., 2011).   However the recent 
development of the novel pan-BCR-ABL inhibitor, ponatinib, has provided the 
opportunity to target this mutation.  Ponatinib has activity against all forms of BCR-
ABL in addition to various other intracellular kinases including FLT3, SRC, LYN, c-
KIT, FGFR and PDGFR (O'Hare et al., 2009).  Furthermore it has demonstrated 
activity in CML, including patients harbouring a clone with the T315I mutation and 
was reasonably well tolerated in a phase 1 clinical trial (Cortes et al., 2012a).  Its 
efficacy has been further investigated in the phase 2 PACE trial looking at heavily 
pre-treated patients and patients with T315I.  In this study 50% of CP CML patients 
had achieved at least a MCyR at 9 months and this included 70% of those 
harbouring T315I (Cortes et al., 2012b).  
Non BCR-ABL-related mechanisms of resistance include relative 
expression of plasma membrane transporter molecules and the influence of 
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parallel signalling pathways e.g. SRC kinase signalling, RAS signalling or JAK2 
signalling.  Initial studies suggested that imatinib is actively excreted from cells via 
the ABC family of transporters, ABCG2 and ABCB1 (MDR-1), therefore over-
activity of these protein complexes might confer resistance through reducing 
intracellular imatinib concentrations.  ABCB1 over-expression influenced imatinib 
concentration in K562 (Mahon et al., 2003 ). ABCG2 is over-expressed in CD34+ 
cells but does not affect intracellular imatinib levels (Jordanides et al., 2006).    
Second generation TKIs nilotinib and dasatinib are also substrates of ABCB1 and 
ABCG2 (Hegedus et al., 2009).  However, thus far the clinical role for TKI efflux 
appears to be limited (Crossman et al., 2005; Mahon et al., 2003). Other in vitro 
and clinical studies have implicated imatinib import via the human organic cation 
transporter 1 (hOCT1) in resistance.  Low expression of this complex is associated 
with reduced intracellular imatinib concentration and indeed has been found to 
have a negative prognostic influence in some studies (Thomas et al., 2004; White 
et al., 2007).  Notably neither dasatinib nor nilotinib intracellular levels are affected 
by hOCT1 expression (Hiwase et al., 2008; White et al., 2006) 
Cooperative signalling via other signalling pathways might cause TKI 
resistance.  Indeed SRC family kinases have been implicated in resistance via 
direct activation of BCR-ABL.  BCR-ABL+ CML cells cultured in the presence of 
imatinib or obtained from patients with imatinib-resistant CML have been shown to 
have increased expression and activity of the SRC kinases LYN and HCK (Dai et 
al., 2004; Donato et al., 2003; Mahon et al., 2008). 
1.3.3.4.2 Disease persistence  
It is recognised that even considering optimally responding patients, the 
majority continue to have evidence of persisting disease despite prolonged TKI 
therapy (Bhatia et al., 2003; Druker et al., 2006; O'Hare et al., 2007).  Additionally, 
the majority of patients who achieve a CMR have persisting evidence of disease 
when more sensitive approaches are employed and suffer molecular relapse 
shortly after TKI withdrawal (Chomel and Turhan, 2011; Chu et al., 2011; Mahon et 
al., 2010; Ross et al., 2010; Sobrinho-Simoes et al., 2010).  Thus it is clear that, in 
the majority of responding patients at least, there is a residual population of CML 
cells that are resistant to TKI therapy persist despite treatment and can cause 
disease relapse.  This residual population is thought to include the CML LSC.   
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1.3.4 The CML stem cell  
The organisation of CP CML is considered to be akin to that of normal 
haemopoiesis.  The cell of origin as described above is an aberrant HSC with 
similar qualities of self-renewal and multipotency giving rise to leukaemic 
progenitors and differentiated cells.  Surface phenotype has been considered to be 
indistinguishable from the normal HSCs with enrichment possible based on 
surface expression of CD34, CD38 and CD90 (Eaves et al., 1998a; Eaves et al., 
1998b; Petzer et al., 1996).  Recent work has suggested that there might be 
additional leukaemia-specific surface markers e.g. IL1-RAP which has been found 
to segregate with BCR-ABL expression (Jaras et al., 2010).  Chronic myeloid 
leukaemia LSC have altered cell-cell adhesion, altered cell cycle kinetics and 
increased ROS levels as a consequence of expression of BCR-ABL (Deininger et 
al., 2000; Eaves et al., 1998b; Quintas-Cardama and Cortes, 2009). Both 
progenitor progeny and LSC are cycling faster than their normal counterparts 
(Eaves et al., 1998b).  Analysis of PB and BM from patients in CP CML has 
suggested that there is significant progenitor expansion and mobilisation. 
However, hierarchically more primitive cells e.g. LTC-IC are present in equivalent 
quantities in the BM, but in excess in the peripheral circulation due to their altered 
adhesive qualities (Eaves et al., 1998b; Eaves et al., 1993).   Chronic myeloid 
leukaemia cells also exhibit GF independence and do not undergo apoptosis in the 
absence of exogenous GF signalling due to autocrine secretion of IL3 (Holyoake et 
al., 2001). 
  Not all the LSCs are in cycle however – a quiescent (G0) cell fraction can 
be identified in PB or BM specimens from patients with CML through CFSE or by 
Hoechst 33342 / Pyronin Y staining, even following culture in a proliferative 
cytokine cocktail (Holyoake et al., 1999).  This population comprises approximately 
0.5% of the total CD34+ compartment and is competent to replicate the disease in 
xenograft transplantation studies (Holyoake et al., 1999).  These LSCs have 
demonstrable resistance to TKI-mediated apoptosis in vitro and leads to an 
accumulation of quiescent leukaemic cells (Copland et al., 2006; Graham et al., 
2002; Jorgensen et al., 2007).  While various possible mechanisms have been 
suggested to explain lack of TKI-mediated apoptosis in LSC e.g. quiescence, low 
intracellular levels of TKI due to drug efflux, high levels of BCR-ABL expression or 
cooperative signalling via other related pathways (Jiang et al., 2007b), evidence is 
now emerging from in vitro and in vivo models suggesting that CML LSCs may not 
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actually be dependent on BCR-ABL kinase signalling for survival (Corbin et al., 
2011; Hamilton et al., 2012).  If this is the case then TKI inhibition alone will be 
unlikely to result in depletion of the leukaemic clone and cure of the disease and 
attention will require to be focused on alternative targets. 
1.3.4.1 Targeting the CML stem cell 
If, unlike their progeny, CML LSCs are not dependent on BCR-ABL 
signalling for survival, two questions arise: what are they dependent on and how 
might they be targeted?  Intensive effort from various laboratories to better 
understand the biology of the CML LSC in CP and advanced phase disease has 
uncovered a multitude of important survival mechanisms.  Investigation of these 
processes with a view to finding an Achilles heel in the CML LSC has been the 
challenge in recent years.  One intriguing concept has been the direct targeting of 
mechanisms regulating self-renewal activity in CML LSC (Figure 1-7).  
 
Figure 1-7:  Diagram indicating possible mechanisms for targeting the CML stem cell by 
influencing HSC behaviour. 
This diagram shows the potential fates of the quiescent LSC.  Black block arrows indicate 
possible fates that could be accentuated, while faded arrows indicate fates that could be 
reduced or abrogated to deplete the LSC fraction.  Thus, hypothetically, the quiescent 
CML HSC population could be reduced by accentuating apoptosis (either through 
inhibition of survival pathways or toxicity), causing senescence or driving quiescent cells 
into cell cycle but preventing or reducing self-renewal and/or accentuating 
differentiation.    
1.3.4.2 Self-renewal in CML  
Extending from the initial observation that expression of BCR-ABL was 
sufficient for oncogenesis was doubt as to whether BCR-ABL really was the sole 
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agent of malignant transformation (Daley et al., 1990b).  If that was the case, BCR-
ABL would have to confer extensive self-renewal activity. Therefore a key question 
is whether BCR-ABL, of itself, bestows self-renewal activity to cells lacking this 
quality or altered cell fate decisions at the Ph+ LSC level.  There are several lines 
of evidence that strongly suggest that BCR-ABL does not confer self-renewal and 
that its net effect may be to reduce self-renewal activity.  Firstly, the clonal nature 
of CP CML, the ordered haemopoietic hierarchy and the fact that BCR-ABL is 
expressed across most lineages argues against the possibility that self-renewal 
activity could be conferred by BCR-ABL alone.  Secondly, while the CP CML LSC 
is thought to be phenotypically similar to normal HSC, it is not functionally 
equivalent.  Chronic myeloid leukaemia LSCs can be assessed in the same in vitro 
and in vivo assays used to functionally define HSCs (Eaves et al., 1985b; 
Udomsakdi et al., 1992a).  It has become apparent that CML LSCs have reduced 
in vitro measures of self-renewal and exhibit poorer engraftment and reduced 
transplantability in vivo compared to their normal counterparts or to other 
leukaemias (Jiang et al., 2002; Petzer et al., 1997; Schemionek et al., 2010; 
Udomsakdi et al., 1992b).  Consistent with the previous point, conditional 
expression of BCR-ABL in murine models of CML resulted in reduced stem cell 
function in transplantation experiments (Schemionek et al., 2010). Thirdly, and 
most importantly, various viral transduction studies where BCR-ABL was 
introduced into haemopoietic tissue indicate that leukaemia occurs only in the 
presence of an HSC population.  Thus transduction of whole BM or HSC 
populations may result in myeloid leukaemia but transduction of more stringently 
sorted populations of progenitors e.g. CMP or GMP uncontaminated with HSC will 
not. This is in direct contrast to other leukaemogenic translocations e.g. MOZ-TIF2 
(Daley et al., 1990a; Elefanty et al., 1990; Huntly et al., 2004; Perez-Caro et al., 
2009).  These experimental findings are supported by the clinical observation that 
BCR-ABL transcripts are transiently detectable in normal adults who remain 
healthy (Biernaux et al., 1995; Bose et al., 1998).  It can be inferred from these 
observations that the expression of BCR-ABL is only leukaemogenic in the correct 
cellular context; a cell with intrinsic or reacquired self-renewal capacity.   
It has also been observed that NUP98-HOXA9 expression in primitive 
haemopoietic cells markedly alters the balance between symmetrical and 
asymmetrical divisions compared to uninfected normal controls, whereas BCR-
ABL does not (Wu et al., 2007).  This is significant as NUP98-HOXA9 is 
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associated with AML and BC CML and suggests that in NUP98-HOXA9 LSC, 
intrinsic self-renewal mechanisms are massively deregulated, whereas BCR-ABL+ 
LSC have a more normal phenotype keyed to maintenance rather than expansion 
of the stem cell compartment.   
Thus the overall impression is that CP CML LSC can be considered to have 
intrinsically impaired self-renewal compared to normal HSC.  It has been 
suggested that the BCR-ABL-mediated autocrine production of cytokines, with a 
predominant role in proliferation and differentiation and the observed increase in 
cycling LSC might be responsible for this phenotype (Sloma et al., 2010).  
Deregulation of other signalling pathways may also contribute, for instance PTEN 
is shown to be down regulated in CML LSC, since PTEN has a predominantly cell 
cycle suppressive role. This occurs through inactivation of PI3K/AKT signalling, 
therefore reduced expression of this molecule would be expected to result in 
increased proliferation (Peng et al., 2010).  Likewise the FOXO family of 
transcription factors are inactivated by BCR-ABL signalling possibly via PI3K/AKT 
signalling (Naka et al., 2010a; Naka et al., 2010b).  FOXO proteins are 
transcription factors that transit between the nucleus and the cytoplasm (Tothova 
et al., 2007).  In the activated state they reside in the nucleus resulting in cell cycle 
inhibition and promotion of apoptosis signalling. Inactivation leads to their 
cytoplasmic relocation and degradation.  FOXO3a expression has a potential role 
in the maintenance of the LSC phenotype, therefore down regulation of FOXO3a 
by BCR-ABL might represent another mechanism reducing the self-renewal 
potential of BCR-ABL bearing cells (Naka et al., 2010b). Many other pathways 
have also been implicated, for example hypoxia inducible factor 1a (HIF1a) is 
critical for CML LSC maintenance through its action on CDKI (e.g. p16ink4a, p19arf 
or p57) (Zhang et al., 2012b).  Other pathways currently under scrutiny include 
TGF, ALOX5, BCL6 and JAK2 signalling (O'Hare et al., 2012).   
 Lastly, niche interactions are likely to play a significant role in vivo.  BCR-
ABL+ cells exhibit abnormal cell adhesion qualities and increased migration out of 
the BM.  Expression of BCR-ABL causes reduced expression of CXCR4 and CML 
cells are therefore less able to respond to stromal derived factor 1 (SDF-1, 
CXCL12) and home to the niche where they would be exposed to this protective 
environment and the multitude of cell-to–cell interactions and GF/cytokine 
signalling that occurs therein  (described in detail above) (Geay et al., 2005). This 
includes TGF a mediator of HSC quiescence recently reported as having a 
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significant role in maintaining the CML LSC population via FOXO signalling (Naka 
et al., 2010b).  It is noteworthy that TKI therapy reverses BCR-ABL effect on 
CXCR4 allowing redistribution to the protective niche (Jin et al., 2008).  
The internal mechanisms conferring self-renewal in CP CML are likely to be 
those that are active in normal HSC and have been discussed in detail in previous 
sections.  Certainly, expression of several HOX family members is evident in CML 
cells (Lawrence et al., 1995; Strathdee et al., 2007; Tedeschi et al., 2010; Wu and 
Minden, 1997).  Hypermethylation of HOXA5 (associated with differentiation (Fuller 
et al., 1999)) was associated with advancing disease (Strathdee et al., 2007). 
Furthermore, Sloma et al found that forced expression of a NUP98-HOXA10 fusion 
gene led to increase in LSC, as measured by serial LTC-IC cultures or 
xenotransplantation into NSG mice, in both normal cord and CP CML cells (Sloma 
et al., 2013).  This quality was largely restricted to the most primitive cell 
populations (CD34+38- or CD34+/Rho-) (Sloma et al., 2013).  Additionally BMI1, 
another key regulator of stem cell function is over-expressed in CML in comparison 
to non-malignant cells and co-expression with BCR-ABL in model systems is 
associated with expansion of the LSC population and enhanced self-renewal 
(Merkerova et al., 2007; Rizo et al., 2010; Sengupta et al., 2012a).  Furthermore, 
BMI1 expression levels correlate with disease stage and prognosis (Bhattacharyya 
et al., 2009; Mohty et al., 2007).  As discussed previously BMI1 is critical in normal 
HSC self-renewal where it represses key cell fate mediators e.g. INK4A locus 
CDKIs, and itself is a downstream target of developmental signalling pathways 
such as Hh. 
1.3.4.3 Embryonic developmental signalling in CML 
One area of significant interest is the role of the ligand-dependent 
developmental pathways Wnt and Hh in the context of CML.  The critical role of 
these pathways in directing and sustaining stem cell fate in HSC and CSC has 
been discussed in previous sections.  While these factors have a critical role to 
play in the development of the haemopoietic system, their role is greatly 
diminished in fully developed adult haemopoiesis (Gao et al., 2009; Hofmann et 
al., 2009; Koch et al., 2008; Zhao et al., 2007). In contrast to normal haemopoiesis, 
recent evidence suggests that they continue to play an important role in CML LSC 
survival and propagation both in chronic and advanced phases of the disease.   
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This is illustrated by the work of Jamieson et al who demonstrated that in 
BC CML, cells with LSC activity are found in the mature GMP progenitor 
population and that Wnt signalling through -catenin was responsible for the 
reacquisition of self-renewal activity in these cells (Jamieson et al., 2004).  
Inhibition of -catenin expression reduced BCR-ABL driven leukaemogenesis and 
transplantability in murine models underlining its potential importance in this 
context (Hu et al., 2008; Zhao et al., 2007).  Furthermore, adhesion of CML cells to 
MSC in in vitro culture led to direct activation of -catenin signalling via N-cadherin 
resulting in protection from TKI treatment (Zhang et al., 2013).  As a consequence 
of these observations, pharmaceutical strategies aimed at inhibiting Wnt signalling 
are under evaluation as a potential therapeutic approach to CML (Heidel et al., 
2012; Nagao et al., 2011). 
Hedgehog signalling is increased in BCR-ABL+ stem and progenitor cells 
becoming more active with disease progression (Long et al., 2011; Radich et al., 
2006).  Two groups have explored the effect of Smo deletion in murine models of 
CML (Dierks et al., 2008; Zhao et al., 2009).  Zhao et al used the Vav-Cre-Lox 
system to create Smo deficient mice from which to isolate Smo-/- HSC whereas 
Dierks et al utilised foetal liver cells from Smo deficient mouse embryos.  Both 
groups expressed BCR-ABL in these cells prior to transplant (Dierks et al., 2008; 
Zhao et al., 2009).  Despite differing approaches, broadly similar results were 
obtained. Smo deletion reduced LSC numbers and reduced incidence of 
leukaemia with prolonged latency in primary transplantation and greatly reduced 
capacity to recrudesce disease in secondary hosts.  Both groups performed 
complementary pharmacological inhibitor studies with cyclopamine demonstrating 
prolonged survival in diseased mice, reduced LSC population and lower functional 
activity in vivo and in vitro following cyclopamine treatment (Dierks et al., 2008; 
Zhao et al., 2009).   Importantly, the combination of TKI therapy with cyclopamine 
resulted in the largest reduction in LSC in vitro and in vivo (Dierks et al., 2008).  
Furthermore, constitutive activation of Smo resulted in accentuation of 
leukaemogenesis (Zhao et al., 2009).  Thus Hh signalling is active in CML (as 
opposed to normal homeostatic adult haemopoiesis) and has a clear role in the 
maintenance and expansion of the diseased LSC in these models of CML. 
Therefore Hh signalling presents a new potential therapeutic target in CML LSC.  
Early phase clinical evaluation of several targeted small molecule inhibitors of Hh 
signalling in CML is currently underway (see chapter 7, Table 7-1). 
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While the above work clearly demonstrates an important role for Wnt and 
Hh signalling in the maintenance of the LSC population in CML, it is curious that 
Wnt/Hh signalling is dispensable in normal HSC.  It is tempting to speculate that 
CML LSC are more dependent on the cell fate signals delivered along these 
pathways by virtue of their intrinsically impaired self-renewal characteristics, 
perhaps mediated by BCR-ABL as discussed above.  It is also striking that 
inhibition of either pathway independently has similar outcomes suggesting that, 
although there is significant similarity between both pathways, and both potentially 
interact at multiple levels, they are not redundant, and signals from both pathways 
are required to maintain the LSC phenotype (Dierks et al., 2008; Hu et al., 2008; 
Zhao et al., 2007; Zhao et al., 2009).  
One criticism that might be levelled at these studies is that they principally 
define the role of Wnt and Hh signalling in the advanced phase of the disease as 
they largely used primary samples from BC patients and retroviral mediated BCR-
ABL expression models of CML which have limitations in replicating CP disease 
(Koschmieder and Schemionek, 2011).  As has been discussed above, there may 
be significant differences between BC and CP disease in terms of dominant LSC 
phenotype, self-renewal kinetics, requirement for Hh or Wnt signalling and 
response to their inhibition. Therefore, it is not clear that these results can be 
extrapolated to CP disease.  This is significant because the majority of patients 
with CML are in CP and their numbers are increasing due to effective TKI therapy.  
Intervening with a directed stem cell therapy at an earlier stage might avert 
progression, limit chronic use of TKIs and through intervening at a point where 
disease burden is lower and accumulated additional mutations less prevalent 
might be expected to be more effective in eradicating the LSC population.  This 
theme will be expanded on in subsequent chapters. 
1.4 Microarray Analysis in Haematology  
1.4.1 Gene expression analysis  
Studying gene expression patterns involves measuring the quantity of 
different mRNA species in the cells or tissue of interest.  Historically, this required 
Northern blotting / in situ hybridisation or targeted PCR (Raval, 1994).  A pre-
condition of these techniques was that the target sequence required being known 
and specific primers for that sequence developed and applied experimentally.  A 
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corollary of this is that gene expression experiments were targeted at a small 
number of transcripts that were thought to be of interest, limiting the scope of these 
investigations.  Few phenotypic changes result from changes in expression of a 
single or even a few genes. Most require sequential changes in large 
transcriptional networks, and to understand how complex networks of positive and 
negative interactions vary from cell to cell requires a more global approach.   
Conventional gene expression techniques are limited in this regard as they are 
labour intensive and therefore experiments designed to interrogate these complex 
interactions experiments can quickly grow beyond manageable proportions.  
Advances in manufacturing, chemical and biological sciences and computing and 
biostatistics have combined to enable the development of increasingly 
comprehensive and high throughput processes e.g. gene expression microarray 
analysis and next generation sequencing techniques (Mortazavi et al., 2008; 
Schena et al., 1995).  Microarrays enable the simultaneous measurement of the 
abundance of tens to hundreds of thousands of transcripts simultaneously from a 
single sample and are therefore extremely powerful tools that have the ability to 
interrogate gene expression on a genome-wide scale.  As the technology has 
matured, these methods have become more comprehensive, reproducible and 
affordable. 
1.4.2 Anatomy and function of a gene expression microarray 
Fundamentally a gene expression microarray provides a means of 
simultaneously analysing gene expression across a very large number of gene 
targets throughout the known genome.  The basic principle that underlies this 
technology is hybridisation of a fluorescent or otherwise labelled target sample 
DNA or RNA fragment to unique and complementary probe sequence strands 
immobilised on a supporting structure.  
 The resultant signal (e.g. fluorescence output) can then be measured, 
related to the probe layout of the chip and the abundance of the target calculated.  
Microarray technology has moved forward at pace over the last 15 years and 
deserves some explanation (Auer et al., 2009; Bemmo et al., 2008; Dalma
Weiszhausz et al., 2006; Forozan et al., 1997; Ha et al., 2009; Lipshutz et al.; 
Robinson and Speed, 2007; Schena et al., 1995).  The most common type of 
commercially available gene expression microarrays are oligonucleotide arrays 
such as the Affymetrix Genechip Gene ST 1.0 array.  Here oligonucleotide probes 
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that have been designed to be complementary to a known or predicted open 
reading frame are synthesised directly onto a silicon chip by photolithography.  
Each probe sequence is similar in terms of optimal hybridisation temperature.  A 
microarray chip is comprised of millions of “features”, themselves consisting of 
millions of identical unique 25mer oligomer probe sequences.  Each target 
sequence is represented by several features scattered over the face of the chip.  
Additionally each chip has internal control probesets to assess sample labelling, 
hybridisation and background noise.  The experimental samples are prepared; 
RNA is extracted, processed and labelled with a fluorescent probe prior to 
application to the array chip.  Following incubation and washing, the fluorescent 
fragments of the original target are left hybridised to their specific probes.  The chip 
can be visualised by laser scanning and the intensity of fluorescence at each 
feature can be calculated and is representative of the amount of target binding at 
each feature.  The fluorescence at each identical feature can be summarised to 
provide a single overall value for fluorescence which, following normalisation and 
correction for background, is used to calculate the expression level of the target 
(Figure 1-8).  As the technology has improved it has become possible to shrink 
down the size of the individual features increasing the density of genome coverage 
and thereby the sensitivity and reproducibility of the assay.  Modern Affymetrix 
microarrays are designed to ensure that there are unique probe-set targets in 
every exon across the entire transcript, this reduces bias compared with older 3’ 
based arrays and ensures that alternate splicing variants are not missed.   
 
Figure 1-8:  Anatomy and function of an Affymetrix Genechip     
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1.4.3 Data handing – the bioinformatics pipeline 
High throughput, comprehensive experimental strategies like microarray 
analysis are extremely demanding in terms of data handling at all levels of 
analysis.  A summary of the bioinformatics pipeline is provided in Figure 1-9. 
Following scanning, a raw image file is produced in which all the feature 
fluorescence intensities are digitally represented (DAT file).  Initial quality control 
needs to be performed to ensure that sample preparation occurred correctly, that 
hybridisation occurred as expected and that the resulting images are complete with 
no physical flaws or obvious abnormalities.  Each feature intensity value is related 
to its associated probe and all probe level intensities are combined (CEL file).  This 
can be exported to a microarray analysis package for further analysis.  Since 
comparison between different chips will be required in most experiments, the raw 
expression data in each chip needs to be normalised for non-specific background 
fluorescence and differing fluorescence intensities between chips.  Additionally, 
the individual values for each probe set require to be summarised, providing a 
single value for each probe, exon target and finally each gene.  There are a variety 
of different approaches to these requirements and biostatistics packages will 
perform these manipulations during import.  Probably the most widely accepted 
method is to utilise robust multichip analysis (RMA) (Irizarry et al., 2003).  This 
method is applied across the whole set of arrays in an experiment, correcting for 
background, normalising across arrays to cause the medians and distributions of 
each chip to be similar, performing log transformation of the probe intensity values 
followed by a probe-set summarisation process e.g. median polishing (Irizarry et 
al., 2003).  
Following normalisation and summarisation, it is now possible to analyse 
the data for differences in gene expression.  Proprietary software – for instance 
Partek Genomic Suite (Partek GS) have been developed to make this process less 
onerous. Broad representations of whole transcript differences between the 
different groups can be made using grouping strategies like principle components 
analysis (PCA) (Peterson, 2003).  This enables the examination of the data as a 
whole between the groups of interest and allows broad conclusions to be drawn 
regarding the similarities or differences in the data sets.   Specific comparisons can 
be made between different groups, (e.g. malignant / non-malignant or treated / 
untreated) to determine the differential expression level of any target and 
significance analysis performed using parametric (T-test or ANOVA) or non-
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parametric (e.g. rank product analysis) tests.  Given the comprehensive nature of 
array analyses, the treatment of multiple comparisons is particularly relevant and 
must be addressed in order to provide meaningful interpretation of the data.  The 
problem briefly stated is that the more statistical comparisons that are made, the 
greater the likelihood that some will be found to be significant that are in fact due to 
random chance (false positive results).   Some method of controlling for the 
number of comparisons is therefore required.  One method is to employ 
Bonferonni’s correction, which simply requires that to be considered significant, 
any member of a series of comparisons must have a p value of less than the 
accepted level of significance for the whole family divided by the number of 
members in the family (i.e. if p<0.05 was considered significant for a family of 100 
tests, each member would be significant with a p value of <0.0005).  This controls 
for the occurrence of false positives by preventing the sum of p values for the 
individual comparisons rising above the originally accepted significance level for 
the whole family.  It is highly conservative and may lead to an unacceptably high 
false negative rate, particularly in the context of microarray and related analyses 
(Abdi, 2007).  A different approach is to utilise a false discovery rate (FDR) 
correction.  The FDR is the proportion of false positives that would be acceptable 
within the significant results returned (i.e. FDR 0.05 in1000 significant tests implies 
that 50 are likely to be falsely positive).  This is less conservative and in many 
circumstances is a more appropriate correction for hypothesis generating 
experiments like global gene expression analysis (Benjamini and Hochberg, 1995; 
Storey and Tibshirani, 2003).   
By making contrasts between the experimental groups and controlling for 
the multiple comparisons undertaken, a list of differentially expressed genes can 
be produced.  Such lists provide specific target expression information but can be 
difficult to synthesise. It may not be readily apparent how the differential 
expression of these genes is ultimately related to (a) each other or to (b) the 
phenotype of the cell.  Biological understanding of the expression data requires it 
to be placed in a functional context (Thomas et al., 2007).  Here gene annotation 
and ontological classification can be of assistance. Gene ontologies are consistent 
vocabularies that describe gene function in a cellular context across species.  
There are three broad classifications, cellular components, molecular function and 
biological process, and with each hierarchical step the classification becomes 
more specific. Thus gene expression data can be related to expected molecular, 
92 
 
 
biological or cellular function (www.geneontology.org).  Finally the data can be 
analysed using known pathway interactions and relationships utilising pathway 
analysis tools e.g. Kyoto Encyclopedia of Genes and Genomes (KEGG) 
classification or Ingenuity Pathway Analysis (IPA), providing detailed information 
about relative gene expression of elements with consistent or antagonistic 
biological functions (www.genome.jp/kegg and www.ingenuity.com).  In this way 
expression data can begin to provide a more comprehensive understanding of the 
transcriptional events that underpin the phenotype of the cell and a global insight 
into the interactions and networks that cooperate to influence these cells (see 
Figure 1-9 below). 
 
Figure 1-9:  The bioinformatics pipeline indicating the process from samples 
hybridisation, through statistical analysis and ultimate biological interpretation. 
1.4.4 Limitations and validation of microarray analysis 
Microarray analysis is the first step in hypothesis generation.  Gene 
expression activity can yield important insights into the biological activity of a cell 
population however no direct information regarding protein abundance or activity 
of any of the multitude of post transcriptional regulatory processes.  Additionally 
the microarray platform utilised, how the data is treated and analysed statistically 
can have significant effects on the results obtained.  This is highlighted by the lack 
of consistent data from similar studies in some instances (Fortunel et al., 2003).    
It is imperative that the findings are corroborated in some way.  Corroboration 
might include demonstration of modulation of the relevant effector molecule e.g. at 
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protein level or the use of a secondary focused measure of gene expression e.g. 
qRTPCR to ensure that similar results are obtained.  
1.4.5 Microarrays in normal and malignant haemopoiesis 
Microarray analysis of gene expression lends itself to the study normal and 
malignant HSC.  The key advantages of this approach are that it can be employed 
on very limited quantities of starting material (a prerequisite in the study of very low 
abundance populations like relatively pure stem cell populations) and that a 
snapshot of the entire transcriptional activity of a cell population is provided 
allowing an appreciation of the prevailing biological processes that are active and 
the potential inter-relations and networks that are formed.  Since their 
development, microarrays have been utilised extensively in the characterisation of 
normal and malignant haemopoiesis, classification of haemopoietic malignancies, 
analysis of factors that are associated with prognosis and progression and cellular 
responses to treatment (Forsberg et al., 2006; Golub et al., 1999; Nunoda et al., 
2007; Rosenwald et al., 2002; Valk et al., 2004; Villuendas et al., 2006).  Global 
microarray analysis has also been used to try and establish the central expression 
programmes that characterise stem cell behaviour in haemopoietic and other 
tissue stem cells (Fortunel et al., 2003; Ivanova et al., 2002; Ramalho-Santos et 
al., 2002). However, these studies did not provide concordant results (Fortunel et 
al., 2003).    Subsequent analysis of HSC and their progeny have provided detailed 
information regarding the transcriptional activity associated with HSC populations 
and differentiation to progenitor populations (Chambers et al., 2007; Liu et al., 
2007; Novershtern et al., 2011; Terskikh et al., 2003).   
The apotheosis of this investigative approach is found in a recent study by 
Novreshtern et al comparing gene expression across 211 human samples 
representing 38 prospectively isolated haemopoietic populations extending from 
HSC to mature differentiated lymphoid and myeloid cells (Novershtern et al., 
2011).  Transcriptional activity was divided into 80 groups or modules, many of 
which had lineage-specific function and proposed transcriptional networks 
operating to establish and sustain module expression in different cell populations 
(Novershtern et al., 2011).  These results provide a comprehensive insight into the 
complex nature of transcriptional regulation occurring throughout haemopoiesis. 
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1.4.5.1 Gene expression studies in CML 
Gene expression profiling by microarray analysis has been utilised 
extensively in the study of CML.  The focus of these gene expression experiments 
has been to understand the differences between normal and CML haemopoiesis at 
the gene expression level, to investigate the effect of treatment and mechanisms 
of resistance to treatment, to understand the biology of disease progression and to 
try and produce clinically useful tools to predict response to treatment and 
prognosis.   It is not necessarily easy to directly compare these studies, microarray 
technology advanced rapidly and therefore the platforms on which these 
experiments were performed was heterogeneous and the experimental design 
differed, likewise the cell populations used were disparate.  Despite these 
problems there are certain broad themes that have repeatedly come to the fore.  A 
brief discussion of the contribution of microarray study of primary CML cells and to 
cells derived from different stages of the disease is relevant. 
1.4.5.2 Gene expression profiles associated with CML progression 
 An area of great interest relates to the transcriptional events that presage, 
accompany or drive disease progression in CML. The most comprehensive gene 
expression study in this area was performed by Radich et al, who looked at the 
expression profiles in CD34+ cells derived from 42 patients with CP CML, 17 
patients with AP CML and 32 patients with BC CML (of whom 4 were in remission).  
Broadly speaking they found that – at a gene expression level - CML behaves like a 
2 stage (chronic and advanced) rather than the accepted 3 stage model of 
progression (Radich et al., 2006).  In comparison with CP CML, advanced CML 
exhibited profound up regulation in many gene groups involved in cellular 
metabolism, DNA replication, RNA transcription and processing, apoptosis, cell 
structure and adhesion and up regulation of several genes with potential 
oncogenic functions and down regulation of several tumour suppressors (Radich et 
al., 2006).  They noted up regulation of preferentially expressed antigen in 
melanoma (PRAME; which has a known role in inhibition of myeloid 
differentiation), the oncogene Wilms tumor 1 (WT1), growth arrest-specific 2 
(GAS2; involved in cell cycling and apoptosis), components of the IL3 receptor and 
the growth regulator suppressor of cytokine signalling 2 (SOCS2), whereas they 
noted down regulation of several heat shock proteins (HSP) (Radich et al., 2006).  
They also noted down regulation of various factors with potential roles in regulating 
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HSC fate in BC CML including FBJ murine osteosarcoma viral oncogene homolog 
(FOS), Cbp/p300-interacting transactivator 2 (CITED2) and the kruppel-like factor 
4 (KLF4), the serine (or cysteine) proteinase inhibitors B8 and B10 and cell 
structure and adhesion molecules including cadherin (CDH) 1 and CXCR4 (Du et 
al., 2012; Ishizawa et al., 2011; Kharas et al., 2007; Okada et al., 1999; 
Przygodzka et al., 2010; Radich et al., 2006; Sugiyama et al., 2006). 
Critically, they also found that components of the developmental pathways 
were deregulated in advancing CML.  Of particular interest GLI2, the Hh signalling 
mediator was the second most up regulated gene in their dataset and several 
members of the Wnt signalling pathway were differentially regulated lending 
credence to their putative role in advanced phase CML.  
1.4.5.3 A CML gene expression signature 
The earliest microarray studies in primary CML samples were in BM 
mononuclear cells (MNC).  Nowicki et al studied gene expression in 15 CML 
specimens (5 in CP, 5 in BC BM and 5 BC PB) compared to 3 normal BM and 4 
PB specimens in a limited microarray (Nowicki et al., 2004).  They found 
considerable heterogeneity between specimens and under half of the probesets in 
their array (5315/12530) gave useable signal, but nonetheless significant 
differences between normal and CML, according to disease stage and whether BM 
or PB derived (Nowicki et al., 2004).  Many of the genes identified were known to 
be regulated by BCR-ABL.  Broad categories included promotion of cell cycling, a 
mixed effect on cellular apoptosis apparatus, up regulation DNA repair apparatus, 
down regulation of adhesion mediators, up regulation of metabolic genes, 
differential regulation of mediators of chromosomal dynamics and reduced 
expression of mediators of the cellular response to pathogens (Nowicki et al., 
2004).  
Diaz-Blanco et al and Kronenwatt et al both employed CD34+ selection in 
BM samples to obtain a purer primitive cell population to investigate CP CML 
specific gene expression (Diaz-Blanco et al., 2007; Kronenwett et al., 2005).    
Kronenwatt et al compared 5 samples from patients with newly diagnosed CML 
with 10 normal volunteers using a limited array of 1185 probes; 158 genes were 
differentially regulated.  Diaz et al compared peripheral or BM CD34+ cells from 8 
healthy donors with PB or BM from 9 patients with CP CML at diagnosis using a 
more comprehensive microarray of 8746 probes and found 1539 differentially 
96 
 
 
expressed genes (Diaz-Blanco et al., 2007).  Again, in addition to up regulation of 
BCR-ABL signalling mediators and targets, both groups found significant up 
regulation of factors involved in driving the cell cycle and down regulation of 
several factors known to retard the cell cycle (Diaz-Blanco et al., 2007; Kronenwett 
et al., 2005).  Both groups also demonstrated differential expression of cell 
adhesion molecules, reduction in expression of several factors involved in DNA 
damage response and detoxification, altered expression of various GFs and their 
receptors and differential expression of several key transcription factors (Diaz-
Blanco et al., 2007; Kronenwett et al., 2005).  Interestingly both groups also noted 
slight increases in the expression of key factors involved in the regulation of stem 
cell fate and self-renewal in CP CML CD34+ cells (Diaz-Blanco et al., 2007; 
Kronenwett et al., 2005).  Kronenwett et al also noted increased expression of 
neurologically related G protein signalling molecules such as neurotrophin 3 in 
addition to up regulation of the oncogenes SKI and cMYC but significant down 
regulation of FOS, V-jun avian sarcoma virus 17 oncogene homolog (JUN) and v-
myb avian myeloblastosis viral oncogene homolog-like 2 (MYBL2) (Kronenwett et 
al., 2005).  These authors also reported a marked disparity in the expression of key 
differentiation-associated genes between CP CML and normal CD34+ samples. 
This included marked up regulation of erythroid associated genes (e.g. 
haemoglobin, GATA1, kruppel-like factor 1 (KLF1) or the transferrin receptor), but 
significant down regulation of genes associated with a granulocyte/monocyte 
phenotype (e.g. myeloperoxidase [MPO], neutrophil elastase [ELA2] or 
CCAAT/enhancer binding protein  [C/EBP] (Diaz-Blanco et al., 2007). They also 
noted increased expression of TGF signalling related genes (Diaz-Blanco et al., 
2007). Interestingly in both studies there was no significant difference between 
circulating or BM CD34+ CP CML cells at a transcriptional level (Diaz-Blanco et al., 
2007; Kronenwett et al., 2005).   
A major problem in these studies is the heterogeneity of the cell tissue 
under investigation.  Gene expression data produced by microarray studies 
necessarily reflects the composition of the cell populations analysed and the 
expression data is essentially an average value from all cells within the population 
(Szaniszlo et al., 2004).  While CD34+ selected populations were utilised in the two 
studies described, the CD34+ population is itself comprised of both stem and 
progenitor fractions and varied in composition between normal volunteers and CP 
CML patients.  One would expect even greater diversity in the MNC populations 
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used by Nowicki et al, possibly reflected in the heterogeneity of their results 
(Nowicki et al., 2004).  However the problem is illustrated particularly well by Diaz-
Blanco et al who found an excess of MEP and a significant reduction in HSC and 
GMP in CP CML samples compared to normal samples in their study.  The gene 
expression profile thus obtained reflected these differences (Diaz-Blanco et al., 
2007).   
In order to further investigate the gene transcriptional profile in CP CML and 
avert the problems associated with sample heterogeneity, the same group 
performed an additional microarray experiment on stem and progenitor 
populations derived from the BM of 6 newly diagnosed patients with CP CML and 
5 normal patients (Bruns et al., 2009).  Using cell sorting, they collected HSC 
(CD34+/38- ), CMP (CD34+/38+/CD45RA-IL3Rlo), GMP 
(CD34+/38+/CD45RA+/IL3Rlo) and MEP (CD34+/38+/CD45RA-/IL3R-) 
populations from the BM MNC populations.  They found, in terms of absolute 
numbers, CML and normal HSC were in approximate proportion, an excess of 
progenitors was seen in the CML populations with the most enriched populations 
being CMP and MEP.  They then analysed the gene expression signature between 
sub-populations in normal and leukaemic samples.  In this analysis the authors 
found many similarities with their previous study, for example, CML HSC had a 
more mature phenotype and was more akin to normal CMP progenitors, than 
normal HSC.  The authors then compared normal and leukaemic progenitors.  In 
this comparison, 362 genes were up regulated and 252 genes down regulated in 
CML LSC with respect to normal HSC.  Again, the major functional groups 
highlighted were cell cycle, adhesion, transcriptional regulation and stem cell fate.  
Notably adhesion factors like CDH2 and CXCR4 were significantly down regulated 
in this population (Bruns et al., 2009).  Additionally, there was significant down-
regulation of critical transcription factors such as C/EBP, nuclear receptor 4 A2 
and A3 (NR4A2 & 3) and KLF2 & 11 and other molecules (e.g. SOX4, ectopic viral 
integration site [EVI] 2B, CD133, FLT3, PTEN and CD53) with known involvement 
in primitive haemopoiesis (Bruns et al., 2009). 
As discussed above, while TKI therapy can rapidly reduce populations of 
proliferating differentiated cells, a population of primitive quiescent (non-cycling – 
G0) but entirely functional leukaemic cells persists.  To more rigorously focus on 
this population Affer et al and Graham et al performed global gene expression 
profiling on normal and leukaemic quiescent and cycling CD34+ selected cell 
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populations sorted by Hoecht 33342 and Pyronin Y staining using Affymetrix 
oligonucleotide gene expression arrays (HG-U133A) (Affer et al., 2011; Graham et 
al., 2007). 
Graham et al compared G0 and cycling populations from mobilised CD34
+ 
cells from 3 normal volunteers and from 5 patients with CP CML (Graham et al., 
2007).  This work indicated that the transcriptional difference between normal 
quiescent and dividing cells was greater (188 genes differentially expressed at 
>3fold) than the equivalent comparison in CP CML (37 genes differentially 
expressed at >3 fold) and highlighted a list of 168 genes differentially expressed at 
>3 fold between each G0 population.  Not unsurprisingly, one of the key 
differentially expressed groups in G0 vs dividing cells in normal and CP CML was 
those related to cell cycle status (Graham et al., 2007).  In normal haemopoiesis 
this was also associated with up regulation of genes related to DNA repair and 
oxygen transport; this was not the case in CP CML.  Additionally, G0 cells 
expressed various pro-inflammatory chemokine ligands including CXCL1, 2, 3 and 
6 (Graham et al., 2007).  Specifically, looking at the differences between the 
dividing CML and normal populations, there were relatively few differences. 
However, there was increased expression of mitotic spindle and DNA structure-
related genes but relative down regulation of antigen presentation, chemotaxis and 
chemokine activity-related genes (Graham et al., 2007).  Looking at the similar 
comparison between quiescent cells, CP CML G0 CD34
+ cells had enriched 
expression of various categories of genes involved in DNA replication, cell cycle, 
mitosis and spindle regulation as well as haemoglobin and oxygen transportation 
genes (Graham et al., 2007).  
 Affer et al reported significant differences in the gene expression signature 
of CML G0 cells compared to normal G0 cells, although it must be noted that their 
comparison was between CD34+ G0 cells from 4 normal BM samples and 8 PB 
CML samples (5 CP and 3 AP) (Affer et al., 2011). The authors found significant 
differential expression of genes involved in many of the functional groupings 
discussed in the previous arrays; that is perturbed cell cycle regulation and mitotic 
apparatus, apoptosis signalling and DNA replication in addition to stem cell related 
factors and key differentiation associated genes (Affer et al., 2011).  With respect 
to cell cycle, expression of genes favouring cell cycle progression and inhibition 
was seen in approximately equal numbers.  Similarly to Bruns et al, the authors 
found that the expression of many factors associated with an HSC phenotype in 
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normal haemopoiesis were significantly down regulated in the CML G0 population 
compared to the normal G0 population (Affer et al., 2011; Bruns et al., 2009).  
These included CD133, NMYC, FLT3, HOXA3, HOXA5, HOXB3, HOXB6 and the 
Notch target HES1.  Similarly, they saw down regulation of key members of the 
polycomb complexes PRC1 and PRC2.   In contrast, up regulation of key 
differentiation associated genes was seen, including KLF1, GATA1 and CD36.  
Similarly to the study of Diaz-Blanco et al, megakaryocytic and erythroid 
associated genes were preferentially expressed in CML G0 cells. They concluded 
that the gene expression signature of the CML G0 populations analysed was 
significantly more mature than that of the normal G0 population (Affer et al., 2011). 
Thus, the congruent findings of the gene expression studies thus performed 
are an up regulation of mediators and ultimate genetic targets of BCR-ABL 
signalling, in most cases, a general activation of cell cycle, DNA replication, 
mitosis and proliferation machinery accompanied by reduction in expression of 
elements of the DNA damage response apparatus.  Most confirm a reduction in 
cellular adhesion and adhesion molecules.  Some reported intriguing and 
unexpected findings such as the lower expression of genes involved in antigen 
presentation and cellular response to infection in CML.  The picture with regard to 
HSC-associated molecules and drivers of stem cell fate and differentiation is more 
complicated with some studies reporting up regulation of HSC-associated factors, 
while others reporting a profound down regulation of HSC factors and up 
regulation of differentiation associated factors in the CML LSC populations 
analysed, suggesting a more mature transcriptional phenotype in these 
populations.   
1.5 Aims  
It was in this context that I sought to better define the key differences 
between normal and leukaemic HSC at a transcriptional level.  In particular, I 
wished to determine whether there was evidence of deregulated self-renewal 
signalling - particularly through the Hh pathway - in CML LSCs or their progeny 
compared to normal haemopoiesis.  Lastly I sought to establish whether a novel, 
clinically relevant inhibitor of Hh signalling influenced in vitro measures of self-
renewal in CP CML. 
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1.5.1 Specific objectives 
 
(1) To establish the global gene expression programme in pure populations of the 
most rigorously defined stem and progenitor populations identified by surface 
immunophenotype in non-leukaemic patient samples and in CML through a 
combination of flow sorting and gene microarray analysis using modern 
Affymetrix oligonucleotide gene chips. 
(2) To establish whether Hh signalling is active in the CP CML CD34+ cell 
population. 
(3) To establish whether targeted inhibition of Hh signalling in CP CML CD34+ 
cells: 
a. Resulted in measurable transcriptional differences. 
b. Affected in vitro culture through measurement of apoptosis, proliferation 
and cell cycle status. 
c. Resulted in reduced in vitro measures of self-renewal in CP CML CD34+ 
cells.  
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2 Materials and Methods 
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2.1 Materials 
2.1.1 Tissue culture 
2.1.1.1   Tissue culture plastics 
Plastics Supplier 
Cryotubes Fisher Scientific, Loughborough, UK 
Falcon tubes (15, 50mL)  Fred Baker Scientific, Cheshire, UK 
FACS tubes (sterile/unsterile) BD Biosciences, Oxford, UK 
Media filtration system Scientific Lab supplies, Coatbridge, UK 
Syringes (5, 10, 20, 50 mL) Invitrogen, Paisley, UK 
Syringe filters (22 micron) Invitrogen, Paisley, UK 
Blunt ended needles Invitrogen, Paisley, UK 
Eppendorf tubes (0.5 / 1.5ml) Invitrogen, Paisley, UK 
Non-adherent tissue culture dishes (35mm 
/ 100mm) 
Scientific Lab supplies, Coatbridge, UK 
Non-adherent tissue culture flasks (75cm3) Scientific Lab supplies, Coatbridge, UK 
Pipette tips  
(p10, p20, p100, p200, p1000) 
Greiner Bio one, Gloucestershire, UK 
Sterile tissue culture pipettes  
(5, 10, 25, 50mL) 
Scientific Lab supplies, Coatbridge, UK 
Flat bottomed culture plates 
(6, 12, 24, 48, 96 well) 
Greiner Bio one, Gloucestershire, UK 
Flat bottomed culture plates coated with 
collagen type 1 (6 and 24 well) 
Scientific Lab supplies, Coatbridge, UK 
White opaque culture plates (96-well) Scientific Lab supplies, Coatbridge, UK 
Tissue culture flasks (25, 75, 150 cm3 ) Greiner Bio one, Gloucestershire, UK 
Haemocytometer Hawksey, UK 
2.1.1.2   Tissue culture reagents 
Reagent Supplier 
β-mercaptoethanol Invitrogen, Paisley, UK 
Bovine serum albumin (BSA) Sigma-Aldrich, Dorset, UK 
Bovine serum albumin, Insulin/Transferrin 
(BIT)  
Stem Cell Technologies, BC, Canada 
BrdU incorporation proliferation assay kit R&D systems, Abingdon, UK 
Bright Glo Luciferase system Promega, UK 
CliniMACS CD34+ beads Miltenyi Biotec, Auburn CA 
CliniMACS PBS/EDTA buffer Miltenyi Biotec, Auburn CA 
CliniMACS tubing set and columns Miltenyi Biotec, Auburn CA 
Demecolcine (Colcemid; N-Deacetyl – N – 
Methylcolchicine) 
Invitrogen, Paisley, UK 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, Dorset, UK 
DNase I (Recombinant human DNAse) Stem Cell Technologies, BC, Canada 
Dulbecco’s Modified Eagle Medium (DMEM) Sigma-Aldrich, Dorset, UK 
Dulbecco’s Phosphate Buffered Saline (DPBS) Sigma-Aldrich, Dorset, UK 
Ethanol 100%  Sigma-Aldrich, Dorset, UK 
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Foetal calf serum (FCS) Invitrogen, Paisley, UK 
G418 (1013-027) Invitrogen, Paisley, UK 
Ham’s F12 / DMEM (F12/DMEM) Invitrogen, Paisley, UK 
Hanks Balanced Salt Solution (Ca2+ Mg2+ free) 
(HBSS-CMF) 
Invitrogen, Paisley, UK 
Horse serum (HS) Invitrogen, Paisley, UK 
Human serum albumin 20% (HSA 20%) Baxter, NHS pharmacy 
Human serum albumin 4.5% (HSA 4.5%) Scottish National Blood Transfusion Service,  
Hydrocortisone 21 – Hemisuccinate  Stem Cell Technologies, BC, Canada 
Hygromycin Invitrogen, Paisley, UK 
Iscove’s Modified Dulbecco’s Media (IMDM)  Invitrogen, Paisley, UK 
L-glutamine 200mM (100x) Invitrogen, Paisley, UK 
Low density lipoprotein 10mg/mL (LDL)   Sigma-Aldrich, Dorset, UK 
Magnesium Chloride (1.25M) Sigma-Aldrich, Dorset, UK 
Methocult H4034 Stem Cell Technologies, BC, Canada 
Mitomycin C Invitrogen, Paisley, UK 
Myelocult 5100 Stem Cell Technologies, BC, Canada 
Penicillin (5000u)/ streptomycin (5mg/ml) 
solution (Pen/Strep) 
Invitrogen, Paisley, UK 
Porcine Gelatin (Sigma – 2500 – type A)  Sigma-Aldrich, Dorset, UK 
Recombinant human erythropoietin (EPO) NHS pharmacy 
Recombinant human Flt-3 ligand (Flt3L) Stem Cell Technologies, BC, Canada 
Recombinant human GCSF (GCSF) Chugai Pharma, London, UK 
Recombinant human IL3 (IL3)  Stem Cell Technologies, BC, Canada 
Recombinant human IL6 (IL6) Stem Cell Technologies, BC, Canada 
Recombinant human Indian Hedgehog Ligand 
N-Terminus C24II modified (IHH) 
R&D systems, Abingdon, UK 
Recombinant human SCF (SCF) Stem Cell Technologies, BC, Canada 
Recombinant human Sonic Hedgehog Ligand 
N-Terminus C24II modified (SHH) 
R&D systems, Abingdon, UK 
RPMI 1640 medium (RPMI) Invitrogen, Paisley, UK 
Sodium azide Sigma-Aldrich, Dorset, UK 
Sonic Hedgehog ELISA Kit  Abcam, UK 
Sterile water (dH20) Baxter Healthcare, Northampton, UK 
Tri-sodium citrate (0.155M) Sigma-Aldrich, Dorset, UK 
Trypan blue solution (0.4%) Sigma-Aldrich, Dorset, UK 
Trypsin-EDTA (0.25%) Sigma-Aldrich, Dorset, UK 
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2.1.1.3   Composition of tissue culture media 
2.1.1.3.1   Medium for culture of K562 cell line (RPMI*) 
Constituent Volume 
RPMI 1640 460mL 
FCS 50mL 
L-Glutamine 5mL 
Penicillin / Streptomycin 5mL 
2.1.1.3.2   Medium for culture of GLI-Luc TM3 cell line 
Constituent Volume 
1:1 mix of Hank’s F12 medium and DMEM with  
HEPES 15mM 
440mL 
FCS 50mL 
Horse serum (HS) 5mL 
Penicillin / Streptomycin 5mL 
Add  200L of  G418 solution per 20mL media for selection 
2.1.1.3.3   Medium for culture of modified M210B4 cell line 
Constituent Volume 
RPMI 1640 430mL 
FCS 50mL 
Penicillin / Streptomycin 10mL 
L-Glutamine 10mL 
Every 2 weeks add 160L of  G418 solution and 25uL of Hygromycin B per 20mL media 
2.1.1.3.4   Medium for culture of modified SL/SL cell line 
Constituent Volume 
DMEM 430mL 
FCS 50mL 
Penicillin / Streptomycin 10mL 
L-Glutamine 10mL 
Every 2 weeks add 320L of  G418 solution and 50uL of Hygromycin B per 20mL media 
2.1.1.3.5   Serum Free Medium (SFM) for primary cell culture 
Constituent Volume 
IMDM 97.25mL 
BIT 25mL 
L-Glutamine 1.25mL 
Penicillin / Streptomycin 1.25mL 
-Mercaptoethanol  (200mM) 250uL (400M) 
LDL (10mg/mL) 250uL (40g/mL) 
Filter sterilise through 0.22m filter before use 
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2.1.1.3.6    SFM with high concentration 5 growth factor cocktail (SFM+HGF) 
Constituent Volume Final Concentration 
SFM 10mL  
IL3 (50g/mL) 4L 20ng/mL 
IL6 (50g/mL)  4L 20ng/mL 
GCSF (50g/mL)  10L 20ng/mL 
SCF (50g/mL) 20L 100ng/mL 
Flt3L (50g/mL) 20L 100ng/mL 
Filter sterilise through 0.22m filter before use 
2.1.1.3.7   SFM with low concentration 5 growth factor cocktail (SFM+LGF) 
Constituent Volume Final Concentration 
SFM 50mL  
IL3 (50g/mL) 1L 1ng/mL 
IL6 (50g/mL)  1L 1ng/mL 
GCSF (50g/mL)  0.5L 1ng/mL 
SCF (50g/mL) 4L 20ng/mL 
Flt3L (50g/mL) 4L 20ng/mL 
2.1.1.3.8     Methocult for colony forming cell assay and re-plating assays 
Constituent Volume Composition 
Methocult™ H4034 100mL IMDM, Methylcellulose, BSA, FBS, 2-mercaptoethanol 
rh SCF, rh GM-CSF, rh G-CSF, rh IL-3, rh  EPO 
2.1.1.3.9 Myelocult supplemented with hydrocortisone for LTC-IC culture   (long 
term myeloid culture medium - LTMCM) 
Constituent Volume Final Concentration 
Myelocult 5100 500mL  
Hydrocortisone hemisuccinate (1x10-4M) 1mL 0.2x10-6M 
2.1.1.4 Composition of tissue culture solution  
2.1.1.4.1   Thawing solution for cryopreserved primary cells (DAMP) 
Constituent Volume Final Concentration 
DPBS 418.75ml  
Tri-sodium citrate (0.155M) 53ml 8.2mM 
HSA 20% 25ml 1% 
DNase I (~2500U/1mL vial)  2ml 10U/mL 
MgCl2 (1.0M) 1.25ml 2.5mM 
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2.1.1.4.2  PBS/2%FCS washing buffer 
Constituent Volume 
DPBS 490mL 
FCS 10mL 
2.1.1.4.3   PBS/20%FCS quenching solution 
Constituent Volume 
DPBS 400mL 
FCS 100mL 
2.1.1.4.4   Cryopreservation solution for primary cells (2x final concentration) 
Constituent Volume 
4.5% HSA 80mL 
DMSO 20mL 
2.1.1.4.5   Cryopreservation solution for cell lines (2x final concentration) 
Constituent Volume 
90% FCS 80mL 
DMSO 20mL 
2.1.1.4.6   LTC-IC harvest washing buffer  
Constituent Volume 
IMDM 500mL 
FCS 2mL 
2.1.1.4.7   Annexin buffer 
Constituent Volume 
Annexin 10x buffer 1ml 
IMDM 9ml 
2.1.1.4.8   Cell culture equipment 
Equipment  Supplier 
Inverted microscope with camera Nikon 
Spectramax M5 plate reader Molecular Devices 
2.1.1.4.9   Drugs 
Reagent Supplier 
LDE225 Novartis Pharmaceuticals, Basel, Switzerland 
LEQ506 Novartis Pharmaceuticals, Basel, Switzerland 
nilotinib Novartis Pharmaceuticals, Basel, Switzerland 
purmorphamine Santa Cruz Biotechnology Inc, Santa Cruz, California, USA 
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2.1.2   Flow Cytometry 
2.1.2.1   Flow cytometry reagents 
Reagent Supplier 
7  Amino Actinomycin D (7AAD, Viaprobe solution) BD Biosciences, Oxford, UK 
Annexin V – FITC or Annexin V - APC BD Biosciences, Oxford, UK 
Annexin V 10x Buffer BD Biosciences, Oxford, UK 
Anti-mouse IgG2a FITC  BD Biosciences, Oxford, UK 
Anti-rabbit IgG FITC or PE  Sigma-Aldrich, Dorset, UK 
Anti-rabbit IgG PE  BD Biosciences, Oxford, UK 
Anti-mouse IgG2a FITC BD Biosciences, Oxford, UK 
Anti-goat FITC Santa Cruz Biotechnology Inc 
CFSE Invitrogen, Paisley, UK 
FACS flow solution Becton Dickinson, Oxford, UK 
FACS clean solution Becton Dickinson, Oxford, UK 
Fix and Perm Kit  Invitrogen, Paisley, UK 
Propidium Iodide (PI) BD Biosciences, Oxford, UK 
2.1.2.2   Flow cytometry antibodies 
Reagent Supplier 
Mouse anti-human IgG  Cell Signaling Technology, Inc. Boston 
Rabbit anti-human IgG Cell Signaling Technology, Inc. Boston 
Goat anti-human IgG Santa Cruz Biotechnology Inc, California 
Mouse anti-human-CD34 FITC / PE / APC 
antibodies 
BD Biosciences, Oxford, UK 
Mouse anti-human-lin cocktail -FITC BD Biosciences, Oxford, UK 
Mouse anti-human-CD123–APC antibody BD Biosciences, Oxford, UK 
Mouse anti-human-CD34 PERCP antibody BD Biosciences, Oxford, UK 
Mouse anti-human-CD45 FITC antibody BD Biosciences, Oxford, UK 
Mouse anti-human-CD45RA Pacific blue 
antibody 
BD Biosciences, Oxford, UK 
Mouse anti-human-CD90-PE antibody BD Biosciences, Oxford, UK 
Mouse anti-human-CD133-PE antibody BD Biosciences, Oxford, UK 
Mouse anti-human-CD38-PECy7 BD Biosciences, Oxford, UK 
Mouse anti-human-CD133-PE antibody BD Biosciences, Oxford, UK 
Mouse IgG1a FITC BD Biosciences, Oxford, UK 
Mouse IgG1a PE BD Biosciences, Oxford, UK 
Mouse IgG1a PERCP BD Biosciences, Oxford, UK 
Mouse IgG1a APC BD Biosciences, Oxford, UK 
Rabbit anti-human-Ki67 FITC antibody Cell Signaling Technology, Inc. Boston 
Rabbit anti-human-Ki67 APC antibody Cell Signaling Technology, Inc. Boston 
Mouse anti-human-lineage cocktail (lin1), FITC 
(CD3, 4, 14, 16, 19, 20, 56)    
BD Biosciences, Oxford, UK 
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2.1.2.3 Composition of flow cytometry solutions 
2.1.2.3.1   Flow cytometry fixation solution  
Constituent Volume 
DPBS 49.5mL 
39% Formaldehyde solution 0.5mL 
2.1.2.3.2   Flow cytometry permeabilisation solution 
Constituent Volume 
DPBS 49.9mL 
Triton-X-100 0.1mL 
2.1.2.3.3   FACS Equipment 
Constituent Volume 
FACS Aria BD Biosystems 
FACS Canto BD Biosystems 
2.1.3 Molecular Biology 
2.1.3.1   Molecular biology reagents 
Equipment Supplier 
RNA easy mini kit Qiagen, Crawley, UK 
RNA easy micro kit Qiagen, Crawley, UK 
RNA later Qiagen, Crawley, UK 
DNAse 1  Qiagen, Crawley, UK 
Agilent Bioanalyser kit  Agilent Technologies, UK Ltd Berkshire 
High capacity reverse transcription kit  Applied Biosystems, Warrington, UK 
Pre-amplification master mix Applied Biosystems, Warrington, UK 
Gene expression master mix Applied Biosystems, Warrington, UK 
Various Taqman®  probe mixes Applied Biosystems, Warrington, UK 
TE buffer pH 8.0 Applied Biosystems, Warrington, UK 
Molecular biology grade 100% Ethanol Qiagen, Crawley, UK 
Molecular biology grade H20 Qiagen, Crawley, UK 
2.1.3.2 Molecular biology equipment 
Equipment Supplier 
Nanodrop 2100 Nanodrop technologies, Wilmington USA 
Agilent Bioanalyzer Agilent Technologies, UK Ltd Berkshire 
Taqman®  7900 machine Applied Biosystems, Warrington, UK 
Fluidigm Biomark Analyser Fluidigm, San Francisco, USA 
Nucleotide free tips eppendorfs and PCR tubes Applied Biosystems, Warrington, UK 
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2.1.3.3   Taqman® probesets 
Probe Applied Biosystems 
identifier 
Probe Applied Biosystems 
identifier 
AURKA Hs01582072_m1 HOXA3 Hs00601076_m1 
BIK Hs00154189_m1 HOXA9 Hs00365956_m1 
BIRC5 Hs04194392_s1 HPRT1 Hs01003267_m1 
BMI1 Hs00995536_m1 IGF1 Hs01547656_m1 
BMP4 Hs00370078_m1 IGF1R Hs00609566_m1 
BRCA1 Hs01556193_m1 IGFBP2 Hs00236877_m1 
CADPS2 Hs00604528_m1 IHH Hs00745531_s1 
CCNA2 Hs00996788_m1 KIF11 Hs00189698_m1 
CCNB1 Hs01030097_m1 KIF23 Hs00370852_m1 
CCNB2 Hs00270424_m1 KLF4 Hs00358836_m1 
CCND1 Hs00765553_m1 LEF1 Hs01547250_m1 
CCND2 Hs00153380_m1 MECOM Hs00602795_m1 
CDC25C Hs00156411_m1 NUMB Hs01105433_m1 
CENPA Hs00156455_m1 PLAG1 Hs04186040_m1 
CHEK2 Hs00200485_m1 PLK1 Hs00153444_m1 
CPA3 Hs00157019_m1 PRC1 Hs00187740_m1 
CRIP2 Hs00373842_g1 PTCH1 Hs00181117_m1 
CXCL1 Hs00236937_m1 PTCH2 Hs0018404_m1 
CXCL12 Hs00171022_m1 RAD51 Hs00153418_m1 
CXCR4 Hs00607978_s1 RASSF6 Hs00698249_m1 
DACH1 Hs00974297_m1 RUNX2 Hs00231692_m1 
DHH Hs00368306_m1 SELP Hs00174583_m1 
EBF Hs00395513_m1 SERPINB4 Hs00741313_g1 
ESPL1 Hs00202246_m1 SETBP1 Hs01098447_m1 
EZH2 Hs01016789_m1 SHCBP1 Hs00226915_m1 
FAM38B Hs00401026_m1 SHH Hs00179843_m1 
FANCD1 Hs00609073_m1 SMO Hs01090242_m1 
FOS Hs00170630_m1 SOX5 Hs00753050_s1 
FOXM1 Hs01073586_m1 SPINT1 Hs00173678_m1 
GAPDH Hs02758991_g1 ST14 Hs01058386_m1 
GARS Hs00157653_m1 STIL Hs00161700_m1 
GAS2 Hs01086684_m1 SUFU Hs00171981_m1 
GATA1 Hs01085823_m1 TCF4 Hs00162613_m1 
GATA2 Hs00231119_m1 TCF7 Hs00175273_m1 
GATA3 Hs00231122_m1 TMTC1 Hs00230491_m1 
GLI1 Hs01110766_m1 TOP2A Hs00172214_m1 
GLI2 Hs01119974_m1 TSHZ3 Hs01583885_m1 
GLI3 Hs00609233_m1 WEE1 Hs01119384_g1 
GUSB Hs00939627_m1 TOP2A Hs00172214_m1 
HES1 Hs00172878_m1 TSHZ3 Hs01583885_m1 
HES5 Hs01387463_g1 WEE1 Hs01119384_g1 
HHIP Hs01011015_m1 YWHAE Hs00356749_g1 
* BCR-ABL probe 
and primers 
ENP541F-MGB;   6FAM-CCCTTCAGCGGCCAGT 
ENF501:               TCCGCTGACCATCAAYAAGGA 
ENR561:              CACTCAGACCCTGAGGCTCAA  
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2.1.4 Immunofluorescence 
2.1.4.1   Immunofluorescence reagents 
Equipment  Supplier 
Fix and Perm Reagents A/B Invitrogen, Paisley, UK 
DAPI Invitrogen, Paisley, UK 
Poly L Lysine Invitrogen, Paisley, UK 
LS1 BCR-ABL Dual Colour FISH probe set Abbott Diagnostics, Maidenhead, UK 
Rubber cement Halfords, Braehead, UK 
SSC Invitrogen, Paisley, UK 
Formamide Invitrogen, Paisley, UK 
Nail polish Various suppliers 
100% Ethanol University of Glasgow, 
100% Methanol University of Glasgow, 
KCl 0.75M  University of Glasgow, 
Acetic acid University of Glasgow, 
2.1.4.2   Composition of fluorescence in situ hybridisation (FISH) 
solutions 
2.1.4.2.1   Hypotonic KCl solution 
Reagent  Quantity 
KCl 0.75M  1mL 
Sterile H20 10mL 
2.1.4.2.2   Fixative 
Reagent  Quantity 
Acetic acid 3mL 
Methanol 9mL 
Make fresh 
2.1.4.2.3   Stock SSC buffer (x20 concentration) (20xSSC) 
Reagent  Quantity 
SSC 132g 
dH20 500mL 
Pure HCl  Titrate to pH 5.3 
2.1.4.2.4   FISH wash buffer 1 (2xSSC 0.1% NP40) 
Reagent  Quantity 
20xSSC 100mL 
dH20 899mL 
NP40 1mL 
Pure HCl  Titrate to pH 7 
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2.1.4.2.5   FISH wash buffer 2 (0.4xSSC 0.3% NP40) 
Reagent  Quantity 
20xSSC 10mL 
dH20 493.5mL 
NP40 1.5mL 
Pure HCl  Titrate to pH 7 
2.1.4.2.6   FISH denaturation buffer 
Reagent  Quantity 
Formamide 70% 49mL 
SSCx20 7mL 
dH20 14mL 
Pure HCl Titrate to pH 7 
2.1.4.2.7   FISH hybridisation mixture (for 4 spots on a multisport slide) 
Reagent  Quantity 
Hybridisation buffer 7uL 
Probe mix 1uL 
H20 2uL 
2.1.4.3   FISH Equipment 
Reagent  Quantity 
Poly L Lysine coated slides Invitrogen, Paisley, UK 
Water baths N/A 
Mercury thermometer N/A 
Humidified hybridisation box N/A 
2.1.5   Microarray 
Equipment Supplier 
Affymetrix ST1.0 Gene Expression DNA Chip Affymetrix 
PARTEK GS  Partek  
Ingenuity Pathway Analysis Ingenuity 
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2.2   Methods 
2.2.1   Drugs and reagents 
LDE225 (FW: 681.51), LEQ506 (FW:  423.5) and nilotinib (FW:  566.0) were 
kindly provided by (Novartis Pharma, Basel, Switzerland).  Purmorphamine (FW:  
520.6), cyclopamine (FW:  411.6) and GANT61 (FW: 429.6) were obtained from 
Santa Cruz Biotechnology Inc. (Santa Cruz, California, USA).  Ten millimolar (mM) 
stock solutions were prepared in DMSO and stored at -20oC.  Dilutions of these 
stock solutions were freshly prepared for each experiment in appropriate cell 
culture media.  Growth factors were reconstituted according to the manufacturer’s 
instructions and stored in single use aliquots at -80oC. 
2.2.2   Standard cell culture conditions 
All cell culture procedures were performed using sterile technique in a 
laminar air flow hood.   All cell culture was in a humidified incubator at 37oC in 5% 
CO2. 
2.2.3   Patient samples 
Leukapheresis or PB specimens were obtained with written informed 
consent, in accordance with the declaration of Helsinki and with Greater Glasgow 
and Clyde NHS Trust Ethics Committee approval from patients newly diagnosed 
with CML.  Each sample was determined to be Ph+ by FISH and BCR-ABL+ by 
PCR.  Samples were processed by Alan Hair and others with responsibility for cell 
banking.  Samples were assessed for viability and proportion of CD34+ cells.  If 
suitable for further processing, small volume samples (50mL) were purified using 
Histopaque 1077  to enrich for MNC followed by CD34+ enrichment using CD34+ 
selection columns and larger volume samples (apheresis samples) were purified 
directly through the CliniMACS system.  Both are immuno-magnetic beads 
systems which positively select CD34+ cells using super-paramagnetic beads 
coupled with a suitable CD34+ monoclonal antibody.  Briefly, CD34+ beads were 
added to the primary cell sample and the resulting suspension passed through a 
magnetic separation column which resulted in the retention of the magnetic beads 
as the sample passed through.  These beads, along with the attached CD34+ cells, 
can be recovered by simply removing the magnetic field.  Following recovery, 
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purity was assessed by flow cytometry to identify the CD34+ fraction prior to 
cryopreservation.  All samples were >95% CD34+ following purification. 
Non-CML CD34+ samples were obtained from the PB of patients with 
lymphoma or multiple myeloma undergoing G-CSF mobilisation following 
chemotherapy.   These samples were processed and stored as described above. 
2.2.4   Cryopreservation of cells 
Primary cells were re-suspended in 5% HSA and mixed in a 1:1 ratio with 
20% DMSO / 5% HSA solution and transferred to 2mL cryo-tubes in aliquots of 
4x106/2mL or 20 x 106/2mL.  Cell lines were re-suspended in 10% DMSO / 90% 
FCS and transferred to cryo-tubes in aliquots of 1-10x106 cells/2mL.  These cryo-
tubes were then placed in a 5100 Cryo -1oC cell freezing container to enable 
controlled cooling at -1oC per minute until they were at -80oC at which point they 
were transferred to the vapour phase of liquid nitrogen until required. 
2.2.5   Cell recovery post cryopreservation 
CD34+ primary cells were removed from liquid nitrogen and immediately 
thawed at 37oC in a water bath.  Following this, 10mL of thawing solution (DAMP) 
was gradually added to the cells over 10 minutes (min) with constant gentle 
agitation to prevent clumping.  The cells were then centrifuged at 1000rpm for 10 
min and washed a further twice in 10mL DAMP. Finally the cell pellet was re-
suspended in SFM+HGF; cell number and viability was assessed by trypan blue 
dye exclusion and the cells cultured overnight at 37oC with 5% CO2 in a non-
adherent tissue culture flask at a maximum density of 1x106/mL. Culture in 
SFM+HGF maximises cell recovery post thaw.  The following day these cells were 
washed twice in DPBS / 2%FCS, re-suspended in fresh SFM±GF supplementation 
and a viable cell count performed; in general a recovery of approximately 25% of 
the cryopreserved cell number was expected. 
Cell lines were removed from liquid nitrogen and immediately thawed at 
37oC in a water bath.  Then they were washed once in their relevant media, re-
suspended in media, viable cells counted and seeded in standard tissue culture 
flasks at the appropriate density.   
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2.2.6   Cell counting and viability assessment 
All cell counts were performed using a haemocytometer.  Cell viability was 
assessed by vital dye exclusion.  Trypan blue stock solution (8mM) was diluted 
1:10 with DPBS to give a working solution of 0.8mM.  Cells were diluted in the 
trypan blue working solution and added to a haemocytometer counting chamber.  
Cell count was performed on an inverted microscope using the x10 objective.    
Given that the cover-slide is held 0.1mm above the counting surface, each 1mm2 
square has a volume of 0.1L.  Non-viable cells absorb trypan blue whereas viable 
cells do not.  Therefore the absolute viable cell count per mL was the number of 
unstained cells per mm2 multiplied by the trypan blue dilution factor and then by 
104.  
2.2.7   Primary CD34+ cell culture experiments 
In most instances CD34+ CML cells following recovery were cultured in SFM 
alone or supplemented with low GFs.  Non-CML cells were grown in SFM+LGF 
supplementation. For certain cell tracking experiments it was considered important 
to drive cell expansion and these were therefore carried out with SFM+HGF 
supplementation.  Cells in culture with the agents under investigation were 
harvested at 1d-12d post exposure.  In the case of longer exposure fresh media 
and drug were added at d4 and d8. 
2.2.8   Cell line culture 
A variety of cell lines were utilised and are listed below.  All cell lines were 
passaged according to American Type Culture Collection (ATCC) or Leibniz –
Institut Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) 
instructions. 
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2.2.8.1   Cell lines  
Cells Species 
/ Type 
Information Supplier / Reference  
K562 Human 
CML BC 
 
Established from the pleural effusion of a 53 year old 
women with CML in BC in 1970.  BCR-ABL
+
 (b3a2) 
Media used:  RPMI* 
Split ~1:5 every 3d.  Seeded at ~ 1x10
5
/mL 
Maximum density: 1.5x10
6
/mL 
DSMZ /ACC10 
(Drexler, 1994; Lozzio 
and Lozzio, 1977; Lozzio 
and Lozzio, 1975) 
TM3 (GLI Luc) Murine  Mouse leydig cell line engineered to stably express a 
GLI responsive luciferase reporter element (8xGLI-Luc) 
Media used:  TM3 media 
Split ~1:10-20 every 3-4d.  Seeded at ~ 1x10
5
/mL 
Requires selection with G418 100ul/10mL 
Gift from Marian Dorsch, 
Novartis Pharma  
(Pan et al., 2010) 
(Miller-Moslin et al., 
2009) 
(Frank-Kamenetsky et al., 
2002) 
M210B4 Murine  
Stromal 
A clone derived from bone marrow stromal cells from a 
(C57BL/6J X C3H/HeJ) F1 mouse.  These cells were 
engineered to stably express and secrete human IL3 
and human GCSF.  These cells will support human 
myelopoiesis in long term culture. 
Media used:  RPMI* 
Split:  ~1:5 every 3d  
Gift from C Eaves / Stem 
Cell Technologies 
(Sutherland et al., 1991) 
 
SL/SL Murine 
Stromal 
A clone derived from BM of the SL/SL mouse.  These 
cells have been engineered to produce human IL3 and 
SCF.  These cells will support human myelopoiesis in 
long term culture. 
Media used:  DMEM 10% FCS 
Split:  ~1:5 every 3d  
Gift from C Eaves / Stem 
Cell Technologies 
(Sutherland et al., 1991) 
 
 
2.2.9  Flow Cytometry 
All flow cytometry was performed on the BD FACS Canto II flow cytometer, 
data was acquired using BD FACS Diva (BD Biosciences) software, and analysed 
using FACS Diva or FlowJo (Tree Star, Inc.) software. 
2.2.9.1   General aspects of flow cytometry 
Flow cytometry is a method for simultaneously counting and measuring 
various properties of individual particles e.g. cells as they are passed, suspended 
in a stream of fluid, through an array of electronic detectors.  This technology can 
be used to measure physical properties e.g. size, shape and granularity or can be 
combined with fluorescent dyes or fluorochrome conjugated antibodies raised 
against particular surface or intracellular epitopes.  The combination of different 
antibodies conjugated to fluorochromes with different emission spectra permits the 
measurement of several different cell surface antigens simultaneously.  In 
contemporary flow cytometry, using modern flurochromes with emission 
wavelengths spanning the detectable spectra and utilising mathematical 
116 
 
 
compensation algorithms, it is possible to combine multiple fluorochromes to 
measure several different parameters simultaneously. 
  Flow cytometry requires that the cellular sample under investigation is 
carried in a stream of fluid that is hydrodynamically focused in order to cause the 
cells in question to be in single file as they pass across the path of one or more 
lasers of differing wavelengths focused onto the fluid stream.  The laser light is 
scattered as it contacts the passing cell.  Forward scatter (scatter in the original 
direction of travel of the laser) is proportionate to the size of the cell and side 
scatter (scatter perpendicular to the original direction of travel of the laser) is 
proportionate to the granularity of the cell.  Additionally as the laser contacts the 
cell, it may excite fluorescence from certain associated fluorochromes e.g. from 
fluorochrome conjugated antibodies raised to a specific epitope.  A series of filters 
and detectors are arranged in order to pick up and quantify these fluorescent 
emissions which can be mapped to the known spectral emission qualities of the 
fluorochromes used.  Therefore it is possible to measure the physical properties of 
a cell, the presence of any fluorescent dye or, using conjugated antibodies, the 
level of expression of any suitable cell surface or intracellular target on individual 
cells simultaneously and both isolate a particular population of cell within a 
heterogeneous cell mixture and measure the relative abundance of various surface 
and intracellular proteins.   
2.2.9.2   Measuring surface antigen expression by flow cytometry 
Cells were harvested, washed and re-suspended in DPBS / 2% FCS.  
Fluorochrome conjugated antibodies were added at the specified concentrations 
and well mixed prior to incubation for 15min at room temperature (RT) in the dark.  
Cells were then washed twice in DPBS / 2% FCS, re-suspended and analysed 
immediately.  Appropriate isotype controls and an unstained control were utilised 
to set the voltages and compensation when required.  The viable cell population 
was gated using FSC and SSC characteristics.  For targets where no fluorochrome 
conjugated antibody was available, I incubated the cells for 30min with an 
unconjugated antibody or the same concentration of a non-specific control prior to 
washing and re-suspending in DPBS / 2% FCS.  A secondary fluorochrome 
conjugated antibody raised against the immunoglobulin species of the primary 
antibody was then added to the resultant cell suspension, thoroughly mixed and 
incubated for a further hour.  A secondary only control was included in order to 
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determine non-specific secondary antibody binding. The cells were then washed 
twice in DPBS / 2% FCS, re-suspended and analysed. 
2.2.9.3   Assessment of apoptosis by flow cytometry 
  As cells enter apoptosis, one of the earliest events is the translocation of 
negatively charged phosphatidylserine from the inner (cytosolic) to the outer 
(external) surface of the phospholipid bilayer that comprises the plasma 
membrane (Koopman et al., 1994; Martin et al., 1995).  Annexin V is a 
phospholipid binding protein with a high affinity for phosphatidylserine in the 
presence of physiological concentrations of Ca2+.  Phosphatidylserine is also 
accessible to annexin V during necrosis due to disruption of plasma membrane 
integrity.  In this case, although annexin V staining still occurs, the cells will also 
stain with a vital dye, in this case 7-amino-actinomycin D (7AAD; Viaprobe 
solution).  The principle of these experiments was to measure the proportion of 
viable, early apoptotic and late apoptotic cells following exposure to the test drug 
combinations. Primary CD34+ CP CML cells were assessed for apoptosis by flow 
cytometry using fluorochrome conjugated annexin V (annexin V–FITC) and 7AAD.  
Thus viable cells would be negative for both annexin V and 7AAD; cells in early 
apoptosis would be annexin V positive but 7AAD negative and cells in late 
apoptosis would be positive for both annexin V and 7AAD.  Primary CD34+ CP 
CML cells were cultured in SFM in the presence of the various combinations of test 
drugs or over the course of 72 hours (h).  At each time point these cells were 
harvested, washed twice in DPBS / 2% FCS,  re-suspended in 100µL annexin V 
binding buffer and stained with 5µL annexin V–FITC and 10L 7AAD for 15min.  
Prior to analysis a further 400µL binding buffer was added to the samples which 
were then immediately analysed.  Annexin V staining was measured on channel 
FL1 and 7AAD staining was measured on channel FL3.  Unstained and single 
fluorochrome stained control cells were used to set voltages and compensation 
(Figure 2-1). 
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Figure 2-1:  Annexin V / Viabrobe apoptosis assay.   
On the left is a schematic map indicating the position of the flow cytometry populations 
in the annexin V / 7AAD apoptosis assay.  On the right is a representative flow cytometry 
plot from an apoptosis assay. 
2.2.9.4   High resolution cell cycle analysis by flow cytometry 
The series of events that occur in a eukaryotic cell as it prepares for and 
undergoes division are termed the cell cycle.  This can be divided into two distinct 
periods; interphase – representing the period when the cell is growing and 
duplicating its genetic material; and mitosis where the cell splits its cytoplasmic 
and nuclear material to form two distinct cells.  Interphase can be further divided 
into 3 phases; G1 from the end of the previous mitosis to the beginning of DNA 
synthesis, when there is considerable biosynthetic activity, growth and preparation 
for DNA synthesis; S in which there is duplication of the cell’s genetic material and 
G2 where there is further biosynthetic activity and preparation for mitosis. G0 
denotes cells that are quiescent – i.e. not in cycle.  It is possible to use flow 
cytometry to measure progress through the cell cycle.  As cells cycle the amount of 
DNA that they have increases from diploid (normal) to tetraploid (just before 
mitosis). Fluorescent dyes that bind in a stoichiometric manner to double stranded 
DNA (e.g. 7AAD) can be utilised to measure relative quantity of DNA per cell by 
flow cytometry.  This will not easily allow differentiate between G0 and G1 as in 
both cases the quantity of DNA present will be similar.  Jordan et al published a 
refinement that allows the high resolution analysis of G0 and G1 phases of the cell 
cycle through measuring DNA content using 7AAD and the addition of a further 
parameter – the measurement of the intracellular protein; Ki67 (Jordan et al., 
1996).  This is a nuclear protein and is involved in cellular proliferation and 
ribosomal RNA transcription.  It is expressed in all active phases of the cell cycle 
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but is absent in quiescent cells (G0).  Thus by combining both parameters it is 
possible to discern the proportion of cells in G0 (Ki67
-/7AADlo); G1 (Ki67
+/7AAD-) 
and G2/S/M (Ki67
+/7AAD+)  
In these experiments primary CD34+ CP CML cells were cultured in SFM in 
the presence of the various combinations of test drugs or ligands over 72h.  At 
each time point these cells were harvested, washed twice in DPBS / 2% FCS and 
then re-suspended in 500µL DPBS/0.4% formaldehyde and incubated on ice for 
30min to fix the cells.  Following this, the cells were washed a further time with 
DPBS / 2% FCS and then re-suspended in PBS / 0.2% Triton-X-100.  These cells 
were incubated overnight at 4oC.  The following day the cells were again washed 
and re-suspended in 200L of DPBS.  Eight L of Ki67-FITC or Ki67-APC 
conjugated antibody were added to the cell suspension which was mixed 
thoroughly prior to incubation in the dark at RT for 30min. After a further wash the 
cells were re-suspended in DPBS 200L / 2% FCS and incubated with 1L of 
7AAD (final concentration:  1g/mL) for at least 6h at 4oC.  The appropriate isotype 
and unstained controls were used to set the flow cytometer voltages, set gates and 
where necessary to adjust compensation.  The viable cell population was gated 
using forward and side scatter characteristics.  Ki67 was assessed using a log 
scale on FL1 (FITC) or FL4 (APC).  7AAD staining was assessed on a linear scale 
on channel FL3.  Gates were set around the G0, G1 and G2/S/M populations 
allowing the calculation of the relative proportions of cells in each of these phases 
to be recorded from a minimum of 10,000 events (Figure 2-2).  
 
Figure 2-2:  High resolution cell cycle analysis.   
On the left is a schematic map indicating the positions of the respective cell cycle 
populations in high resolution cell cycle analysis.  On the right is a representative flow 
cytometry plot (note Ki67 is in log scale whereas 7AAD is represented on a linear scale).  
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2.2.9.5   Cell division tracking by flow cytometry 
 CFSE is an intracellular dye which is widely used to follow cell division in 
heterogeneous and asynchronous cell populations.  The principle was first 
described by Lyons and Parish in 1994 when this technique was used to track 
lymphocyte subset divisions (Lyons and Parish, 1994).  It has subsequently been 
applied to many different cell types and is of particular relevance to this work to 
monitor haemopoietic progenitor cell division following GF exposure and drug 
treatment (Graham et al., 2002; Holyoake et al., 1999).  
CFSE readily crosses the plasma membrane of cells. Once inside, 
intracellular esterases cleave the acetate groups to yield the fluorescent 
carboxyfluorescein molecule and the succinimidyl ester group reacts with primary 
amines on intracellular proteins, cross-linking the dye and fixing it within the 
cytoplasm of the cell (Lyons and Parish, 1994).  When a cell divides, the CFSE 
molecules are shared equally between daughter cells.  This can be represented as 
a successive halving of the measured CFSE fluorescence intensity as related to a 
similarly treated undividing control population and the number of divisions 
estimated by the fold reduction of CFSE fluorescence intensity.  CFSE 
fluorescence is measured in channel FL1 although analogous substances can be 
measured in other flow cytometer channels.   
In these experiments CD34+ CP CML cells were recovered from liquid 
nitrogen, washed counted and re-suspended in DPBS / 2% FCS as previously 
described.  Stock CFSE solution (5mM CFSE in DMSO) was diluted at a ratio of 
1:10 with DPBS / 2% FCS and the resultant working solution added to the cell 
suspension to a final concentration of 1M.  This cellular suspension was then 
incubated in a water bath at 37oC for exactly 10min prior to quenching with 10 x 
volume of ice cold PBS / 20% FCS.  These cells were washed twice in DPBS / 2% 
FCS prior to re-suspension in SFM+HGF and overnight culture in non-adherent 
75cm2 tissue culture flasks at a maximum density of 1x106/ml.  In addition to the 
CFSE stained sample, about 10% of the original sample was retained and cultured 
in SFM+HGF as a CFSE- unstained control. 
The following day the CFSE+ and CFSE- samples were harvested, washed 
in DPBS / 2% FCS, re-suspended in SFM + LGF and viable cell count determined.  
An aliquot of cells was removed and assessed by flow cytometry to determine the 
fluorescence of the undivided CFSEmax cells.  The following day cells were seeded 
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at a concentration of 1x105/ml in SFM+LGF with incremental concentrations of Hh 
inhibitor, nilotinib, Hh ligand or combinations thereof.   For each experiment a non-
dividing control was set up using CFSE stained cells treated with 100ng/mL 
demecolcine (Colcemid).  This facilitated identification of the CFSEmax peak at 
each time point.  Stained and unstained controls were included to allow for 
unstained, single stained and isotype controls at each stage of FACS analysis. 
In each experiment, the wells were thoroughly mixed and an aliquot of cells 
was taken from each experimental arm at d4, d8 and d12.  The cells were washed 
in DPBS / 2% FCS and divided into aliquots for viable cell count, flow cytometric 
analysis and reseeding. Viable cell count was assessed by trypan blue exclusion 
as described previously.  In different experiments I also assessed the CD34+ cell 
fraction and the CD133+ cell fraction.  For CD34 and CD133 I added 5L of CD34-
APC and/or CD133-PE to the cell suspension, mixed, and incubated for 15min at 
RT in the dark.   These cells were then washed twice in DPBS / 2% FCS, re-
suspended in 500L DPBS / 2% FCS prior to FACS analysis.  In each case, 
unstained cells and single stained isotype controls were included (Figure 2-3).  
Lastly, in the case of d4 and d8, the remaining cells were re-seeded in fresh media 
and drug at approximately the original cellular concentration for the next time point. 
  
122 
 
 
 
Figure 2-3:  Cell division tracking by dye dilution.   
(A) Schematic demonstrating the effect of successive dilution on CFSE fluorescence in a 
cell population.  (B) Representative flow cytometry dot plot with CFSE treated primary CP 
CML cells cultured for 4d in SFM+HGF with nilotinib and LDE225.  (C) – (E) Histograms at 
the same time point in the same sample tracking the division history of total viable cells, 
CD34+ cells and CD133+ cells. (F) Colcemid control to determine the level of CFSEmax (the 
undivided population). 
2.2.9.6   Flow cytometry considerations and calculation of cell 
numbers 
At each time point the viable cell count was obtained by trypan blue 
exclusion prior to flow cytometry analysis. Unstained cells and single stained 
isotype controls were included to assist the setting of voltages and compensation 
where required.  The viable cell population was identified through FSC / SSC 
properties.  
On this population I used a histogram to visualise number of events across 
the spectrum of CFSE in channel FL1 fluorescence.  The colcemid treated control 
allowed gating of the undivided population.  Gates could then be set using 
successive 2 fold diminutions of the geometric mean of FL1 fluorescence, 
encompassing cell populations within the sample that had similar levels of FL1 
fluorescence and thus had divided a similar number of times. 
Comparing fluorescence from CD34-APC or CD133-PE as surface markers, 
in addition to CFSE, I could then simultaneously measure proportion of cells in 
each cell division that expressed CD34-APC and CD133-PE.   
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In order to compare the effect of the drug and ligand treatments on the 
quiescent primitive fraction and on the proliferation behaviour of the CP CML 
CD34+ cells, the percentage recovery of viable CD34+ cells in the undivided 
fraction was calculated at each time point for each experimental condition.  In 
essence, through looking at the number of viable and CD34+ cells in each division, 
the percentage of the original cells that could be accounted for in each arm was 
sought.  The total number of viable cells, as well as the percentage of CD34+ cells, 
(and where relevant the percentage of CD133+ cells) in each division for each 
condition at each time point were recorded.  For example, percentage recovery of 
CD34+ input cells in division x was calculated by multiplying the % CD34+ cells in 
division x by the total number of viable cells and dividing by the number of input 
cells.   
2.2.9.7   Fluorescence activated cell sorting  
A refinement of flow cytometry allows the physical sorting of a 
heterogeneous mixture of cells into different containers according to their physical 
size, granularity and fluorescence profile.   The cell suspension of interest is 
hydrodynamically focused such that cells pass through the detectors in single file 
in the centre of a rapidly flowing fluid stream.  These cells are comparatively far 
apart therefore a vibrating mechanism can break the stream into individual droplets 
with most droplets containing only one cell event.  These droplets can be given an 
electrical charge and then diverted into specific containers in accordance with that 
charge as they pass through an electrostatic deflection system.  The charge that 
the droplets acquire can be dictated by the operator, dependent on the measured 
physical or fluorescence characteristics of the cell. 
The cell sorts were performed by Dr Mhairi Copland.  Enriched CD34+ 
samples were thawed, viable cell count performed and cultured as described 
above.  The following day the cells were washed twice in DPBS / 2% FCS and a 
viable cell count performed.  The cells were simultaneously stained with lineage 
(lin) cocktail-FITC, CD90-PE, CD34PerCP, CD38PE-Cy7, CD123-APC and 
CD45RA-Pacific Blue for 30min at RT in the dark.  They were then washed twice in 
DPBS / 2% FCS prior to re-suspension in multiple FACS tubes placed on ice.   
 This allowed sorting of the cells into HSC CD34+38-lin-CD45RA-CD90+; 
MPP CD34+38-lin-CD45RA-CD90-; CMP CD34+38+lin-CD123+ CD45RA-; [GMP] 
CD34+38+lin-CD123+ CD45RA+ and MEP CD34+38+lin-CD123-CD45RA-  sub-
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populations on a FACS Aria cell sorter. This machine allows for the concurrent 
sorting of up to 4 populations, the fifth population (MPP) was swapped in when 
sufficient cells for one of the other populations had been collected (Majeti et al., 
2007).  
Following sorting the cells were counted and divided into aliquots either for 
cell culture (progenitor and proliferation assays) or for RNA purification using the 
RNEasy mini or micro kit.  Cell culture assays and RNA purification were 
performed by Dr Copland.  Isolated RNA was subsequently checked for purity and 
integrity as described below.  All samples were subject to FISH analysis to confirm 
the presence and the proportion of cells carrying BCR-ABL in each sample in each 
sub-population.  RNA processing and microarray analysis were carried out at the 
Sir Henry Wellcome Functional Genomics Facility (SHWFGF, University of 
Glasgow) using the Affymetrix GeneChip Human Gene 1.0 ST arrays according to 
the manufacturer’s instructions. The raw data .CEL files were analysed as 
described in the next chapter.  Quantitative RTPCR was performed on various 
genes to validate the microarray findings and investigate other gene expression 
patterns of interest.  This sorting process required many cells and could only be 
performed a limited number of times and additionally was limited by the number of 
samples available in sufficient quantity to allow the necessary sorting.  We were 
able to utilise 3 non CML samples, 6 CP CML samples, 4 AP CML samples and 2 
BC CML samples. 
2.2.10 Short term cellular techniques 
2.2.10.1 GLI responsive luciferase assay 
The TM3(GLI-Luc) cells (a murine Leydig cell line with intact Hh signalling 
characteristics) previously transfected with a GLI-responsive luciferase reporter 
gene such that luciferase production was dependent on GLI activation through Hh 
signalling was obtained.  These cells were cultured as described above in a 0.1% 
gelatine coated tissue culture flask under G418 selection. When required the 
TM3(GLI-Luc) cells were harvested using 2mL trypsin 0.25% under standard 
conditions, washed twice and re-suspended in standard media prior to seeding at 
1x105 cells per well in an opaque white 96 well tissue culture plate.  In the first set 
of experiments, the cells were stimulated with escalating concentrations of Hh 
ligand (50-500ng/mL; SHH) or the Hh agonist purmorphamine (0.5 – 5g/mL).  
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Luciferase activity was assessed at 24, 48 and 72h using the Bright-Glo system 
and a plate reading luminometer.  All measurements were performed in triplicate. 
In the second set of experiments the TM3(GLI-Luc) cells were plated as before.  
The following day escalating concentrations of the Hh inhibitors were added and 
6h later the cells were stimulated with the minimum concentration of 
purmorphamine that yielded maximum luciferase production as derived from the 
first experiment.  Again, luciferase activity was assessed at 24, 48 and 72h using 
the Bright-Glo system and a plate reading luminometer and all measurements 
were performed in triplicate.     
2.2.10.2 Measuring cell proliferation using BrdU incorporation  
A measure of cellular proliferation can be gained through quantifying DNA 
synthesis.  A convenient way to measure DNA synthesis is to measure the quantity 
of labelled DNA precursors incorporated into the genomic DNA of a cell over a set 
labelling period, the quantity of incorporated label is then proportionate to the rate 
of DNA synthesis and hence cell division in the sample. 
In these experiments, 5x104 CD34+ CP CML cells were cultured in 96 well 
plates in 100L SFM or appropriate cell line culture media in the presence of 
escalating concentrations of Hh inhibitor (1-1000nM LDE225; 1-50M 
cyclopamine) for between 24 and 96h.  Assays were performed in a minimum of 
triplicates.  At each time point the thymidine analogue BrdU was added to the cell 
culture (final concentration: 10M BrdU) and re-incubated for a further 24h.  At this 
stage the culture plate was centrifuged at 300g for 10min to fix the cells to the 
bottom of the plate and the media plus labelling solution removed by inverting and 
tapping the plate.  After this the cells were dried using a hairdryer for 15min and 
stored at 4oC for up to 4d.  Analysis was by colorometric immunoassay.  Briefly, 
the cells were fixed and denatured by the addition of 200L fix-denat solution at 
RT for 30min.   Following this the solution was removed by inverting and tapping 
the plate.  Anti-BrdU antibody peroxidise conjugate solution was then added to 
each well and the plate incubated at RT for 90min after which the antibody 
conjugate was removed and the wells washed 3 times in 200µl DPBS.  Following 
the final wash, the washing solution was removed from the wells and 100µL of 
substrate solution (tetramethyl benzidine; TMB) added and the plate incubated at 
RT for 15min.  The reaction was quantified by absorbance measured at 370nm 
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(reference wavelength: 450nm) on a scanning plate reader.  Both blank (no cells) 
and background controls (no BrdU) were performed for each plate.  
2.2.10.3 Ligand expression by enzyme-linked immunosorbant assay   
In order to determine the amount of Hh ligand produced by various cell 
types, we collected cell conditioned supernatants from cultured cells under 
standard conditions.  CD34+ enriched CP CML and non CML cells were cultured in 
SFM+LGF at a concentration of 0.5 x 106 /mL for 24h.  Stromal cell lines and 
primary human BM MSCs cultured from healthy individuals, patients with CP CML 
and an immortalised embryonic MSC (EMSC) line (<passage 2-6) were plated at 
the cell concentrations used for supporting haemopoiesis (M210B4 & SL/SL: 1x105 
cells/mL and primary and EMSCs:  4x104mL in 1mL relevant media for 24h.)  
Following culture the cell suspension was harvested, centrifuged at 1200rpm for 
10min then the supernatant was collected, filtered and stored at -20oC until 
required. 
 I used the ab100639 Human SHH (SHH N Terminus) enzyme linked 
immunosorbant assay (ELISA) kit.  An antibody specific to the N terminus of the 
human SHH had been immobilised in the wells of a 96 well plate.  Standards and 
samples were added to the wells (100µL of undiluted sample or standard) and any 
SHH present in the sample binds to the antibody on the plate.  The wells were then 
washed thoroughly and a biotinylated anti-human SHH antibody was added.  The 
wells were washed; HRP-streptavidin was added, incubated for 30min and then 
washed out thoroughly.   Finally TMB substrate solution was added to the wells 
and colour developed proportionate to the quantity of SHH originally present in the 
sample.  Finally stop solution was added.  The reaction was quantified by 
absorbance measured at 370nm (reference wavelength: 450nm) on a scanning 
plate reader and the quantity of SHH present could be deduced from the standard 
curve. 
2.2.11 Functional Assessment of Haemopoietic Progenitors 
Functional assessment of progenitor and stem cell characteristics can be 
achieved by using a number of different in vitro and in vivo assays. While the 
reconstitution of a haemopoietic system in xenotransplantation experiments 
remains the gold standard, in vitro examination of stem cell numbers and function 
are important.   As time has progressed in vitro clonogenic assays have become 
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more reproducible due to advances in assay systems and the availability of 
recombinant standard GF combinations and now provide a comparatively cheap, 
fast and reproducible means of investigating the effect of a drug on stem or 
progenitor cell function.  These assays can be divided into long and short term 
assays based on the length of time and number of divisions that are required to 
produce a detectable colony.  Thus committed progenitor assays will run over 
approximately 2-3 weeks and assays for more primitive cells e.g. LTC-IC require 
significantly longer >5 weeks.   
2.2.11.1 Colony forming cell assay 
Colony forming cell (CFC) assays are clonal progenitor assays which 
measure the proliferation capacity and multipotency of haemopoietic progenitors.  
Cells of interest are inoculated into a semisolid culture medium containing a 
standard GF cocktail.  The cells and their progeny will therefore be kept separate 
from neighbouring cells.  Following culture for 2 – 3 weeks all progenitor cells with 
colony forming potential in that specific GF context will have proliferated and 
differentiated fully.  The resultant colonies can then be assessed for size (broadly 
reflective of original proliferative capacity) and constituent cell types from which 
can be inferred the degree of lineage commitment and hence the maturity of the 
originator cell.  Thus in the case of myeloid CFCs, the distribution and maturity of 
the progenitor cells assayed can be deduced from the number and relative 
frequency of single cell myeloid colonies. 
Methylcellulose supplemented with GFs (Methocult H4034) was thawed at 
4oC overnight, well mixed and divided into 2.6mL tubes.  These aliquots could then 
be stored at -20oC until required.  Following recovery, CD34+ CML cells were 
cultured for 72h in either SFM alone, escalating concentrations of LDE225, 
nilotinib 5M or a combination of both treatments.  The cells were then harvested, 
washed in DPBS, re-suspended in fresh SFM and a viable cell count performed.  
Each of the different cell suspensions was inoculated into a single tube of 
Methocult to give a final concentration of 4x103 cells/mL and the final volume of 
inoculum made up with SFM to equal 10% of the original volume of Methocult.  
These tubes were thoroughly mixed, left to settle at RT and then 1.1mL of resultant 
single cell suspension plated in duplicate into 35mm culture dishes.  The duplicate 
assays were placed in a 100mm culture dish with a further 35mm dish containing 
3mL sterile H20 to maximise humidity. The cells were cultured under standard 
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conditions for 14-18d prior to colony assessment using an inverted microscope 
and a counting grid. 
2.2.11.2 Long term culture initiating cell assay  
While the CFC assay measures a relatively mature and lineage committed 
progenitor population, it is not capable of detecting more primitive progenitors. 
These cells have differing optimal GF requirements and require a longer time and 
more cell divisions to give rise to differentiated progeny than can be achieved in 
the CFC system.  Extended culture over 5 to 8 weeks is required for the 
assessment of more primitive progenitors. This time allows the immature cell to 
complete its differentiation and excludes contribution to the resultant colony 
formation from residual CFC.  Additionally, prolonged in vitro culture of HSC will 
result in differentiation and irrevocable loss of their stem cell characteristics.  
However if HSC are cultured in the presence of a suitable supportive stromal 
environment e.g. BM MSCs or similar immortalised stromal cell lines, human HSC 
can be maintained in vitro for at least 8-10 weeks (Cashman et al., 1985; 
Coulombel et al., 1984; Coulombel et al., 1983; Dexter et al., 1977; Eaves and 
Eaves, 1988; Eaves et al., 1985a, b; Hogge et al., 1996; Humphries et al., 1981; 
Sutherland et al., 1989; Sutherland et al., 1990).  
LTC-IC is a well-established technique for the enumeration and functional 
assessment of the primitive progenitor population in haemopoietic samples.  
Following prolonged stromal–supported culture in conditions favouring myeloid 
differentiation, the resultant cells are harvested and inoculated into myeloid colony 
supporting CFC assays.  The presence of LTC-IC can then be inferred from the 
colony growth in the CFC assay (Hogge et al., 1996; Sutherland et al., 1989; 
Sutherland et al., 1993b; Sutherland et al., 1990).  Variations in LTC-IC numbers 
between treatment arms in an experiment would suggest a difference in stem cell 
fate and self-renewal. 
In these LTC-IC experiments I utilised two immortalised and genetically 
modified murine bone marrow fibroblast cell lines; SL/SL and M210B4 (Hogge et 
al., 1996; Sutherland et al., 1991).  The SL/SL cell line had been previously 
genetically modified to stably express human SCF and IL3 and the M210B4 cell 
line to stably express human IL3 and GCSF.  This combination of supportive 
stroma and GFs has been shown to optimally support myeloid haemopoiesis 
(Hogge et al, 1996).   Both cell lines were cultured and maintained under selection 
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pressure as described above.  Prior to initiating the LTC-IC, the fibroblast cell lines 
were trypsinised, counted and re-suspended in fresh media in a new tissue culture 
flask with a non-breathable lid.  In order to prevent further proliferation these cells 
were irradiated under a cobalt -ray source for a total of 80Gy.  Following 
irradiation, the cells were trypsinised, washed in DPBS and then re-suspended in 
optimised long term culture media.  A viable cell count was performed and the 
concentration of each cell type adjusted to 1.5x105/mL.  The resultant cell 
suspensions could then be mixed in a 1:1 ratio and 1mL added to each central well 
of a 24 well type 1 collagen coated plate (8 central wells) to create a fully confluent 
stromal layer.  Sterile water (2mL) was used to fill all peripheral wells to maximise 
humidity and the stromal layers were placed in an incubator until required (plates 
could be kept for up to a week prior to use). Long term myeloid culture medium 
(LTMCM) was prepared by supplementing Myelocult with hydrocortisone succinate 
(FW: 484.52) to a final concentration of 1M.  This media was stored at 4oC in 
aliquots and used for all subsequent LTC-IC culture. 
In the first set of experiments, following recovery, CD34+ CP CML cells or 
non CML CD34+ were cultured for 72h in SFM (or in the case of non CML CD34+ 
cells; SFM+LGF) in the treatment conditions described in the relevant results 
sections.  Following this the cells were harvested, viable cell count assessed, 
washed in DPBS / 2%FCS and re-suspended in LTMCM.  Myelocult was carefully 
aspirated from the pre-prepared stromal layer wells and equal quantities of treated 
cells in LTMCM were added to duplicate LTC-ICs.  The final volume was made up 
to 1mL and the plates cultured under standard conditions for 5 weeks.  Each week 
500L of media was carefully removed without disturbing the stromal layers and 
replaced with fresh media.  After 5 weeks culture, the entire contents of each well 
were harvested and inoculated into CFC clonal progenitor assays to assess the 
presence of LTC-IC.  Firstly, the supernatant from each well was collected into a 
15mL falcon harvest tube then the wells were washed twice with 1mL HBSS with 
all liquid added to the harvest tubes.  The stromal layer and any adherent cells 
were removed through the addition of 500L 0.25% trypsin and incubation at 37oC 
with intermittent gentle pipetting.  Following trypsinisation, 25L of FCS was added 
to each well to inactivate the trypsin and the entire contents collected to the 
harvest tube.  The wells were washed in 1mL IMDM / 2% FCS twice with the liquid 
collected to the harvest tube.  The harvest tubes were then centrifuged for 10min 
at 1000 rpm.  Following this the supernatant was carefully poured off and the cells 
130 
 
 
re-suspended in the remaining volume.  This volume was recorded and viable 
haemopoietic cells counted.  Each of the different cell suspensions was inoculated 
into CFC assays as described in section 2.2.11.1. This allowed comparison of the 
resultant CFCs generated from the input cells in each treatment arm (Figure 2-4). 
 
Figure 2-4:  Experimental schema for the LTC-IC assay.   
Supportive stromal layers were prepared from a 1:1 mixture of irradiated (80Gy) M210B4 
and SL/SL cell lines.  Primary cells were thawed as discussed above and treated with the 
test compounds.  Following treatment the cells were washed and cultured over 
supportive stroma in LTMCM for 5 weeks.  Stem cells formed cobble stone areas under 
the stroma as shown above (central image).  Following 5 weeks culture the entire 
contents of the wells were harvested, washed and inoculated into CFC assays.  Colony 
formation was assessed after 14-18d. 
A second set of experiments was undertaken to more closely examine the 
potential role of stromal interactions in the context of the test drugs.  Briefly, CD34+ 
CP CML cells were inoculated into duplicate LTC-IC wells without prior culture with 
test drugs.  Instead, the LTMCM in each LTC-IC well was supplemented directly 
with the relevant concentration of the drug. Assays for LTC-IC progressed as 
described above except that 80% of the LTMCM was removed and replaced with 
fresh media and drug each week.  Therefore, both the supportive stroma and 
haemopoietic cells were both exposed to the drug continuously over the 5 week 
culture period.  Following the 5 week culture period the LTC-IC wells were 
harvested as described above and inoculated into CFC assays for assessment as 
above.  
2.2.11.3 Re-plating assay 
While differences in stem cell fate can be inferred from the results of 
prolonged supported culture experiments, another approach to measuring the 
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stem cell property harks back to the original experiments performed by Till and 
McCulloch in 1961 where HSCs in murine BM were found to form colonies in the 
spleens of irradiated mice and that the cells from these colonies form similar 
colonies following secondary transplantation (Till and McCulloch, 1961, 1963; Wu 
et al., 1967).  Re-plating colonies from CFC assays with or without supportive 
stromal support and under various GF conditions is a well-established technique 
for estimating self-renewal behaviour of cell populations in vitro.  Essentially each 
colony formed in a CFC is the progeny of a single cell with a given proliferative 
potential.  Following 14d culture proliferation potential of that cell and its progeny 
will be extinguished.  If this colony is then re-dispersed in fresh media the resultant 
colony formation will represent the number of daughter cells in the primary colony 
that have residual proliferative capacity, the existence of cells with secondary 
colony formation capacity suggests the presence of primitive progenitors / HSC in 
the primary colony and can be used to approximate self-renewal activity in the 
sample.  This technique has been widely employed in the investigation of HSC 
properties of normal and leukaemic cells (Carow et al., 1993; Gordon et al., 1998; 
Humphries et al., 1981; Lu et al., 1993b; Marley and Gordon, 2005; Marley et al., 
2001).  Here CFC assays were prepared as described above, after 14d culture 
colonies were assessed and 20-40 non-erythroid colonies were plucked from the 
Methocult using a pipette and an inverted microscope prior to re-dispersal in 
100L fresh Methocult in a 96 well plate ensuring no air bubbles were introduced 
and that there were no cell clumps.  The plates were incubated at 37oC in a 
humidified atmosphere with a row of empty wells around the edges filled with 
sterile H20.  After 7d the wells were assessed for secondary colony formation.  The 
total contents of the wells were then re-dispersed in a further 100L Methocult and 
tertiary colony formation was assessed a further 7d later as shown in Figure 2-5. 
 
Figure 2-5:  Schematic for CFC re-plating assay.   
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2.2.11.4 Fluorescent in situ hybridisation  
Fluorescent in situ Hybridisation (FISH) is a cytogenetic technique that can 
be used to demonstrate the presence of a particular DNA sequence in the genetic 
material of a given cell.  This technique relies on the use of one or more 
fluorescent DNA probes designed to be complementary to a highly specific 
sequence within the gene target(s).  Generally speaking the cell sample is treated 
in hypotonic salt solution to swell the cells and then fixed onto a glass slide prior to 
dehydration, prolonged hybridisation with the probe and then a series of washes to 
remove the non-specific signal.  The slide preparation can then be visualised by 
fluorescence microscopy.   
In these experiments, the Vysis LSI t(9;22)(q34;q11.2) dual colour, dual 
fusion translocation probe set produced by Abbott was utilised.  Dual colour, dual 
fusion probes increase the specificity of the FISH signal, reducing the likelihood of 
false positives. This probe comprises an orange ABL probe and a green BCR 
probe.    The ABL probe binds a 650kb region of chromosome 9 extending from 
beyond the 5’ end of the arginosuccinate synthase gene which is 5’ of the ABL 
gene to beyond the 3’ end of the ABL gene.  The BCR probe spans a 600kb region 
of chromosome 22, across the variable segments of the IGL locus and across the 
entire BCR gene, misses a 300kb region directly 3’ of the BCR gene and then 
spans another 600kb region telomeric of the BCR gene.  Generally speaking cells 
that are BCR-ABL negative would be expected to have 2 green signals 
representing the two copies of BCR that they possess – one for each chromosome 
22 and 2 orange signals representing 2 copies of ABL - one for each chromosome 
9.  The expected signal from a BCR-ABL+ cell would be to have one orange signal 
(normal chromosome 9) one green signal (normal chromosome 22) and two yellow 
fusion signals (one for the BCR-ABL fusion on the shortened chromosome 22; the 
Ph chromosome, and one from the reciprocal translocation on chromosome 9).  
Although there are other possible patterns in more complex translocations the dual 
fusion BCR-ABL FISH probe increases specificity by about 5 fold. 
Sorted cell subpopulations were re-suspended in 100L of pre-warmed 
(37oC) 0.075M KCl and carefully added to Poly L Lysine pre-treated and pre-
labelled microspot slides.  The cells were incubated at RT for a minimum of 20min 
or until dry.  Freshly made fixative was added to each microspot and allowed to 
dry.  Fixing was repeated 3 times and for the final fixation the slides were 
immersed in a coplin jar containing fresh fixative for 10min.  The slides were then 
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dried overnight and stored in parafilm at -20oC.  For clonogenic assays and LTC-
IC, colonies were plucked from the Methocult and processed individually or in 
pools.  The cells were repeatedly washed in DPBS in order to remove the 
Methocult and then processed as above.   
To perform hybridisation, the slides were warmed to RT.  They were then 
placed in a coplin jar containing 2xSSC / 0.5%NP40 pre-warmed to 37oC and then 
subjected to alcohol dehydration (3 coplin jars were prepared with 70%, 85% and 
100% ethanol in DH20; the slides were placed in the ethanol, starting at the lowest 
concentration and moving towards the highest for 5min each).  Following 
dehydration the slides were incubated in formamide denaturation buffer which had 
been pre-warmed to exactly 73oC±1oC for 5min, following which they were again 
dehydrated by alcohol immersion (5 min in 70, 85 then 100% ethanol).  The slides 
were then air dried and warmed to 40-50oC. The probe and hybridisation buffer 
were mixed according to the manufacturer’s instructions, denatured at 73oC ± 1oC 
in the water bath for 5min and 2.5L of the resulting solution applied per microspot.  
The slides were sealed with rubber cement and a coverslip prior to hybridisation in 
a humid environment for 16-24h.  Following this the coverslip and the rubber 
cement were removed, the slides were then washed with 2xSSC / 0.1% NP40 at 
RT in a foil covered coplin jar for 1min followed by washing in 0.4xSSC / 0.3% 
NP40 pre-heated to 73oC ±1oC in a foil covered coplin jar for 3min and then in 
2xSSC / 0.1%NP40 at RT in a foil covered coplin jar for 1min.  The slides were 
dried by capillary action in the dark, DAPI and mounting medium added and sealed 
by coverslip and nail varnish.  The resulting slides could then be examined by 
fluorescent microscopy and scored as positive, negative or unclear according to 
the signal seen.  In most cases all available cells were examined.  Scoring was not 
blinded, however to minimise interpretational bias, some results were compared 
with those of a blinded second observer.
2.2.12 Molecular Biology Techniques 
2.2.12.1 Extraction of RNA 
Following thaw, culture and treatment or FACS, cells were collected, 
washed in DPBS / 2% FCS, and pelleted in a 1.5ml eppendorf.  RNA was either 
extracted immediately or the pellets were snap-frozen in dry ice prior to storage at 
-80oC until use.  Total RNA was isolated from pellets using the RNeasy mini or 
micro kits available from Qiagen according to the manufacturer’s instructions.  The 
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resulting RNA was quantitated using the Nanodrop 2100 spectrophotometer with 
absorbance measured at 260nm and the 260/280 ratio determined to ascertain 
purity.   Additionally, RNA integrity was assessed using the Agilent 2100 
Bioanalyser platform.   
2.2.12.2 Preparation of cDNA 
Reverse transcription was performed using the high capacity cDNA kit 
(Applied Biosystems, Warrington, UK) according to the manufacturer’s 
instructions.  In each experiment the same quantity of RNA was processed in each 
experimental arm to minimise inter-arm variation and in order that the same 
concentration of cDNA was obtained. 
2.2.12.3 Quantitative RTPCR  
PCR allows the isolation and amplification of short specific regions of DNA 
provided at least part of the sequence is known.  Briefly, two short oligonucleotide 
primers are designed, one to be complementary to an area on each of the DNA 
strands comprising the DNA double helix at opposite ends of the sequence to be 
amplified (forward and reverse primers).  These act as primers for a heat stable 
DNA polymerase (Taq polymerase).  In the presence of these oligonucleotide 
primers, excess nucleotides and the correct salt balance, heating causes the 
double stranded DNA to separate - each strand thereby able to act as a template 
for DNA polymerisation.  Cooling allows the primers to anneal to their 
complementary sequences.   The DNA sequence 3’ to the primer can then be 
copied by Taq polymerase forming 2 new complete double stranded DNA 
molecules extending from forward to reverse primer sequences and incorporating 
the region of interest between.  Successive rounds of heating and cooling will 
therefore geometrically amplify the sequence of interest for as long as the DNA 
polymerase works efficiently and primer and nucleotide concentrations in the 
reaction mixture are not limiting.  To investigate gene expression, mRNA species 
in the cells of interest can be reverse transcribed to cDNA to allow subsequent 
PCR amplification. Quantitative RTPCR is a well-established technique for 
measuring gene expression levels in different tissues and is more accurate and 
precise than standard PCR as measurement occurs after each cycle as the 
reaction is proceeding and allows assessment of amplicon levels at the 
exponential phase of the reaction.   While there are several qRTPCR strategies 
available, I utilised the Taqman® system.  Here, in addition to the two unlabelled 
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specific PCR primers on either side of the area of interest there is a specific dual-
labelled probe for an area within the target sequence.  This probe has a 5’ reporter 
fluorophore (e.g. 6-carboxyfluorescein - FAM) covalently bound to the 5’ end and a 
quencher dye (e.g. tetramethylrhodamine –TAMRA) covalently bound to the 3’ end.  
Due to fluorescent resonance energy transfer (FRET) – a distance-dependent 
phenomenon whereby electronic excitation of a high energy fluorescent molecule 
is transferred to a nearby low energy acceptor molecule instead of being emitted, 
as long as both dyes are in close proximity laser excitation will not cause reporter 
fluorescence.  However, when the dye and quencher are separated reporter 
fluorescence will occur.  During annealing, all three complementary sequences 
bind to the target DNA increasing the specificity of the reaction over conventional 
PCR and, during the DNA synthesis stage, the 5’ – 3’ exo-nuclease activity of the 
Taq polymerase cleaves the probe releasing the reporter fluorophore and causing 
a measurable increase in reporter signal that is directly proportionate to the 
amount of target product produced (Figure 2-6). 
 
Figure 2-6:  Schematic diagram of Taqman® chemistry 
  Step 1 (A) - Denaturation: The DNA template is heated and the strands of the double 
helix separate. Step 2 (B) -Annealing: The specific primers and the dual labelled probe 
bind to their complementary sequences.  Taq polymerase can begin to initiate nascent 
strand elongation and the fluorescent reporter label is quenched by FRET due to its very 
close proximity to the quencher dye.  Step 3 (C) – Elongation: Taq polymerase completes 
DNA synthesis, and 5’-3’ exo-nuclease activity degrades the dual labelled probe releasing 
the reporter dye which fluoresces under the light source of the machine.  These steps are 
cycled repeatedly and the quantity of reporter fluorescence increases in line with the 
quantity of amplified product which is determined by the quantity of template initially 
present. 
The amount of fluorescence is measured at every cycle and is usually 
plotted on a logarithmic scale.  The exponential phase of amplification can be 
readily seen and the point at which fluorescence increases above background is 
the cycle threshold (Ct).  Comparison of Ct values provides information about the 
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abundance of target species and when compared to the expression level of an 
endogenous control gene chosen because of its stable expression between 
samples, allows the relative levels of target expression between different samples 
to be considered (Figure 2-7). The difference between the Ct of the target gene 
and the endogenous control can be expressed as; 
 
Ct = Ct (target) – Ct (control) 
 
Furthermore the relative change in expression between e.g. treated and 
untreated cells can be ascertained by calculating the difference in Ct between the 
cell types; 
 
Ct = Ct (treated) – Ct (untreated) 
 
Thus, as each cycle represents a doubling, the fold difference in expression 
is approximated by the calculation below, assuming that the relative amplification 
efficiencies are similar between the comparators. 
 
Fold difference = 2-Ct 
 
I specifically utilised Taqman® probe-sets as they are rigorously quality 
controlled, optimised mixtures of target-specific forward and reverse primers and 
dual fluorescence labelled probes.  The majority are exon spanning to eliminate 
genomic DNA amplification and each one has been proven to have a minimum of 
90% amplification efficiency. 
In this work, three manifestations of Taqman® technology were utilised; 
individual reactions in 384-well PCR plates, Taqman® Low Density Arrays (TLDA) 
and Fluidigm qRTPCR arrays.  The former 2 manifestations were run on the 
Taqman® 7900 platform and the latter using the Fluidigm Biomark platform.   
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Figure 2-7:  Schematic and representative example of Taqman® qRTPCR 
  The left panel indicates the significant features of a Taqman® qRTPCR reaction where A  
and B are two different target genes that are amplified at different rates (A representing a 
high abundance gene target and B a low abundance target gene).  C is a target that is not 
amplified.  The threshold line, cycle thresholds for each target gene and the difference 
between the two (Ct) are indicated.  The right panel shows a representative qRTPCR 
tracing following a set of qRTPCR reactions. 
2.2.12.4 Selecting an endogenous control gene 
Suitable endogenous control genes were selected by comparing the relative 
stability of 16 common candidate genes across three different CD34+ primary CP 
CML specimens at baseline and following culture in the presence or absence of 
LDE225 100nM and nilotinib 5M for up to 72h.  Isolation of RNA, sample quality 
control and reverse transcription to cDNA were performed as described above.  
Each gene expression assay was performed in triplicate. The cDNA synthesised 
from 100ng RNA from each specimen was mixed in a 1:1 ratio with Applied 
Biosystems universal master mix, the resultant mixture was loaded into the ports of 
an Applied Biosystems endogenous control array TLDA card, spun at 1200rpm 
twice for 1min each, sealed and loaded and run on the Applied Biosystems prism 
7900HT real time PCR machine at the standard recommended settings.  Variability 
was assessed by calculating the standard deviation of the Ct values for each 
candidate endogenous control gene across all samples and by utilising the 
geNorm program of Vandesompele et al to calculate the average expression 
stability values for the candidate control genes (Vandesompele et al., 2002).  For 
our samples I found ACTB, PPIA, HRPT1, RPLP0 and GAPDH to have the most 
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stable expression and I utilised GAPDH or HRPT1 as endogenous control genes in 
all subsequent PCR experiments.   
2.2.12.5 Standard individual well qRTPCR 
Standard qRTPCR was performed in 384 well PCR plates.  All reactions 
were performed in triplicate 10µL reactions.  Equal quantities of cDNA template for 
each sample were diluted with sufficient nuclease free H20, thoroughly mixed and 
4.5L of the resulting mixture added to each relevant well.  Mixtures of 5L gene 
expression master mix and 0.5L of the required Applied Biosystems gene 
expression probe set per well (with a minimum of 10% overage) were prepared, 
well mixed and 5.5L added to each reaction well.  No template controls were 
included in each run.  The plates were then sealed, spun at 1200rpm and carefully 
inspected to ensure that there were no bubbles prior to being loaded onto the 
Applied Biosystems Prism 7900HT real time PCR machine on standard 384 well 
settings (50°C for 2 min, 95°C for 10 min followed by 40-50 cycles of 95°C for 15 
seconds and 60°C for 1min).  The resultant fluorescence was measured, recorded 
and interpreted by the native software (SDS 3.0 and RQ manager) prior to being 
exported to Microsoft Excel files for further analysis.  Relative quantification was 
performed as described above.  
2.2.12.6 Fluidigm Biomark 
The Fluidigm Biomark system is a high throughput, microfluidic dynamic 
array qRTPCR platform.  It utilises integrated fluidic circuits comprised of 
reservoirs for samples and assays at either side (48 or 96) connected to a network 
of microfluidic channels, miniscule (10nL) mixing chambers and valves that 
function automatically to mix the templates and reagents during the PCR reaction.  
This reduces pipetting steps, and the quantity of reagents required and permits the 
simultaneous performance of many different qRTPCR reactions on a single 
sample.  Most importantly, the amount of initial starting material can be very small. 
All samples require to be pre-amplified prior to use.    
Briefly, 200ng of RNA from each sorted subpopulation was reverse 
transcribed as previously described.  A 5L aliquot of each sample was pre-
amplified using the Applied Biosystems pre-amplification kit and Applied 
Biosystems Taqman® probe sets. Following pre-amplification the resultant 
amplified products were loaded in triplicate onto 2 primed 48x48 Fluidigm 
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microfluidic dynamic arrays.  The desired Taqman® probe sets were loaded onto 
the chip.  The assays and samples were automatically combined on chip prior to 
thermal cycling and fluorescence detection.  This allows the comparison of 48 
assays across 15 samples in triplicate and 1 in duplicate.  I included a common 
sample across chips to ensure that inter chip variation was minimal.  Amplification 
curves were produced for each reaction, and expression levels calculated from the 
mean cycle threshold (Ct) of each triplicate reaction.  I utilised GAPDH as an 
endogenous control gene, calculating the Ct as the Ct of the target – the 
expression of GAPDH.  I expressed the fold change as 2 to the power of the 
negative difference between the Ct of the target sample and the mean of all the 
non CML samples i.e. (2-(Ct [CML sample]) – (mean Ct [Non CML samples])). 
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2.2.12.7 Pre-amplification of cDNA 
As primary cell numbers were limited and the gene targets of interest not 
abundant, in some experiments it was found necessary to amplify the cDNA 
product prior to quantitative PCR.  This was performed using the Taqman® Pre-
amp master mix kit.  This protocol enables the unbiased amplification of up to 100 
specific gene targets from extremely small quantities of cDNA (1-250ng).  Before 
pre-amplification, the probe sets of interest were pooled according to the 
manufacturer’s instructions.  Each sample was amplified over 14 cycles in a 25L 
reaction comprising 12.5L of optimised pre-amplification master mix, 6.25L of 
pooled assay mix and 6.25L of cDNA template.  Following amplification, the 
product could be diluted 1:20 in TE buffer and stored in aliquots at -80oC until 
required.  In order to ensure non biased amplification of Hh mediators and targets, 
parallel qRTPCR reactions were performed using amplified and non-amplified 
cDNA templates on test cDNA according to the manufacturer’s protocol. Here, 
triplicate 10L qRTPCR reactions were set up comprising of 5L Taqman® gene 
expression master mix, 0.5L Taqman® gene expression assay, 2L nuclease free 
water and either 2.5L of the pre-diluted (1:20) pre-amplified cDNA product or 
2.5L of the original cDNA template at a final concentration of 0.3ng/L (assuming 
1:1 RNA to cDNA conversion).  Uniformity of amplification could be checked by 
subtracting the average Ct of the endogenous control from the average Ct of the 
target genes to provide the Ct for each gene in the non-amplified and amplified 
samples and then subtracting the C t (unamplified) from the C t (amplified) to 
yield the Ct; a value close to 0 indicated amplification uniformity – I found that all 
but one probe set (GLI2) gave values that were satisfactory (Ct =-0 +/- 1.5). 
2.2.12.8 Statistical Analysis 
Statistical analyses of results were performed using Microsoft Excel 2010 or 
Graphpad Prism v5.0 software to perform Students’ T-test or ANOVA as 
appropriate.  
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3 Gene Expression Analysis of CML Stem and Progenitor 
Cells 
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3.1 Introduction 
CML represents an excellent model to investigate the transcriptional 
changes that occur in oncogenesis and progression of a stem cell driven 
malignancy.  There is also a powerful clinical impetus to better understand the 
mechanisms that underlie the apparent resistance of CML LSC to current optimal 
therapy with a view to developing novel therapeutic strategies to target resistant 
cells.  This need has become all the more pressing with the accumulating evidence 
that CML LSCs persist and remain functional for many years in optimally 
responding patients. Therefore the majority of patients with robust molecular 
responses to TKI still relapse following treatment withdrawal. Furthermore, CML 
LSCs are not dependent on BCR-ABL signalling for survival suggesting that 
alternative approaches will be required to eradicate this population (Bhatia et al., 
2003; Chomel and Turhan, 2011; Chu et al., 2011; Hamilton et al., 2012; Mahon et 
al., 2010; Ross et al., 2010).   
The rapid progress in microarray technology and the bioinformatics that are 
required to deal with the vast quantities of data produced, now affords the 
researcher an extremely comprehensive approach to the analysis of gene 
expression in various tissues.  Since the gene expression data that is produced 
from a given population is ultimately an average of the gene expression activity in 
every cell therein, in the study of rare cell types, such as HSCs, it is important to 
begin with as homogenous a population as possible.  Recent data refining our 
hierarchical models of normal and malignant haemopoiesis afford the capacity to 
purify increasingly enriched HSC populations (Majeti et al., 2007).  This affords the 
opportunity to more clearly establish the transcriptional profile of HSCs and their 
progenitors, in addition to the changes that occur during differentiation. 
As was discussed in detail in chapter 1 (section 1.4.5), several groups have 
made use of microarray analysis in CML and a wealth of information exists 
regarding response to treatment, progression to advanced phases of the disease 
and most relevant to the work undertaken here, defining the differences between 
various normal populations and the relevant BCR-ABL+ equivalents. 
The first microarray comparison between diseased and normal 
haemopoietic cells was in the highly heterogeneous BM MNC populations (Nowicki 
et al., 2004).   Two subsequent studies employed cell fractionation utilising CD34+ 
as a marker for primitive haemopoietic populations in CML and normal tissue 
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(Kronenwett et al., 2005) (Diaz-Blanco et al., 2007).  While CD34+ identifies the 
population containing the vast majority of cells with stem cell characteristics, these 
are relatively rare cells within this population which is largely comprised of 
committed mature progenitors whose abundance is different in CML compared to 
normal samples (Kronenwett et al., 2005) (Diaz-Blanco et al., 2007).  An 
alternative approach utilising hoescht and pyronin to identify quiescent and cycling 
haemopoietic cells has been employed by another two groups (Affer et al., 2011; 
Graham et al., 2007).  Lastly Bruns et al performed gene expression analysis on 
the more primitive CD34+38-lin- cell population and progenitor populations from CP 
CML and normal volunteers (Bruns et al., 2009).  These studies have yielded 
some insights regarding the transcriptional landscape in CML compared to normal 
populations but have also provided differing and non-coherent results – particularly 
with regard to the expression of genes involved in early haemopoiesis and stem 
cell function.  This may be due to the difficulty in comparing these disparate 
studies as a consequence of differences between microarray platforms used and 
the purity/method of sorting the populations analysed.   
Additionally the above studies investigated transcriptional behaviour in 
populations in which the transcriptional activity of the HSC population may be 
obscured by the much greater progenitor population.  In order to gain greater 
insight into the transcription regulation that is required for the maintenance of the 
HSC population in CML greater resolution is necessary. 
One possible refinement could be the expression of CD90 (see detailed 
discussion in chapter 1, section 1.1.2.4) CD34+90+ cells are known to harbour an 
enriched HSC population that is transplantable in mice and in humans (Michallet et 
al., 2000; Murray et al., 1995).  Seminal work by Majeti et al and Notta et al 
recently led to significant refinements in our model of early human haemopoiesis.  
Both groups phenotypically defined human populations with substantially 
increased HSC activity in CB and BM.  Majeti et al defined the population 
CD34+38-45RA-90+ as having the greatest HSC activity in human CB (1:10) and 
suggested that the population CD34+38-45RA-90- might represent the human 
equivalent of the murine MPP population although this population was not entirely 
functionally distinct from the HSC population CD34+38-45RA-90+ (Majeti et al., 
2007).  Notta et al very recently went even further and found that expression of 
CD49f (integrin 5) in CD34+38-45RA-90+/- cells was associated with highly 
enriched HSC activity (Notta et al., 2011).  Thus in normal haemopoiesis, at least, 
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refinement of phenotypic sorting strategies has resulted in increasingly pure HSC 
populations.    
The relevance of such populations in the context of CML is not yet known.  
While CD34+38-45RA-90+ cells have been well characterised in normal human CB 
and BM this population has not been adequately functionally defined in CML.    
Brendel et al reported that the majority of CD34+/90+ cells from patients with CML 
were BCR-ABL positive (Brendel et al., 1999).  Similarly Janssen et al recently 
reported the presence of a long term colony forming CD34+ population with high 
expression of CD90 in CML and furthermore suggested that the long term CFC 
within the co-existing residual normal haemopoietic population had a much lower 
expression of CD90 (Janssen et al., 2012).  Likewise the CD34+38-45RA-90- “MPP” 
population has not been characterised in CML haemopoiesis.    However more 
rigorous phenotypic selection along these lines followed by transcriptional and 
functional analysis might yield significant insights into the genetic and cellular 
behaviour of the LSC population in CML, in particular a greater understanding of 
the survival/proliferation mechanisms and transcriptional programmes that drive 
LSC fate decisions in CML and, most importantly, how they are altered from the 
normal state.   
Thus, I sought to better define the key differences between normal and 
leukaemic HSC/LSC by performing global gene expression analysis using new 
generation Affymetrix whole transcript microarrays on the purest obtainable 
populations of rigorously defined stem and progenitor populations identified by 
surface immunophenotype in non-leukaemic patient samples and equivalent 
immunophenotypic populations in CML.   
3.2 Cell Preparation, FACS and Preparation of RNA 
Cell processing and sorting were performed by Dr M Copland. 
Approximately 6-8x107 cryogenically preserved CD34+ cells from normal 
volunteers or patients with CML were thawed and cultured overnight in SFM 
supplemented with HGF.  While it is appreciated that the transcriptome will 
inevitably change following overnight culture, all samples were treated similarly 
and this method is consistent with previous methodology from this laboratory and 
allows the removal of non-viable and apoptotic cells which would otherwise 
contaminate the transcriptional landscape of the populations under analysis.  The 
following day the cells were thoroughly washed, suspended in PBS with 2% FCS 
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and stained with antibodies to cell surface proteins.   Sorting was performed to 
isolate the rigorously defined populations described by Majeti et al  and Manz et al 
(Majeti et al., 2007, Manz et al. 2002) (see Figure 3-1 and chapter 2 section 
2.2.9.7).  Briefly, the cells were simultaneously stained with lineage (lin) cocktail-
FITC, CD90-PE, CD34PerCP, CD38PE-Cy7, CD123-APC and CD45RA-Pacific 
Blue.  This allowed sorting of the cells into HSC CD34+38-lin-CD45RA-CD90+; MPP 
CD34+38-lin-CD45RA-CD90-; CMP CD34+38+lin-CD123+ CD45RA-; [GMP] 
CD34+38+lin-CD123+ CD45RA+ and MEP CD34+38+lin-CD123-CD45RA-  sub-
populations. Concurrent sorting of up to 4 populations was possible with the fifth 
population (MPP) swapped in when sufficient cells for one of the other populations 
had been collected (Majeti et al., 2007) unfortunately CP CML MPP were not able 
to be collected.  Table 3-1 and Figure 3-1 below summarise the sub-populations 
and samples used.  Following sorting, cell populations were confirmed to be highly 
enriched for BCR-ABL by FISH and RNA extraction was performed.  A table 
providing sorted cell numbers and RNA quantity for each sub-population in each 
sample is provided in Appendix 1 and the FISH results are shown in Table 3-2 
below.  This sorting process required many cells and could only be performed a 
limited number of times and additionally was limited by the number of samples 
available in sufficient quantity to allow the necessary sorting.  Three non CML 
samples, 6 CP CML samples, 4 AP CML samples and 2 BC CML samples were 
utilised yielding a total of 67 specimens for analysis.  
Sub-
population 
Immunophenotype Number of biological samples 
Normal CP CML AP CML BC CML 
HSC CD34
+
38
-
lin
-
CD45RA
-
CD90
+
 3 6 4 2 
MPP CD34
+
38
-
lin
-
CD45RA
-
CD90
-
 3 0 2 2 
CMP CD34
+
38
+
lin
-
CD123
+
 CD45RA
-
 3 6 4 2 
GMP CD34
+
38
+
lin
-
CD123
+
 CD45RA
+
 3 6 4 2 
MEP CD34
+
38
+
lin
-
CD123
-
CD45RA
-
 3 6 4 2 
Table 3-1:  Table indicating the immunophenotype and number of samples in each of 
the progenitor populations analysed. 
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Figure 3-1:  Haemopoietic hierarchy and cell sorting strategy.   
Panel A shows a simplified view of the haemopoietic hierarchy adapted from Majeti et al 
indicating the cell surface phenotype associated with each population.  Panel B shows a 
representative flow cytometry plots indicating the cell sorting strategy employed.  Panel C 
shows the relative proportions of progenitor sub-populations obtained from sorting 
CD34+ lin- cells from CP, AP and myeloid BC CML or normal cells.  Panels B and C are 
courtesy of Dr Copland 
3.3 FISH Analysis of Sorted Populations 
Each subpopulation in each sample was analysed by dual fusion FISH (D-
FISH) for the presence of the Ph chromosome and scored (see section 2.2.11.4).  
Virtually all cells of all subpopulations were Ph+ by D-FISH analysis.  There was no 
significant difference between subpopulations from individual patients or between 
subpopulations derived from samples from differing stages of the disease.  Greater 
than 90% of the LSCs in all patients were Ph+ confirming that the translocation 
arises in the most primitive haemopoietic cells that can be isolated by surface 
phenotype and is the dominant clone in all myeloid progenitor subpopulations 
(Table 3-2).   
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Patient 
% BCR-ABL FISH positive 
HSC MPP CMP GMP MEP 
CP CML 1 98 - 100 100 99 
CP CML 2 89 - 90 89 90 
CP CML 3 - - - - - 
CP CML 4 100 - 91 98 100 
CP CML 5 98 - 97 100 100 
CP CML 6 87 - 94 91 97 
AP CML 1 98 - 97 100 100 
AP CML 2 92 - 98 95 98 
AP CML 3 100 100 100 100 100 
AP CML 4 100 92 100 100 100 
BP CML 1 100 92 100 100 100 
BC CML 2 98 98 100 98 100 
Table 3-2:  FISH for BCR-ABL translocation in samples utilised for gene expression 
studies.   
Percentage of cells Ph+ by FISH analysis in each sorted population across CP, AP and BC 
samples.  FISH was performed by David Irvine and Heather Morrison. 
3.4 Affymetrix Gene Expression Microarray  
Affymetrix gene expression arrays are economical in comparison to high 
throughput sequencing and represent a relatively mature and robust platform for 
global gene expression analysis.  Advances in technology have led to both 
increased density of probesets, increased signal to noise ratio (enabling rarer 
transcripts to be detected with greater sensitivity), and a reduced requirement of 
starting material.  We elected to run our samples on the Affymetrix GeneChip 
Human Gene 1.0ST array system.  This is a modern whole transcript gene 
expression array that represents a significant improvement from prior 
manifestations of this technology.  It is designed to interrogate 28,869 well 
annotated transcript targets with 764,885 distinct 25-mer oligonucleotide probes.  
The RNA samples were provided to the Sir Henry Wellcome Functional Genomics 
Facility (SHWFGF) at the University of Glasgow who performed sample quality 
control, processing, labelling, application of the samples to the microarray chips 
and post hybridisation quality control (QC).  The data was returned in the form of 
.CEL files (recording fluorescence intensities for each genetic target in the array).  
The process is briefly described below.  RNA samples were quantitated and 
contamination measured by spectrophotometry using the Nanodrop system and 
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RNA integrity assessed by Agilent Bioanalyser microfluidics system at the 
SHWFGF. 
 Sample preparation was according to the manufacturer’s instructions for 
the Ambion WT Expression system.   Labelled, fragmented cDNA was prepared 
from total RNA through a series of steps which minimise ribosomal RNA 
contamination while amplifying and maximising recovery of target sequences.  The 
resulting samples were hybridised to the microarray chips, washed and then 
scanned. In the Affymetrix GeneChip Human Gene 1.0ST array the hybridisation 
reaction requires terminally labelled cDNA prepared from the target RNA to anti-
sense probes.  Here, perfect match only probe-sets are used, but there are internal 
background assessment probes in addition to labelling and hybridisation control 
probe-sets enabling both initial QC and background normalisation.   Each 
interrogated gene has probe-set targets in every exon throughout the transcript (a 
median 26 probes per gene).  Thus these microarrays have increased sensitivity, 
less bias, should correctly register all splice variants of each gene and can be 
analysed at either exon or gene level.  For each microarray a .DAT file is produced 
(raw pixelated image of the scanned array) and following comparison with the 
probe library and grid structure of the array a single fluorescence intensity value is 
provided for each feature (.CEL) file which is ready for normalisation, 
summarisation and down-stream analysis. 
3.5 Validation of Microarray Findings using qRTPCR and 
the Fluidigm Platform 
Despite the substantial improvements in technology discussed above, 
microarray analysis remains only the first step in analyses of the molecular events 
that underpin cellular behaviour. Gene expression at the RNA level may not 
correspond to variations in protein levels.  Validation is required using a different 
platform and preferably one would wish to confirm, not only that the gene 
expression data produced is replicable, but that there are commensurate changes 
in the effector molecules, usually proteins.  This can represent a challenge in stem 
cell biology as cell numbers are limiting and protein studies therefore extremely 
difficult to perform.  Here qRTPCR using the Fluidigm Biomark platform was 
chosen to validate the microarray findings (see methods section 2.2.11.4).  Several 
groups of genes differentially regulated in the microarray dataset were selected 
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and qRTPCR performed to determine their relative expression. The qRTPCR are 
presented for comparison alongside the microarray data as it is discussed. 
3.6 Results 
Both the raw CEL files from this work and the normalised expression data 
derived from my analysis have been uploaded onto the public GEO database 
(http://www.ncbi.nlm.nih.gov/geo) and can be accessed under accession number 
GSE 47927. 
3.6.1 Global gene expression analysis 
The annotated raw fluorescence intensity (.CEL) files were uploaded into 
Partek Genomic Suite (Partek GS), a third party bioinformatics platform.  Quality 
control metrics were assessed and no outliers or problematic arrays were 
identified; therefore all were included in subsequent analyses.  Background 
correction and normalisation was performed using Partek GS which implements 
RMA – a well-recognised multichip normalisation method (Shah et al., 2004) in 
which the background is corrected for by subtraction of the background values 
from the positive match (PM) probes, followed by quintile normalisation across all 
the arrays, log2 transformation of the values and final summarisation using the 
median polish procedure (a robust summarisation that reduces the effect of 
outliers on the median value).  Summarisation of probe intensities to gene level 
targets was then performed.  The uploaded, summarised and normalised dataset 
was subject to global analysis and clustering to investigate broad differences in 
expression.  I performed PCA on the entire data set. This is a statistical technique 
that allows very complex multi-dimensional variability in a data-set to be 
represented by a smaller (e.g. 3) number of uncorrelated components (principal 
components) (Peterson, 2003).   This analysis is particularly good for graphical 
representation of the variation within data sets and groups as differences can be 
visualised as distances along axes representing the various principal components.  
The results of this analysis are presented in Figure 3-2. 
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Figure 3-2:  PCA of non CML and CP CML populations. 
 Each axis represents a principal component of the variability in the normal and CP 
samples described in Table 3-1.  Each microarray is represented by an individual point 
within the axes and each sub-population grouping by a different colour as shown (red; 
HSC/LSC, blue; MPP, green; CMP, purple; GMP, and orange; MEP).  An ellipse is 
positioned at 2 standard deviations (2SD) around each population. 
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In the normal samples it is immediately apparent that the variation within 
each sub-population group is small compared to the CP CML samples and that 
each cellular sub-group represents a distinct entity at the transcriptional level.   
Furthermore, there is a striking progression from primitive to relatively mature sub-
populations in terms of general similarity in global gene expression.   In CP CML 
this progression appears to be significantly disordered; in particular the LSC 
grouping significantly overlaps the progenitor groupings indicating similarity in 
global gene expression.  Furthermore when both normal and CP CML sub-
populations are plotted together it is clear that LSC from patients with CP CML 
have a global gene expression signature that appears significantly more mature 
than healthy HSC, and is positioned between  the normal MPP and other 
progenitor sub-populations in the PCA plot in Figure 3-3. 
 
Figure 3-3:  PCA of non CML and CP CML HSC/LSC and MPP populations.  
Here the PCA analyses of CP CML HSC and non CML HSC / MPP are superimposed on the 
same axes.  Again each microarray is represented by an individual point and each sub-
population grouping of interest is differently coloured (green for HSC and orange for 
MPP).  An ellipse is positioned at 2SD around the non CML HSC (red), non CML MPP 
(orange) and CP CML LSC (black).  The other progenitor populations are shown but not 
circumscribed by ellipses. 
In advanced CML there is increased overlap between the sub-populations 
indicative of increasing variation both between different biological specimens and 
within the different sub-populations in each specimen.  This is reflective of 
increasingly disordered gene expression and loss of the gene expression patterns 
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seen in normal haemopoiesis (Figure 3-4).   The two BC specimens analysed were 
found to have quite different gene expression profiles demonstrating significant 
biological variability in advanced disease.  
 
Figure 3-4:  Principal components analysis of AP CML populations.  
Each axis represents a principal component of the variability in the samples.  Each 
microarray is represented by an individual point within the axes and each sub-population 
grouping by a different colour as shown.  An ellipse is positioned at 2 standard deviations 
(2SD) around each population.  The different populations are as before: red; HSC, blue; 
MPP, green; CMP, purple; GMP and orange; MEP.   
3.6.2   Contrasts and comparative gene expression analysis  
In order to look specifically at gene expression differences between our 
populations, the raw data was imported into Partek GS which is an ANOVA based 
bioinformatics system designed for analysis of microarray and similar data.  
Essentially ANOVA is a model based system that allows the variability within a 
dataset and the contribution of various experimental factors to that variance to be 
assessed jointly.  Partek GS implements a sophisticated and flexible ANOVA 
model allowing balanced or unbalanced experiments, random and fixed effects 
with any number of factors and linear contrasts (comparisons between one group 
and another group) (Ayroles and Gibson, 2006; Churchill, 2004).  Following log 
transformation, normalisation and summarisation, which presents the data in a 
more evenly distributed manner, I performed one way ANOVA using Partek GS, 
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sequentially contrasting every sub-population with every other sub-population in 
our data set.  Figure 3-5 indicates the possible contrasts between microarray 
samples.    As a result of these analyses lists of differentially expressed genes with 
fold change and p-value data for each possible comparison were generated and 
then ranked in descending order of significance.   
 
Figure 3-5:  Diagram showing potential microarray contrasts.   
Here the ANOVA contrasts performed are represented.  Population groups are noted 
across the top and left hand side of the table.  Contrasts can be made between mean 
gene expression levels in each grouping.  Each box above the diagonal represents a 
potential comparison.  Contrasts between disease states are represented in red whereas 
contrasts between sub-populations within a particular disease state are represented in 
blue.  Population abbreviations are as follows (N; normal, C; CP CML, A; AP CML, B; BC 
CML, 1; HSC/LSC, 2;  MPP, 3; CMP, 4; GMP, 5; MEP). 
Due to the volume of data and the difficulties involved in the analysis of 
multiple cell populations across multiple disease states, I elected to focus our 
subsequent investigations largely on the differences between CP CML and normal 
haemopoietic tissue and given our findings from our global analyses above I was 
particularly interested in the gene expression differences that appeared to exist 
between normal and malignant HSC and their progeny.  Multiple comparisons 
were controlled by utilising the FDR as described by Benjamini and Hochberg 
electing a threshold of 0.05 (Benjamini and Hochberg, 1995; Storey and Tibshirani, 
2003).  I analysed differential gene expression by comparing each CP CML sub-
population with its normal counterpart and also by comparing differentially 
expressed genes between primitive and mature sub-populations in normal and CP 
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CML populations.  Lists of differentially expressed genes were prepared as 
illustrated in Figure 3-6. 
 
Figure 3-6:  Comparison of gene expression along each haemopoietic hierarchy and 
between each corresponding sub-population isolated from normal and CP CML patients.   
The numbers next to the arrows indicate the number of differentially expressed genes 
between the two populations specified.  CP CML is presented in red and normal 
haemopoiesis is presented in green.  Additionally, Venn diagrams illustrate the 
differentially expressed genes in each transition unique to CP CML (red), normal 
haemopoiesis (green) and those in common (intersection).  Thus for example in the HSC 
to CMP transition, 1274 genes were differentially regulated between normal HSC and 
CMP whereas 556 were differentially regulated between CP CML LSC and CMP and 452 
were differentially regulated in both normal and CP CML. 
An initial appraisal indicates that there are many significantly deregulated 
genes between CML and normal subpopulations and that the relative difference 
between sub-populations both along the differentiation path and between normal 
and malignant tissue becomes progressively smaller with maturity.  Following 
creation of these lists I utilised gene ontology classification, gene ontology (GO) 
ANOVA in Partek GS and IPA software to place the data in a functional context to 
better understand the biological differences between CML and normal HSC and 
progenitors.  
GO ANOVA utilises the gene ontology database and has the advantage of 
being able to be applied directly to the data rather than requiring post processing 
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and filtration.  I performed GO ANOVA on the signal intensity imported normalised 
data sheet using the standard settings.  Partek GS maps the genes to functional 
groupings. The ANOVA model was configured to compare the different sub-
populations and disease states in order to determine the significance and average 
fold change of each GO category across all the comparator groups.  These results 
were visualised using dot plots where the average expression of all genes in that 
functional group is represented as a single dot.  The average expression is plotted 
on a log2 scale on the y axis – and each subpopulation in each disease state on 
the x axis.  
3.6.2.1   Genes expressed at different stages of maturity  
The patterns of gene expression in normal and malignant haemopoiesis 
were compared as transiting occurred from the HSC population to the more mature 
progenitor populations.  It was anticipated that this would provide evidence that the 
sorting strategy had isolated defined populations at the gene expression level in 
both sample groups.  The median expression of CD34, CD38 and CD90 was as 
expected both in normal and malignant haemopoiesis (Figure 3-7). 
 
Figure 3-7:  Relative expression of the primary cell surface antigens used to sort the HSC 
populations.   
Here each point represents a single sample.  The box describes median and quartile 
values, whiskers represent 10th and 90th percentiles.   Population abbreviations are as 
follows (N: normal, C: CP CML, 1: HSC, 2:  MPP, 3: CMP, 4: GMP, 5: MEP).   
Further confirmation of the segregation of these populations was obtained 
by the demonstration of increased expression of both granulocytic/monocytic and 
megakaryocytic/erythroid specific genes in the CMP population but differential 
expression of genes related to erythroid/megakaryocytic function and development 
in the MEP population and genes related to monocytic/granulocytic development 
and function in the GMP population in both normal and malignant tissue although 
the expression differences are less marked in CP CML (Figure 3-8). 
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Figure 3-8:  Heat map demonstrating expression of haemopoiesis related genes across 
HSC and progenitor populations from normal and CP CML samples. 
Mean expression levels between normal control and CP CML sub-populations from the 
microarray experiment described above and shown table 3-1.    Expression are ordered 
with respect to the normal MEP population and expressed relative to the normal HSC 
population (blue denotes down regulation and red denotes up regulation).  Genes were 
selected from GO classifications from Partek GS and IPA to reflect different haemopoietic 
cell signatures e.g. erythroid, megakaryocytic, granulocytic and HSC cell function.  The 
majority of megakaryocytic genes localise to the top as they are most highly expressed in 
the normal MEP population, several granulocytic/monocytic genes are present in the 
middle of the heat map and the majority of genes with a role in primitive haemopoiesis 
localise to the bottom of the heat map.   Population abbreviations are as follows (N: 
normal, C: CP CML, 1: HSC, 2:  MPP, 3: CMP, 4: GMP, 5: MEP).  Expression levels are the 
mean of the biological replicates described in section (N: n=3; C; n=6). 
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3.6.2.2   Comparison of normal MPP and HSC population 
Comparing normal HSC with MPP it was surprising to find that only 9 gene 
targets appeared to be differentially regulated when the significance criteria were 
applied (Figure 3-6).   These included down regulation of Ca2+-dependent 
secretion activator 1 (CADPS2), a plasma membrane protein normally involved in 
exocytosis of neurotransmitter vesicles and transmembrane and tetratricopeptide 
repeat containing 1 (TMTC1), a cytoplasmic protein with poorly defined role in 
mitochrondrial function, as well as up regulation of non-SMC condensin I complex, 
subunit H (NCAPH), a regulatory protein involved in chromatin condensation, 
dermokine (DMKN), a developmental cytokine, solute carrier family 7, amino acid 
transporter light chain, L system member 5, (SLC7A5), critical for the transport of 
neutral amino acids into cells, and LMNB1, a nuclear laminar protein providing 
nuclear stability and interacting with chromatin and other nuclear proteins notably 
HOXA9, cAMP responsive element binding protein (CREB) and MEIS1 to 
influence gene expression. The remaining three targets were unclassified.  The 
small numbers probably reflects the stringency of our criteria as applied to two 
populations which are comparatively similar - i.e. the global expression difference 
may be comprised of relatively small changes in abundance of transcripts that are 
not reliably detectible in this system due to biological variability and the lack of 
sufficient replicates or that small differences were obscured by the microarray 
normalisation procedure (Table 3-3). 
Symbol Gene p- value FC 
LOC1720 - 1.22E-05 -4.4 
NCAPH  non-SMC condensin II complex, subunit H2 7.24E-06 -4.4 
LMNB1  lamin B1 1.24E-05 -2.5 
SLC7A5 solute carrier family 7 1.12E-05 -2.0 
TMTC1  transmembrane and tetratricopeptide repeat containing 1 2.34E-07 1.6 
DMKN  Dermokine 7.35E-06 1.7 
CADPS2 Ca
2+ 
dependent secretion activator 2 1.28E-15 1.9 
Table 3-3:  Differentially expressed genes between normal HSC and MPP.   
Positive values indicate increased expression in HSC.  Expression levels are the mean of 
several biological replicates as described in table 3-1 (n=3). 
3.6.2.3  Comparison of HSC and CMP 
When the HSC populations were compared to their equivalent CMP 
population in normal haemopoiesis or CP CML, 1726 and 1008 differentially 
expressed genes were identified between the primitive and mature populations 
respectively (Figure 3-6).  These genes were further analysed in IPA.  The 
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predominant functions were related to cell cycle control and cell assembly, 
haemopoiesis, development, differentiation and DNA replication and repair 
reflecting the transit to the more proliferative but increasingly lineage restricted 
state expected of the progenitor population.   
A direct comparison between CMP from CP CML patients and CMP from 
our normal volunteers was performed.  In total 105 differentially expressed genes 
met significance criteria. These were subjected to gene ontology and pathway 
analysis in IPA and Partek GS.  The most differentially regulated functional 
classification was related to immunosurveillance and antigen presentation.  
Significantly reduced expression of class 1 and class 2 histocompatibility complex 
and related genes were noted in CP CML CMP.  Figure 3-9 and Table 3-4 indicate 
expression of key antigen presentation genes identified in Partek GS gene GO 
classifications for antigen presentation.  Interestingly, in this category there was up 
regulation of 2 genes ATP7A and RGS6 in CP CML; ATP7A is an important 
mediator of copper homeostasis and RGS6 is a G protein associated protein.   
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Figure 3-9:  Heat map representing the expression level of various genes associated 
with antigen presentation in normal haemopoiesis and in CP CML.   
All gene expression was expressed relative to the normal HSC population with blue 
representing reduced expression and red increased expression.   Gene symbols are 
summarised in the list of abbreviations. Population abbreviations are as follows (N: 
normal, C: CP CML, 1: HSC, 2:  MPP, 3: CMP, 4: GMP, 5: MEP).  Expression levels are the 
mean of the biological replicates described the preceding sections and table 3-1(N: n=3; 
C; n=6). 
Symbol Gene p- value FC 
HLA-DMA major histocompatibility complex, class II, DM alpha 2.51E-07 -1.8 
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 1.11E-07 -1.8 
CD74 CD74 molecule, major histocompatibility complex, class II 
invariant chain 
1.47E-07 -1.8 
HLA-F major histocompatibility complex, class I, F 1.20E-04 -2.0 
HLA-A major histocompatibility complex, class I, A   
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 2.68E-03 -2.1 
CIITA class II, major histocompatibility complex, transactivator 8.70E-04 -2.1 
HLA-DRA major histocompatibility complex, class II, DR alpha 3.85E-07 -2.1 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 6.74E-05 -2.3 
HLA-DQB2 major histocompatibility complex, class II, DQ beta 2 9.10E-05 -2.4 
Table 3-4:  Expression of selected antigen presentation genes in normal versus CP CML 
CMP.   
Negative fold change represents reduced expression in CP CML CMP.  
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Several other classes of genes were also differentially expressed between 
CMP in normal and CP CML samples.  I noted significantly increased expression 
of several genes associated with erythroid development and function such as 
ankyrin 1 (ANK1), spectrin B (SPTNB) and blood group Kell (KEL). This has been 
previously reported in CML CD34+ cells and may represent an MEP bias in 
developing CML progenitors (Bruns et al., 2009; Diaz-Blanco et al., 2007; Graham 
et al., 2007).  Additionally several genes involved in cell-cell interaction and 
adhesion were significantly reduced in CML, these included epithelial cell adhesion 
molecule (EPCAM), N-cadherin (CDH2) an important constituent of niche 
signalling, fibulin 5 (FBLN5) and CD96.  Interestingly, in CP CML, I found down 
regulation of several genes with a role in cell fate determination including insulin-
like growth factor receptor 1 (IGFR1) – which has a role in oncogenesis and cell 
survival (Shimon and Shpilberg, 1995), and brain and acute leukaemia, 
cytoplasmic (BAALC) which interacts with the HOX transcription factors and has a 
role in differentiation inhibition and leukaemogenesis (Heuser et al., 2012).  
Additionally there was down regulation of the self-renewal modulator and 
candidate oncogene SET binding protein 1 (SETBP1) which is discussed in 
greater detail in subsequent paragraphs.  Thus CP CML CMP have down 
regulated antigen presentation machinery and exhibit a relatively mature 
transcriptional profile that does not include an excess of stem cell or self-renewal 
associated genes. 
3.6.2.4  Comparison between the GMP and MEP progenitor 
populations 
The relatively mature GMP and MEP populations were more similar, with 
few differentially expressed genes between normal and CML haemopoiesis, 
reflecting the fact that as haemopoiesis progresses normal differentiation 
programmes are established and functional progenitors and effector cells are 
produced in both normal and CP CML.   
3.6.3 Comparison between normal and leukaemic HSC 
While the above contrasts yielded interesting information about potential 
differences in gene expression between normal and CP CML at the committed 
progenitor level, it is the comparison between the HSC/LSC populations that was 
felt to be most interesting.  There were two reasons for this; firstly, no prior 
microarray analyses has been performed comparing normal and CP CML LSC at 
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this resolution and secondly, from the analyses above it is clear that the largest 
differences at the gene expression level are between the HSC/LSC populations.  
At an FDR level of 0.05 over 1200 genes were differentially expressed between 
the HSC/LSC populations. These genes were subject to ontological and pathway 
analysis using Partek GS and IPA to place these differences in a functional 
context.  The key functional differences between these populations were related to 
cell cycle progression, DNA replication, recombination and repair, cellular 
organisation, maintenance and movement and energy production and nucleic acid 
metabolism.  Many of these entities mapped to functional categories associated 
with cancer signalling and haematological disease or to physiological processes 
related to embryonic or adult tissue development and differentiation e.g. 
haemopoietic myeloid and lymphoid tissue development (Figure 3-10 and Figure 
3-11).   
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Figure 3-10:  Ingenuity® pathway analysis comparing normal HSC and CP CML LSC.  
Differentially expressed genes are assigned to broad functional groupings or to canonical 
pathways according to their known function and interactions.  This graph shows the most 
significantly enriched functional groupings in CML HSC compared to normal HSC i.e. C1 
compared with N1.  Significance is presented as the negative log of the p-value of the 
group overlapping with the functional category and is measured using Fishers exact test.  
A significance threshold (p=0.05 or –log1.3) is shown by the orange line. 
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Figure 3-11:  Ingenuity® pathway analysis comparing normal HSC and CP CML LSC 
showing the most significantly differentially expressed canonical pathways. 
Data is presented as a stacked bar chart where red represents up regulation in CP CML 
and green down regulation. The total number of genes included in the pathway is 
presented at the head of the bars and the proportion of differently regulated genes 
represented by the bars as a percentage of that total. Orange line denotes significance 
level (-log p value). 
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3.6.3.1  Cell cycle, growth and proliferation 
There was evidence of profound up regulation of the cell cycle machinery in 
CP CML LSC compared with non CML HSCs. In total 209 genes mapped to GO 
classifications across all aspects of the cell cycle were differentially expressed; 
these included significant up regulation of genes associated with all aspects of cell 
cycle progression, segregation of chromosomes, spindle formation and mitosis.   
Additionally, 132 genes mapping to cellular assembly and organisation in 
processes primarily related to organisation, segregation and re-alignment of 
chromosomes and of nuclear material during and post mitosis had altered 
expression in CP CML LSC.  Deeper analysis suggested that while the vast 
majority of differentially expressed genes favoured positive regulation of cell cycle 
progression i.e. progression through all stages of the cell cycle, mitosis and 
proliferation in the CML LSC as compared to normal HSC, a minority of the 
differentially expressed genes were predicted to act by inhibiting cell cycle 
progression.  The relative expression of a selected group of cell cycle genes are 
shown in Figure 3-12.  Downstream analysis was also performed in IPA. This is a 
statistical test that seeks to predict the net effect of differences in gene expression 
on particular biological functions by relating the expression levels of the 
constituents of a functional group to what is known about their cellular function. 
Thus, if the majority of a functional group of genes is up regulated and its function 
is known to be advancement through the cell cycle then this would result in a 
prediction that cell cycle progression would be increased (if the gene function is 
not clear or variable, no prediction is made), a z score is provided measuring the 
strength of the prediction; >2 is considered significant.  Thus in CP CML, IPA 
predicted that centrosome cycling, S phase progression, interphase progression, 
M phase progression and mitosis were all likely to be increased.  Accordingly in 
CML, there was significant up regulation of several cyclins (CCN) (CCNA2, CCNB 
1 and 2, CCND3, CCNE1 and 2 and CCNF); several cyclin dependent kinases 
(CDK) (CDK1,2 and 4), several E2F transcription factors (E2F1,3 and 7), the 
FOXM1 proto-oncogene, in addition to the aurora kinases (AURK) (AURK-A and 
B) and polo like kinases (PLK) (PLK1 and 4).  There was also significant up 
regulation of genes involved in the orchestration of cellular, nuclear and 
chromosomal architecture through mitosis.  These included broad increase in 
expression of most of the kinesin family, critical in mitotic spindle dynamics and 
separation of the centrosomes during mitosis; broad up regulation of the 
centrosomal associated proteins (CENP) including CENPA involved in kinetochore 
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formation, mitotic progression and chromosomal segregation and various other 
genes whose products have significant roles in these processes, for example 
centrosomal protein 55 (CEP55), budding uninhibited by benzimidazoles 1 
homolog (BUB1),  ZW10 interactors ZWINT and ZWILCH; mitotic arrest deficient-
like (MAD) 2 binding protein (MAD2L) and the HAUS augmin like complex 
constituents (HAUS6 and 7).  On the other hand there was also comparative up 
regulation of several genes with a predominant cell cycle inhibitory function in CP 
CML, for example, protein kinase, membrane associated tyrosine/threonine 1 
(PKMYT1)  which inhibits the action of CDC2 and prevents progression from G2 to 
M phase; pituitary tumour-transforming 1 (PTTG1) which has an inhibitory effect on 
mitosis;  the DNA replication inhibitor geminin (GMNN) and the cell cycle 
dependent kinase inhibitor CDKN3 although no significant difference in the cell 
cycle inibitors p15,16,18,21 or 57 was noted.  Interestingly there was up regulation 
of MYBL2, retinoblastoma like 1 (RBL1), retinoblastoma binding protein (RBBP4) 
4, transcription factor DP (TFDP) 1 and several Lin homologue genes including 
Lin52 and Lin54.  These molecules are constituents of the LINC complex which 
exists in quiescent cells and inhibits expression of CDK genes, thereby negatively 
regulating the cell cycle (Litovchick et al., 2007).  See Table 3-5, Figure 3-12 and 
Figure 3-13 below for selected expression data relating to genes derived from 
Ingenuity® IPA categories related to cell cycle, growth and proliferation.  In order 
to validate the microarray results, qRTPCR was performed to independently 
quantify selected differentially regulated genes in pre-amplified cDNA from 
specimens utilised in the initial microarray analysis, the results are presented in 
Figure 3-13 where broad up regulation of selected cell cycle genes can be seen in 
CP CML HSC compared with normal HSC. 
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Symbol Gene p- value FC 
 CCNB2   cyclin B2  3.70E-11 14.1 
TOP2A topoisomerase (DNA) II alpha 170kDa 8.75E-12 11.7 
 PLK1   polo-like kinase 1 (Drosophila)  3.90E-12 11.6 
 CDK1   cyclin-dependent kinase 1  9.10E-09 8.6 
 FOXM1   forkhead box M1  2.80E-10 8.5 
 KIF20A   kinesin family member 20A  4.30E-07 7.5 
 CEP55   centrosomal protein 55kDa  3.60E-08 7.4 
 KIF15   kinesin family member 15  4.20E-07 7.2 
 MYBL2   v-myb myeloblastosis viral oncogene homolog like 2 3.30E-07 6.9 
 CCNA2   cyclin A2  1.60E-08 6.5 
 KIF11   kinesin family member 11  3.10E-07 6.4 
 KIF23   kinesin family member 23  5.90E-09 6.3 
 BUB1   budding uninhibited by benzimidazoles 1 homolog (yeast)  1.40E-08 5.8 
 PKMYT1   protein kinase, membrane associated tyrosine 2.40E-06 5.7 
 CENPI   centromere protein I  1.40E-06 5.6 
 PLK4   polo-like kinase 4 (Drosophila)  3.90E-07 5.6 
 KIF4A   kinesin family member 4A  6.80E-07 5.5 
 KIF2C   kinesin family member 2C  3.50E-08 5.3 
BIRC5  baculoviral IAP repeat-containing 5  1.81E-08 5.0 
STIL  STIL (SCL interrupting Locus 4.25E-11 4.7 
 AURKB   aurora kinase B  6.50E-09 4.6 
 ZWINT   ZW10 interactor  3.20E-07 4.5 
 CENPM   centromere protein M  1.00E-08 4.2 
 AURKA   aurora kinase A  1.70E-07 4.0 
 CCNB1   cyclin B1  1.20E-05 3.9 
 CCNE2   cyclin E2  1.90E-04 3.8 
 E2F8   E2F transcription factor 8  1.80E-05 3.7 
 E2F7   E2F transcription factor 7  3.20E-06 3.6 
CDC25C cell division cycle 25 homolog C 7.79E-07 3.4 
 CCNE1   cyclin E1  2.70E-04 3.4 
 CENPA   centromere protein A  1.00E-11 3.4 
 CDKN3   cyclin-dependent kinase inhibitor 3  2.50E-05 3.3 
 CCNF   cyclin F  6.10E-06 3.2 
 E2F1   E2F transcription factor 1  1.00E-06 3.1 
 CENPK   centromere protein K  1.70E-05         3.0 
 KIF18B   kinesin family member 18B  6.40E-05 3.0 
 PTTG1   pituitary tumour-transforming 1  1.30E-05 2.7 
 CENPO   centromere protein O  2.50E-07 2.6 
 MAD2L1   MAD2 mitotic arrest deficient-like 1 (yeast)  2.30E-05 2.6 
 WEE1   WEE1 homolog (S. pombe)  8.20E-04 2.6 
 CENPN   centromere protein N  1.90E-05 2.5 
 GMNN   geminin, DNA replication inhibitor  4.40E-04 2.4 
 HAUS6   HAUS augmin-like complex, subunit 6  1.10E-06 2.3 
 RBL1   retinoblastoma-like 1 (p107)  4.60E-04 2.1 
 CCND3   cyclin D3  4.70E-04         2.0 
 CDK2   cyclin-dependent kinase 2  5.50E-04 1.9 
 KIF4B   kinesin family member 4B  3.70E-05 1.9 
 ZWILCH   Zwilch, kinetochore associated, homolog (Drosophila)  3.30E-06 1.9 
 TFDP1   transcription factor Dp-1  1.10E-03 1.8 
 CDK4   cyclin-dependent kinase 4  1.90E-03 1.6 
 E2F3   E2F transcription factor 3  6.60E-05 1.6 
 HAUS7   HAUS augmin-like complex, subunit 7  5.50E-03 1.5 
RBBP7  retinoblastoma binding protein 7  1.65E-05 1.4 
 LIN52   lin-52 homolog (C. elegans)  6.80E-04 1.4 
Table 3-5:  Differential expression of selected cell cycle / proliferation genes in CP CML 
LSC compared to normal HSC.   
FC values indicate fold change in CML LSC over normal HSC. 
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Figure 3-12:  Selected cell cycle active genes that were differently expressed between 
normal and CP CML LSC. 
The mean relative expression of a selection of cell cycle active genes across all sub-
populations between normal and CP CML (normal n=3, CP CML n=6, see Table 3-1) 
normalised to the normal HSC population. The positive regulators of cell cycle progression 
are denoted in red whereas primarily negative regulators are in blue.  In the heat map 
blue indicates reduced expression and red increased expression relative to the normal 
HSC population.   
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Figure 3-13:  Validation of microarray expression levels of selected cell cycle active 
genes by qRTPCR. 
The relative expression levels of a selection of deregulated cell cycle active genes in 
qRTPCR validation experiments comparing the normal HSC and LSC populations from 
several biological replicates (normal n=3, CP CML n=5-6).  Error bars indicate the SEM. 
Expression expressed as 2-Ct.   Significance values as follows * p<0.05; ** p<0.01 
(unpaired T-test).   
3.6.3.2   DNA replication, recombination and repair 
Another highly deregulated functional gene set was the DNA replication, 
recombination and repair grouping.  Maintaining genomic integrity is critical 
throughout the process of cellular replication.  Here I noted significant deregulation 
of various systems involved in the correct regulation of DNA replication with 
significant over expression of origin recognition complex (ORC) subunits (ORC1,3 
and 6); many of the minichromosome maintenance complex (MCM) components 
(MCM 2-7); chromatin licensing factors e.g. CDT1 and the cell division cycle 45 
homolog (CDC45).  All these factors are critical in the initiation of DNA replication.   
Genomic instability or loss of fidelity of DNA replication or DNA damage 
would normally result in activation of DNA repair pathways at checkpoints at 
various phases of the cell cycle (at G1/S within S and at G2/M).  It is recognised 
that CML LSC have an unusual genetic instability. There is accumulating evidence 
that suggests that BCR-ABL causes this directly through induction of ROS 
inducing DNA breaks requiring repair and by interacting directly with the repair 
machinery to inhibit its performance (Sallmyr et al., 2008).  It has also been shown 
that BCR-ABL directly drives expression of certain members of the DNA repair 
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pathways e.g. RAD51 and the over abundance of these molecules results in 
increased DNA instability (Sallmyr et al., 2008).  In this study, a total of 217 genes 
assigned to GO categories related to DNA replication, recombination and repair 
were shown to be differently regulated.  The expression levels of selected 
molecules are shown in Table 3-6.  I saw consistent and significant down 
regulation of the master regulator ataxia telangiectasia mutated (ATM) and up 
regulation of many genes involved in DNA repair, either by homologous 
recombination or by mismatch repair.  Regarding mismatch repair of DNA, 
significant up regulation of exonuclease 1 (EXO1), various members of the mutS 
homolog family (MSH) (MSH1, 2 and 6) and the replication factor C family (RFC2-
5) was present.  Up regulation of several factors involved in DNA repair by 
homologous recombination was noted. Consistent with previous reports I saw 
strong up regulation of RAD51 in CML LSC (Slupianek et al., 2001).    Additionally  
there was up regulation of the breast cancer genes (BRCA1) and associated 
molecules e.g. BRCA1 associated RING domain (BARD1) and BRCA1 interacting 
protein (BRIP1), various members of the Fanconi anaemia complementation group 
genes (FANC) (FANCA, B, C, D2, G), the checkpoint kinase genes (CHEK1,2) and 
E2F transcription factors 1-4.  Expression levels of selected genes are presented 
in Table 3-6 and Figure 3-15.  Again, I selected several genes of particular interest 
and quantified their expression in the original microarray samples by qRTPCR to 
ensure that similar results were obtained (Figure 3-14).   
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Figure 3-14:  Selected genes with a role in DNA recombination and repair.   
Panel A indicates the mean relative expression of a selection of genes across all sub-
populations between normal and CP CML sub-populations (see Table 3-1) all normalised 
to the normal HSC population.  Blue indicates reduced expression and red increased 
expression.  Panel B shows the relative expression levels of a selection of these genes in 
qRTPCR validation experiments comparing the normal HSC and LSC  from several 
biological replicates (non CML n=3, CP CML n=5-6).  Expression values are expressed as 2-
Ct.  Error bars indicate the SEM.  Significance values as follows * p<0.05; ** p<0.01 
(unpaired T-test). 
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Symbol Gene p value FC 
 CDC45   cell division cycle 45 homolog (S. cerevisiae)  9.31E-09 9.0 
 MCM10   minichromosome maintenance complex component 10  2.80E-07 8.6 
 EXO1   exonuclease 1  3.84E-07 7.9 
 CDC20   cell division cycle 20 homolog (S. cerevisiae)  2.27E-07 7.6 
 RAD51   RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)  4.63E-09 7.6 
 CDCA5   cell division cycle associated 5  7.46E-09 7.0 
 RAD51AP1   RAD51 associated protein 1  1.81E-07 5.6 
 MCM4   minichromosome maintenance complex component 4  1.59E-06 5.6 
 CDC25A   cell division cycle 25 homolog A (S. pombe)  1.75E-07 5.5 
 BRCA1   breast cancer 1, early onset  1.03E-06 5.4 
 ORC1L   origin recognition complex, subunit 1-like (yeast)  2.21E-07 5.3 
 CDCA2   cell division cycle associated 2  5.55E-08 4.8 
 BRIP1   BRCA1 interacting protein C-terminal helicase 1  1.13E-05 4.8 
 FANCD2   Fanconi anaemia, complementation group D2  1.21E-08 4.7 
 FANCI   Fanconi anaemia, complementation group I  1.69E-08 4.5 
 MCM2   minichromosome maintenance complex component 2  1.01E-06 4.3 
 CHEK1   CHK1 checkpoint homolog (S. pombe)  3.44E-08 3.9 
 CDT1   chromatin licensing and DNA replication factor 1  1.35E-08 3.7 
 RFC3   replication factor C (activator 1) 3, 38kDa  7.34E-05 3.7 
 FANCB   Fanconi anaemia, complementation group B  4.45E-06 3.5 
 CDC25C   cell division cycle 25 homolog C (S. pombe)  8.25E-07 3.3 
 ORC6L   origin recognition complex, subunit 6 like (yeast)  2.86E-06 3.0 
 RFC4   replication factor C (activator 1) 4, 37kDa  1.93E-06 3.0 
 MCM6   minichromosome maintenance complex component 6  1.24E-04 2.9 
 MCM5   minichromosome maintenance complex component 5  2.14E-05 2.9 
 MCM8   minichromosome maintenance complex component 8  3.62E-04 2.8 
 FANCA   Fanconi anaemia, complementation group A  6.82E-05 2.8 
 BRCA2   breast cancer 2, early onset  (FANCD1) 5.19E-06 2.7 
 BRI3BP   BRI3 binding protein  5.15E-04 2.5 
 CHEK2   CHK2 checkpoint homolog (S. pombe)  7.71E-04 2.4 
 MCM3   minichromosome maintenance complex component 3  4.71E-05 2.4 
 RFC5   replication factor C (activator 1) 5, 36.5kDa  3.09E-05 2.3 
 MSH6   mutS homolog 6 (E. coli)  6.64E-04 2.2 
 RFC2   replication factor C (activator 1) 2, 40kDa  1.63E-04 2.0 
 FANCM   Fanconi anaemia, complementation group M  3.13E-03 1.7 
 ORC3L   origin recognition complex, subunit 3-like (yeast)  9.13E-04 1.5 
 ATM   ataxia telangiectasia mutated  5.01E-03 -1.7 
 CDC23   cell division cycle 23 homolog (S. cerevisiae)  1.97E-08 -1.6 
 CDC14B   CDC14 cell division cycle 14 homolog B (S. cerevisiae)  5.00E-08 -2.8 
 MCM7   minichromosome maintenance complex component 7  9.20E-04 -2.9 
Table 3-6:  Differential expression of selected DNA replication, recombination and 
repair genes (CP CML LSC compared with normal HSC).   
Negative values of fold change indicate reduced expression in CML. 
3.6.3.3   Antigen presentation in HSC 
As with the CMP comparison above, a significant reduction in expression of 
several of the type 1 and 2 histocompatibility molecules and associated entities 
were noted in the CP CML LSC as compared to normal HSC and this reduction is 
maintained and deepened throughout maturation; see Table 3-7 
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Symbol Gene p value FC 
HLA-E major histocompatibility complex, class I, E 8.77E-03 -1.6 
HLA-A major histocompatibility complex, class I, A 2.42E-06 -1.6 
HLA-DQB2 major histocompatibility complex, class II, DQ beta 2 3.72E-03 -1.8 
HLA-B major histocompatibility complex, class I, B 1.26E-03 -1.8 
HLA-DOB major histocompatibility complex, class II, DO beta 1.94E-03 -2.2 
HLA-DOA major histocompatibility complex, class II, DO alpha 4.01E-05 -2.8 
HLA-F major histocompatibility complex, class I, F 1.00E-05 -4.2 
Table 3-7:  Differential expression of selected antigen presentation genes (CP CML LSC 
compared with normal HSC).   
Negative values of fold change indicate reduced expression in CML. 
3.6.3.4   Haemopoietic cell development and stem cell function 
Chronic myeloid leukaemia is a paradigm for the CSC hypothesis and the 
first malignancy in which a clonal stem cell origin was demonstrated (Fialkow et al., 
1977).  I wished to determine whether there were fundamental differences in 
expression of factors that influence stem cell fate decisions between CP CML and 
normal HSC.  An analysis of our data set was performed to determine whether 
there was differential regulation in factors that are proposed to influence this 
process in HSC.  A comprehensive list of all genes with GO functions relating to 
haemopoietic differentiation and self-renewal were collated from IPA, this yielded 
1407 non-duplicated entities.  This list was then used to filter our dataset.  Our 
significance criteria were then applied yielding a list of 116 significantly 
differentially expressed genes with functions related to haemopoiesis and stem cell 
function, thus in our data set the vast majority of genes purported to regulate stem 
cell quiescence, activity, self-renewal and differentiation were not significantly 
differentially expressed between normal and CP CML HSC/LSC.   Of those 
differentially expressed, the majority were in fact down regulated in CP CML.  For 
example it was noted that expression of the HOX transcription factors (HOXA3, 
A4, A7, A9, B3 and B4) were significantly reduced.  These transcription factors all 
have well established roles in haemopoiesis, HSC function and leukaemogenesis.       
Other factors with roles in HSC fate were also down regulated including 
MDS1 and EVI1 complex locus (MECOM), fms-related tyrosine kinase 3 (FLT3), 
mixed-lineage leukaemia translocated to 3 (MLLt3), runt related transcription factor 
(RUNX2), Kruppel like factor (KLF) 4, transducin-like enhancer of split (TLE) 4, 
transcription factor 4 (TCF4), SRY (sex determining region Y)-box (SOX) 5 and 
pleomorphic adenoma gene (PLAG)1.   FLT3 and MECOM are expressed in 
primitive HSC and play an important role in both normal haemopoiesis and 
leukaemogenesis, in addition to having prognostic relevance in a clinical context 
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(Goyama and Kurokawa, 2010; Groschel et al., 2010; Parcells et al., 2006; 
Steinleitner et al., 2012).  RUNX2 has a role in development and differentiation of 
bone and other tissues and interacts with various developmental signalling 
pathways e.g. TGF and BMP signalling (Cohen, 2009).  KLF4 is a transcription 
factor with a role in the maintenance of pluripotency and directing ES cell fate 
(Bernhardt et al., 2012; Pei, 2009).   TCF4 is a transcription factor effector of Wnt 
signalling, whereas TLE4 is a transcriptional repressor of -catenin / TCF 
signalling involved in cell determination in multiple tissues, tumour suppressor 
activity and appears to inhibit proliferation and survival of myeloid leukaemic 
progenitors through interaction with RUNX1(Dayyani et al., 2008; Hanson et al., 
2012; Yao et al., 1998).  SOX5 belongs to a large, highly conserved family of 
transcription factors with a role in regulation of embryonic development and in the 
determination of the cell fate (Lefebvre, 2010).  PLAG1 is a developmentally 
regulated Zn2+ finger transcription factor which is up regulated in various tumours, 
including pleomorphic ademonas and lipoblastomas.  It is active in haemopoietic 
tissue, has been shown to expand primitive myeloid progenitor numbers and 
enhance self-renewal capacity in addition to cooperating with CBF translocations 
to cause leukaemia in murine models (Landrette et al., 2005). 
As previously mentioned, the gene SETBP1 was significantly down 
regulated in CP CML HSC and CMP.  This is intriguing as the SET protein is up 
regulated by BCR-ABL signalling in CML, contributing to leukaemogenesis through 
inhibition of protein phosphatase 2A (PP2A) (Neviani et al., 2005).  SETBP1 binds 
SET and may stabilise it by protecting it from proteolytic cleavage thereby 
enhancing its effect (Cristobal et al., 2010; Minakuchi et al., 2001).  SETBP1 
appears to have a role in regulation of HSC function promoting self-renewal (Du et 
al., 2005).  Co-expression of SETBP1 with BCR-ABL into myeloid progenitors 
confers self-renewal activity and results in aggressive myeloid leukaemia (Oakley 
et al., 2012).   Additionally, over expression of SETBP1 is seen in AML where it is 
a poor prognostic factor and in CML where it may be associated with progression 
(Cristobal et al., 2010; Neviani et al., 2005).  Deregulation of SETBP1 is also seen 
in chronic myelomonocytic leukaemia (CMML) and atypical AML (Damm et al., 
2013; Piazza et al., 2013).  Recent studies have demonstrated a role for SETBP1 
in the maintenance of self-renewal activity through interaction with HOXA9 and 
A10 in murine myeloid progenitors (Oakley et al., 2012).   
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I also noted deregulation of members of the polycomb repressive 
complexes.  There was differential regulation of several members of both PRC1 
and PRC2 complexes (both up and down regulation of components) between CML 
LSC and normal HSC.  Perhaps most interestingly, there was a significant and 
consistent up regulation of EZH2 in CML LSC.  EZH2 is cell cycle regulated but is 
also a constituent of PRC2 and is important in HSC maintenance and self-renewal.  
It also has a well established role in myeloid malignancies (Martin-Perez et al., 
2010).  There was also significant up regulation of another component of PRC2 - 
SUZ12, which is purported to have a role in stem cell maintenance and also has 
been implicated in haemopoietic malignancies particularly lymphoma (Majewski et 
al., 2008; Martin-Perez et al., 2010).  In this study BMI1 and EED were not found to 
be significantly differently expressed between CML LSC and normal HSC 
populations.   Significant deregulation of members of the PRC1 complex was also 
noted.  This included comparative down regulation of CBX 7, differential 
expression of the polycomb group ring finger protein (PCGF) family with PCGF5 
down regulated but PCGF6 up regulated in CML.   
These findings are interesting because polycomb complexes are 
evolutionarily conserved mechanisms which maintain the transcriptional profile of 
cells through the regulation of chromatin structure.  They are broad suppressors of 
transcriptional activity and are critical to normal embryonic development, 
maintenance of tissue homeostasis and stem cell function.  Polycomb complexes 
are thought to regulate stem cell function by repression of genetic programmes 
favouring differentiation and play a vital role in regulating normal haemopoietic 
function. Furthermore, aberrant polycomb function is a feature of many disparate 
haematologic and solid human malignancies (Martin-Perez et al., 2010).  
Differential expression of components of these complexes may have a significant 
effect on their overall function (Gao et al., 2012).  For example, over expression of 
EZH2 increases HSC self-renewal potential, prevents exhaustion and cooperates 
with other lesions in leukaemogenesis (Kamminga et al., 2006) whereas 
heterozygosity for Suz12 appeared to enhance HSC activity in a murine model 
(Majewski et al., 2008) and CBX7 has a critical role in the maintenance of 
pluripotency in ES cells and has tumour suppressor activity (Forzati et al., 2012; 
Morey and Helin, 2010). 
Additionally, differential regulation of the GATA transcription factors was 
noted.  GATA transcription factors have key roles in haemopoiesis.  GATA1 is 
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associated with megakaryocytic and erythroid differentiation, GATA2 has a role in 
HSC function and GATA3 is primarily involved in lymphoid, particularly T cell, 
specification and differentiation (Bresnick et al., 2012).  In this study, GATA3 was 
down regulated and GATA1 was up regulated in CML LSC.  Notably, expression of 
GATA2 was not significantly different between the two populations.   
 Several other intriguing differences were noted.   Multiple components of 
the IGF signalling pathway were differentially expressed e.g. there was down 
regulation of IGF1 and its receptor (IGF1R) which are involved in cellular 
proliferation and survival and may have a role in maintaining self-renewal 
properties in leukaemic HSC (Medyouf et al., 2011) but up regulation of IGF 
binding protein (IGFBP2) – which has been shown to expand human CB HSC in 
culture (Yilmaz et al., 2006).  Additionally there was down regulation members of 
the RAS associated factor family (RASSF) especially RASSF6 in CML LSC.  This 
family has a tumour suppressor role and have been found to be epigenetically 
inactivated in some malignancies, including ALL.  Their cellular function is to 
modulate the mitogenic effects of RAS signalling (Hesson et al., 2009; Richter et 
al., 2009). 
Lastly I noted differential expression of several adhesion molecules 
including down regulation of cadherin (CDH) 9, protocadherin 17 and also 
intriguingly CDH2 which plays a role in osteoblastic niche signalling and may be 
involved in protecting CML LSC from TKI-mediated apoptosis (Calvi et al., 2003; 
Zhang et al., 2013). Several other molecules with roles in cell-cell interaction and 
adhesion were also differentially regulated. These included reduction in expression 
of several lectin domain family members, particularly C type lectin domain 
molecules (CLEC) (CLEC2B, 4A, 7A).  Many of those down regulated are 
expressed in nerve tissue and have roles in normal neuronal development 
(neuronal cell adhesion molecule 2 [NCAM1], contactin1 [CNTN1], cell adhesion 
molecule with homology to L1CAM [CHL1]).  In contrast CP CML LSC over 
expressed several integrin molecules e.g. ITGA9 (part of the receptor for VCAM1 
and osteopontin – a potent mediator of quiescence (Nilsson et al., 2005)), ITGA2B 
and ITGB3.  Additionally CXCR4 expression has been reported to be down 
regulated in BCR-ABL expressing cells (Geay et al., 2005); however, in this work, 
CXCR4 expression was variable and therefore no significant difference in 
expression was detected between CP CML and normal LSC/HSC in our dataset.   
See Table 3-8, Figure 3-15 and Figure 3-16 for expression levels of a selection of 
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haemopoiesis and stem cell associated genes.  In order to confirm the microarray 
findings expression levels of genes of particular interest were independently 
assessed in the original specimens by qRTPCR using the Fluidigm platform.  The 
results obtained are presented for comparison in Figure 3-16.  Of those tested the 
majority followed the expression pattern described by the microarray, however in 
the case of GATA1, EZH2, SOX5 and KLF4, the difference in expression did not 
reach statistical significance (see Figure 3-16). 
 
Figure 3-15:  Selected genes with roles in stem cell fate, differentiation and self-renewal 
that were differentially regulated in the microarray comparison.  
 The relative expression of a selection of genes across all sub-populations between 
normal and CP CML (see table 3-1) all normalised to the normal HSC population is shown.  
Blue indicates reduced expression and red increased expression.   
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Figure 3-16:  Validation of microarray expression levels of selected stem cell fate, 
differentiation and self-renewal genes by qRTPCR.   
The relative expression levels of a selection of deregulated genes in qRTPCR validation 
experiments comparing the normal HSC and LSC from several biological replicates (non 
CML n=3, CP CML n=5-6) is shown.  Error bars indicate the SEM. Expression values are 
expressed as 2-Ct.   Significance values as follows * p<0.05; ** p<0.01; ***p<0.005 
(unpaired T- test). 
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Symbol Gene p value FC 
RASSF6 Ras association domain family member 6  2.30E-13 -30.1 
 PLAG1   pleiomorphic adenoma gene 1  5.45E-23 -12.1 
 CHRDL1   chordin-like 1  3.28E-09 -10.3 
 CDH2   cadherin 2, type 1, N-cadherin (neuronal)  2.17E-10 -7.8 
 SETBP1   SET binding protein 1  2.47E-10 -7.7 
 CDH9   cadherin 9, type 2 (T1-cadherin)  3.25E-05 -7.6 
 CLEC4A   C-type lectin domain family 4, member A  2.21E-05 -5.4 
 TLE4   transducin-like enhancer of split 4  2.73E-03 -4.7 
PCDH17 protocadherin 17 1.91E-11 -4.4 
 IGF1R   insulin-like growth factor 1 receptor  1.55E-07 -4.1 
 HOXA4   homeobox A4  1.12E-03 -3.4 
 FLT3   fms-related tyrosine kinase 3  7.60E-04 -3.3 
 SOX5   SRY (sex determining region Y)-box 5  4.69E-06 -3.2 
 TSHZ3   teashirt zinc finger homeobox 3  1.58E-12 -2.9 
 CLEC2B   C-type lectin domain family 2, member B  8.07E-04 -2.8 
 SMAD1   SMAD family member 1  2.29E-05 -2.8 
 RUNX2   runt-related transcription factor 2  1.09E-03 -2.7 
 HOXA3   homeobox A3  9.67E-04 -2.6 
 IGF1   insulin-like growth factor 1  3.61E-04 -2.6 
 RASSF9   Ras association domain family member 9 2.07E-06 -2.6 
 DLK1   delta-like 1 homolog  5.79E-05 -2.5 
 GATA3   GATA binding protein 3  5.58E-04 -2.4 
 MAML2   mastermind-like 2  6.65E-03 -2.4 
 BMP4   bone morphogenetic protein 4  1.23E-09 -2.3 
 CBX7   chromobox homolog 7  7.35E-05 -2.3 
 MECOM   MDS1 and EVI1 complex locus  8.76E-08 -2.3 
 NCAM2   neural cell adhesion molecule 2  5.39E-05 -2.2 
 HOXB3   homeobox B3  7.98E-03 -2.1 
 CLEC7A   C-type lectin domain family 7, member A  3.65E-03 -2 
 DACH1   dachshund homolog 1  6.82E-03 -1.9 
 EZH1   enhancer of zeste homolog 1  1.09E-04 -1.9 
 KLF4   Kruppel-like factor 4  3.12E-05 -1.9 
MLLT3 myeloid/lymphoid or mixed-lineage leukaemia 4.83E-05 -1.8 
 CHL1   cell adhesion molecule homology (L1CAM/VCAM1) 2.71E-03 -1.7 
 CLEC3B   C-type lectin domain family 3, member B  5.62E-04 -1.7 
 GLI3   GLI family zinc finger 3  5.00E-03 -1.7 
 HOXA9   homeobox A9  3.68E-03 -1.7 
 TCF4   transcription factor 4  3.72E-04 -1.7 
 HOXA7   homeobox A7  7.93E-03 -1.5 
 HOXB4   homeobox B4  4.81E-05 -1.5 
 SUZ12   suppressor of zeste 12 homolog  1.35E-04 -1.3 
 FZD5   frizzled homolog 5  4.77E-04 1.9 
 ITGA9   integrin, alpha 9  5.62E-04 1.9 
PCGF6  polycomb group ring finger 6 3.06E-04 1.9 
 GATA1   GATA binding protein 1 (globin transcription factor 1)  1.84E-03 2.6 
 EZH2   enhancer of zeste homolog 2 (Drosophila)  1.77E-07 2.9 
 ITGA2B   integrin, alpha 2b  1.10E-04 3.8 
 IGFBP2   insulin-like growth factor binding protein 2  1.50E-04 6.4 
 ITGB3   integrin, beta 3 (CD61) 4.25E-04 8.3 
Table 3-8:  Differential expression of selected genes with roles in stem cell fate, 
differentiation and self-renewal (CP CML HSC compared with normal HSC).   
Negative values of fold change indicate reduced expression in CP CML. 
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3.6.3.5   Embryonic signalling pathways 
Self-renewal behaviour is modulated by micro-environmental signalling and 
there is a wealth of data implicating embryonic signalling pathways as key signals 
governing HSC fate.  I was keen to establish whether constituents and targets of 
the embryonic morphogenic pathways e.g. BMP/TGF, Hh, Notch and Wnt were 
differently expressed in CP CML as compared to normal haemopoiesis in our data.  
In our initial analysis these pathways were not highly represented in the lists of 
differentially expressed genes indicating broadly consistent expression between 
sample groups.  However differential expression of several constituents and 
downstream targets of these pathways was noted.  Most strikingly there was 
significant reduction in the expression of BMP4, the inhibitor of BMP signalling, 
chordin-like (CHRDL)1, as well as the target SMAD1 in CP CML LSC.  I confirmed 
BMP4 expression by qRTPCR (see Figure 3-15, Figure 3-16 and Table 3-8).   This 
is interesting because BMP signalling plays an important role in the haemopoietic 
niche in normal haemopoiesis, can expand the stem and progenitor cell pool and 
appears to act downstream of Hh signalling in haemopoiesis (Bhardwaj et al., 
2001; Sadlon et al., 2004).   
Regarding canonical Wnt signalling, I discussed down regulation of TCF4 
and TLE4 in the paragraph above, however I also noted up regulation of frizzled 
receptor FZD5 in CP CML LSC (Table 3-8).  No significant difference in expression 
was noted in the other main constituents of canonical Wnt signalling in this 
comparison. 
   With regard to Notch signalling, reduced expression of delta like 
homologue (DLK) 1 and marginal reduction in mastermind like (MAML) genes 
were demonstrated (Table 3-8).  No significant difference in expression of other 
components of the pathway or of the downstream targets hairy enhancer of split 
(HES) 1 or 5 was noted.   
Finally, the data was interrogated to demonstrate whether constituents and 
targets of the Hh pathway were differentially expressed.  I did not note significant 
differences in expression of the core elements of Hh signalling (e.g. Hh ligands, 
PTCH, SMO or the positive GLI transcription factors) between the sample groups.  
I did demonstrate significant up regulation of other members and targets of the 
pathway including the B type cyclins, FOXM1 and the cell cycle regulator STIL, 
although these may have alternative stimulae and I noted a decrease in 
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expression of the Hh repressive transcription factor GLI3.  A more detailed review 
of Hh signalling is the subject of the next chapter.   
During data analysis it was apparent that differential expression in these 
pathways was either subtle or variable between biological replicates, thus our 
studies may not have had the sensitivity or the power to detect variations in 
expression of pathway elements or evidence of their relative activation.   
3.6.3.6   The relative position of the CML LSC 
Given that in both overall and specific microarray analyses, CP CML LSC 
appeared to have a transcriptional signature that was significantly more mature 
than normal HSC and, in PCA, most closely resembled the normal MPP or CMP 
population, a cross-wise comparison between CP CML LSC and both these 
normal populations was performed.  The results are shown in Figure 3-17.  
Specific analysis of the differentially expressed genes between normal MPP and 
CP CML LSC indicated that CP CML LSC had up regulation of genes related to 
cell cycle progression, organisation of mitosis and DNA replication or repair, even 
compared to the MPP population (see Table 3-9).  Notably the differences seen in 
the HSC populations were retained in many instances; thus EZH2 was up 
regulated in CML LSC.  Several of the previously mentioned adhesion molecules 
e.g. CDH2 and 9 were reduced compared to MPP.  Additionally, the tumour 
suppressor RASSF6, SETBP1, IGF1R and PLAG1 remained significantly down 
regulated.   Also the BMP signalling target SMAD1 and the BMP4 inhibitor 
CHRDL1 were also down regulated in CP CML.   Thus it appears that in some 
respects, the CML LSC population has a more mature and proliferative 
transcriptional profile than normal MPP. 
 
Figure 3-17:  Relative similarity of CP CML LSC and normal HSC and progenitors.  
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Symbol Gene p value FC 
CHRDL1 chordin-like 1 4.53E-08 -9.3 
CDH9 cadherin 9, type 2 (T1-cadherin) 2.32E-04 -6.6 
RASSF6 Ras association (RalGDS/AF-6) domain family member 6 5.26E-08 -6.2 
PLAG1 pleiomorphic adenoma gene 1 6.24E-12 -4.1 
SETBP1 SET binding protein 1 9.98E-08 -3.8 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) 8.45E-07 -3.1 
IGF1R insulin-like growth factor 1 receptor 1.92E-07 -2.8 
SMAD1 SMAD family member 1 7.72E-05 -1.9 
WNT10B wingless-type MMTV integration site family, member 10B 8.42E-05 1.5 
CD109 CD109 molecule 2.46E-04 1.5 
EZH2 enhancer of zeste homolog 2 (Drosophila) 2.35E-04 1.7 
CDC25C cell division cycle 25 homolog C (S. pombe) 2.21E-04 2.3 
PTTG1 pituitary tumour-transforming 1 3.02E-05 2.3 
BIRC5 baculoviral IAP repeat containing 5 1.09E-04 2.4 
CCNB1 cyclin B1 1.45E-04 2.5 
LEPR leptin receptor 1.75E-04 2.6 
THY1 Thy-1 cell surface antigen 8.03E-06 2.8 
CENPA centromere protein A 1.94E-05 2.9 
AURKB aurora kinase B 2.08E-05 3.1 
PLK1 polo-like kinase 1 8.19E-05 3.1 
CCNB2 cyclin B2 1.29E-04 3.1 
KIF20A kinesin family member 20A 1.78E-04 3.9 
EBF1 early B-cell factor 1 2.19E-04 6.0 
Table 3-9:  Differential expression of selected genes in CP CML LSC compared with 
normal MPP.   
Negative values of fold change indicate reduced expression in CP CML LSC. 
3.7 Summary and Conclusions 
Microarray assessment of gene expression is an extremely powerful tool 
allowing the researcher to obtain a snapshot of the expression, not just of a gene, 
pathway or set of genes, but of the entire transcriptional landscape of the 
specimens under analysis.  This has the capacity to identify, for example, new 
targets for pharmacological intervention or allow interrogation of the interrelated 
processes and networks that underlie the biological behaviour of a cell.  CML 
represents a paradigm of a stem cell driven malignancy, however transcriptional 
analysis of the LSC activity at its root has been hampered by the lack of sufficiently 
pure populations of HSC.  In this study, the transcriptional differences between 
normal and CP CML CD34+38-45RA-Lin-90+ cells and their progeny have been 
characterised.  This population represents a highly refined HSC population in CB 
where 1:10 cells have HSC activity and, it was reasoned, was likely to represent a 
similarly enriched population in adult PB.  Given that CML is thought to generate 
from a malignant HSC, HSC activity may reside in a phenotypically similar 
population.  Therefore a comparison between these populations in CML would 
allow a better appreciation of the transcriptional differences between the two 
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states.  The consequence of increasing stringency in terms of defining a cell 
population for analysis is reduced cell numbers for analysis.  We addressed this 
through sorting large numbers of pre-enriched CD34+ cells to obtain sufficient HSC 
material to proceed to the microarray analysis.  Our work represents the only gene 
expression comparison between these extremely small cell populations to date.  
These studies demonstrate that, at a transcriptional level, mature progenitors from 
CML and normal haemopoiesis are very similar.  As CML, as a clinical entity, is 
characterised by accumulation of functional terminally differentiated myeloid 
effector cells, this is not unexpected, however it is interesting to note that 
expression of BCR-ABL in the more mature sub-populations (MEP or GMP) did not 
have a significant impact on the expression levels of many genes.  As more 
primitive populations are considered, I saw increasing differences in gene 
expression between the normal and malignant haemopoietic populations that we 
isolated.  The difference is largest between the normal HSC and CP CML LSC 
and, interestingly, CML LSC would be much more akin, in terms of overall gene 
expression, to normal MPP or CMP cells.  These results are supported by the 
results of PCA analysis of the dataset.  Similar findings have been reported in less 
refined populations by Bruns et al who concluded that the CD34+38- population 
was transcriptionally similar to normal CMP and also by Graham et al and Affer et 
al who reported that the G0 CD34
+ population utilised in their gene expression 
studies exhibited transcriptional similarity to dividing cells rather than the similarly 
isolated population in normal cells (Affer et al., 2011; Bruns et al., 2009; Graham et 
al., 2007).   Thus, the further phenotypic selection that was performed in this study 
did not reveal a CML population with an HSC transcriptional signature; rather it 
suggests that even this population of rigorously sorted CP CML LSC are, at a 
transcriptional level at least, behaving more like progenitor cells than their normal 
counterparts. 
Following general analyses of the dataset as a whole, a number of analyses 
were performed with the intention of ascribing biological meaning to the data 
produced.  Here Partek GS, a powerful bioinformatics platform was used to 
compare relative expression between samples and classify the data produced into 
functional groupings while pathway analysis was performed using IPA.  These 
processes allowed lists of differentially expressed genes to be defined according to 
our criteria and determine their relevance in a biological context.  Broad up 
regulation of many aspects of cellular machinery required for proliferation, DNA 
replication and repair and segregation and mitosis was demonstrated in CML LSC 
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in comparison to the similar normal population.  These findings are strikingly 
similar to other published microarray studies in CML, for example Norwicki et al, 
Kronenwett et al, Diaz-Blanco et al and Bruns et al, all reported up regulation in 
various mediators of proliferation, cell cycle advancement and mitosis, with up 
regulation of several cyclins e.g. CCND/B/A, cyclin dependent kinases e.g. CDK4 
and up regulation of factors involved in DNA tertiary structure and those mediating 
mitosis e.g. BUB1, MAD2L and TOP2A in concordance with the data presented 
here (Bruns et al., 2009; Diaz-Blanco et al., 2007; Kronenwett et al., 2005; Nowicki 
et al., 2003).  Indeed, even in populations sorted according to cell cycle (G0) status 
there is an apparent up regulation of genes involved in DNA replication or mitosis.  
Thus even when the CP CML HSC population is not dividing, there is evidence of a 
capacity to rapidly do so.  Likewise, previously performed analysis of gene 
expression in CML highlighted DNA replication and repair systems as being highly 
deregulated in CML compared to normal haemopoiesis.   One explanation for this 
might be the ubiquitous expression of BCR-ABL in all of the populations analysed.  
BCR-ABL is associated with promiscuous activation of intracellular mitogenic 
pathways therefore its expression might be expected to result in a transcriptional 
activity akin to that described.  Thus the proliferative profile seen across all the 
CML populations analysed in this way (from MNC to the rigorously sorted 
population described here) may represent active BCR-ABL signalling irrespective 
of the phenotypic population isolated.   
This study demonstrated comparative down regulation of genes involved in 
adhesion.  In particular, there was reduction in expression of CDH2 and 9 and 
differential expression of several integrins and other adhesion molecules.  Both 
Bruns et al and Diaz Blanco et al reported similar findings (Bruns et al., 2009; 
Diaz-Blanco et al., 2007).  One of the most striking findings, however, was the 
significant and consistent reduction in many genes known to be expressed in 
primitive haemopoietic cells, in particular, those with potential roles in directing 
stem cell fate.  There was consistently lower expression of many of the HOX genes 
e.g. HOXA3, A4, A7, A9, B3 and B4, reduction in FLT3, SETBP1, GATA3, RUNX2, 
and MECOM.  There was also differential regulation in PRC complex components 
notably up regulation of EZH2 and down regulation of SUZ12 and CBX7.  Previous 
expression studies have produced disparate results; Kronenwett et al found 
increased expression of several self-renewal determinants in CD34+ CP CML cells 
(e.g. GATA2 & C/EBP) and suggested that CML HSC may in fact have greater 
self-renewal capacity than similarly defined non CML HSC (Kronenwett et al., 
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2005).  Similarly Diaz-Blanco et al found up regulation of several HSC, quiescence 
and self-renewal associated genes in their CP CML population (e.g. ALDH1A1, 
GATA2, HOXA10, HOXA9, MEIS1, PBX3 and PCGF4). They also concluded that 
CP CML CD34+ cells had enhanced self-renewal activity (Diaz-Blanco et al., 
2007).  In contrast to the above, Bruns et al found reduced levels of expression of 
genes with purported roles in directing stem cell fate (e.g. FLT3, PTEN, CD133, 
CD53 and ZFP64) and suggested reduction of self-renewal capacity in CP–CML 
HSC (Bruns et al., 2009).  Finally, Affer et al, found reduced expression of various 
stem cell factors in CP CML G0 CD34
+ cells (e.g. CD133, FLT3, MUSASHI-2  
(MSI2), HOXA3, A5, B3, B6 as well as several members of the PRC complexes 
including CBX7 and PCGF3 ) and concluded that CML LSC are more mature than 
their normal equivalents (Affer et al., 2011).  Our results are more consistent with 
the latter view.  However the picture is not straightforward, EZH2 was found to be 
up regulated in CML and SUZ12 down regulated.  These entities have roles in 
controlling HSC fate and some haemopoietic malignancies but have not been 
described in CML.   
In this study I also report significant differential regulation of several novel 
factors not previously uncovered  by gene expression analysis; for example down 
regulation of genes with tumour suppressor activity e.g. TLE4 and the RASSF 
family of RAS inhibitors as well as down regulation of PLAG1, a foetal transcription 
factor and a potential oncogene.  Recent proteomic work has suggested that 
RASSF factors and PLAG1 may interact within a complex to modulate TGF1 
signalling (Bhaskaran and Souchelnytskyi, 2008).  Lastly, there was broad 
reduction in the expression of molecules important in antigen presentation in CML 
LSC and progenitor cells.  Thus, the picture of the CP CML LSC that emerges from 
these studies is again very much of a cell with a far more mature phenotype than 
the equivalent normal HSC population.  It is also more mature, in many respects, 
than the normal MPP population, a population that has the capacity to more readily 
enter and progress through cell cycle, more readily enter myeloid differentiation 
and which generally has lower expression of genes associated with an on-going 
capacity for self-renewal.  Furthermore CP CML LSC and their progeny would 
appear from this study, to have significant deficiencies in molecules that would 
allow interaction with the immune system and present antigen for 
immunosurveillance; this has potential ramifications for therapeutic intervention 
with immuno-modulatory approaches.   Of note, Nowicki et al also noted a 
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reduction in expression of various genes related to cellular response to infection in 
CML MNC (Nowicki et al., 2003).    
This transcriptional landscape is consistent with functional observations.  
Although there is a relatively quiescent population within the broader CD34+ 
population in CML, the majority of cells are in cycle (Eaves et al., 1998b).  
Additionally in vitro and in vivo measures of self-renewal indicate that CML LSC 
have significantly impaired stem cell activity (Jiang et al., 2002; Udomsakdi et al., 
1992b; Wisniewski et al., 2011).   
A second question relates to the populations isolated.  Although more 
stringently defined than other similar studies, our HSC population is still 
heterogeneous with true HSC residing within a mixed population. Again these 
proportions may be variable between CML and normal populations; if the 
proportion of Lin−CD34+CD38− CD45RA−CD90+ cells with HSC activity amidst the 
committed progenitors were generally less in CML this might explain the 
transcriptional differences in self-renewal and stem cell associated genes.   
In the work by Majeti et al Lin−CD34+CD38− CD45RA−CD90+ and CD90- 
cells could both contribute to long term haemopoiesis but CD90- did so with less 
frequency and with lesser capacity for secondary transplantation (Majeti et al., 
2007).  It is possible that the efficient ordered process of normal haemopoiesis is 
significantly disrupted in CML and that overlap occurs between expression of pro-
cycling and differentiation elements and some pro-stem cell maintenance and self-
renewal elements in this population.  When I compared the CML LSC population to 
the normal MPP population, I demonstrated that the HSC population still had 
comparatively high levels of expression of cell cycle related genes coupled with 
down regulation of various cell adhesion and self-renewal associated genes.  This 
is concordant with a recent study that demonstrated significantly reduced 
engraftment potential of Lin−CD34+CD38− CD45RA−CD90+ from CML patients 
compared to normal PB and CB samples (Wisniewski et al., 2011).  Thus, the 
distinction between Lin−CD34+CD38− CD45RA−CD90+ and CD90- populations may 
be less relevant in CML compared to normal haemopoiesis.  This is important as 
the immunophenotypic populations under discussion in this work were resolved 
and functionally defined through analysis of human CB and adult BM  and may not 
be directly applicable in the context of adult CP CML (Manz et al., 2002,  Majeti et 
al., 2007).  Functional analysis of these stem and progenitor populations in CP 
CML is underway in this laboratory.  
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One of the main objectives of this study was to identify potential gene 
expression differences between CML and normal haemopoiesis at the stem cell 
level with a view to the development of a targeted therapy that would facilitate the 
eradication of the malignant clone. A wealth of information has been obtained from 
these studies so far and its analysis is indeed on-going.  However it is fascinating 
to speculate that self-renewal behaviour may be more tenuous in CP CML HSC, 
possibly less due to intrinsic cellular properties, with less capacity to reside in the 
niche and greater likelihood of division resulting in differentiation.  Under these 
circumstances abrogation of externally generated cues signalling for self-renewal 
might, in time, result in preferential clonal extinction.   
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4 Expression of Components and Targets of the Hh 
Signalling Pathway in CML 
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4.1 Introduction 
As experience with TKI therapy against the BCR-ABL oncogene has grown, 
it has become clear that, for the majority of patients at least, TKI therapy alone will 
not eradicate the disease.   Investigative efforts of various groups have turned 
towards defining other potential pharmacological targets in the LSC that might 
individually, or in combination with conventional treatment, target this resistant 
population.  Extending from the CSC hypothesis, one attractive target might be the 
processes that govern the maintenance and self-renewal behaviour of the CSC 
themselves as if these factors could be altered to diminish or abrogate self-
renewal, extinction of the malignant clone would result.   
As discussed in chapter 1, section 1.3.4, there is convincing evidence that 
BCR-ABL does not, of itself, have the capacity to convey self-renewal and that 
BCR-ABL expressing cells have impaired self-renewal capacity.  This in turn has 
re-focused attention on the mechanisms governing LSC fate and self-renewal 
activity in CML LSC and led to consideration as to whether these signalling 
pathways may constitute valid LSC specific targets.   
Several different pathways have been analysed and found to be implicated 
in HSC/LSC expansion and survival (discussed in depth in chapter 1, sections 1.2 
and 1.3.4), however one of the major pathways influencing stem cell self-renewal 
is the Hh signalling pathway.  This pathway has a critical role in haemopoietic 
development and embryonic morphogenesis but remains active in adult tissue 
where it contributes to tissue homeostasis, regeneration and healing through 
control of HSC function.  Aberrant Hh signalling is implicated in human 
oncogenesis and has been proposed to have an important role in CSC activity.  Hh 
signalling mechanics, its function in normal haemopoiesis, not to mention its role in 
oncogenesis, CSC maintenance and CML are discussed in detail in chapter 1 
(sections 1.2.6, 1.2.8.1, 1.2.9.5 and 1.3.4.3) however a summary diagram is shown 
below for reference. 
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Figure 4-1:  Key components of Hh signalling.    
Canonical Hh signalling is ligand-dependent and comprises a series of repressive reactions 
which are released following receptor activation. In vertebrates there are three related 
ligands DHH, SHH, and IHH which bind to two 12-span trans-membrane receptors PTCH 1 
and 2 (Pathi et al., 2001; Stone et al., 1996).  In the inactive state, PTCH1 exerts an 
inhibitory effect on SMO - a G-protein like 7-span trans-membrane protein. When Hh 
signalling occurs, this inhibition is removed allowing active SMO accumulation on the 
plasma membrane.  The effect of Hh signalling through SMO is to alter the balance of 
active versus repressive forms of the GLI family of  Zn2+ finger transcription factors (GLI1, 
GLI2 and GLI3)  mediated through alteration of their capacity to interact with an 
inhibitory complex in the cytoplasm including SUFU (Hui and Angers, 2011; Ruiz i Altaba 
et al., 2007). This activates the Hh signalling program which includes cell cycle regulators, 
inhibitors of apoptosis and positive and negative feedback loops through expression of 
GLI1 and PTCH1 respectively (Dierks et al., 2007; Duman-Scheel et al., 2002; Sasaki et al., 
1999).  Here the predominant function of the component is colour coded; 
positive/activators – red; negative regulators/repressors - blue and GLI2 which has 
significant positive and negative roles – green.    
Mounting evidence, albeit largely from gene expression studies in advanced 
CML primary cells and from murine modelling, suggest a potential role for Hh 
signalling in CML (Dierks et al., 2008; Sengupta et al., 2007; Zhao et al., 2009).  
Two studies have directly related Hh signalling to CML pathogenesis using 
different murine models (Dierks et al., 2008; Zhao et al., 2009).  Both indicated that 
Smo deletion reduced LSC numbers and reduced the incidence of leukaemia, with 
prolonged latency in primary transplantation and greatly reduced capacity to 
recrudesce disease in secondary hosts. Both groups also performed 
pharmacological inhibitor studies, demonstrating prolonged survival in diseased 
190 
 
mice, reduced LSC population, and lower functional activity in vivo and in vitro 
after exposure to the non-clinical grade SMO inhibitor cyclopamine (Dierks et al., 
2008; Zhao et al., 2009).  Therefore Hh signalling is active in CML and appears to 
be critical to the maintenance and expansion of the disease clone in primary 
human CML samples and in murine models of CML.   
Whether Hh signalling is also active and important in CP CML is not clear 
as both studies were largely conducted on primary human BC samples and murine 
models that most closely resemble advanced phase CML (Koschmieder and 
Schemionek, 2011).  This is critically important as the vast majority of CML 
patients are in CP and any stem cell-directed therapy might arguably be more 
effectively employed at early stages of the disease. 
In chapter 3, a global gene expression approach was adopted to investigate 
the transcriptional differences between CML and normal LSC/HSC or progenitor 
cells.  Here a more focused, hypothesis driven approach is employed specifically 
to investigate whether Hh signalling mediators and targets were differentially 
regulated in CML (particularly in CP CML but also in advanced phase CML stem 
and progenitor cells) compared with normal haemopoiesis.  Three simultaneous 
investigative lines were adopted; 
 
(1)  Gene expression was measured by qRTPCR on primary CD34+ cell 
populations from patients with CP CML and compared with mobilised non CML 
CD34+ cells. 
(2) Quantitative RTPCR to measure relative gene expression of constituents and 
targets of the Hh pathway in primary stem and progenitor populations from 
patients with CP, AP and BC CML compared with normal haemopoietic sub-
populations and in relation to BCR-ABL expression. 
(3) Global gene expression microarray data interrogation to determine the level of 
Hh related gene expression within the global gene expression analysis. 
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4.2 Results 
4.2.1 Expression of Hh constituents and targets in primary CP CML 
CD34+ cells in comparison to normal CD34+ cells 
Quantitative RT-PCR was used to assess the relative gene expression of 
components of the Hh signalling pathway in CD34+ cells from patients with CP 
(n=7-9) CML compared with normal CD34+ haemopoietic cells (n=6-7).  RNA was 
extracted from CD34+ cells from normal donors or patients with CML in CP, similar 
quantities were reverse transcribed prior to qRTPCR analysis using Applied 
Biosystems validated and optimised probe and primer sets (see methods section 
2.2.12).  As the comparison was between two populations the data is presented as 
2-Ct (Schmittgen and Livak, 2008) and is shown in Figure 4-2.   When performing 
comparisons between different patient samples, the inherent biological 
heterogeneity often results in far greater variability of gene expression when 
compared with cell line based experiments.  This can make it difficult to 
demonstrate statistically significant differences in primary cell samples.  There was 
variably increased expression of several downstream Hh target genes including 
HHIP (CP CML vs normal: 3.3 fold; p=0.02), GLI1 (CP CML vs normal: 2.4 fold; 
p=0.08), PTCH1 (CP CML vs normal: 2 fold; p=0.28) and GLI2 (CP CML vs 
normal: 3.5 fold; p=0.07).  In contrast to Dierks et al who had previously 
demonstrated up regulation of SMO at the gene and protein level, no difference in 
SMO gene expression was noted (Dierks et al., 2008).  Interestingly, SUFU, a 
repressor of the Hh pathway was significantly more abundant at the mRNA level in 
normal than in CP CML CD34+ cells (1.6 fold; p=0.02).  Furthermore GLI3, the 
main repressor of Hh signalling, was down regulated in CP CML compared with 
healthy CD34+ specimens (3 fold; p = 0.21).  Hh ligands were expressed at very 
low levels, however both IHH and SHH expression were higher in CML than in 
healthy CD34+ cells (6 fold; p=0.3 and 5 fold; p=0.05 respectively). 
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Figure 4-2:  Comparison of Hh pathway related gene expression in PB CD34+ cells in CP 
CML versus normal haemopoiesis.   
Expression of GLI1, GLI2, GLI3, PTCH1, SMO, SHH, SUFU, HHIP and IHH in PB CD34+ cells 
derived from patients with CP CML at diagnosis compared with normal CD34+ cells. 
Purification of CD34+ cells is described in section 2.2.3.  Results shown represent the 
mean ± SEM for a minimum of 6 samples normalised to GAPDH and expressed as 2-Ct.  
The reader’s attention is drawn to the fact that y-axis scale vary between the differing 
gene targets due to their variable abundance.  Significance values; * p<0.05. n≥6 
(unpaired T-test). 
Thus, while constituents and targets of Hh signalling are expressed in CML 
cells, their expression is low level, rather variable amongst the primary specimens 
analysed and the differences in expression small.  As a result, few of the 
comparisons generated statistically significant differences.  Nonetheless, we see 
an intriguing pattern whereby Hh ligands and downstream targets (PTCH1, GLI1 
and HHIP) are up regulated and predominantly inhibitory molecules (GLI3 and 
SUFU) are comparatively down regulated in CP CML.    
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4.2.2 Gene expression analysis of Hh signalling molecules in CML 
compared with normal stem and progenitor populations 
The previous experiments established that Hh signalling molecules were 
expressed in primary CML CD34+ cells and moreover suggested that there may be 
differential expression of key targets and pathway regulators between normal and 
malignant primary CD34+ cells however the results were not conclusive.  The key 
problems identified were that expression of Hh components was, generally 
speaking, low in the samples analysed and there was a significant degree of 
variation in expression between different biological samples, particularly between 
the primary CP CML CD34+ cells analysed.  The CD34+ population spans the 
entire stem and progenitor pool with expression values being determined by the 
net expression of all cells within this grouping whereas self-renewal activity in 
normal haemopoiesis and CP CML is largely confined to the most primitive cells 
within this group.  Thus it will be difficult to compare levels of expression of these 
key mediators of self-renewal in populations comprised largely of non self –
renewing committed haemopoietic cells and variable numbers of HSC.     
To better understand alterations in Hh signalling in CML stem and 
progenitor cell populations I assessed gene expression of Hh pathway mediators 
and downstream targets in pure populations of  LSC/HSC, CMP, GMP and MEP 
subpopulations in CP and advanced phase CML versus normal haemopoiesis.  
These experiments were performed in parallel with and utilising the same sorted 
samples as the microarray experiments detailed in chapter 3.  Gene expression 
analysis was performed by qRTPCR utilising the Fluidigm Biomark system with 
validated Applied Biosystems probe and primer sets following pre-amplification as 
detailed in chapter 2, section 2.2.12.  Note the 2-Ct values are larger than in Figure 
3-2 due to the fact that in the Fluidigm analysis pre-amplification of targets but not 
GAPDH was performed.  
4.2.3 Analysis of key Hh signalling mediators and targets 
I observed that the most primitive populations had the highest expression of 
Hh mediators and targets and that expression typically reduced with degree of 
maturation (see Figure 4-3).  For example, expression of the key downstream 
target of Hh signalling, GLI1 is down regulated with maturity in normal 
haemopoiesis.  This pattern is less clear in CML, with larger variation in expression 
between the biological replicates and expression was noted to be slightly 
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increased in the CMP progenitor population in CP CML.  In advanced phases even 
more disruption is evident.  Other key downstream targets of Hh signalling, PTCH1 
and 2, are also comparatively reduced in expression in mature subpopulations, 
particularly in CMP and GMP subpopulations and may increase in the MEP 
population.   A similar pattern albeit with greater variability is seen in PTCH2 
expression.  Additionally, it appears that expression of PTCH1 in mature 
populations may increase with disease phase whereas this pattern is not evident 
with PTCH2.   Comparing overall expression of GLI1, PTCH1 and PTCH2 between 
normal populations and their relevant equivalent in CP, AP and BC CML, the only 
difference that reaches significance is PTCH2 expression between normal and CP 
GMP populations.  There was a trend towards a slight increase in GLI1 expression 
in CP CML LSC and CMP over normal HSC and CMP and an increase in GLI1 
expression in the BC CML samples.  For PTCH1 there was a tendency for 
expression to increase with worsening disease severity in CML.   
In contrast to GLI1 and PTCH1/2 I noted a significant reduction in 
expression of the key Hh pathway inhibitors GLI3 and SUFU in CML stem and 
progenitor cells when compared with normal haemopoiesis.  In normal 
haemopoietic maturation, there was a progressive down regulation of GLI3 from 
HSC with maturity.  This pattern was not evident in CML, where GLI3 was reduced 
in LSC and remained similarly low in CMP and GMP populations.    Likewise 
SUFU expression was comparatively high in normal HSC reduced with maturity 
whereas in CML SUFU was reduced in LSC and similarly expressed across the 
sorted sub-populations.  Again, there was no alteration in expression of SMO in 
the various HSC/LSC populations analysed however there was a tendency for 
SMO expression levels to be increased in the CMP population in comparison to 
the HSC/LSC population which reached significance only in the advanced phase 
comparisons. 
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Figure 4-3:   Relative expression of key targets and modulators of Hh signalling in sorted 
sub-populations (HSC, CMP, GMP and MEP) from PB CD34+ cells derived from patients 
with CP, AP or BC CML at diagnosis compared with normal sub-populations.    
Results are presented as the mean ± SEM for multiple samples normalised to GAPDH and 
are expressed as 2-Ct.  Significance values (unpaired T-test); NS, not significant, ≈ 
borderline p<0.1, *, p<0.05; **, p<0.01; CP CML, n=6; normal, n=3, AP CML, n=4, BC CML 
n=2 (note BC CML LSC is a single sample and statistical analysis is not presented for BC 
CML comparisons) 
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Furthermore I analysed the expression levels of the downstream targets of Hh 
signalling, CCNB1, CCNB2, FOXM1 and STIL (Figure 4-4).   
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Figure 4-4:   Relative expression of additional targets of Hh signalling across sub-
populations in normal, CP, AP and BC CML haemopoiesis.   
Gene expression of HSC, CMP, GMP and MEP sub-populations from PB CD34+ cells 
derived from patients with CML at diagnosis compared with normal sub-populations.   
Results are presented as the mean ± SEM for multiple samples normalised to GAPDH and 
are expressed as 2-Ct.  Significance values (unpaired T-test); ≈ borderline p<0.1, *, p<0.05; 
**, p<0.01, *** p<0.005; CP CML, n=6; normal, n=3, AP CML, n=4, BC CML n=2 (note BC 
CML LSC is a single sample).  Statistical analysis is not presented for BC CML samples. 
In these analyses markedly increased expression of FOXM1, CCNB1 and 2 
and STIL was noted in CML compared with normal HSC and in the progenitor 
populations compared to HSC in both normal and malignant haemopoiesis.  No 
difference in expression was noted between CP and advanced phase disease or 
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between different progenitor populations within or between different disease 
states.   
4.2.4 Analysis of hedgehog ligand expression  
The expression of Hh ligands in CML and normal haemopoietic stem and 
progenitor cells was analysed. The results of these analyses confirmed that 
expression levels are extremely low in haemopoietic cells despite pre-
amplification.  Consistent expression results were not obtained for DHH and IHH. 
However SHH was not expressed by normal HSC, CMP and GMP populations but 
interestingly was expressed in CP through advanced phase CML, see Figure 4-5.  
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Figure 4-5:  Relative expression of SHH ligand across sub-populations in normal, CP, AP 
and BC CML haemopoiesis.    
Relative gene expression of SHH in sorted sub-populations (HSC, CMP, GMP and MEP), 
from PB CD34+ cells derived from patients with CML at diagnosis compared with normal 
sub-populations.   Results are presented as the mean ± SEM for multiple samples 
normalised to GAPDH and are expressed as 2-Ct CP CML, n=6; normal, n=3, AP, n=4, BC 
n=2 (note BC CML LSC is a single sample and statistical analyses are not presented for BC 
CML samples). 
Given the expression results above, I attempted to determine whether SHH 
ligand was actively secreted by primary normal and CML cell populations.  To 
achieve this I performed SHH-specific ELISA as described in chapter 2, section 
2.2.10.3.  Briefly, equal quantities of cells (0.5x106 cells/mL) were cultured for 24h 
after which the supernatant was collected and equal quantities added as 
appropriate to the pre-prepared ELISA plates.  Sonic HH production between 
normal and CP CML MNC and CD34+ cells was compared.  Media obtained from 
culture of similar quantities of various stromal cell lines and primary MSC and 
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relevant fresh media was also included in the analysis.  The culture and collection 
of conditioned media was performed by Jennifer Richmond.  No difference was 
demonstrated between supernatants obtained from either the CD34+-enriched 
fractions or the MNC fractions between CML and normal haemopoietic cells, in fact 
no difference in optical density was noted above baseline in either supernatant 
suggesting that SHH was not expressed at appreciable levels by either cell type (at 
least down to 10ng/mL – the lower range of the SHH ELISA kit).  Low levels of SHH 
were detected in supernatants obtained from the human stromal line HS-5 and in 
some primary MSC cultures. 
4.2.5   BMP4 expression 
Assessment of BMP4 expression levels was performed as BMP4 is known 
to co-operate with Hh signalling in determining HSC fate both in embryonic and 
adult haemopoiesis (Bhardwaj et al., 2001).  It was surprising and intriguing to find 
that BMP4 is abundantly expressed in normal HSC but is down regulated 
significantly with maturation.  However in CP and advanced CML a significant 
reduction in BMP4 expression was demonstrated at the HSC and progenitor 
(CMP) level, see Figure 4-6. 
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Figure 4-6:  Relative expression of BMP4 across sub-populations in normal, CP, AP and 
BC CML haemopoiesis.   
Relative gene expression of BMP4 in sorted sub-populations (HSC, CMP, GMP and MEP), 
from PB CD34+ cells derived from patients with CML at diagnosis compared with normal 
sub-populations.   Results are presented as the mean ± SEM for multiple samples 
normalised to GAPDH and are expressed as 2-Ct.  Significance values (unpaired T-test): *, 
p<0.05; **, p<0.01, *** p<0.005; CP CML, n=6; normal, n=3, AP CML, n=4, BC n=2 (note 
BC CML LSC is a single sample and statistical analyses are not presented for BC CML 
samples 
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The significance of this finding is uncertain, however it may be that 
autocrine and/or paracrine BMP4 signalling from HSC to HSC and haemopoietic 
cell to niche is a further mechanism important in determining stem cell fate and 
could co-operate with Hh signalling.  Reduced expression in CML LSC may be 
reflective of the fact that CML LSC populations comprise a greater number of 
committed cells or may suggest fundamental differences in cellular signalling 
between normal and CML cells at the HSC fate determination level. It is possible 
that lack of autocrine BMP4 may ultimately render CML LSC more dependent on 
other signalling pathways e.g. Hh, to control HSC fate decisions.   
4.2.6 Gene expression analysis of Hh signalling molecules in CML 
compared with normal haemopoiesis from gene expression 
microarray 
As I briefly discussed in chapter 4, global microarray analysis failed to 
identify the majority of Hh constituents as being differentially expressed in CP CML 
LSC compared with normal HSC.  However, there are a number of factors that 
made further analysis desirable. Firstly standard microarray normalisation has the 
effect of compressing differences between genes, thus differences in expression 
are generally less marked and may be less accurate and more variable in gene 
products with low abundance (Bemmo et al., 2008; Canales et al., 2006).  
Secondly, in global analysis, multiple comparisons must be borne in mind; 
however this is less relevant when the analysis is performed with a specific 
hypothesis.  In this section, I present the expression data from a specific analysis 
of the Hh pathway in order to provide a comparison with the data above.  The 
results are presented below in the form of a heat map and comparison of selected 
expression intensity plots both generated from Partek GS.    From the results 
presented in Figure 4-7, differences in expression are small and the variability 
between different biological specimens is comparatively large (especially in 
advanced CML) for some genes (e.g. GLI1 in comparison with GLI3 or STIL).   
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Figure 4-7:   Microarray comparison of selected Hh related genes.   
In (A) I present a heat map created in Partek GS representing the expression levels of 
various genes associated with Hh signalling in normal and CML haemopoiesis.  All gene 
expression was relative to the normal HSC population with blue representing reduced 
expression and red increased expression.   In (B) the relative expression levels for various 
Hh related genes are shown microarray by microarray.  Samples are grouped by disease 
stage and each column represents the mean expression level for each cell population, 
individual microarrays are represented by a hollow dot. Samples denoted as follows; 1: 
HSC/LSC, 2: MPP, 3: CMP, 4: GMP, 5: MEP. 
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4.2.7 BCR-ABL expression in CML LSC and progenitor sub-
populations  
All CML progenitor cells harbour the BCR-ABL mutation, and as a 
consequence of their proliferative rate and mobilisation into the PB, will constitute 
the vast majority of circulating progenitors.   The proportion of stem cells 
expressing BCR-ABL has been noted to be lower as this will reflect the proportion 
of remaining normal HSC compared with the number of LSC in primary BM 
samples.  Our samples were all derived from PB and as such might be expected to 
have a higher proportion of LSC than BM.  It was felt important to determine the 
frequency of BCR-ABL positive cells and the relative levels of expression of BCR-
ABL in each sample and sub-population of CP and advanced phase CML.   
Each sub-population in each sample was analysed by dual fusion FISH (D-
FISH) as discussed in chapter 3, with results shown in Table 3-2.  I also assessed 
BCR-ABL gene expression in the different stem and progenitor cell populations in 
CP, AP and BC CML by qRTPCR.  Although all LSC populations had substantially 
increased levels of BCR-ABL RNA, quantities were variable and the difference 
between the means in the different sub-populations in CP, AP or BC CML did not 
reach statistical significance by unpaired T-test; see Figure 4-8.    
 
Figure 4-8:  BCR-ABL expression in CP and advanced CML stem and progenitor cells. 
 Panel A shows relative gene expression BCR-ABL in sorted sub-populations, (HSC, CMP, 
GMP and MEP), from PB CD34+ cells derived from patients with CML at diagnosis.   Results 
are presented as the mean ± SEM for multiple samples normalised to GAPDH and are 
expressed as 2-Ct.  (CP CML, n=6; normal, n=3, AP CML, n=4, BC CML n=2; note BC CML 
LSC is a single sample).   
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4.3 Discussion  
In this chapter I have presented the results of gene expression analysis for 
constituents and targets of the Hh morphogenic pathway in primary cells derived 
from CML in various phases and from normal controls in selected CD34+ cells in 
total and also across the haemopoietic stem and progenitor sub-populations that 
comprise this CD34+ population.   
I assessed BCR-ABL gene expression in the different stem and progenitor 
cell populations using qRTPCR and demonstrated expression in all sub-
populations.  I was intrigued to discover whether BCR-ABL expression was 
comparatively up regulated or down regulated in the leukaemic HSC over other 
sub-populations as this population (CD34+38-45RA-Lin-90+) has not been 
previously studied.  Most previous reports have concluded that BCR-ABL 
expression is increased in CD34+38- CML cells compared to progenitors (Copland 
et al., 2006; Jamieson et al., 2004; Jiang et al., 2007b), however, two early reports 
suggested that BCR-ABL might be transcriptionally repressed in primitive CML 
cells (Bedi et al., 1993; Keating et al., 1994).   In all of the CML samples analysed, 
there was variably increased BCR-ABL expression in the LSC populations 
compared to the progenitor populations.  Given that I had already determined that 
the prevalence of BCR-ABL+ cells was largely equivalent in each sub-population 
this suggests that BCR-ABL transcription appears to be increased in CML LSCs. It 
is not clear however whether higher expression of BCR-ABL is clinically relevant 
as recently Modi et al demonstrated that cells with high levels of BCR-ABL 
expression were more sensitive to TKI therapy in a human cell model of CML and 
Kumari et al reported that persistent BCR-ABL+ cells following TKI therapy had low 
levels of BCR-ABL expression compared to the initial diagnostic samples (Kumari 
et al., 2012; Modi et al., 2007). 
Interesting differences were seen between the expression of key elements 
of Hh signalling across the progenitor populations.  Quantitative RTPCR 
demonstrated that expression of the key targets of Hh signalling GLI1 and PTCH1 
is highest in the HSC population in normal haemopoiesis but tends to decline with 
maturity.  In CML, GLI1 expression is seen in the leukaemic HSC but is retained at 
a higher level in some progenitor populations (CMP, GMP) whereas PTCH1 
expression falls with maturity (Figure 4-3).   Both of these genes are widely utilised 
as reporters of Hh activity as both are regulated at the gene expression level and 
expression is responsive to Hh signalling. The presented results also indicate that 
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the main negative regulators of Hh signalling, GLI3 and SUFU are also down 
regulated with degree of maturity in normal haemopoiesis, but stably expressed at 
a low level in CML. I saw no difference in expression of the key positive regulator 
of Hh signalling SMO across sub-populations. 
Whether Hh signalling is differentially expressed in CML compared to 
normal haemopoiesis is less clear.  In our initial analysis of CD34+ cell populations 
between normal and CP CML I found that the expression of key Hh mediators and 
targets was variable between biological samples.  I noted a tendency for increased 
expression of targets GLI1, PTCH1 and HHIP over normal CD34+ cells but this did 
not reach statistical significance.  I also noted that, while SMO did not appear to be 
differentially expressed, GLI3 and SUFU, both negative regulators of Hh signalling, 
were significantly down regulated in CML.  This was confirmed by the results 
obtained from careful dissection of the transcriptional profile of the constituent sub-
populations in CML and normal samples.  Here I demonstrated a striking reduction 
in expression of the inhibitory molecules (SUFU and GLI3) in CML, both in CP and 
AP.  Additionally, a tendency for higher levels of expression of GLI1 and PTCH1 in 
CML LSC, possibly rising with disease progression was noted, but no differential 
expression of SMO was seen.  These are intriguing results; the lack of difference 
in expression of the key positive regulator of Hh signalling SMO is in contrast with 
Dierks et al who demonstrated that Smo expression was up regulated at the RNA 
and protein level in murine BCR-ABL+  cells (Dierks et al., 2008).  This provided a 
possible mechanism for Hh over activity in CML cells.  Our results hint toward an 
alternative mechanism of activation relating to reduced expression of key inhibitory 
elements.  If SUFU and GLI3 are down regulated, the result would likely be to 
make a cell more sensitive to Hh signalling and the production of a stronger and 
more prolonged response (Ruiz i Altaba et al., 2007).  This would require further 
work to confirm differential expression at the protein level to take forward but is an 
area of great mechanistic interest.  
Expression of several other targets of Hh signalling are differentially 
expressed between normal and CML HSC. These include FOXM1, CCNB1/2 and 
STIL.  While these targets are all significantly up regulated here, other signalling 
pathways converge on these molecules and expression may also be driven by 
other factors.  For example FOXM1 is a transcription factor with a role in cell 
proliferation and DNA repair, and in addition to Hh signalling, is regulated by input 
from various other paths at a transcriptional level e.g. FOXO3A (Delpuech et al., 
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2007), p53 and E2F1(Millour et al., 2011).  STIL is involved in haemopoiesis and is 
regulated by various factors including GATA transcription factors (Bockamp et al., 
1997). 
Additionally, I measured expression of Hh ligands in CML compared to 
normal volunteers.  I found extremely low levels of expression in both CD34+ bulk 
population and in sorted HSC and progenitor populations.  Intriguingly, I noted up 
regulation of SHH in CML, however this did not translate into detectable levels of 
SHH protein following culture.  This may be due to lack of sensitivity of our ELISA 
or instability of the protein.  Longer culture of the cells prior to harvesting the 
supernatant or concentration of the supernatant might improve sensitivity.   
I compared the results of our qRTPCR with those of the global expression 
microarray described in chapter 3.  No significant differences in expression levels 
were noted after adjustment for multiple comparisons.  One reason for this is the 
variability between biological replicates evident, however another contributory 
factor may be that the normalisation procedures involved in microarray analysis 
are known to compress differences and may result in smaller differences between 
populations than would be seen by other techniques. This is most evident in low 
abundance targets (Bemmo et al., 2008; Canales et al., 2006).   It is therefore 
perhaps not surprising that Hh signalling (or for that matter, other low abundance 
targets) were not highlighted in the initial microarray analysis.  Further replicates 
would have been beneficial but were precluded by the cost and resource 
implications.     
During this study I was fortunate to be able to develop collaboration with 
Professor Ravi Bhatia at the City of Hope, Duarte, California.  In a set of parallel 
qRTPCR expression experiments in the Scl-tTa-BCR-ABL murine model of CML 
(Koschmieder et al., 2005), Professor Bhatia and his team demonstrated  
increased expression of Gli1, Ptch1, CcnB1 and Ptch2 in CML LT-HSC compared 
to control cells, and a significant difference in Gli3 was noted in CML BM 
compared to normal BM and are presented in Appendix 2.  
Previous studies have investigated whether Hh signalling components are 
up regulated in CML.  These studies have largely, but not exclusively, been 
confined to advanced phase disease and/or murine models of CML and have been 
discussed in chapter 1.  More recently other studies have reported variably 
increased expression of Hh mediators and targets in patients with CML.  Long et al 
and Su et al have performed semi-quantitative PCR on MNC from patients with 
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CML at diagnosis and during treatment.  Both groups found up regulation of GLI1, 
PTCH1 and SMO, the key positive components of Hh signalling but did not 
investigate the expression of the negative regulators of the pathway.  In these 
studies it is not clear to what extent their findings reflected the likely 
heterogeneous composition of the samples analysed (Long et al., 2011; Su et al., 
2012).  While several studies (noted above) have investigated the expression of 
Hh mediators and targets at the gene expression level in CML, none have 
convincingly approached the expression of these entities at the protein level.  This 
is most probably due to the difficulty inherent in performing techniques such as 
Western blotting for low abundance proteins in highly purified and hence highly 
limited cell populations, not to mention the paucity of available human reactive Hh 
antibodies.  Proteomic analysis would certainly be desirable, particularly for 
investigating the interactions between GLI2, GLI3 and other cytoplasmic proteins 
that have both positive and negative roles in Hh signal propagation depending on 
cytoplasmic protein complex associations, phosphorylation and ubiquitination and 
partial truncation.  Dierks et al performed immunohistochemistry on human and 
murine BM confirming expression of SMO and GLI1 at the protein level.  
Additionally they saw elevation of SMO expression by flow cytometry in cells 
obtained from their murine model (pMSCV/Bcr-Abl/GFP) (Dierks et al., 2008).  
Western blot analyses in primary cells were not attempted as this would have 
required a prohibitively large number of cells.  Attempts to measure SMO and GLI1 
by flow cytometry in primary cells in our studies were not successful. 
Lastly I noted the associated signalling molecule BMP4 was highly 
expressed in the normal HSC population but down regulated rapidly with maturity; 
however BMP4 was significantly reduced in all CML LSC populations.  BMP4 is a 
member of the TGF family of growth factors and acts via cell surface heteromeric 
receptors to activate intracellular SMAD signalling through phosphorylation of 
SMAD1/5/8 which interact with SMAD4, translocate to the nucleus and activate a 
transcriptional programme that includes GATA1/2, SCL and LMO2 (Sadlon et al., 
2004).   BMP4 has an important role in developmental haemopoiesis and 
cooperates with IHH to specify haemopoietic development (Sadlon et al., 2004).  In 
vitro studies of adult haemopoiesis have demonstrated potential dose-dependent 
roles for BMP4 in the maintenance or differentiation of HSC populations in culture 
(Bhatia et al., 1999).  BMP4 signalling also interacts with Hh signalling in this 
context, functioning downstream of Hh and cooperating with it to maintain or 
expand the HSC population in vitro (Bhardwaj et al., 2001).   In vivo, reduced 
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microenvironmental expression of BMP4 resulted in reduced maintenance and 
transplantability of normal HSC (Goldman et al., 2009).  BMP4 signalling is an 
important component of microenvironmental signalling and may affect HSC 
function directly or indirectly through affecting the cells that comprise the niche 
(Goldman et al., 2009).  There is evidence that osteoblasts and endothelial cells 
are responsive to BMP4 (Suzuki et al., 2008; Zhang et al., 2003).  Therefore the 
fact that BMP4 is reduced in CML LSC might have functional consequences 
through CML LSC to LSC autocrine/paracrine signalling or indirectly by influencing 
stromal cells and consequently the signalling milieu in which the CML LSCs reside.  
It might also be the case that as CML LSC are less likely to be resident in the BM 
niche due to reduced adhesion and chemotaxis, that autocrine/paracrine signalling 
is comparatively more important.  Certainly, particular aspects of extramedullary 
haemopoiesis in the mouse, e.g. development of stress erythroid progenitors in the 
spleen, require interaction of BMP and Hh signalling (Perry et al., 2009).   
In summary I have confirmed expression of the key mediators of Hh 
signalling in CML and in normal haemopoiesis.  Active signalling is suggested by 
the expression of the key targets GLI1 and PTCH1 amongst others, and this 
activity is largely confined to the more primitive HSC populations in normal 
haemopoiesis.  In CML, expression of these targets tended to be increased in the 
LSCs and, in the case of GLI1, the CMP population as well.  There was consistent 
reduction in expression of the key negative regulators SUFU and GLI3, which may 
result in increased magnitude and duration of response to received signal.   
Therefore HH signalling may be considered a possible stem cell target in CML, 
although its utility would be dependent on there being a therapeutic window of 
effect between normal and malignant haemopoiesis.  
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5 Effect of Specific Inhibitors of Hh Signalling on CP CML in 
Short Term in vitro Culture 
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5.1 Introduction 
In chapter 1 we discussed the critical role of Hh signalling during 
embryogenesis and in early haemopoiesis, in contrast to its function in adult 
organisms, where it has a potential role in regeneration, directing stem cell fate 
and potentially as a driving force in malignancy.  While the Hh signalling pathway 
is one of many with overlapping functions in the complex processes that govern 
self-renewal behaviour, development of Hh inhibitors have had a head start 
compared with other self-renewal pathways.  In the first instance, a prototype SMO 
inhibitor is available from nature; the steroidal alkaloid cyclopamine has been 
studied extensively, both in terms of its pharmacological and biochemical effect 
and in terms of functional outcome in models of Hh-dependent tumours.  
Cyclopamine acts by binding directly to the hepta-helical bundle of SMO, 
preventing the conformational change that would normally occur when PTCH 
repression is removed (in response to Hh ligand) and causing an alteration in its 
sub-cellular distribution (figure 1-4, chapter 1) (Chen et al., 2002).  The effect of 
this is to prevent downstream activation of the GLI transcription factors and 
therefore implementation of the Hh signalling transcriptional programme (Chen et 
al., 2002; Taipale, 2000).  
Cyclopamine is unsuitable for clinical use due to instability, significant off-
target effects and toxicities (Heretsch et al., 2010). However, it has provided the 
impetus to develop more clinically relevant compounds, including LDE225 
(Erismodegib) and its derivative LEQ506.  LDE225 was identified as a highly 
selective SMO inhibitor in a cell-based high throughput screen looking for 
compounds with highly selective Hh inhibitor activity.   Mechanistically, LDE225 
was shown to displace BODIPY-cyclopamine from human and murine SMO in 
competitive assays (Pan et al., 2010).  Thus, LDE225 appears to interact directly 
with SMO in a similar way to cyclopamine.  Functionally, LDE225 has been shown 
to reduce expression of downstream targets of Hh signalling in various cell lines 
and clinical models of Hh-driven malignancy (Pan et al., 2010).   Unlike 
cyclopamine, LDE225 represents a clinical – grade SMO inhibitor with real 
translational potential and is currently under clinical evaluation in solid 
malignancies. 
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5.1.1 Measuring the activity of Hh signalling in cells 
In order to assess the effects of LDE225 on the Hh pathway in vivo and in 
vitro, biomarkers of Hh activity are required. The measurement of Hh activity is 
most readily achieved through assessing its effect on gene expression (measured 
by qRTPCR) of immediate downstream targets.   The most widely accepted direct 
targets of Hh signalling are GLI1 and PTCH1/2 (Marigo and Tabin, 1996; Pearse et 
al., 2001; Shahi et al., 2010; Vokes et al., 2007; Vokes et al., 2008; Yang et al., 
2011; Yang et al., 2010; Yoon et al., 2002; Zhu and Lo, 2010). While PTCH1/2 
exhibit basal expression that increases following Hh signalling, GLI1 is principally 
controlled by activated GLI2 itself, influenced by upstream Hh signalling, and is not 
normally expressed (Dai, 1999; Hui and Angers, 2011). 
5.1.2 Hh modulation of cell cycle and proliferation 
As discussed in chapter 1, Hh signalling exerts a cell type and context 
specific influence on cell cycle progression and cell proliferation (Yoon et al., 
2002). Potential downstream targets of the Hh pathway include elements acting at 
various stages in the cell cycle including several cyclins e.g. CCNB1/2, CCND1/2 
and CCNE in addition to other cell cycle active proteins, such as SCL/TAL, 
FOXA2, FOXM1 and p57kip2 (Barnes et al., 2001; Duman-Scheel et al., 2002; Hao 
et al., 2006; Hochman et al., 2006; Kenney and Rowitch, 2000; Roy and Ingham, 
2002; Shahi et al., 2010; Teh et al., 2002; Trowbridge et al., 2006; Yoon et al., 
2002) (see chapter 1 table 1-4).   Hh signalling generally has a stimulatory effect 
on cell cycle and proliferation, driving proliferation of sensitive tissues and Hh-
dependent tumours (Berman et al., 2002; Berman et al., 2003; Cayuso et al., 2006; 
Duman-Scheel et al., 2002; Roy and Ingham, 2002; Stecca et al., 2007).   
In normal haemopoiesis, as discussed in chapter 1 section 1.2.6.1, Hh 
signalling drives the expansion of haemopoietic precursors.  Bhardwaj et al 
reported that exogenous Hh ligands caused primitive haemopoietic cell 
proliferation and expansion of cell numbers in in vitro culture that could be 
abrogated by specific antibody or pharmacological inhibition (Bhardwaj et al., 
2001; Sengupta et al., 2007).  Trowbridge et al reported expansion of primitive 
haemopoietic cells in Ptch +/- heterozygotic mice, a model of Hh activation, 
associated with modulation of several cell cycle mediators including Ccnd1 prior to 
HSC exhaustion (Trowbridge et al., 2006).    Additionally, Merchant et al reported a 
reduction in proliferation associated with reduced expression of Ccnd1 in HSCs 
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and myeloid precursors derived from a murine model lacking expression of Gli1 
(Merchant et al., 2010).  However in the Smo deletion models reported by Gao et 
al and Hofmann et al, no evidence of reduction of the HSC or progenitor 
populations was found nor was there a difference in cell cycle distribution in these 
cells (Gao et al., 2009; Hofmann et al., 2009). 
5.1.3 Hh as a survival signal 
Hedgehog signalling can also influence apoptosis and survival.  The anti-
apoptosis regulator BCL2 has been shown to be a downstream target of Hh 
signalling.  (Abe et al., 2008; Bigelow et al., 2004; Cayuso et al., 2006; Regl et al., 
2004).  Additionally, Hh signalling affects sensitivity to p53-mediated apoptosis 
through down regulation of expression and up regulation of MDM2-mediated 
ubiquitination and clearance in breast cancer (Abe et al., 2008).  Inhibition of Hh 
signalling results in reduced viability and increased apoptosis in disparate tumours 
e.g. models of pancreatic or colon cancer and diffuse large B cell lymphoma 
(Berman et al., 2003; Dierks et al., 2007; Guo et al., 2009; Singh et al., 2010).  
5.1.4 Measuring Hh activity and its effect in CML haemopoiesis 
Studies in CML have utilised these markers to demonstrate Hh activity.  
Dierks et al demonstrated modulation of GLI1 expression in response to genetic or 
pharmacological SMO inhibition in their murine model but the murine models of 
Zhao et al did not directly look at downstream transcriptional effects of Smo 
inhibition either in Smo deleted or cyclopamine treated cells (Dierks et al., 2008; 
Zhao et al., 2009).  Neither study directly assessed downstream transcriptional 
effects of Hh inhibition in primary CML samples.  The only study to do so was by 
Sengupta et al, who witnessed a 2-fold induction of GLI1 in response to 24h 
culture with SHH in CP CML CD34+ cells, but no effect of CCND1 or PTCH1 
expression (Sengupta et al., 2007).  Reduction of GLI1 and PTCH1 transcription 
was seen following exposure to forskolin.  However the dose of SHH used was 
supra-physiological (3000ng/mL) and inhibition was indirect as forskolin acts via 
PKA activation through adenyl cyclase leading to reduced GLI activation (Tiecke et 
al., 2007).  Additionally, it is now appreciated that, particularly in malignancy, 
alternative activation pathways converge on GLI reflecting the complex network of 
interactions between various converging signalling pathways that determine cell 
fate (Blotta et al., 2012; Katoh, 2007; Lauth and Toftgard, 2007; Li et al., 2007a; 
Maeda et al., 2006; Nolan-Stevaux et al., 2009; Sengupta et al., 2007). Thus the 
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question of the optimal biomarker for Hh activity in CML has not been 
comprehensively studied and requires further investigation, particularly in the 
context of in vitro treatment of primary CML samples.  In CML, contrasting with 
normal haemopoiesis, Dierks et al reported both significant levels of apoptosis and 
alteration in cell cycle distribution in BCR-ABL+ cells in their murine model 
following short term culture with 2M or 5M cyclopamine.  However, these may 
be non-specific, as in their study, Zhao et al utilised 1M cyclopamine and 
demonstrated off target effects with 3M cyclopamine (toxicity in Smo-/- cells) 
(Dierks et al., 2008; Zhao et al., 2009). 
Thus, from the above discussion, a key question relates to whether more 
specific inhibition of Hh signalling with LDE225 can be measured through 
assessment of downstream transcriptional targets in CML cells in in vitro culture 
and whether such inhibition would affect cell cycle status, proliferation and 
apoptosis in primitive primary CP CML cells.   
In this chapter, I sought to: (1) determine if LDE225 inhibited transduction of 
Hh signalling, through inhibition of transcription of its immediate downstream 
targets thereby identifying a biomarker for SMO inhibition in CP CML; and (2) 
characterise the effect of LDE225 alone and in combination with conventional 
treatment with nilotinib, a potent TKI against BCR-ABL, on primary CP CML CD34+ 
cells in short term in vitro culture. 
Specific objectives covered in this chapter are described below; 
(1) Examination of the effect of LDE225 on downstream targets of Hh 
signalling:  
a. In a GLI-driven luciferase reporter assay; 
b. In the K562 BC CML cell line; 
c. In primary CP CML CD34+ cells. 
(2) Examination of the effect of inhibition of SMO with LDE225 alone and in 
combination with nilotinib on:  
a. CD34+ CP CML cell viability and apoptosis measured by vital dye 
exclusion and annexin V / 7AAD apoptosis assays; 
b. CD34+ CP CML cell proliferation and cell cycle status; 
c. CP CML cell division history and expression of primitive cell surface 
markers.  
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5.2 Results  
5.2.1 LDE225 and LEQ506 cause dose dependent reduction in 
luminescence in a GLI responsive luciferase reporter assay 
  In order to measure the concentration of SMO inhibitor required to inhibit 
expression of downstream targets, TM3 (GLI-Luc) cells were first obtained from 
Marion Dorsch, Novartis.  This is a murine Leydig tumour line with intact Hh 
signalling machinery, stably transfected with a retroviral vector selectable by G418 
sensitivity, carrying 8 GLI-responsive elements and a luciferase gene, such that 
luciferase expression is dependent on GLI activation.  Therefore, increased Hh 
signalling will result in increased luciferase expression (Pan et al., 2010).  These 
cells were cultured in TM3 media under G418 selection.  In a first set of 
experiments, the optimal concentration of agonist was determined.  The TM3 cells 
were seeded at 10,000 cells per well in an opaque white 96 well culture plate and 
exposed to incremental concentrations of the direct SMO agonist purmorphamine.  
Luciferase activity could then be assessed in triplicate, at 24, 48 and 72h.  The 
results of this experiment indicate that maximal luciferase activity was 
demonstrated following 48h exposure to 2.5g /mL purmorphamine, as shown in 
Figure 5-1.  In a second set of experiments, the TM3 cells were again seeded as 
above but this time with incremental concentrations of the SMO inhibitors under 
analysis.  After 6h the optimal dose of purmorphamine indicated by the first 
experiment was added and luciferase activity measured at 48h.  Two clinical grade 
SMO inhibitors were assessed in this way; LDE225 and LEQ506.   The results of 
this experiment indicate that LDE225 has an IC50 for inhibition of GLI activity of 
approximately 8nM and LEQ506 has an IC50 for inhibition of GLI activity of 
approximately 2nM Figure 5-1.  Despite the higher potency of LEQ506, further 
experiments were performed using LDE225 as material transfer agreements with 
Novartis prevented publication of data pertaining to LEQ506. 
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Figure 5-1:   SMO activation and inhibition in Hh responsive TM3 reporter cell line. 
  Panel A indicates the luciferase activity following culture of TM3GLI-Luc cells in TM3 media 
supplemented with incremental doses of the known direct SMO inhibitor purmorphamine 
at 24h (red), 48h (black) and 72h (blue).  Maximal luciferase activity was demonstrated 
after 48h culture with 1g/mL purmorphamine.  Panel B demonstrates the relative 
activity of two small molecule SMO inhibitors in TM3GLI-Luc cells.  Cells were exposed to 
incremental doses of SMO inhibitor and stimulated by 2.5g /mL purmorphamine.  
Results are expressed as a percentage of the luminescence of the untreated control 
(stimulated, but no SMO inhibitor).  The point represents the mean of at least 3 replicates 
and error bars indicate the SEM. NDC, no drug control. 
5.2.2 SMO inhibition with LDE225 reduces expression of downstream 
Hh target genes in K562 cells 
In the previous section, I demonstrated the effect of LDE225 on GLI1, a key 
downstream target of Hh signalling in a non-haemopoietic luciferase reporter 
system. It would be desirable to demonstrate whether the effect of LDE225 could 
be similarly measured in a more suitable system.    An early culture and 
expression experiment using the BC CML cell line, K562, demonstrated that K562 
cells expressed GLI1 and PTCH1 and CCND1 and that following 16h exposure to 
high concentrations of LDE225 there was a reduction in GLI1 and CCND1 
expression but not PTCH1 (Figure 5-2).   
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Figure 5-2:  Gene expression analysis of the BC CML cell line K562 following exposure to 
LDE225.   
K562 cells were cultured in standard media with LDE225 at the stated concentrations 
over 16h.  Extraction of RNA, conversion to cDNA and amplification were performed as 
indicated in the methods section. Expression levels are shown as fold change (2-Ct) 
relative to the untreated control using GAPDH as an endogenous control.  The mean of 
three reactions in a single experiment are presented with error bars indicating SEM and 
significance p<0.01 represented by ** (paired T-test). 
5.2.3 SMO inhibition with LDE225 reduces expression of GLI1 in 
CD34+ CP CML cells 
While a number of CML-derived cell lines exist and offer a plentiful supply of 
cellular material for investigation, these cell lines, including K562, are derived from 
advanced phase disease, have become immortal and consequently are likely to 
have radically altered self-renewal behaviour and machinery.  Primary CD34+ CP 
CML cell populations offer a more relevant model in which to study potential 
biomarkers of Hh activity following SMO inhibition as they retain cells with stem 
cell activity derived from the stage of disease that was of primary interest.  
 In order to define a potential biomarker for LDE225 activity in CP CML, 
CD34+ cells were cultured in SFM in the presence of incremental concentrations of 
LDE225 (10-1000nM) over 6, 24 and 72h.  Following culture the cells were 
harvested for expression analysis of downstream targets and constituents of the 
Hh pathway by qRTPCR as described in detail in the methods section (section 
2.2.12).   The results are presented in Figure 5-3 and are discussed below.  No 
significant alteration in expression of target genes GLI1, CCND1, CCND2, PTCH1 
or PTCH2  was detected at 6 or 24h following exposure to up to 1000nM LDE225 
(Figure 5-3A; 24h; 6h data not shown).  At 72h, a small down regulation of GLI1 
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expression was noted following exposure to LDE225 (LDE225 10nM, 0.7 fold, 
LDE225 100nM 0.73 fold; Figure 5-3B).   Cells treated with LDE225 at 1000nM 
concentration showed a non-significant reduction in GLI1 expression (0.84 fold).   
A non-significant reduction in PTCH1 expression was also noted (LDE225 
1000nM, 0.72 fold).  As would be anticipated, no alteration in the expression of 
GLI2 or SMO was seen at any time point following treatment with LDE225 (they 
are components but not direct targets of Hh signalling).   
 
Figure 5-3:  Quantitative RTPCR measuring expression of several constituents and 
targets of Hh signalling in CD34+ CP CML cells after  (A) 24h  and (B) 72h culture in SFM  
in the presence of  LDE225.   
Primary CD34+ cells were cultured in SFM in the presence of LDE225 10, 100 or 1000nM 
as stated for 24 or 72h, prior to qRTPCR analysis. Expression levels are shown as fold 
change (2Ct) relative to the untreated control with GAPDH as an endogenous control. 
The mean of 5-8 independent samples are presented with error bars indicating SEM and 
significance p<0.05 represented by * (paired T-test).   Data for non-targets SMO and GLI2 
is not shown. 
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Closer analysis of the distribution of response to LDE225 between different 
samples demonstrated significant biological variability in LDE225-mediated GLI1 
response (Figure 5-4).  From the samples tested, several respond to exposure to 
LDE225 by reducing expression of GLI1 whereas others do not, suggesting that 
susceptibility to Hh inhibition may be variable or dependent on as yet unknown 
cooperating factors.  It would be of great interest to test a significantly larger cohort 
of samples in order to validate this observation and investigate potential causes. 
 
Figure 5-4:  Quantitative RTPCR measuring expression of GLI1 in CD34+ CP CML cells 
after 72h culture in SFM  in the presence of  LDE225.   
Individual sample values plotted by fold difference in GLI1 expression indicating the 
variability between independent biological samples following exposure to LDE225 in 
culture over 72h as above.  Expression levels are shown as fold change (2-Ct) relative to 
the untreated control with GAPDH as endogenous control.  The mean of 5-8 reactions are 
presented with error bars indicating SEM and significance p<0.05 represented by *(paired 
T-test).  Non-responding samples are shown as follows - 339; red and 274; blue. 
Additionally, in an attempt to enhance baseline Hh signalling, several CP 
CML CD34+ samples were also cultured in the presence of rSHH (at up to 
500ng/mL) over 24 and 72h. Up regulation of downstream targets was noted as 
shown below, however the response to rSHH was variable and the differences 
seen did not reach statistical significance (Figure 5-5).  This is in contrast to work 
published by Sengupta et al who did note a 2-fold up regulation of GLI1 and a 1.5 
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fold up regulation of PTCH1 in the presence of rSHH.  One possible explanation 
for this difference is that Sengupta et al used considerably higher doses of rSHH 
(3000ng/mL) (Sengupta et al., 2007).  
 
Figure 5-5:  Quantitative RTPCR measuring expression of GLI1 and other downstream 
targets of Hh signalling in CD34+ CP CML cells after 24h culture with rSHH.   
Primary CD34+ cells were cultured in SFM in the presence of rSHH as stated for 24h, prior 
to qRTPCR analysis. Expression levels are shown as fold change (2Ct) relative to the 
untreated control with GAPDH as endogenous control.  The mean of 3 independent 
samples are presented.  Error bars represent the SEM. 
5.2.4  SMO inhibition with LDE225 alone and in combination with 
nilotinib does not influence viability in CP CML CD34+ cells in 
short term in vitro culture 
Primary CD34+ CP CML cells were cultured in SFM in incremental 
concentrations of LDE225 (up to 1000nM LDE225) alone or in combination with 
5M nilotinib for 24, 48 and 72h.  Viable cell counts were performed using trypan 
blue exclusion and the results are presented in Figure 5.6 below.  Additionally, 
separate cultures were performed with CD34+ CP CML cells in SFM+HGF and in 
the presence of LDE225 (5-50nM) and/or nilotinib (5M).  These were extended 
over 12d with re-seeding in fresh media and drug every fourth day.  No difference 
in viable cell count was seen compared to the untreated control in SFM alone at up 
to 72h following drug exposure as assessed by trypan blue dye exclusion.  
Furthermore while nilotinib, as expected, reduced viable cell counts after 4d, 
addition of LDE225 at up to 50nM did not enhance the effect of nilotinib in culture 
at up to 12d duration (Figure 5-6). 
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Figure 5-6:  Viable CD34+ CP CML cells following exposure to LDE225 +/- nilotinib. 
The top panel indicates the number of viable cells at 72h following culture in SFM with 
incremental concentrations of LDE225 (n=3-6).  The bottom panel indicates the number 
of viable cells at 4, 8 and 12d following culture with LDE225 +/- nilotinib at the stated 
concentrations in SFM +HGF.  Error bars represent the SEM (n=4). 
5.2.5 SMO inhibition with LDE225, alone and in combination with 
nilotinib, does not influence proliferation of CP CML CD34+ 
cells in short term in vitro culture 
While incorporation of vital dye provides some indication of comparative 
proliferative rate and viability, there are limitations to its usefulness e.g. counting 
accuracy, homogeneity of cell solution, the fact that staining increases over time 
and that the recognition of viable cells by membrane integrity will not count cells as 
non-viable until fairly late in apoptosis.  Therefore apoptosis was also measured by 
annexin V / 7AAD staining and proliferation by BrDU incorporation (see methods 
section 2.2.9.3 and 2.2.10.2). Chronic phase CML CD34+ cells were cultured in 
SFM in the presence of incremental concentrations of LDE225 over 24-72h.  To 
measure proliferation, BrDU was added to the culture wells 16h prior to harvest, 
the cells were then washed, fixed and the quantity of BrDU incorporation was 
measured by colourometric change according to the manufacturer’s instructions.  
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No difference in overall proliferation rate was seen by BrDU incorporation at up to 
1000nM LDE225 for up to 72h (Figure 5-7).   
 
Figure 5-7:  Chronic phase CML CD34+ cell proliferation in presence of LDE225 at 72h. 
The mean proliferation of 3 independent CD34+ CP CML samples as measured by BrDU 
incorporation at 72h is shown above.  Values are presented as a percentage of untreated 
control.  Error bars indicate the SEM. 
5.2.6 SMO inhibition with LDE225, alone and in combination with 
nilotinib, does not cause apoptosis in CP CML CD34+ cells in 
short term in vitro culture 
To measure apoptosis, CD34+ CP CML cells were cultured in SFM in the 
presence of LDE225 (5-500nM) and/or nilotinib 0.5M-5M.  Apoptosis was 
assessed at 24h intervals for 72h by annexin V and 7AAD incorporation, measured 
by flow cytometry.  As expected, nilotinib caused increased apoptosis in CP CML 
CD34+ cells.  LDE225 neither caused apoptosis nor accentuated the apoptotic 
effect of nilotinib (Figure 5-8).  
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Figure 5-8:  Apoptosis assays in CP CML CD34+ cells exposed to LDE225 and/or nilotinib. 
 Panel A shows representative FACS plots following exposure to LDE225, nilotinib or the 
combination over 72h.  The CD34+ cells were stained with annexin V and 7AAD prior to 
analysis by flow cytometry.  The percentages shown indicate the proportion of total 
events that fell within the respective gates.  The combination shown is LDE225 50nM and 
nilotinib 5M.  Panel B provides the schema for interpretation of the flow cytometry 
plots.  Panel C indicates the proportion of viable cells, those in early apoptosis and those 
in late apoptosis in 3 independent CD34+ cell samples following 72h culture with LDE225 
and or nilotinib at the concentration shown. Error bars represent the SEM. 
5.2.7 SMO inhibition with LDE225, alone and in combination with 
nilotinib, does not influence cycle distribution of CP CML 
CD34+ cells in short term in vitro culture 
To assess cell cycle status CD34+ CP CML cells were cultured in SFM in 
the presence of LDE225 at 5 or 50nM +/- nilotinib at 5M.  Cell cycle status was 
assessed by flow cytometry using the high resolution cell cycle analysis employed 
by Jordan et al (Jordan et al., 1996) and described fully in methods section 2.2.9.5.  
Briefly, cells under analysis were stained with Ki67 and 7AAD.  The resultant 
stained cells could then be assessed by flow cytometry which allowed identification 
of cells in G0 (Ki67
-/7AADlo), G1 (Ki67
+/7AADlo) and G2/S/M (Ki67
+/7AAD+).  While, 
as expected, nilotinib caused accumulation of cells in G0, previously reported by 
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Jorgensen et al, LDE225 neither affected the cell cycle distribution of CD34+ CP 
CML cells at up to 72h exposure and up to 50nM concentration or accentuated the 
effect of nilotinib (Figure 5-9) (Jorgensen et al., 2007).     
 
Figure 5-9:  High resolution cell cycle analysis in CP CML CD34+ cells exposed to LDE225 
and/or nilotinib.   
Panel A shows representative FACS plots following exposure to LDE225, nilotinib or the 
combination over 72h.  The CD34+ cells were stained with Ki67 and 7AAD prior to flow 
cytometry analysis.  The combination shown is LDE225 50nM and nilotinib 5M.  The flow 
cytometry plots are represented on log/linear axes with Ki67-PE staining represented on 
the logarithmic y axis and 7AAD detected in FL-3 on the linear x axis.  Panel B provides the 
schema for interpretation of the flow cytometry plots.  Panel C indicates the proportion 
of cells residing in G0 in 3 independent CD34
+ cell samples following 72h culture with 
LDE225 and or nilotinib at the concentration shown, the asterisk indicates the presence of 
nilotinib 5M.  Error bars represent the SEM, significance p<0.05 represented by *(paired 
T-test). 
5.2.8 SMO inhibition with LDE225, alone and in combination with 
nilotinib does not influence cell division kinetics or retention of 
primitive cell surface markers on CP CML CD34+ cells 
If Hh inhibition was influencing self-renewal behaviour of HSC it might be 
expected to have a demonstrable effect on the division kinetics of primitive cells 
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and the expression of surface markers associated with immaturity.  Additionally, 
previous studies have demonstrated the existence of a quiescent fraction within 
the CD34+ population that are seen not to divide in CFSE tracking experiments 
and that this population increases following treatment with TKIs (Holyoake et al., 
1999; Jorgensen et al., 2007). Therefore, it is possible that the combination of 
LDE225 with TKI might mitigate this accumulation through inhibition of self-
renewal.   
If an agent was able to alter the balance between the number of self-
renewing and commitment divisions that occur, there would be less primitive cells 
at each division gate due to the resultant increased differentiation which should be 
measurable through reduced expression of primitive surface phenotypic markers 
(e.g. CD34 and others) compared to untreated and TKI treated arms.  
 In order to investigate the effect of LDE225 alone or in combination with 
nilotinib on cell division kinetics of CD34+ cells, CFSE dye incorporation was used 
with subsequent flow cytometry as described in detail in the methods section 
2.2.9.5.   Briefly, CP CML CD34+ cells were thawed, stained with CFSE and 
cultured in the presence of incremental concentrations of LDE225 (0.5, 5 and 
50nM) and/or nilotinib (0.5 or 5M).  At d4, 8 and 12 samples were harvested for 
viable cell count, flow cytometry analysis and re-seeding in fresh media and drug.  
Flow cytometry was performed as previously described; CD34+ expression was 
assessed with a monoclonal CD34+ antibody conjugated to the fluorescent dye 
APC.   Antibody treated cells were passed through the flow cytometer, only events 
in the viable cell gate (set by FSC and SSC criteria) were included in the analysis.  
CFSE intensity (FL1) formed the x axis of the resultant plot with APC intensity 
(hence CD34+ expression) on the y axis.  Gates were placed to isolate all viable 
cells and subsequently to identify all CD34+ expressing cells.  These gates allowed 
the creation of two FL1 plots demonstrating, respectively, the relative CFSE 
fluorescence in total viable cells and purely in the CD34+ fraction.  A series of 
gates extending from the CFSEmax population, encapsulating successive 
populations with 2-fold reductions in CFSE intensity, was generated.  These gates 
therefore contained sub-populations having undergone a similar number of cell 
divisions (see Figure 5-10).  
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Figure 5-10:  Representative CFSE flow cytometry plot indicating the effect of LDE225 
and nilotinib on CD34+ CML CP cells.   
These cells were stained with CFSE and cultured in SFM+HGF in the presence or absence 
of nilotinib and/or LDE225 over 12d with analysis occurring on d4, d8 and d12. (A) Viable 
cells were gated according to FSC and SSC characteristics (P1).  (B) CFSE intensity is 
demonstrable in FL1 (FITC) channel and CD34+ expression was assessed with CD34-APC 
conjugated monoclonal antibody FL4 / APC channel.  P2 thus includes all CD34+ cells.  (C) 
Event histograms were produced for total viable cells and for CD34+ stained cells for all 
experimental arms,  shown here are untreated (brown), nilotinib 5M alone (blue), 
LDE225 50nM alone (green) and nilotinib 5M in combination with LDE225 50nM (red) .  
Divisions (peaks) are seen passing from right (high CFSE fluorescence intensity) to left 
(low fluorescence intensity) as indicated.  
After 4d culture, CD34+ cells had undergone several divisions.  The 
proportion of undivided cells or cells with a low number of divisions reduced with 
prolonged (8d or 12d) culture.  The nilotinib containing arms underwent fewer 
divisions in comparison to the other treatments as has been previously described 
(Jorgensen et al., 2007).  LDE225 was not found to be anti-proliferative at up to 
50nM; LDE225 single treatment arms overlaid the untreated control and LDE225 
and nilotinib-containing arms overlaid the nilotinib single treatment arm.      
Indeed no significant difference in the mean percentage of total viable cells 
in each division gate after 4, 8 or 12d culture was noted either between untreated 
and single agent LDE225 up to 50nM or between nilotinib 5M as a single agent or 
in combination with LDE225 up to 50nM (Figure 5-11). 
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Figure 5-11:  CFSE stained viable cells following culture for 4, 8 and 12d in SFM+HGF, 
untreated or with nilotinib and LDE225 alone and in combination.   
Primary CD34+ CP CML cells were stained with CFSE and cultured in SFM+HGF with 
nilotinib 5µM and/or LDE225 5 or 50nM.  The percentage of the total viable cells that 
reside in each division gate is shown for each time point.  The bars represent the mean 
value from 4 primary samples, while the error bars represent SEM.  Similar results were 
obtained with LDE225 0.5nM and nilotinib 0.5M and are not presented here.   
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In order to more closely examine the effect of LDE225 ± nilotinib on CD34+ 
CP CML cell division, the recovery of viable input CD34+ cells was calculated for 
each division in each treatment arm at each time point as described in the 
methods section 2.2.9.6.  This allows the assessment of the number of original 
input cells contributing to the population within each division gate.  The results 
were normalised to the untreated arm at the given time point and division gate and 
were expressed as a percentage relative to the untreated control (100%).  In the 
nilotinib-containing arms relative recovery of viable CD34+ cells that had 
undergone few divisions (0-3) was increased while recovery of viable CD34+ cells 
in later divisions (>3) was reduced compared to no drug control, confirming the 
anti-proliferative effect of nilotinib and is consistent with previous reports 
(Jorgensen et al., 2007).  LDE225 with or without nilotinib had no significant effect 
on CD34+ cell recovery (Figure 5-12). 
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Figure 5-12:  Percentage recovery of input cells following culture for 4, 8 and 12d in 
SFM+HGF untreated or with nilotinib and LDE225 alone and in combination.  
Primary CP CML cells were stained with CFSE and cultured in SFM+HGF with nilotinib 5M 
and/or LDE225 5 or 50nM.  The percentage recovery of input CD34+ in each division from 
4 independent primary samples is presented normalised to the untreated control (100%) 
from that time point and division gate.  Error bars represent SEM. Significance p<0.05 is 
indicated by * (paired T-test). 
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Given that a self-renewal inhibitor may influence the type but not 
necessarily the number or frequency of cell divisions, it was intriguing to analyse 
the expression of cell surface markers that are associated with stem cell 
phenotype.  It was reasoned that a reduction in self-renewal behaviour might lead 
to discernible reductions in the expression of these markers as 
commitment/differentiation choices are favoured and on the other hand, 
stimulation of self-renewal through exposure to rSHH might have the opposite 
effect.  In order to test this hypothesis, a further set of CFSE experiments was 
performed as above with the following modifications; cells were cultured in SFM 
and a physiological growth factor cocktail (LGF), experimental arms containing 
rSHH at a dose of 100ng/mL were included and, prior to analysis, cells were 
stained with CD133-APC and CD34-PE.   The results of two independent primary 
samples after 4d culture are presented in the figure below (Figure 5-13).   
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Figure 5-13:  CFSE stained cells following culture for 4d in SFM+LGF untreated, with 
nilotinib, LDE225 or rSHH alone and in combination.  
 Primary CD34+ CP CML cells were stained with CFSE and cultured in SFM+LGF with 
nilotinib 5µM +/-LDE225 50nM +/- rSHH 100ng/mL.  Cells were stained with CD34 and 
CD133.  Panel A indicates the percentage of total cells that are CD34+ residing in each 
division gate is shown.  Panel B indicates the percentage of CD34+ cells in each division 
gate relative to the undivided population.  Panel C indicates the percentage of CD133+ 
cells in each division gate relative to the undivided population.  The bars represent the 
mean value from 2 primary samples, while the error bars represent SEM.   
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Consistent with the previously discussed results, the anti-proliferative effect 
of nilotinib can be seen alone and in combination with LDE225.  Neither LDE225 
nor rSHH at a concentration of 100ng/mL materially affected cell division.  There 
was a reduction of expression of CD34 and CD133 with cell division consistent 
with maturation.  Cells treated with nilotinib alone or in combination with LDE225 
lost expression of CD34 and CD133 in fewer divisions than other treatment arms 
or the control.  Cells treated with rSHH retained CD34 over the first 2 divisions 
marginally better than other treatment arms and control. However, by division 3 
this marginal difference had disappeared and additionally was not reflected in the 
expression of CD133. 
5.3 Discussion  
Having demonstrated the expression of components of the Hh signalling 
pathway in the most primitive CP CML LSC, I sought to determine whether Hh 
signalling could be inhibited in primary CML CD34+ cells using a specifically 
designed clinical grade small molecule SMO inhibitor (LDE225), whether a 
biomarker for this activity could be identified in these cells and whether inhibition 
affected cellular proliferation, survival or maturation in short term in vitro culture. 
The compound LDE225 was tested in demonstrated activity in a non-
haemopoietic Hh driven luciferase reporter cell line and reduced the expression of 
the Hh targets GLI1 and CCND1 but not PTCH1 or 2 in the cell line K562.  When 
CD34+ CP CML cells were cultured in the presence of LDE225 at up to 1000nM 
concentration, a significant reduction in expression of GLI1 was noted, however 
this represented a comparatively small mean reduction which was only evident at 
the 72h time point.  The suppression of GLI1 expression is in keeping with the 
expected result following inhibition of Hh signalling. The magnitude of the 
difference is small, indicating that LDE225 is unable to fully suppress GLI1 
expression. One possible reason for this is that the doses utilised were insufficient 
to effect full inhibition, however, the IC50 of LDE225 in our reporter system was 
less than 10nM and CD34+CP CML primary cells were exposed to between 10-
1000nM LDE225 prior to analysis, therefore this seems unlikely.   An alternative 
explanation is that GLI1 expression is not solely driven by Hh activity in CP CML.  
Several recent publications suggest non-Hh driven mechanisms regulating GLI1 
expression in various malignancies (Blotta et al., 2012; Katoh, 2007; Lauth and 
Toftgard, 2007; Li et al., 2012a; Maeda et al., 2006; Nolan-Stevaux et al., 2009).  
Intriguingly, these include RAS/RAF/MEK, PI3K, TGF and CXCR4/SDF1 
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signalling pathways which have emerging roles in the pathogenesis of CML 
(Andreu et al., 2005; Miyazono, 2012; Naka et al., 2010b; Ptasznik et al., 2002; 
Steelman et al., 2004). 
The prolonged exposure to LDE225 that was required to discern any 
inhibitory effect in primary CML was somewhat unexpected and could indicate an 
indirect effect on GLI1 expression.  The GLI proteins have wide ranging effects 
and cooperative relationships in the nucleus influencing the transcription of a great 
number of genes. Many of these genes are involved in the further modification of 
gene expression or chromatin structure themselves.  GLI1 is itself part of a positive 
feedback system reinforcing the Hh signal.  While GLI1 is a downstream target in 
Hh signalling, its expression in primary CML cells is likely to be influenced by the 
whole programme of activity occurring in the nucleus and differences in expression 
might be initiated early but escalate over time. However, it is notable that even in 
our TM3 reporter system, optimal GLI-dependent luciferase expression in 
response to purmorphamine exposure did not occur until 48h. Furthermore, 
studies by Novartis also concluded that GLI1 expression changes were optimally 
detected at 48h post drug exposure (personal communication; Paul Manley, 
Novartis).  Thus, our results from primary patient material are in keeping with 
similar expression studies. 
There was considerable biological variability between primary samples 
across all genes tested.  In one sense, this is problematic as the gene expression 
studies performed thus far have not identified a robust biomarker for Hh signalling 
activity in CD34+ CP CML in an unselected population.  These studies were 
performed in CD34+ CP CML cells and it is possible that similar studies in a more 
enriched stem cell population may have yielded more definitive results. However, 
reductions in GLI1 expression and to a lesser extent, PTCH1 expression were 
detectable in some of the patient samples analysed. It is intriguing to speculate 
that there may be two sub-populations; one responsive, the other not, as indicated 
by GLI1.  If the non-responding samples are analysed separately then the 
magnitude of mean reduction in GLI1 following LDE225 exposure is greater (0.54 
fold; p<0.01) and therefore may be potentially useful in responsive patients. It 
would be of great interest to analyse GLI1 response in many further primary 
samples to determine if such populations truly exist.   
The effect of LDE225 on short term in vitro culture was not marked.  No 
differences in viability, apoptosis, proliferation or cell cycle status were noted 
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following up to 72h culture in SFM with single agent LDE225. Furthermore, there 
was no suggestion of additive activity with combination treatment with up to 50nM 
LDE225 and nilotinib 5M over and above single agent nilotinib. These results 
demonstrate that LDE225 does not readily cause cell death and harbours no 
significant anti-proliferative effect in CML. However, agents that selectively 
influence stem cell fate would not necessarily be expected to affect survival, 
proliferation, apoptosis or cell cycle status over short culture periods and, 
therefore, these results may simply confirm the relative specificity of LDE225 and 
lack of non-specific toxicities at the concentrations used, in contrast to 
cyclopamine (Zhao et al., 2009).   The lack of effect of LDE225 on cell division 
history is confirmed by the CFSE cell division tracking experiments.  It is clear that 
LDE225 does not cause or abrogate accumulation of the quiescent fraction alone 
or in response to nilotinib and no difference in CD34+ recovery was noted at up to 
12d culture.  In very recent published work Okabe et al investigated the effect of 
GDC-0449, another targeted SMO inhibitor in combination with dasatinib in Ph+ 
OM9;22 cells, K562 cells and primary CML samples grown on S9 stromal layers.  
They found that exposure to GDC-0449 or siRNA mediated KD of SMO reduced 
proliferation and augmented dasatinib induced apoptosis.  This is in contrast to the 
findings presented here and while the effect on primary cells was modest these 
results reinforce the importance of microenvironmental context in Hh signalling 
(Okabe et al., 2012). 
A significant shift in the balance of self-renewal or differentiation divisions 
may have altered the observed proportion of cells in each gate that exhibited 
primitive surface markers.  In this work I utilised CD34+ and CD133+ as primitive 
immunophenotypic markers.  No difference in surface expression of these markers 
was noted between experimental arms.  It is likely that neither surface marker was 
sufficiently specific to allow resolution of these differences over the time, 
population nor number of divisions analysed.  A more refined population of LSC 
and/or more specific markers defining either the primitive population or the self-
renewing progeny would facilitate the measurement of these differences.  
In summary I have demonstrated that LDE225 exerts a dose-dependent 
inhibition of Hh signalling in a GLI-driven luciferase reporter system and at higher 
doses modestly reduces expression of the key downstream target GLI1 both in 
K562 cells and in responsive primary CP CML CD34+ cells.  Short term exposure 
to LDE225, either alone or in combination with nilotinib, did not affect viability, 
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apoptosis or cell cycle distribution of CD34+ CP CML cells.  Likewise detailed cell 
division tracking experiments demonstrated no anti-proliferative effect with 
LDE225, either alone or in combination with nilotinib, nor did LDE225 influence 
retention of primitive cell markers over successive divisions.  Whether exposure to 
LDE225 affects LSC function in CML is the subject of the next chapter. 
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6 Effect of LDE225, a Specific Inhibitor of Hh Signalling, on 
Stem Cell Function of CP CML HSC 
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6.1 Introduction 
In chapter 4, expression of key constituents and targets of Hh signalling 
were found to be expressed in the most primitive identifiable CP CML LSC 
population and in chapter 5, LDE225 was demonstrated to modestly reduce 
expression of GLI1 in K562 and CD34+ CP CML populations albeit at higher doses 
and later time points.  In chapter 5 no significant difference was seen following 
short term culture of CP CML CD34+ cells with LDE225 alone or in combination 
with nilotinib on measures of cell cycle activity, proliferation, viability or expression 
of primitive phenotypic markers.  However if the influence of LDE225 was largely 
confined to LSCs, one would not necessarily expect short term alterations in any of 
these measures as any change within the LSC population would be greatly diluted 
by the much larger progenitor population.  As Hh signalling is proposed to 
influence the cell fate decisions of self-renewing stem cells, the key question is 
whether its inhibition with LDE225 had demonstrable effects on functional assays 
of stem cell activity and self-renewal in CP CML. 
6.2 Assessment of Stem Cell Numbers and Self-Renewal  
Self-renewal activity and assays designed to assess stem cell numbers and 
function are discussed at length in the introduction and methods sections.  In 
principal both in vivo and in vitro assays approximate stem cell activity in the 
original population by observing the behaviour of their progeny under various 
conditions.  While possibly the most robust demonstration and quantification of 
self-renewal activity is from limited dilution xenograft transplantation, in vitro 
assays of surrogate measures of self-renewal activity or stem cell quantity are also 
frequently utilised.  One approach is to perform re-plating of primary colonies from 
progenitor (CFC) assays.  This allows quantification of the number of cells within 
the original colony that can give rise to secondary and tertiary colonies thereby 
assessing the proportion of original cells that gave rise to non terminally 
differentiated progeny with significant residual proliferation capacity and can be 
used to approximate self-renewal capacity in HSC and LSC populations (Carow et 
al., 1993; Gordon et al., 1998; Humphries et al., 1981; Lu et al., 1993b; Marley and 
Gordon, 2005; Marley et al., 2001).  LTC-IC assays are another well established 
surrogate for stem cell function.  Following extended culture over > 5 weeks in 
supportive stromal co-culture, cells with residual colony forming capacity (LTC-ICs) 
are assessed and their prevalence in the initial sample inferred.  The LTC-IC assay 
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has been used to assess primitive cell function in normal and malignant 
haemopoiesis alone and in response to various drugs (Copland et al., 2008; 
Heaney et al., 2010; Holtz et al., 2002; Holyoake et al., 2000; Pettengell et al., 
1994). 
As previously discussed in chapter 1 section 1.3.4.3, existing studies in 
retroviral transduction models of CML and in primary CML (largely BC) have 
demonstrated that genetic knockdown of SMO or its pharmacological inhibition 
with cyclopamine resulted in reduced re-plating capacity, reduced LTC-IC and 
reduced capacity to transmit leukaemia to secondary transplanted murine hosts.   
Therefore the aim of this chapter was to examine the effect of the clinical 
grade, specific SMO inhibitor LDE225 alone and in combination with nilotinib on 
primary CP CML LSC on in vitro surrogates of LSC number and function.  
Complementary studies interrogating the effect of this combination in in vivo 
murine models were performed by collaborators and are discussed in Appendix 2. 
 
Specific objectives covered in this chapter are described below; 
 
Examination of the effect of LDE225 alone and in combination with nilotinib in 
CD34+ CP CML in vitro: 
(1) On primary colony formation in CFC assays. 
(2) On secondary re-plating efficiency. 
(3) On LTC-IC frequency following exposure to drug. 
(4) On LTC-IC frequency following prolonged exposure to LDE225 in stromal 
co-culture. 
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6.3 Results 
6.3.1 Inhibition of Hh signalling with LDE225 does not affect primary 
CFC formation but significantly reduces secondary re-plating 
efficiency 
6.3.1.1   Primary CFC formation 
Following recovery, CD34+ CML cells were cultured for 72h in either SFM 
alone, escalating concentrations of LDE225, nilotinib 5M or a combination of both 
treatments.  The cells were harvested, washed, and re-suspended in fresh SFM.  
Equal numbers of cells were inoculated into Methocult H4034 as described in the 
methods section 2.2.11.1.   The CFC assays were cultured under standard 
conditions for 14d prior to colony assessment.  All colony types (>50 cells) were 
counted.  While nilotinib reduced colony formation as would be expected, 
increasing concentrations of LDE225 did not significantly alter primary CFC 
quantitatively or qualitatively and reflects the fact that primary colony formation in 
progenitor assays is largely driven by committed progenitor and not stem cell self-
renewal behaviour (Figure 6-1).   
 
Figure 6-1:  Relative frequency of total CFC in clonogenic colony assays.   
CD34+ CP CML cells were cultured over 72h in SFM in the presence of incremental 
concentrations of LDE225 or nilotinib 5M prior to inoculation into clonal progenitor 
assays.  The graph indicates the mean total number of colony of 3-7 independent primary 
samples after 14d culture normalised to an untreated control.  Error bars represent the 
SEM and ** indicates significance (p<0.01) (paired T-test). 
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6.3.1.2   Secondary and tertiary re-plating capacity 
To determine whether self-renewal behaviour had been altered by exposure 
to LDE225, the secondary re-plating capacity of these colonies was assessed as 
described in the methods section 2.2.11.3.  Following their initial assessment, 
primary colonies were carefully plucked under an inverted microscope using a p10 
pipette and carefully re-dispersed in 100L Methocult H4034 in a 96 well plate 
prior further incubation.  Between 20 and 40 non-erythroid colonies were plucked 
for each treatment condition.  After 7d culture the secondary colonies were 
assessed and counted.  A significant reduction in re-plating capacity with 
increasing concentrations of LDE225 (5, 10 and 50nM LDE225; p<0.01) was noted 
(Figure 6-2).  Wells bearing secondary colonies were re-dispersed in further 
Methocult and incubated for a further week prior to reassessment.  There was a 
similar trend in tertiary colony formation, however due to the reduction in available 
colonies for tertiary re-plating, the results did not reach statistical significance 
(Figure 6-2).   
 
Figure 6-2:  Secondary and tertiary colony formation following re-plating of primary 
colonies. 
Primary colonies derived from CFC assays described in section 6.3.1.1 were plucked and 
re-dispersed into fresh Methocult.  Further culture enabled the assessment of the total 
number of secondary colonies derived from the re-plated colonies at first re-plate (A) and 
second re-plate (B) in each of the treatment arms compared to an untreated control.  (A) 
Indicates the total number of secondary colonies from 3 independent primary samples 
(20-40 colonies re-plated) and (B) indicates the total number of tertiary colonies from 2 
independent primary samples normalised to an untreated control.  Error bars represent 
the SEM and ** indicates significance (p<0.01) (paired T-test).   
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A second set of re-plating experiments was performed to evaluate the effect 
of LDE225 in combination with nilotinib on primary CD34+ CP CML cells.  These 
experiments were performed as described above and in the methods section 
2.2.11.3.  Again, no difference in primary colony formation was noted, however, 
here there was a relative increase in secondary colony formation by colonies 
derived from cells treated with nilotinib and a reduction from colonies derived from 
cells treated with LDE225.  Notably there was a deeper reduction in secondary 
colony formation in cells that had been treated with the combination of nilotinib and 
LDE225 both with respect to the untreated control arm and the single agent 
nilotinib arm (Figure 6-3). 
 
Figure 6-3:  Secondary colony formation following re-plating of primary colonies derived 
from CP CML CD34+ cells exposed to LDE225 ± nilotinib over 72h.    
Primary colonies derived from CFC assays were plucked and re-dispersed into fresh 
Methocult.  Further culture enabled the assessment of the total number of secondary 
colonies derived from the re-plated colonies.  (A) Indicates the total number of secondary 
colonies in at least 3 independent primary samples normalised to an untreated control.  
Error bars represent the SEM.  * indicates significance of p<0.05 and ** indicates 
significance of p<0.01. (paired T-test)  (B) Illustrative examples of secondary colonies after 
secondary re-plating. 
6.3.2 LDE225 in combination with nilotinib significantly reduces LTC-
IC frequency in CP CML 
The LTC-IC assay is the most stringent in vitro surrogate measure of the 
functional activity of HSC.  If LDE225 affected the self-renewal activity of LSCs 
then this would affect LSC abundance and be quantifiable by the LTC-IC assay. 
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Primary CD34+ CP CML cells were incubated in SFM with LDE225 10nM 
and/or nilotinib 5M for 72h then washed, counted and inoculated into a pre-
prepared stromal co-culture comprised of equal quantities of immortalised 
irradiated SL/SL and M210B4 modified murine fibroblast stromal layers optimised 
for the support of human myeloid haemopoiesis (Hogge et al., 1996) and cultured 
for 5 weeks with 50% media changes weekly.  After 5 weeks, the contents of the 
wells were harvested and inoculated into clonal progenitor assays allowing 
comparison of the resultant CFCs generated from the input cells in each treatment 
arm (see methods section 2.2.11.2). 
Compared with the untreated control, LDE225 resulted in a lower LTC-IC 
recovery although the magnitude was not large (38% reduction; p<0.03). As 
previously shown with dasatinib, in prolonged primary CML culture, treatment with 
single agent nilotinib resulted in an increase in LTC-IC (Copland et al., 2008).  
Intriguingly, the combination of LDE225 with nilotinib resulted in a significant 
reduction of LTC-IC relative to nilotinib alone (p<0.05) - see Figure 6-4.   
 
Figure 6-4:  LTC-IC recovery from CP CML CD34+ cells exposed to LDE225 ± nilotinib over 
72h.  
CD34+ CP CML cells were cultured over 72h in SFM in the presence of LDE225 10nM, 
nilotinib 5M or both prior to inoculation into pre-prepared LTC-IC cultures.   The figure 
indicates the total number of colonies produced as a proportion of the total input cells in 
each experimental arm from 5 primary samples, normalised to untreated control.  Error 
bars represent the SEM.  * indicates significance of p<0.05 (paired T-test).   
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In order to determine whether LDE225, nilotinib or the combination of both 
influenced in vitro surrogate measures of HSC activity in normal haemopoiesis, a 
similar experiment was performed using normal CD34+ haemopoietic cells.  
Cryopreserved normal CD34+ haemopoietic cells were thawed and cultured in 
SFM + LGF in the presence of LDE225 10nM, nilotinib 5M or both over 72h prior 
to inoculation into LTC-IC as described above.  No significant alteration of LTC-IC 
abundance was noted between the LDE225, nilotinib or combination arm relative 
to the untreated control in 3 independent primary samples.  There was a small 
increase in LTC-IC recovery from the nilotinib-containing arms.  This may reflect 
the effect of nilotinib on other tyrosine kinase targets e.g. c-KIT also present in 
BCR-ABL negative cells (Weisberg et al., 2005) (Figure 6-5).  
 
Figure 6-5:  LTC-IC recovery from normal CD34+ cells exposed to LDE225 ± nilotinib over 
72h.  
Normal CD34+ cells were cultured over 72h in SFM+LGF in the presence of LDE225 10nM, 
nilotinib 5mM or both, prior to inoculation into pre-prepared LTC-IC cultures.   The figure 
indicates the total number of colonies produced as a proportion of the total input cells in 
each experimental arm from 3 primary samples, normalised to untreated control.  Error 
bars represent the SEM. 
6.3.3 LDE225 in combination with nilotinib significantly reduces LTC-
IC frequency following prolonged treatment in stromal co-
culture  
Stem cell fate decisions are formulated in the context of complex micro-
environmental conditions and signalling cascades (Zon, 2008).  In the LTC-IC 
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experiments described so far, pure populations of CD34+ CML cells were exposed 
to LDE225 and/or nilotinib over a relatively short time frame prior to long term 
culture in the presence of stroma under standard conditions.  Thus, any effects of 
the treatments under evaluation were on CD34+ primary cells in isolation during 
this time frame and are subsequently evaluated by the read-out from the LTC-IC.  
In order to add a further dimension to the analysis by investigating the effect of 
long term exposure to LDE225 ± nilotinib on CML within a more complex 
microenvironment, I performed a final set of in vitro stromal co-culture experiments 
in which CD34+ CP CML cells were not treated in isolation but were directly 
inoculated into the stromal co-cultures as described above and then cultured in 
incremental concentrations of LDE225 (10-1000nM) ± nilotinib 1M over 5 weeks 
with media and drug changes every week.  The stromal layer and haemopoietic 
cells were examined weekly.  After 5 weeks the contents of the wells were 
harvested and inoculated into clonal progenitor assays as described above. 
There was a significant reduction in LTC-IC numbers in all the LDE225 
treated arms (LDE225 10nM: p<0.05; LDE 225 10-100nM: p<0.05; Figure 6-6).  
There was a significant reduction in colony output from the nilotinib arms reflecting 
the ongoing anti-proliferative effect of TKI exposure (p<0.01).  It was interesting to 
note that 5 weeks of continual exposure to nilotinib did not entirely deplete the 
LTC-IC population and a significant number of LTC-IC remained (28% of the 
untreated control). Lastly, in the experimental arms containing the combination of 
LDE225 and nilotinib, there was a trend to further reduction in the LTC-IC recovery 
over nilotinib alone, suggesting that LDE225 targets a population of cells in CML 
that are resistant to TKI (Figure 6-6).  
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Figure 6-6:  CFC recovery from CD34+ CP CML cells following prolonged stromal co-
culture in the presence of LDE225 ± nilotinib.   
CD34+ CP CML cells were thawed and inoculated directly into pre-prepared stromal co-
culture and cultured over 5 weeks in the presence of incremental concentrations of 
LDE225, nilotinib or both. (A) Indicates the mean total number of resultant colonies as a 
proportion of the total input cells in each experimental arm from 4 primary samples, 
normalised to untreated control.  Error bars represent the SEM.  * indicates significance 
of p<0.05 and ** indicates significance of p<0.01 (paired T-test).  (B) Representative 
photographs of CD34+ CP CML cells during stromal co-culture with drug, so called “cobble 
stone” areas of LSC expansion under the supporting stroma can clearly be seen.  (C) 
Representative colonies derived from harvested cells in clonal progenitor assays. 
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6.4 Discussion 
In this chapter I have described the effect of LDE225 alone and in 
combination with standard treatment with TKI (nilotinib) in normal or CP CML 
CD34+ cells in prolonged in vitro culture experiments.  These experiments were 
designed to investigate the effect of these drugs alone and in combination on in 
vitro measures of HSC/LSC abundance and self-renewal behaviour.  The results of 
these experiments are encouraging.  The specific SMO inhibitor LDE225, alone or 
in combination with nilotinib, was found to reduce the primitive leukaemic cell 
population as measured by LTC-IC and reduces self-renewal activity as evidenced 
by re-plating capacity. These results suggest that SMO inhibition with LDE225 
specifically targets the TKI-resistant primitive stem/progenitor cell population in 
CML but not normal HSC. 
The clonal progenitor assays performed here demonstrated that SMO 
inhibition had no effect on primary colony formation, whereas TKI inhibition with 
nilotinib demonstrated marked reduction in progenitor output likely due to the 
combination of direct toxicity and potent anti-proliferative effect exerted by nilotinib 
and other TKIs on this population as has been extensively reported (Deininger et 
al., 1997; Druker et al., 1996; Konig et al., 2008a; Konig et al., 2008b).  
This is in contrast to results reported by both Zhao et al and Dierks et al who 
found that cyclopamine reduced primary colony formation in BCR-ABL+ murine 
cells (Dierks et al., 2008; Zhao et al., 2009).  This may reflect the non-specific 
toxicity of cyclopamine and be due to the presence of the drug in the clonal 
progenitor assay medium, or indeed the different biology of the cells from their 
respective retroviral models.  Interestingly, Zhao et al demonstrated a similarly 
significant reduction in colony formation in CFC assays performed on primary BC 
CML CD34+ cells (Zhao et al., 2009). Blast crisis CML cell populations are known 
to harbour progenitors that have re-acquired stem cell characteristics, thus it may 
be that they are more dependent on self-renewal signalling for survival/proliferation 
(Jamieson et al., 2004; Schairer et al., 2010). 
While CFC assays measure progenitor expansion, re-plating capacity is a 
well established in vitro surrogate for self-renewal activity in normal and malignant 
haemopoiesis.  In normal haemopoiesis, re-plating capacity is greater in primitive 
multi-lineage or mixed colonies and declines with maturity (Carow et al., 1991; 
Carow et al., 1993; Leary and Ogawa, 1987; Lu et al., 1993a; Marley et al., 2003).   
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Re-plating has been utilised previously as a tool in the study of CML, where 
it was found to be variable between different patients and related to patient 
characteristics like prognostic score (Gordon et al., 2003).  Other groups have 
demonstrated modulation of re-plating capacity in CFCs derived from patient 
samples following activation or inhibition of WNT signalling, through forced 
expression of -catenin, axin or misspliced GSK3(Abrahamsson et al., 2009; 
Jamieson et al., 2004; Zhao et al., 2007).   
In these studies, it was demonstrated that while exposure to nilotinib 
modestly enhanced re-plating efficiency, LDE225 or the combination of both 
agents significantly reduced secondary colony formation.  The former is most likely 
to be explained by the anti-proliferative effect of nilotinib preventing stem cell 
division during drug exposure, resulting in a population that was relatively enriched 
for more primitive cells compared to the untreated control (Copland et al., 2008).  
The reduction in secondary re-plating capacity demonstrated by LDE225 suggests 
reduction in the number of primitive cells with the capacity to form secondary 
colonies in these treatment arms.  This is consistent with our hypothesis that SMO 
inhibition shifts the balance of stem cell self-renewal divisions in favour of 
differentiation (hence loss of capacity to self-renew) in the population analysed.  
The reduction relative to the untreated arm and the single treatment with nilotinib 
arm is intriguing as LDE225 appears to completely counteract the enrichment of 
cells with re-plating capacity seen with nilotinib.  I previously demonstrated that 
LDE225 has no effect on cell cycle or apoptosis and therefore LDE225 cannot be 
directly neutralising the anti-proliferative effect of nilotinib or influencing cell 
survival.  One explanation could be that SMO inhibition has already influenced the 
intracellular machinery controlling stem cell fate such that when the anti-
proliferative stimulus is removed (through washing and inoculation into CFC) and 
the cells can divide, a lower proportion of self-renewal divisions occur, leading to a 
reduction in re-plating potential. 
Long term culture-initiating cell assays were developed for quantitative 
assessment of HSC function and have been extensively used for this purpose 
(Hogge et al., 1996; Sutherland et al., 1989; Sutherland et al., 1993b; Sutherland 
et al., 1990).  As CML haemopoiesis, particularly CP CML haemopoiesis, is not 
dissimilar (Sloma et al., 2010), these assays have also been extensively used to 
quantify CML LSCs at baseline and to measure the effect of various compounds 
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on the LSC population (Copland et al., 2008; Heaney et al., 2010; Pellicano et al., 
2011). 
In this work, the LTC-IC assay results corroborated the findings from the re-
plating assays and, furthermore, demonstrated that normal CD34+ cells were 
unaffected by exposure to LDE225 or nilotinib.  This is important as it indicates that 
there is a potential therapeutic window for the clinical use of LDE225 in CML.  
These results are in keeping with and build on published data.  Dierks et al 
demonstrated a marked increase in secondary re-plating capacity in BCR-ABL+ 
Ptch1+/- murine cells and a reduced re-plating capacity in BCR-ABL+ Smo+/- and 
Smo-/- cells in vitro.  They also found that cyclopamine with or without nilotinib 
reduced LTC-IC recovery in primary BC CML samples but not in normal healthy 
CD34+ cells (Dierks et al., 2008).   
  While these in vitro assays have provided a wealth of information, they 
cannot hope to reflect the complex interactions present in the stem cell niche.  In 
an attempt to better reflect this multi-directional signalling environment the LTC-IC 
protocol was modified to allow CP CML haemopoietic cells and supportive stroma 
to be continuously exposed to LDE225 and nilotinib.  This is important, as although 
autocrine / paracrine Hh signalling between LSCs has been postulated, it is not 
clear at this juncture whether this is the dominant signalling mechanism.  
Examples from other malignancies have suggested that Hh signalling from CSC to 
stroma or vice versa may play a role (Dierks et al., 2007; Tian et al., 2009).  
The results from these experiments demonstrate significant reduction of 
LTC-IC recovery at low doses of LDE225.  They also suggest an additive effect 
with nilotinib, although the number of colonies surviving in the nilotinib-containing 
arms was relatively small and therefore the differences with LDE225 in 
combination did not reach significance. 
As discussed in the introduction to this chapter the gold standard proof of 
HSC/LSC function extends from the reconstitution of a haemopoietic system in 
xenotransplantation experiments.  Additionally, while the effect of treatment with 
LDE225 ± nilotinib on LSC in a supportive stromal microenvironment had been 
addressed in vitro, it was considered important to assess the effect of LDE225 and 
nilotinib treatment in vivo in a complete haemopoietic system. 
In order to pursue these goals, collaboration with Professor Ravi Bhatia’s 
team at City of Hope, San Diego, California was instigated.  Professor Bhatia and 
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his team have considerable expertise in murine modelling of CML and have 
access to the severely immunocompromised NSG mice and the transgenic 
inducible Scl-tTa-BCR-ABL-GFP murine model of CML(Koschmieder et al., 2005; 
Shultz et al., 2005; Zhang et al., 2012a).  These parallel studies have since been 
completed and provide a strong validation to the in vitro work discussed in this 
chapter.   
Pre-treatment with the combination of LDE225 and nilotinib reduced the 
capacity of CP CML CD34+ cells to contribute to haemopoiesis in NSG mice at 6 
weeks post engraftment but did not affect normal CB engraftment.  Additionally 
there was a significant reduction in BCR-ABL+ cells recovered following 
engraftment suggesting a specific anti-leukaemic effect.  Further validation was 
obtained from the results of in vivo treatment of the Scl-tTa-BCR-ABL-GFP+ 
inducible transgenic mouse model of CML (Koschmieder et al., 2005; Zhang et al., 
2012a) demonstrating that LDE225 in combination with nilotinib reduced the 
frequency of LT-HSC in the spleen, reduced the leukaemogenicity of BM and 
splenic LT-HSC in secondary transplantation and prolonged survival of treated 
animals.  A more in depth treatment of Professor Bhatia and Dr Zhang’s results is 
presented in Appendix 2. 
6.5 Conclusion 
In this chapter, evidence is presented demonstrating that the SMO inhibitor 
LDE225 alone and in combination with nilotinib targets CP CML HSC, most 
probably through influencing LSC self-renewal activity.  In in vitro measures of LSC 
number and function, LDE225 alone and in combination with nilotinib reduced CFC 
secondary re-plating capacity and LTC-IC recovery.  These results are 
corroborated by murine modelling experiments by our collaborators demonstrating 
reduced engraftment of CD34+ CP CML cells in immunocompromised murine 
xenografts and by reduced splenic LT-HSC, improved survival and reduced 
capacity to recapitulate leukaemia in secondary hosts in the Scl-tTa-BCR-ABL 
murine model of leukaemia.   
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7 General Conclusion 
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7.1 Summary of Results 
Presented here are the results of a detailed gene expression array, taking 
advantage of the modern improvements in microarray technology to identify 
expression differences between the most rigorously defined pure HSC and 
progenitor populations from CML and normal haemopoietic tissue to date.  These 
studies demonstrate that, while there is an ordered progression in terms of 
transcriptional activity from the HSC to progenitor populations in normal 
haemopoiesis, this is substantively deregulated in CP CML particularly at the LSC 
level.  There are marked transcriptional differences between HSC and the 
equivalent CP CML LSC population.  Here the CML LSC are transcriptionally more 
mature, exhibiting increased expression of programmes associated with 
proliferation and differentiation, but reduced expression of many genes associated 
with HSC populations and self-renewal. 
In parallel in in vitro expression studies on primary CP CML samples, 
positive regulators of the developmental signalling pathways were found to be up 
regulated and negative regulators down regulated in CML compared to normal 
haemopoiesis.  Targeted inhibition of Hh signalling with LDE225 only minimally 
affected the transcription of downstream targets of the pathway, but nevertheless, 
alone or in combination with nilotinib led to reduction of in vitro surrogate measures 
of self-renewal in primary CP CML, but not normal CD34+ cells, corroborated by 
consistent results in two mutually supportive murine models.  The effect both in 
vitro and in vivo is most marked in combination with nilotinib.  Thus, from this and 
similar published work, Hh inhibition through SMO antagonism in combination with 
conventional TKI therapy appears to be a promising approach in dealing with the 
persisting LSC population in CML (Dierks et al., 2008; Zhao et al., 2009). 
7.2 A Combinatorial Approach to Therapy 
The data presented here and in other published work are consistent in that 
the effect of SMO inhibition, both in vitro and in vivo, is most marked in 
combination with TKI therapy.  While this is welcome and strongly suggests that, 
therapeutically, LDE225 and other SMO inhibitors would be best employed in 
combination with conventional TKI treatment, it is perhaps surprising, given that 
CML LSC are reportedly resistant to TKI-mediated BCR-ABL kinase inhibition.    
The augmented effect seen in combination strongly suggests that SMO inhibition 
and TKI are working in concert in the CML LSC.  This challenges the model where 
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TKI and SMO inhibition have discrete effects on progenitors and LSC respectively 
and suggests a mode of action more consistent with the induction of synthetic 
lethality in CML LSC (Kaelin, 2005).  In this model, CSCs are dependent on 
multiple parallel pathways for maintenance and survival.  They are not “addicted” 
to the input of any single pathway and, in all probability the input of one may 
completely or partially compensate for loss of another.  In order for the target cell 
to be rendered sensitive to the effect of one drug, the compensatory or alternative 
survival pathways must also be inhibited.  In the context of CML, there are multiple 
examples of this e.g. inhibition of autophagy in TKI treated cells leading to 
augmented apoptosis, co-inhibition of the mitogen activated protein kinase / 
extracellular receptor kinase (MAPK/ERK) and JAK2 signalling pathways with TKI.  
(Bellodi et al., 2009; Chen et al., 2013; Naka et al., 2010a; Packer et al., 2011).  
BCR-ABL kinase has a promiscuous effect in the cell, activating multiple different 
pathways and additionally while nilotinib is comparatively specific for BCR-ABL 
kinase, it also inhibits a number of other intracellular kinases and other targets 
including discoid domain receptor family member 1 (DDR1), NAD(P)H 
dehydrogenase quinine 2 (NQO2), Abelson related gene (ARG), KIT and PDGFR.  
Thus, the augmented effect seen in CML LSC in this and other studies might relate 
to inhibition of both BCR-ABL and non-BCR-ABL mediated kinase activity or other 
off target effects of nilotinib (Dierks et al., 2008; Zhao et al., 2009).  Alternatively, it 
has been shown that the microenvironmental signalling of the stem cell niche 
provides a protective effect to CML LSC during treatment with TKI (Seke Etet et 
al., 2012; Zhang et al., 2013).  In this work, I demonstrated that Hh ligands are 
expressed at low levels by CML LSC, so there remains a possibility of 
autocrine/paracrine signalling. I also demonstrated SHH secretion by some 
stromal cell lines which may contribute to LSC survival in the niche. This has also 
been reported in other contexts e.g. lymphoma (Dierks et al., 2007; Seke Etet et 
al., 2012).  Niche signalling of this nature might be more relevant in the context of 
TKI therapy as niche homing and adhesion is rectified by the effect of TKI (Jin et 
al., 2008).  Additionally SDF1 signalling through CXCR4 promotes SHH production 
and Hh signalling in pancreatic cancer, whereas Hh augmented CXCR4 surface 
localisation and signalling in medulloblastoma (Li et al., 2012a; Sengupta et al., 
2012b; Singh et al., 2012).    This is as yet unstudied in CML but may prove to be 
important as TKI therapy recovers CXCR4 expression and therefore SDF1 signal 
transduction (Jin et al., 2008).   
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While the precise mechanism of combinatorial action requires resolution, 
these pre-clinical studies of combinatorial treatment with SMO inhibitors and TKI 
have yielded promising results suggesting this therapeutic avenue should be 
explored in further in vivo and clinical studies.  Since this work was commenced, 
and as a consequence of it and other pre-clinical studies, several phase 1 clinical 
trials and one phase 2 clinical trial of Hh inhibition in CML have been instigated 
(see Table 7-1). 
Treatment Sponsor Commenced / 
Recruitment / 
No. pts 
Phase Patient population Identifier 
LDE225 
+ Nilotinib 
Novartis 2012 
Recruiting 
(36) 
1b CP CML 
Failure of prior CML therapy  
NCT01456676 
BMS833923 
+/- Dasatinib  
BMS 2011 
Not recruiting 
(271) 
2 Newly diagnosed  CP CML  
(1y Dasatinib alone 
followed by 2y combination 
if suboptimal response) 
NCT01357655 
 
BMS833923 
+ Dasatinib 
BMS 2011 
Not recruiting 
(36) 
1 CML (any) & Ph+ ALL 
Suboptimal response, 
resistance or progression 
NCT01218477 
PF04449913 
+ Dasatinib or 
Bosutinib 
Pfizer 2010 
Not recruiting 
(52) 
1 Myeloid malignancies 
refractory resistant or 
intolerant to prior therapy 
NCT00953758 
Table 7-1:  Clinical trials in CML utilising various small molecule SMO inhibitors in 
combination with conventional TKI therapy 
7.3 Current and Future Directions in CML 
Rarely has there been such astonishing progress in the treatment of a 
malignant disease. The application of our understanding of the pathophysiology of 
the disease has fundamentally changed our therapeutic approach to the condition 
and yielded truly remarkable improvements in the survival of patients diagnosed 
with CML over the last 15 years.  Modern treatment with potent TKIs means that 
most patients newly diagnosed with CML can generally expect to achieve rapid 
disease control with complete cytogenetic resolution and in many cases deep 
molecular remission, which correlate with long term PFS (Bjorkholm et al., 2011; 
Jabbour and Kantarjian, 2012).  In the case of resistance there is the opportunity 
for dose modification and switch to an alternative agent and with the advent of 
ponatinib this even extends to the highly resistant T315I mutation (O'Hare et al., 
2009).  Additionally, recent evidence suggests that, in some patients at least, TKI 
therapy can be safely withdrawn, suggesting possible TKI-mediated cure (Mahon 
et al., 2011).   
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While generally effective, TKI therapy has clinically significant limitations.  
As has been discussed in chapter 1, CML LSC are not sensitive to TKI therapy 
alone and therefore persist in the BM of optimally responding patients (Bhatia et 
al., 2003; Chu et al., 2011; Corbin et al., 2011; Hamilton et al., 2012; Jiang et al., 
2007b). While their numbers may be low and the likelihood of progression in a 
responding patient reportedly slim there is strong evidence suggesting that 
discontinuation of TKI is likely to lead to molecular relapse (61% in the recently 
updated data from the French STIM study) (Mahon et al., 2011).  Furthermore, 
even with up-front treatment with the potent second generation TKIs, a sizable 
minority of patients do not respond optimally (Kantarjian et al., 2011; Kantarjian et 
al., 2012).  Consequently for most patients at least, TKI therapy is not curative 
meaning that patients are likely to require lifelong therapy in order to maintain 
disease control.  This may become problematic from several angles.  Firstly 
development of secondary resistance and progression are possible and may 
increase with time due to increasing numbers of patients treated with TKI (O'Hare 
et al., 2007; Quintas-Cardama et al., 2009). Furthermore, long term compliance 
with therapy is of increasing clinical concern as it directly relates to the risk of 
progression (Jabbour et al., 2012; Marin et al., 2010). Secondly, while generally 
well tolerated TKIs do have significant side effects and consequently a negative 
impact on the quality of life and health of CML patients (Hochhaus, 2011).  Thirdly, 
the long term effects of TKI therapy are only now becoming evident and will 
become more important with time.  These include class effects and specific 
problems with particular TKIs and are comprehensively reviewed by Steegmann et 
al (Steegmann et al., 2012).  Tyrosine kinase inhibitor therapy potentially impacts 
on many organ systems.  Notable examples include immunomodulatory effects of 
uncertain long term significance, undesirable effects on bone, calcium and 
phosphate metabolism, glucose metabolism not to mention chronic oedema and 
fluid accumulation and vascular disease (Steegmann et al., 2012).  There is also a 
question of health economics, with the advent of effective treatment, the 
prevalence of CML is increasing and with it the burden of TKI related healthcare 
costs (Chen et al., 2012; Huang et al., 2012).  
While these problems do not detract from the utility of TKI therapy in 
comparison to previous alternatives, they do provide a clinical imperative to 
develop novel approaches that may be more effective and, in particular, to really 
closely examine whether an effective cure through eradication of the residual LSC 
may be coming within our reach.  
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7.4 The Potential Role of Hh Inhibitors in the Treatment of 
CML 
To progress from pre-clinical indications of utility to an understanding of 
whether SMO inhibition might augment our therapeutic arsenal in CML, careful 
evaluation in the clinical trial setting is required.   
While the success of current treatments in reducing disease burden and 
controlling CML is a major therapeutic triumph, it leads to difficulty in assessing 
response to novel treatments in a clinical trial context.  This is compounded by the 
relative rarity of the resistant LSC within the leukaemic population.  Additionally 
while molecular responses have been evaluated to determine response to TKI 
therapy at the very lowest detectible levels, the presence of residual genetic 
evidence of BCR-ABL is not necessarily associated with relapse (Bartley et al., 
2010; Ross et al., 2010; Sobrinho-Simoes et al., 2010).  Also relevant in measuring 
very low levels of residual disease is the observation of BCR-ABL mRNA in normal 
populations (Biernaux et al., 1995; Bose et al., 1998). 
Additionally short term use of Hh inhibition in solid tumour trials has 
provided information regarding the potential side effects of such therapy in 
humans.  While these reports suggest that the various SMO antagonists under trial 
are overall reasonably well tolerated and the adverse events generally of low 
grade they are not insignificant comprising alopecia, muscle spasms, dysguesia, 
fatigue, weight loss and diarrhoea (Tawbi et al., 2011; Von Hoff et al., 2009).  
Furthermore from mouse models they appear to affect bone metabolism and their 
mode of action will clearly lead them to be significantly teratogenic.  Therefore, in 
what population would SMO inhibitor therapy be best employed and how its 
additive effect would be measured are important translational questions.   
The obvious patient population would be those who were resistant, 
refractory or sub-optimally responding to conventional TKI therapy.  Their long 
term prognosis is substantially worse than optimal responders and Hh inhibitor 
therapy might offer an opportunity to intervene.  Additionally it would be possible to 
measure augmented response over time through qRTPCR as they, by definition, 
would have measurable residual disease.  Another population might be those with 
evidence of progression that were not transplant candidates as their long term 
outlook is poor.  As we have discussed, in advanced phase patients, there is a 
breakdown in the natural haemopoietic hierarchy with LSCs emerging from mature 
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populations that are dependent on developmental pathway signalling e.g. Wnt and 
from recently reported work with Hh inhibitors in BP CML, also Hh (Jamieson et al., 
2004; Schairer et al., 2010).  The abrogation of these signalling pathways might be 
effective in targeting these populations, however optimism in this regard must be 
tempered by the knowledge that by that stage multiple aberrations have 
accumulated in the malignant clone (Radich, 2007). 
  Conceptually there is an argument for the use of SMO inhibitor therapy in 
all CP CML patients.  Early intervention designed to target the CML LSC prior to 
the development of significant secondary aberrations might be expected to be 
more effective in targeting the resistant LSC; improving speed and depth of 
response to therapy and possibly even eradicating the leukaemic clone.  While 
potentially advantageous, this approach has various challenges: it would involve 
exposing patients to the risks of a second experimental therapy early in the 
disease course and it would be difficult to find appropriate and practical means to 
measure the efficacy of the combinatorial treatment over and above conventional 
therapy.  Conceivably, one might measure the rate and depth of decline of the 
leukaemic clone by sensitive qRTPCR and ultimately genomic DNA quantification.  
Alternatively, quantification of residual leukaemic cells with LSC potential could be 
performed.  Low levels of residual disease would make it impractical to perform 
xenotransplantation assays; however quantification of residual LSC could be 
performed by in vitro assays of stem cell function such as those that were 
performed here.   While an extremely useful research tool these techniques are not 
available in most diagnostic laboratories and are difficult to standardise between 
centres.  Clinical trials are currently underway testing SMO inhibition in all the 
contexts discussed above and detailed information about the clinical effectiveness 
of this approach should be available in the near future. 
7.5  Concluding Remarks 
The introduction of TKI therapy for CML is the culmination of decades of 
research into the pathophysiology of CML and stands as a paradigm for the 
application of rationally designed targeted therapy in cancer.  The initial 
enthusiasm following the demonstration of the remarkable efficacy of TKI therapy 
in CML has been tempered by the realisation that it is, in all probability, not a 
curative intervention for the majority of patients.  However investigation into the 
effect of these targeted therapies and the capacity of leukaemic cells to persist 
despite their action has yielded major insights into the structure, organisation and 
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process of leukaemogenesis that are potentially applicable in the wider oncological 
field.  Not least is a firm validation of the concept of LSC in CML, an increasing 
understanding of their clinical relevance and a rapidly expanding repertoire of 
potential pharmacological targets, including Hh signalling, through which to effect 
their destruction.  The challenge for subsequent years is to develop these insights 
into effective clinical interventions.  
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8 Appendices 
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8.1 Appendix 1:  Samples, Cell Number and Total RNA for 
Microarray and Validation Experiments  
 
 
  
Sample Vol 
/L 
total 
RNA/ 
g 
cell 
number 
Sample Vol 
/L 
total 
RNA/ 
g 
cell 
number 
pool normal HSC 25 737 3.12E+05 264 CP CML HSC 25 701 1.93E+05 
pool normal MPP 25 800 4.00E+05 264 CP CML CMP 55 14198 5.89E+06 
pool normal CMP 55 3745 1.28E+06 264 CP CML GMP 25 856 3.35E+05 
pool  normal GMP 55 5748 1.18E+06 264 CP CML MEP 55 24872 1.73E+06 
pool normal MEP 55 2308 6.16E+05 101 AP CML HSC 24 371 1.45E+05 
15 normal HSC 25 611 3.92E+05 101 AP CML CMP 55 16333 5.96E+06 
15 normal MPP 25 249 1.22E+05 101 AP CML GMP 24 435 1.28E+05 
15 normal CMP 55 4635 2.14E+06 101 AP CML MEP 55 1412 2.63E+05 
15 normal GMP 55 7587 1.44E+06 239 AP CML HSC 25 694 2.00E+05 
15 normal MEP 55 10924 1.91E+06 239 AP CML CMP 55 4462 1.00E+06 
12 normal HSC 25 424 2.37E+05 239 AP CML GMP 25 1627 2.43E+05 
12 normal MPP 55 2636 8.64E+05 239 AP CML MEP 55 16816 3.74E+06 
12 normal CMP 55 7207 1.21E+06 0104 AP CML HSC 25 1282 6.49E+05 
12 normal GMP 55 8567 1.67E+06 0104 AP CML MPP 25 880 5.99E+05 
12 normal MEP 55 10824 1.23E+06 0104 AP CML CMP 25 13816 5.04E+06 
107 CP CML HSC 23 500 1.30E+05 0104 AP CML GMP 55 8822 1.50E+06 
107 CP CML CMP 55 11414 2.11E+06 0104 AP CML MEP 55 8541 2.76E+06 
107 CP CML GMP 17 213 4.00E+04 185 AP CML HSC 25 910 4.18E+05 
107 CP CML MEP 55 11497 3.41E+06 185 AP CML MPP 25 777 2.86E+05 
111 CP CML HSC 24 513 2.24E+05 185 AP CML CMP 55 14025 3.90E+06 
111 CP CML CMP 55 9423 3.89E+06 185 AP CML GMP 25 1280 4.37E+05 
111 CP CML GMP 55 4908 8.16E+05 185 AP CML MEP 55 11456 3.58E+06 
111 CP CML MEP 55 22382 5.57E+06 AMCA BC CML HSC 25 505 2.86E+05 
273 CP CML HSC 23 710 5.55E+04 AMCA BC CML MPP 55 2321 7.76E+05 
273 CP CML CMP 55 12626 4.34E+06 AMCA BC CML CMP 55 5401 1.97E+06 
273 CP CML GMP 23 882 1.76E+05 AMCA BC CML GMP 55 8118 2.40E+06 
273 CP CML MEP 55 34544 8.64E+06 AMCA BC CML MEP 55 3586 9.35E+05 
194 CP CML HSC 24 338 1.95E+05 HP BC CML HSC 25 250 1.08E+05 
194 CP CML CMP 55 4092 1.20E+06 HP BC CML MPP 55 11895 2.91E+06 
194 CP CML GMP 25 1695 4.05E+05 HP BC CML CMP 55 5035 1.67E+07 
194 CP CML MEP 55 10989 2.00E+06 HP BC CML GMP 55 16808 3.32E+06 
110 CP CML HSC 25 430 1.93E+05 HP BC CML MEP 55 4212 1.07E+06 
110 CP CML CMP 55 21985 1.20E+06       
110 CP CML GMP 25 1704 4.05E+05       
110 CP CML MEP 55 7209 2.00E+06       
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8.2 Appendix 2:  Collaborative in vivo Murine Modelling 
Studies  
8.2.1 Introduction 
Immunodeficient murine models (e.g. NOD/SCID mice) can be used as 
hosts for transplantation of human primary CML cells although the engraftment 
rate and duration are much lower than with normal haemopoietic cells (Dazzi et al., 
1998; Lewis et al., 1998; Sirard et al., 1996; Verstegen et al., 1999; Wang et al., 
1998).  One reason for this is the residual immune system in the transplant 
recipient mice and correspondingly, the development of more intensively 
immunocompromised recipient mice (e.g. the NOD/SCID/IL2mouse) has led to 
improvements in engraftment rate and durability with human haemopoietic cells 
(McDermott et al., 2010; Shultz et al., 2005).  Thus, primary CML tissue can be 
cultured in vitro in the presence of test compounds prior to transplantation into 
NSG hosts and the resultant engraftment of malignant cells quantified at a suitably 
distant time point (e.g. 10 weeks) from transplantation to ensure that they derived 
from the LSC population within the original graft.  Variations in engraftment 
between treatment arms in an experiment would suggest differences in LSC 
numbers consequent on treatment effect. 
An alternate approach is the in vivo treatment of a murine model of CML, 
followed by secondary transplantation to assess LSC function.  This approach 
provides insight into the effect that the agent has over a prolonged period of 
treatment in a more physiological context, where the constituents of the murine 
haemopoietic system and microenvironment are complete.  Two fundamental 
limitations to this approach are the degree to which CML is accurately reflected in 
the model system and that murine haemopoiesis differs in significant ways from 
human haemopoiesis (e.g. the role of the spleen and our understanding of the 
haemopoietic hierarchy) and in order to be clinically relevant, the resulting findings 
have to be extrapolated from one system to another.   
A CML-like disease can be efficiently produced by retroviral transduction of 
human BCR-ABL into murine HSCs using a murine stem cell retroviral vector 
(Cuiffo and Ren, 2006; Pear et al., 1998).  Following transplantation of these 
infected cells into lethally irradiated syngeneic mice, a myeloproliferative condition 
akin to CML is reliably produced and is transplantable to secondary hosts where a 
similar phenotype is produced.  The main limitation of this model is that the 
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disease thus produced is rather unpredictable and often exhibits a very aggressive 
phenotype, more akin to advanced CML that results in early death (in about 3 
weeks) of the murine host (Cuiffo and Ren, 2006).  Thus, this model is not ideal for 
studying self-renewal and stem cell function in CP CML.   
An alternate model is available, an inducible transgenic mouse where BCR-
ABL is expressed under control of a tetracycline regulated 3’ enhancer of the 
murine Scl gene (Koschmieder et al., 2005; Zhang et al., 2012a).  This allows 
BCR-ABL expression to be targeted to the murine HSC population and to be 
switched on as desired by withdrawal of tetracycline.   When BCR-ABL expression 
is induced, a chronic myeloproliferative condition akin to CP CML is produced.  
This condition is transplantable to secondary hosts and reversible with 
reintroduction of tetracycline.   Thus in many respects this model is more attractive 
for the in vivo study of CP CML LSC function. 
8.2.2 Inhibition of Hh signalling in primary CML samples and murine 
models of CML  
Previous studies evaluating inhibition of Hh signalling in CML have utilised 
variations of the retroviral transduction model described above.  Zhao et al used 
the Vav-Cre-Lox system to create Smo-deficient mice from which to isolate Smo−/− 
HSCs, whereas Dierks et al used foetal liver cells from Smo-deficient mouse 
embryos (Dierks et al., 2008; Zhao et al., 2009).  Both groups expressed human 
BCR-ABL in these cells before transplantation. Despite differing approaches, 
broadly similar results were obtained. Smo deletion reduced LSC numbers and 
reduced the incidence of leukemia with prolonged latency in primary 
transplantation and greatly reduced capacity to recrudesce disease in secondary 
hosts.  
Dierks et al and Zhao et al also performed complementary pharmacologic 
inhibitor studies both in vivo and in vitro.  In vivo, they demonstrated prolonged 
survival in diseased mice, reduced LSC population, and lower functional activity of 
the residual LSC.  In vitro, both groups reported reduced primary colony formation 
derived from primary patient samples in CFC assays.  Zhao et al found that Smo-/- 
cells had higher levels of the cell determinant Numb and that expression of Numb 
correlated with reduced replating capacity.  Dierks et al found that genetic deletion 
of Smo or Ptch1 resulted in reduced secondary replating capacity and that 
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cyclopamine treatment of CD34+ BC CML cells resulted in reduced LTC-IC 
recovery suggesting a potential stem cell-specific effect in this context. 
It is notable that in the paper by Dierks et al, the dose of cyclopamine used 
was generally in excess of the dose that Zhao et al reported as having off target 
toxicities (3M) (Dierks et al., 2008; Zhao et al., 2009).  While these seminal 
studies have established a role for the Hh pathway in LSC maintenance and 
propagation in CML, they have not provided a clinically applicable approach.  Both 
studies largely utilised BC CML cells and a murine model of CML which has 
significant drawbacks for studying CP CML.  
8.3 Collaborative Results 
As discussed in the introduction to this chapter, the gold standard proof of 
HSC/LSC function extends from the reconstitution of a haemopoietic system in 
xenotransplantation experiments.  Additionally, while the effect of treatment with 
LDE225 ± nilotinib on LSC in a supportive stromal microenvironment had been 
addressed in vitro it was considered important to assess the effect of LDE225 and 
nilotinib treatment in vivo in a complete haemopoietic system. 
 In order to pursue these goals collaboration with Professor Ravi Bhatia’s 
team at City of Hope, Duarte, California was instigated.  Professor Bhatia and his 
team have considerable expertise in murine modelling of CML and have access to 
the severely immunocompromised NSG mice and the transgenic inducible Scl-tTa-
BCR-ABL-GFP murine model of CML.  The work discussed hereafter is a result of 
this collaboration and was performed in San Diego by Professor Bhatia and Dr Bin 
Zhang.  
The effect of LDE225 ± nilotinib on the capacity of normal CB CD34+ cells 
or CP CML CD34+ to engraft immunocompromised mice was assessed.   Primary 
CP CML CD34+ (2x106) cells or CB cells (1x105) were transplanted via tail vein 
injection into lethally irradiated 8 week old NSG mice after 72h in vitro exposure to 
LDE225 (10nM) +/- nilotinib (5µM) or control (no treatment).  Engraftment was 
assessed by flow cytometry for human CD45+ and CD45+/34+ cells in the BM after 
6 weeks.  The results indicated that engraftment of human CD45+/34+ cells was 
significantly reduced following combination treatment compared with the other 
experimental arms.  As discussed in chapter 6, FISH analysis for BCR-ABL 
indicated that there was a preferential reduction in engraftment of BCR-ABL+ cells 
in mice transplanted with combination treated leukaemic cells compared to either 
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single arm treatment or no treatment.  Engraftment of normal CB was not affected 
by pre-treatment.  Additionally colony assays were performed with recovered 
murine BM cells, indicating a reduction in CFC formed in the nilotinib-containing 
arms compared to the untreated and LDE225 treated arms, see Figure 8-1.  These 
results were consistent with the in vitro data described in chapter 6 and suggest 
that combination of LDE225 and nilotinib may selectively target primitive CML cells 
that are capable of repopulating the haemopoietic system in NSG mice.  
 
Figure 8-1:  NSG murine model engraftment with normal and CP CML CD34+ cells after 
pre treatment with LDE225 +/- nilotinib.   
The experimental schema is shown in (A) 2x106 CD34+ CP CML cells or 1x105 cells were 
cultured in SFM+LGF for 72h in the presence of the test compounds. The cells were then 
harvested, washed and injected into lethally irradiated 8 week old NSG mice.  After 6 
weeks the murine BM was harvested and assessed for human CD34+/45+ cell 
engraftment.  (B) Indicates the mean percentage of human CD34+/45+ cells in the murine 
BM as indicated by flow cytometric analysis.  (C) Indicates the relative number of CFC 
derived from BM cells obtained from NSG mice engrafted by cells from the different 
treatment arms per 100,000 BM cells.  (D) FISH analysis for BCR-ABL positive cells was 
performed on recovered human CD45+ cells from the BM of NSG mice transplanted with 
cells treated in the different experimental arms.  Error bars indicate SEM.  ** indicates 
significance of p<0.01 and * significance of p<0.05.  FISH analysis was performed by David 
Irvine 
While the above experiments demonstrate the relative clonogenic potency 
of CD34+ cells pre-exposed to LDE225 ± nilotinib.  In order to demonstrate the 
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effect of these agents alone and in combination on BCR-ABL+ cells where there 
was a fully intact haemopoietic microenvironment and immune system, the Scl-
tTa-BCR-ABL-GFP+ inducible transgenic mouse model of CML was utilised.   
Following withdrawal of tetracycline BCR-ABL expression is induced under control 
of the Scl enhancer and so preferentially expressed in the primitive haemopoietic 
compartment.  After 4 weeks, a pure GFP+ haemopoietic population was isolated 
from these mice and transplanted into irradiated Friend Virus B NIH (FVB/N) 
recipient mice.  These mice developed a CML-like condition within 4 weeks and 
were treated with nilotinib (50mg/kg), LDE225 (80mg/kg), the combination of both 
or simply vehicle alone by oral gavage over the course of the following three 
weeks.   
Interestingly, harvested LSC and progenitor cells from the CML mouse 
model demonstrated up regulation of several mediators and targets of Hh 
signalling.  As briefly discussed in chapter 4, BM MPP exhibited increased 
expression of Hh target genes Gli1 compared to non-leukaemic MPP.  Likewise 
the LT-HSC portion demonstrated increased expression of Gli1, Ptch1 and Ptch2.  
Following treatment with LDE225 there was significant reduction in expression of 
Hh targets, with reduction in Gli1 expression noted particularly in murine LT-HSC 
(Figure 8-2).  
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Figure 8-2:  Expression of Hh mediators and targets in the Scl-tTa-BCR-ABL-GFP+ 
inducible transgenic mouse model of CML at baseline and following treatment.  
 (A)  The expression levels of Gli1, Ptch1 and Ptch2 in whole BM, haemopoietic sub-
populations and BM stroma recovered from the Scl-tTa-BCR-ABL-GFP+ inducible murine 
model of CML (leukaemic compared with non-leukaemic controls).  (B) The expression 
levels of Gli1 in whole BM, haemopoietic sub-populations and BM stroma recovered from 
the Scl-tTa-BCR-ABL-GFP+ inducible murine model of CML following treatment.  Data and 
figures are courtesy of Professor Bhatia and Dr Zhang. 
An initial analysis concluded that the recipient mice receiving nilotinib had 
reduced myeloid progenitors (CMP & GMP) in the spleen, but no reduction in 
splenic LT-HSC.   However, the LDE225 treated mice demonstrated a reduction in 
LT-HSC in the spleen but not in splenic progenitors.  The combination of both 
resulted in reduction of LT-HSC, CMP and GMP in the spleens of treated mice.    
Interestingly these results were not found in the BM of treated mice, where 
treatment was not shown to have any quantitative effect on stem or progenitor cell 
number (Figure 8-3).  
A proportion of the treated mice were followed for 4 months following the 3 
week treatment period.  All the control mice died within 16d of treatment 
discontinuation.  Improved survival compared with the control group was seen with 
nilotinib alone and a further improvement in survival seen in the combination 
treated arm compared to the control group (Figure 8-3).  No increase in survival 
was seen in the LDE225 single arm treated mice alone (Figure 8-3).  
Lastly BM and splenic cells were harvested from treated mice and pooled 
prior to transplantation into secondary recipient mice (5x106 cells per mouse).  
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Secondary recipient mice transplanted with BM or splenic cells from the control 
arm developed leukaemia, however secondary recipients receiving BM or splenic 
cells from mice treated in the combination arm demonstrated reduced levels of 
leukaemia compared with both the control treated and the single arm LDE225 or 
nilotinib treated mice (Figure 8-3). 
It follows from this that the combination of nilotinib and LDE225 is affecting 
the capacity of LSC to recrudesce the disease in secondary hosts. 
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Figure 8-3:  Studies in the Scl-tTa-BCR-ABL-GFP+ inducible transgenic mouse model of 
CML.   
The experimental schema is summarised in (A).  (Bi-vi) After 4 weeks these mice began 
daily treatment with vehicle, LDE225 ± nilotinib.  After treatment had ceased, BM (Biv-vi) 
and splenic (Bi-iii) tissue was assessed by flow cytometry to quantify the number of LSC 
and progenitor cells present.  These graphs indicate the mean absolute number of GMP 
(Bi,Biv), CMP (Bii/Bv) and LT-HSC (Biii/vi) assessed by surface phenotype in 8 mice per 
treatment arm.  Error bars represent the SEM.  Significance of p<0.05 is represented by * 
and p<0.01 represented by **.   (C) Mice were followed for 4 months to ascertain survival 
following treatment.  Survival in the different groups was assessed by creating Kaplan-
Meier curves and the different survival rates between treatment arms were assessed by 
the log-rank test.  Combination treatment was significantly different from single agent 
nilotinib (p<0.01).  (D)  Pooled splenic or BM cells recovered from treated mice were 
transplanted into secondary hosts (8 per arm). Graph Di represents the proportion of 
recipients of BM cells developing leukaemia after 16 weeks, whereas graph Dii represents 
the proportion of recipients of splenic cells developing leukaemia after 16 weeks.  Data 
and figures are courtesy of Professor Bhatia and Dr Zhang. 
Thus, LDE225 in combination with nilotinib is confirmed to reduce 
engraftment of primary CD34+ CP CML cells in immunodeficient mice and to both 
enhance survival and reduce the capacity of BCR-ABL+  cells to recapitulate CML 
in secondary transplanted mice in the Scl-tTa-BCR-ABL mouse model of CML.  
These results are consistent with previous studies reported by Dierks et al who 
demonstrated that BCR-ABL positive Smo-/- foetal liver cells had reduced capacity 
to cause leukaemia in transplanted mice as compared to similarly transplanted 
WT, Smo+/- or Ptch+/- foetal liver cells, that Smo-/- cells were completely unable to 
transmit leukaemia in second transplantation and in vivo treatment with the 
combination of the non-clinical grade SMO inhibitor cyclopamine in combination 
with nilotinib led to a significant prolongation of survival (mean 16d) in the 
combination treatment arm compared to single agent nilotinib (Dierks et al., 2008).  
Likewise Zhao et al demonstrated prolonged survival in competitive transplant 
experiments with retrovirally transduced BCR-ABL+  Smo-/- LSCs compared with 
similarly transduced Smo+/+ mice.  They also demonstrated markedly reduced 
survival of secondary transplanted hosts receiving BCR-ABL+ cells also 
transduced to express constitutively active Smo (Zhao et al., 2009).  The results 
presented in this study extend and expand the results reported by both authors 
into the CP of the disease and provide strong corroboration for the results from the 
in vitro assays described in chapter 6 of the main body of this work. 
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One interesting finding in the murine studies discussed above is the 
difference between the spleen and the BM in terms of LT-HSC and progenitor 
abundance.  Whether this is due to differences in LT-HSC distribution due to 
changes wrought on their interaction and adhesion to the BM and splenic 
microenvironment, or whether Hh signalling is more important in directing LSC fate 
is not answered in this work. It is intriguing to speculate that primitive splenic 
haemopoietic cells may be more dependent on Hh signalling due to different 
microenvironmental conditions.  All three Hh ligands are expressed in the spleen 
and recent reports have attributed functional roles in the regulation of splenic 
haemopoiesis in conjunction with other signalling pathways e.g. BMP4 particularly 
under conditions of haemopoietic stress (Lau et al., 2012; Perry et al., 2009).      
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